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Abstract
Systematic review and economic modelling of 
effectiveness and cost utility of surgical treatments for 
men with benign prostatic enlargement
T Lourenco,1 N Armstrong,2 J N’Dow,3* G Nabi,3 M Deverill,2 R Pickard,4 
L Vale,1 G MacLennan,1 C Fraser,1 S McClinton,3 S Wong,1 A Coutts,1 
G Mowatt1 and A Grant1
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2Health Economics Research Unit, Centre of Health Services Research, University of Newcastle, UK
3Academic Urology Unit, Department of Surgery, University of Aberdeen, UK
4Department of Urology, School of Surgical and Reproductive Sciences, University of Newcastle, UK
*Corresponding author
Objectives: To determine the clinical effectiveness 
and cost utility of procedures alternative to TURP 
(transurethral resection of the prostate) for benign 
prostatic enlargement (BPE) unresponsive to expectant, 
non-surgical treatments.
Data sources: Electronic searches of 13 databases to 
identify relevant randomised controlled trials (RCTs).
Review methods: Two reviewers independently 
assessed study quality and extracted data. The 
International Prostate Symptom Score/American 
Urological Association (IPSS/AUA) symptom score 
was the primary outcome; others included quality of 
life, peak urine flow rate and adverse effects. Cost-
effectiveness was assessed using a Markov model 
reflecting likely care pathways.
Results: 156 reports describing 88 RCTs were 
included. Most had fewer than 100 participants (range 
12–234). TURP provided consistent, high-level, long-
term symptomatic improvement. Minimally invasive 
procedures resulted in less marked improvement. 
Ablative procedures gave improvements equivalent 
to TURP . Holmium laser enucleation of the prostate 
(HoLEP) additionally resulted in greater improvement 
in flow rate. HoLEP is unique amongst the newer 
technologies in offering an advantage in urodynamic 
outcomes over TURP , although long-term follow-up 
data are lacking. Severe blood loss was more common 
following TURP . Rates of incontinence were similar 
across all interventions other than transurethral needle 
ablation (TUNA) and laser coagulation, for which lower 
rates were reported. Acute retention and reoperation 
were commoner with newer technologies, especially 
minimally invasive interventions. The economic model 
suggested that minimally invasive procedures were 
unlikely to be cost-effective compared with TURP . 
Transurethral vaporisation of the prostate (TUVP) was 
both less costly and less effective than TURP . HoLEP 
was estimated to be more cost-effective than a single 
TURP but less effective than a strategy involving repeat 
TURP if necessary. The base-case analysis suggested an 
80% chance that TUVP , followed by HoLEP if required, 
would be cost-effective at a threshold of £20,000 per 
quality-adjusted life-year. At a £50,000 threshold, TUVP , 
followed by TURP as required, would be cost-effective, 
although considerable uncertainty surrounds this finding. 
The main limitations are the quantity and quality of the 
data available, in the context of multiple comparisons. 
Conclusions: In the absence of strong evidence in 
favour of newer methods, the standard – TURP – 
remains both clinically effective and cost-effective. 
There is a need for further research to establish (i) 
how many years of medical treatment are necessary to 
offset the cost of treatment with a minimally invasive or 
ablative intervention; (ii) more cost-effective alternatives 
to TURP; and (iii) strategies to improve outcomes after 
TURP .Health Technology Assessment 2008; Vol. 12: No. 35
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Executive summary
Background
Benign prostatic enlargement (BPE) commonly 
causes older men to have difficulty passing urine. 
If non-surgical management does not alleviate 
symptoms satisfactorily, the standard treatment 
is transurethral resection of the prostate (TURP). 
TURP requires an anaesthetic and a stay in hospital 
and sometimes has unwanted effects. Consequently, 
newer procedures using alternative energy sources 
have been developed. Some do not require a 
general anaesthetic, are carried out in outpatient 
settings and have fewer adverse effects. However, 
there is uncertainty about their clinical effectiveness 
and cost-effectiveness. This review aimed to:
determine the clinical effectiveness of  •	
alternative procedures
model estimates of cost and cost utility •	
rank the clinical effectiveness and risk profile  •	
of newer procedures in terms of benefits, risks 
and cost-effectiveness
identify areas for future research. •	
Description of proposed 
interventions
Surgery for BPE can be divided into ‘minimally 
invasive’ and ‘tissue ablative’ treatments. Minimally 
invasive procedures include transurethral 
microwave therapy (TUMT), transurethral needle 
ablation (TUNA), transurethral ethanol ablation 
of the prostate (TEAP) and transurethral laser 
coagulation. Tissue ablative procedures are as 
invasive as TURP and include laser prostatectomy, 
laser vaporisation, transurethral vaporisation of the 
prostate (TUVP), transurethral vaporesection of 
the prostate (TUVRP), and bipolar TURP, TUVP 
and TUVRP. Although the ablative techniques 
are grouped together for the purposes of this 
review, there are differences in the method of 
ablation of the prostate with some techniques using 
vaporisation (e.g. TUVP) compared with those 
using resection [e.g. holmium laser enucleation of 
the prostate (HoLEP)].
Methods
Clinical effectiveness
Electronic searches of 13 databases were conducted 
to identify randomised controlled trials (RCTs) of 
surgical interventions for BPE. Selected conference 
proceedings were hand searched, websites 
consulted and reference lists scanned.
Two reviewers independently assessed study quality 
and extracted data. The International Prostate 
Symptom Score/American Urological Association 
(IPSS/AUA) symptom score was the primary 
outcome; other outcomes included quality of life, 
peak urine flow rate and adverse effects.
Cost-effectiveness 
A Markov model was produced reflecting likely care 
pathways. Parameter estimates were derived from 
the systematic review of clinical effectiveness, a 
review of previous economic evaluations and other 
UK relevant sources.
Results
A total of 156 reports describing 88 RCTs were 
included. The majority had fewer than 100 
participants (range 12–234). 
TURP provided a consistent, high level of long-
term symptom improvement. Improvements in 
quality of life and flow rate were also observed. 
Minimally invasive procedures result in less 
improvement in symptoms and flow rate. Ablative 
procedures give similar symptom and quality of 
life improvements to TURP. HoLEP additionally 
resulted in greater improvement in flow rate. 
In terms of effectiveness, HoLEP appears to be 
unique amongst the newer technologies in offering 
an advantage over TURP, currently confined 
to urodynamic outcomes, which may not be of 
importance to patients, although long-term follow-
up data are lacking. Severe blood loss was more 
common following TURP. The rate of incontinence 
was similar across all interventions other than for Executive summary
x
TUNA and laser coagulation, which reported lower 
rates. Acute retention and need for reoperation was 
more common with newer technologies, especially 
the minimally invasive interventions. 
The economic model suggested that minimally 
invasive procedures (represented by TUMT) were 
unlikely to be considered cost-effective compared 
with TURP. Strategies involving TUMT with TURP 
as a second procedure as necessary were more 
costly but had a similar effectiveness to TURP. 
Of the other ablative procedures, TUVP was less 
costly than TURP (and also the least costly single 
treatment considered) but less effective. HoLEP 
was estimated to be more effective and less costly 
than a single TURP but less effective than a 
strategy involving repeating TURP if necessary. 
However, the base-case analysis suggested an 80% 
chance that a strategy of TUVP, followed by HoLEP 
if required, would be the cost-effective strategy at a 
threshold of £20,000 per quality-adjusted life-year 
(QALY). At an approximately £50,000 threshold, 
on average, TUVP, followed by TURP as required, 
would be cost-effective, although considerable 
uncertainty surrounds this finding. 
Sensitivity analyses
All changes found in the sensitivity analyses were 
intuitively sensible and their possible impact 
depended on society’s willingness to pay for a 
QALY. 
Limitations of the calculations 
(assumptions made)
The main limitations relate to the quantity and 
quality of the data available, in the context of 
multiple comparisons. Many trials were under-
reported or poorly reported; much of the 
information available was in a form that was 
unsuitable for meta-analysis. Obtaining cost 
estimates was not always straightforward and 
costing under all resource categories was not 
possible. 
Conclusions
For the NHS, increased use of TUVP and/or 
HoLEP would lead to an increased requirement 
for training, which may be costly; in addition, it 
would take time to establish an adequate level of 
provision. In the absence of strong evidence in 
favour of newer methods, TURP remains both 
clinically effective and cost-effective. The use of 
minimally invasive technologies in the NHS is not 
appropriate until a more effective and/or less costly 
technology is available.
Need for further research
For men who might currently be managed  1. 
medically, a systematic review including 
modelling to determine how many years of 
medical treatment are necessary to offset the 
cost of treatment with a minimally invasive or 
ablative intervention in the first instance.
Better research into the true costs of the  2. 
different interventions as a critical driver of 
economic evaluations.
Consensus work in partnership with governing  3. 
bodies such as the British Association of 
Urological Surgeons to agree parameters for 
conducting future trials, such as standardising 
definitions and reporting of outcome measures.
For men judged to need ablative therapy, is  4. 
there an alternative to TURP that is more 
effective, safe or cost-effective? A well-
conducted head-to-head trial of treatment 
strategies – TUVP followed by either TURP 
or HoLEP, versus HoLEP, versus TURP × 2 – 
would be the most desirable to establish the 
gold standard. Such a trial should take prostate 
size into account and should include direct 
measures of utility. Newer technologies could 
then be compared against this gold standard 
and, given the rapid developments in this area, 
a tracker trial approach may be appropriate.
Trials of different strategies aimed at  5. 
improving outcomes and minimising adverse 
effects after TURP, particularly bleeding.Health Technology Assessment 2008; Vol. 12: No. 35
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Chapter 1  
Aim of the review
T
he aim of the planned research is to assess the 
relative clinical effectiveness and cost utility of 
established and emerging interventional treatments 
for men suffering symptoms or complications 
caused by benign prostatic enlargement (BPE). 
The specific objectives are:
To determine the clinical effectiveness of  1. 
alternative procedures.
To determine the magnitude of risk of their  2. 
short- and long-term side effects.
To rank the clinical effectiveness and risk  3. 
profile of new interventional procedures 
against transurethral resection of the prostate 
(TURP), currently considered the gold 
standard of care.
To estimate the cost utility of the alternative  4. 
procedures.
To assess the effects of skill and learning on  5. 
cost-effectiveness.
To identify clinical indications and  6. 
contraindications for specific procedures.
To assess the speed of development in the field. 7. 
To identify areas in which future research is  8. 
required.
The research was based on four inter-related 
components:
Development of care pathways for the chosen  1. 
treatment options for men presenting with 
symptoms or complications resulting from 
BPE.
A systematic review of the literature of the  2. 
effects of the alternative procedures.
A systematic review of economic evaluations to  3. 
inform (4) below.
Construction of a Markov model and cost- 4. 
utility analysis of the treatment options.Health Technology Assessment 2008; Vol. 12: No. 35
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Chapter 2  
Background
Description of the 
underlying health problem
Introduction
Clinical BPE describes a condition affecting 
older men characterised by the combination of 
increased prostate size and urinary symptoms 
such as frequency and poor urinary flow that 
bother the patient. The pathophysiology of benign 
enlargement involves hyperplasia of the epithelial 
and stromal components of the prostate gland 
leading to progressive obstruction of urine flow, 
and increased activity of the bladder (detrusor) 
muscle. These secondary urodynamic changes 
of bladder outlet obstruction and detrusor 
dysfunction are thought to result in the typical 
bladder storage symptoms such as frequency and 
nocturia and voiding symptoms such as poor flow 
and intermittent stream. For simplicity, the variety 
of symptomatic effects are grouped together as 
lower urinary tract symptoms (LUTS). Although the 
precise relationship between symptoms, prostate 
enlargement and detrusor dysfunction can be 
debated, there is no doubt that removal of prostatic 
tissue in affected men results in improvement of 
symptoms, urodynamic parameters and quality of 
life. 
Men are diagnosed as suffering from clinical BPE 
by documenting a combination of storage and 
voiding symptoms, finding a uniformly enlarged 
prostate gland on digital rectal examination 
and the measurement of a reduced peak urinary 
flow rate (Qmax). Qmax is normally used to predict 
response to surgery and acts as a proxy for 
urodynamic studies. Men with a Qmax of less than 
10 ml/s are more likely to have urodynamically 
proven bladder outflow obstruction and as a result 
are more likely to have a good outcome after 
surgery. The usefulness of other indicators of lower 
urinary tract function, in particular the diagnosis 
of bladder outlet obstruction by invasive pressure 
flow studies, continues to be debated. In general, 
such testing before surgery will reduce the number 
of men having a poor outcome at the expense 
of denying a proportion of men classified as not 
obstructed successful surgery. Because Qmax was the 
only urodynamic inclusion criterion for the studies 
included in the systematic review, the utility of 
further testing has not been considered further.1
The diagnosis also requires exclusion of other 
lower urinary tract disorders by urinalysis, 
prostate-specific antigen (PSA) level and use of 
a frequency/volume chart. The severity of the 
disorder is assessed using a validated symptom-
scoring questionnaire, most commonly the 
International Prostate Symptom Score (IPSS).2 
This questionnaire asks the patient to rate 
voiding symptoms (poor stream, intermittent 
flow, incomplete emptying, straining) and storage 
symptoms (urgency, frequency, nocturia) on a scale 
from 0 (none) to 5 (very severe). Completion of 
the IPSS yields a total score ranging from 0 to 35 
defining mild (score 0–7), moderate (score 8–19) 
and severe (score 20–35) symptomatic states. 
In addition, a single disease-specific quality of 
life question scores how bothersome symptoms 
are for each individual [range 0 (delighted) to 6 
(terrible)]. This basic assessment is used to discuss 
management options with each patient, which may 
involve lifestyle changes alone, drug treatment 
or invasive therapy to remove or ablate prostate 
tissue. In some men the predominant clinical 
problem is characterised as a complication of BPE. 
This can be recurrent lower urinary tract infection 
(UTI), bleeding (haematuria) or urinary retention. 
Such complications are generally an indication for 
invasive treatment to remove prostate tissue. Other 
assessment instruments include the well-validated 
American Urological Association (AUA) symptom 
index, which uses seven questions that are identical 
to the IPSS questions with the exception of the 
disease-specific quality of life question, and 
the Madsen–Iversen index, which is no longer 
recommended for assessing symptoms as it was 
not designed to be self-administered by patients. 
The Madsen–Iversen index is usually completed 
by an interviewer and includes questions about 
stream, straining to void, hesitancy, intermittency, 
bladder emptying, incontinence, urgency, nocturia 
and frequency, with different symptoms attracting 
different scoring schemes. Although providing 
semi-objective symptom quantification, these 
questionnaires, including the currently favoured 
IPSS, have been criticised for giving undue Background
4
weight to voiding symptoms at the expense of the 
sometimes more troublesome storage complaints.
Epidemiology and natural history
Clinical BPE is a common disorder, affecting 30% 
of those older than 60 years and 40% of those 
older than 70 years.3 What is becoming increasingly 
clear is the generally progressive nature of BPE.4,5 
In a randomised comparison with TURP, 30% of 
men assigned to advice alone required prostate 
surgery for progressive symptoms during a 3-year 
period of surveillance.6 Longitudinal community 
observational studies such as that performed in 
Olmsted County, USA7 have shown an increase 
in both symptom severity and adverse effects on 
quality of life associated with progressive prostate 
enlargement and deterioration in urine flow. This 
study followed 2115 randomly selected white male 
residents and found that 26% of men aged from 
40 to 49 years and 46% of men aged from 70 to 
79 years reported moderate to severe urinary 
symptoms. Longitudinal data also confirmed an 
annual increase in prostate volume of 1.6%, an 
overall annual increase in symptom score of 0.298 
and a consistent annual decline in peak flow of 
2% across all age groups.9 In the same cohort of 
patients there was an increased risk of acute urinary 
retention with increasing age, with baseline age, 
symptom severity, prostate size and maximum 
flow rate identified as independent predictors.10 
A potential drawback of such community-based 
studies is the lack of histological confirmation of 
benign hyperplasia, which in other studies has been 
found to be present in 40% of men in their 50s and 
around 90% of men in their 80s.11–13 Although the 
natural history of clinical BPE is more accurately 
determined using community-based cohorts such 
as in the Olmsted County study, further insights 
are gained from placebo arms of trials of drugs 
used to treat clinical BPE, such as the medical 
therapy of prostatic symptoms (MTOPS) study14 
which documented that the risk of BPE progression 
averaged 17% at 4 years. 
Significance in terms of ill health
The combination of improved life expectancy and 
reduction in birth rate has resulted in an actual 
or predicted progressive ageing of the population 
in most communities worldwide. For men, it is 
estimated that the population of those aged over 
65 years reached 207 million in 2005, constituting 
6.38% of the world’s male population.15 These 
demographic changes inevitably result in an 
increased prevalence of chronic health problems 
associated with ageing. This has been shown for 
clinical BPE by a number of epidemiological 
studies.16 The prevalence of moderate to severe 
symptoms progressively increases from 18% of men 
in their 40s to 56% of those in their 70s.17 The 
bothersome nature of urinary symptoms is linked 
to adverse changes in quality of life and drives 
men to seek medical advice and treatment. In the 
past the range of treatment was limited to open or 
endoscopic removal of the prostate but now options 
include single or combination drug therapy, 
phytotherapy and the application of various energy 
sources to remove or ablate prostate tissue. The 
increased range of therapies has encouraged more 
men to seek help to alleviate their symptoms 
and has led to a widening of the indications for 
interventional treatments. Thus, although it is 
rarely a life-threatening problem, clinical BPE 
represents a major and increasing health condition 
that consumes a significant proportion of health-
care expenditure.18 
The goals of treatment of clinical BPE are to 
reduce the severity of symptoms together with the 
bother that they cause, to normalise the dynamics 
of the lower urinary tract and to resolve or prevent 
complications. Treatment options balance likely 
benefits with possible occurrence and severity 
of side effects. Simple reassurance and lifestyle 
advice can be sufficient for those men without 
much bother but they incur the risk of later 
complications. Drug treatment can be effective 
for relief of symptoms and evidence suggests that 
long-term treatment with a drug combination 
may also lessen the risk of complications.19 Drug 
treatment is, however, costly, of only moderate 
effectiveness and does not improve urodynamic 
status. Procedures that reduce prostate bulk 
combine higher effectiveness with the attraction 
of a single treatment, but they are associated 
with increasing severity of unwanted effects; 
open removal of the prostate (prostatectomy), 
for example, has the greatest effectiveness but 
results in the highest morbidity. Although still an 
option for larger glands, open prostatectomy is 
not commonly used for the treatment of BPE in 
the UK and will not be considered further in this 
review, which concentrates on newer interventions. 
TURP has been the mainstay of treatment for 
clinical BPE for many years because it combines 
high effectiveness with a previously acceptable 
side-effect profile. More recently, in the UK, men 
have tended to seek help earlier in the natural 
history of the disease and access to secondary 
health care has improved. This, together with 
increasing co-morbidities present in the ageing Health Technology Assessment 2008; Vol. 12: No. 35
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population at risk and the desire of health 
providers to contain costs, has fuelled the search 
for less morbid invasive treatments. There is also 
some evidence that men without complications 
or severe symptoms would prefer a less morbid 
method of prostate ablation with a shorter 
hospital stay.20 Technological developments have 
allowed clinical investigators and medical device 
manufacturers to apply alternative energy sources 
with varying degrees of invasiveness to achieve 
reduction of prostate bulk without some of the side 
effects of TURP, such as bleeding, cardiovascular 
disturbance due to irrigation, incontinence and 
ejaculatory dysfunction. These interventions can be 
subdivided into surgical procedures that generally 
involve removal of prostate tissue requiring 
general or regional anaesthesia and minimally 
invasive options, which do not require general 
anaesthesia and can be carried out in an outpatient 
setting.21 The former group are generally more 
efficacious than the latter group but have higher 
complication rates; however, estimates of beneficial 
and unwanted effects do vary between procedures 
within these two categories.21 
Description of new 
interventions
In this section we describe standard and newer 
interventions that will be compared in the review 
of clinical effectiveness and economic model. The 
UK government-funded health service (NHS) is 
fortunate in having comprehensive centralised 
data collection systems from which numbers of 
procedures and their costs can be extracted.22 
Unfortunately, current coding systems do not 
differentiate between energy sources used in 
prostate ablation, with all procedures coded as 
TURP. This makes it difficult to estimate the 
number of newer interventions being performed, 
and the occurrence rates for specific procedures 
given below should be considered as approximate. 
Considering the relevant OPCS-4 codes (M65.1, 
M65.2, M65.3, M65.8, M65.9, M66.2, M66.8, 
M66.9, M67.8, M67.9, M70.8), a total of 28,799 
procedures were performed within NHS hospitals 
in England during the financial year 2004–2005 
(main operation four-character codes 2004–2005), 
which tallies well with the count of 30,387 using 
the simplified Healthcare Resource Group codes 
L27, L28 and L29 (Healthcare Resource Group 
codes 2004–2005).22 Given a total population of 49 
million and a population at risk (men > 59 years) 
of 4.5 million, this gives crude incidence rates of 60 
per 100,000 per year and 667 per 100,000 per year 
respectively for surgical treatment of clinical BPE.23 
Table 1 provides a summary of the main surgical 
procedures, detailing the main characteristics, 
number of operations performed by the NHS in 
2006 and cost.
Minimally invasive treatments
Introduction
Minimally invasive treatments seek to ablate 
BPE using low-energy heating devices. Typically 
temperatures of 40–80°C are achieved, causing 
areas of coagulative necrosis, which either slough 
via the urethra or are reabsorbed during tissue 
repair. The resultant defect is usually visible on 
transrectal ultrasound scanning but is considerably 
smaller than for TURP. Provided energy delivery is 
kept low these treatments can be carried out in the 
office or outpatient clinic, whereas higher energy 
levels require anaesthesia and hence an operating 
theatre. Delayed necrosis means that relatively 
prolonged catheterisation is required to avoid 
urinary retention and painful micturition and, as a 
consequence, treatment benefit may not be realised 
for 2–3 months.24 The use of urethral stents is also 
discussed in this section.
Interventions
Transurethral microwave 
thermotherapy
Microwave energy is used in transurethral 
microwave thermotherapy (TUMT), achieving 
temperatures of 45–70°C in the prostate 
depending on the device and power setting. 
Initially, energy was delivered at low power 
settings but variable higher energy delivery is 
now more usual. Microwaves induce oscillation 
of water molecules causing heat generation 
and inducing coagulative necrosis of prostatic 
tissue.25 The procedure is typically performed 
using an antenna mounted within a transurethral 
catheter through which cooling fluid circulates. 
Temperature control is regulated by urethral 
and rectal thermometer probes to prevent 
collateral damage. The procedure lasts for 30–60 
minutes and is performed using local anaesthesia 
and oral analgesia together with sedation 
for high-energy protocols. Requirement for 
postoperative catheterisation varies from 1 to 12 
weeks depending on the protocol used.26 
Transurethral needle 
ablation of the prostate
Transurethral needle ablation (TUNA) of the 
prostate involves the delivery of radio frequency 
energy via a modified urethral catheter attached to Background
6
T
A
B
L
E
 
1
 
C
o
m
p
a
r
a
t
i
v
e
 
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
 
o
f
 
m
a
i
n
 
s
u
r
g
i
c
a
l
 
t
r
e
a
t
m
e
n
t
 
o
p
t
i
o
n
s
 
f
o
r
 
c
l
i
n
i
c
a
l
 
B
P
E
 
P
r
o
c
e
d
u
r
e
H
o
s
p
i
t
a
l
 
s
t
a
y
E
n
e
r
g
y
 
s
o
u
r
c
e
M
e
t
h
o
d
 
o
f
 
t
i
s
s
u
e
 
r
e
m
o
v
a
l
P
e
r
i
o
d
 
o
f
 
c
a
t
h
e
t
e
r
i
s
a
t
i
o
n
N
H
S
 
p
r
o
c
e
d
u
r
e
s
 
(
p
e
r
 
y
e
a
r
)
a
C
o
s
t
 
(
£
)
b
M
i
n
i
m
a
l
l
y
 
i
n
v
a
s
i
v
e
T
U
M
T
D
a
y
 
c
a
s
e
M
i
c
r
o
w
a
v
e
C
o
a
g
u
l
a
t
i
v
e
 
n
e
c
r
o
s
i
s
1
–
2
 
w
e
e
k
s
3
0
0
1
8
0
0
T
U
N
A
D
a
y
 
c
a
s
e
R
a
d
i
o
 
f
r
e
q
u
e
n
c
y
C
o
a
g
u
l
a
t
i
v
e
 
n
e
c
r
o
s
i
s
3
 
d
a
y
s
1
0
0
1
6
0
0
H
I
F
U
D
a
y
 
c
a
s
e
U
l
t
r
a
s
o
u
n
d
C
o
a
g
u
l
a
t
i
v
e
 
n
e
c
r
o
s
i
s
2
 
w
e
e
k
s
1
0
0
1
0
0
0
L
a
s
e
r
 
c
o
a
g
u
l
a
t
i
o
n
1
–
2
 
d
a
y
s
L
a
s
e
r
C
o
a
g
u
l
a
t
i
v
e
 
n
e
c
r
o
s
i
s
3
–
7
 
d
a
y
s
5
0
0
7
5
0
A
b
l
a
t
i
v
e
T
U
I
P
1
–
2
 
d
a
y
s
D
i
a
t
h
e
r
m
y
N
o
n
e
1
–
2
 
d
a
y
s
2
5
0
0
1
8
0
0
T
U
R
P
3
–
5
 
d
a
y
s
D
i
a
t
h
e
r
m
y
R
e
s
e
c
t
i
o
n
1
–
3
 
d
a
y
s
2
0
,
0
0
0
2
0
0
0
L
a
s
e
r
 
v
a
p
o
r
i
s
a
t
i
o
n
1
–
2
 
d
a
y
s
L
a
s
e
r
V
a
p
o
r
i
s
a
t
i
o
n
1
–
2
 
d
a
y
s
3
0
0
0
2
6
0
0
T
U
V
P
2
–
3
 
d
a
y
s
D
i
a
t
h
e
r
m
y
V
a
p
o
r
i
s
a
t
i
o
n
1
–
2
 
d
a
y
s
2
0
0
0
1
8
0
0
H
o
L
E
P
2
–
3
 
d
a
y
s
L
a
s
e
r
E
n
u
c
l
e
a
t
i
o
n
1
–
2
 
d
a
y
s
1
5
0
0
1
9
0
0
H
I
F
U
,
 
h
i
g
h
-
i
n
t
e
n
s
i
t
y
 
f
o
c
u
s
e
d
 
u
l
t
r
a
s
o
u
n
d
 
;
 
H
o
L
E
P
,
 
h
o
l
m
i
u
m
 
l
a
s
e
r
 
e
n
u
c
l
e
a
t
i
o
n
 
o
f
 
t
h
e
 
p
r
o
s
t
a
t
e
 
;
 
T
U
I
P
,
 
t
r
a
n
s
u
r
e
t
h
r
a
l
 
i
n
c
i
s
i
o
n
 
o
f
 
t
h
e
 
p
r
o
s
t
a
t
e
;
 
T
U
M
T
,
 
t
r
a
n
s
u
r
e
t
h
r
a
l
 
m
i
c
r
o
w
a
v
e
 
t
h
e
r
m
o
t
h
e
r
a
p
y
;
 
T
U
N
A
,
 
t
r
a
n
s
u
r
e
t
h
r
a
l
 
n
e
e
d
l
e
 
a
b
l
a
t
i
o
n
;
 
T
U
R
P
,
 
t
r
a
n
s
u
r
e
t
h
r
a
l
 
r
e
s
e
c
t
i
o
n
 
o
f
 
t
h
e
 
p
r
o
s
t
a
t
e
;
 
T
U
V
P
,
 
t
r
a
n
s
u
r
e
t
h
r
a
l
 
v
a
p
o
r
i
s
a
t
i
o
n
 
o
f
 
t
h
e
 
p
r
o
s
t
a
t
e
.
a
 
E
s
t
i
m
a
t
e
d
 
f
r
o
m
 
a
 
t
o
t
a
l
 
o
f
 
3
0
,
0
0
0
 
p
r
o
c
e
d
u
r
e
s
 
f
r
o
m
 
h
o
s
p
i
t
a
l
 
e
p
i
s
o
d
e
 
s
t
a
t
i
s
t
i
c
s
 
d
a
t
a
 
(
N
H
S
 
H
e
a
l
t
h
 
a
n
d
 
S
o
c
i
a
l
 
C
a
r
e
 
I
n
f
o
r
m
a
t
i
o
n
 
C
e
n
t
r
e
,
 
2
0
0
6
)
.
2
2
b
 
E
s
t
i
m
a
t
e
d
 
f
r
o
m
 
N
H
S
 
a
n
d
 
m
a
n
u
f
a
c
t
u
r
e
r
 
c
o
s
t
 
d
a
t
a
.Health Technology Assessment 2008; Vol. 12: No. 35
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
7
a generator to ablate prostate tissue. Two adjustable 
needles located at the end of the catheter are 
inserted into the prostate under endoscopic 
control. The radio frequency waves generate ionic 
agitation of molecules within the prostate, which 
in turn produces a localised heating effect of up 
to 115°C resulting in areas of coagulative necrosis. 
Teflon sheaths are advanced over the needles 
following placement to a depth of 5–6 mm to 
protect the urethra. The radio frequency power 
is usually delivered at 2–15 W for 5 minutes per 
lesion.27 Once the coagulative effect has been 
achieved the needles are placed in a different 
area of the prostate and the procedure repeated. 
Depending on prostate size, the procedure 
generally lasts between 30 and 60 minutes and is 
performed under local or regional anaesthesia.28 
An indwelling catheter is placed for up to 3 days 
and antibiotic therapy given.29
Urethral stent
The rationale for stenting of the prostatic urethra 
in men with BPE is to nullify the compressive and 
constrictive obstructive effect of the adenomatous 
tissue and hence reduce the bladder pressure 
required to open the urethra.30 The currently 
available device is made of woven braided wire 
mesh that can be delivered and expanded in the 
prostatic urethra under endoscopic or radiological 
control. The proximal end is engaged in the 
bladder neck and the distal end must lie above 
the external sphincter to prevent incontinence. 
The procedure can be accomplished using local 
anaesthesia. The inner aspect of the stent becomes 
lined with epithelium over a 3- to 12-week period. 
Unfortunately, device migration, ingrowth of 
fibrous stroma and encrustation are common 
longer-term sequelae leading to explantation in up 
to 50% of cases.
High-intensity focused ultrasound
High-intensity focused ultrasound (HIFU) uses 
ultrasound as the energy source, which, when 
tightly focused, can cause coagulative necrosis 
of tissue. It is delivered by a transrectal probe 
equipped with a transducer incorporating both 
imaging and ablative capabilities on the same 
ceramic crystal operating at 4 MHz. Ultrasound 
can be delivered to a precisely located focal zone of 
2 × 10 mm leading to a rapid rise in temperature 
of up to 80–100°C using short exposure duration. 
Multiple lesions are then created throughout the 
prostate by moving the probe, with a treatment 
session lasting about 60 minutes. A catheter 
is placed to drain the bladder throughout 
the procedure and remains in place for about 
2 weeks.31,32 The high temperatures achieved 
necessitate general anaesthesia or sedoanalgesia 
with the procedure carried out as a day case.
Transurethral ethanol 
ablation of the prostate
Transurethral ethanol ablation of the prostate 
(TEAP) is chemical ablation of prostatic tissue 
using dehydrated ethanol. This results in the 
development of intraprostatic necrotic areas due to 
dehydration, protein degeneration and thrombotic 
closure of arterioles and venules.33 Delivery of 
absolute ethanol into the prostate can be achieved 
by injection via a transperineal,34 transrectal35 
or transurethral36 route. The transurethral route 
is the most commonly reported delivery route. 
Commercially available 0.5–2.0 ml injection of 
ethanol (99.5% v/v) is injected into the prostate 
using either an injection and aspiration set for 
periurethral injection (Richard Wolf GmbH, 
Knittlingen, Germany) or a cystourethroscopy 
injection system (Olympus Winter & Ibe GmbH, 
Hamburg, Germany). The sites of injection are 
about halfway between the bladder neck and 
the verumontanum at the 2, 4, 8 and 10 o’clock 
positions, at least 1.5 cm proximal to the external 
sphincter. The number of injections depends upon 
the size of the prostate gland. The requirement 
for postoperative catheterisation is longer than 
in standard TURP and the retreatment rates are 
higher.37 There are no long-term outcome or cost-
effectiveness reports. 
Water-induced thermotherapy
Water-induced thermotherapy (WIT) destroys 
prostate tissue by way of heat energy delivered by 
hot water flowing through a urethral catheter made 
up of four contiguous sections – a urine drainage 
lumen, a positioning balloon, a treatment balloon 
and an insulated shaft.38 The catheter is inserted 
into the urinary bladder and secured by inflating 
the positioning balloon. Hot water circulates 
through the treatment balloon, which lies in the 
prostatic urethra, and is precisely maintained 
at 60°C (140°F) by thermocouples located in 
the catheter and machine. The procedure takes 
approximately 45 minutes under local anaesthesia 
and analgesia. The treatment catheter is removed 
and replaced by a standard urethral drainage 
catheter, which remains for 4–17 days.39 
Transurethral laser coagulation 
of the prostate
Laser-induced coagulative necrosis of the 
prostatic tissue can be achieved either by surface 
application to the prostatic urethra in a technique Background
8
termed visual laser ablation of the prostate 
(VLAP) or by inserting specially designed fibres 
into the prostatic tissue via the urethra, termed 
interstitial laser coagulation (ILC). VLAP uses a 
neodynium:yttrium-aluminium-garnet (Nd:YAG) 
laser to create areas of coagulative necrosis 
extending out from the prostatic urethra. This laser 
has a unique wavelength of 1064 nm and penetrates 
tissue for up to 1.7 cm leading to delayed necrosis 
and sloughing of tissue into the urethra over a 
period of 6–8 weeks. For ILC, a diode laser is 
transmitted through a fine fibre, which is inserted 
into the prostate under endoscopic control to a 
depth of 1 cm to create 3 cm3 lesions within 2–3 
minutes at a temperature of 85°C. Typically, up to 
ten locations can be treated, with the procedure 
lasting for 30–60 minutes under local anaesthesia. 
Catheterisation is typically required for between 3 
and 7 days.40 
Identification of patient subgroups 
and criteria for treatment
The one-off outpatient nature of minimally invasive 
therapy makes it an attractive option for men 
with moderate to severe LUTS who do not wish 
to have long-term medical treatment or who are 
concerned about the side effects of more invasive 
treatments. The reduced need for anaesthesia 
and lower morbidity make it suitable for men with 
extensive co-morbidity.27 These procedures are 
generally not suitable for men with larger prostates 
(> 50 g) because of prolonged treatment time and 
high rates of post-treatment dysuria and urinary 
retention. In addition, they are not indicated for 
men with absolute indications for prostate surgery 
such as urinary retention, bleeding and recurrent 
urinary infection. The use of stents is restricted 
to men with urinary retention with extensive 
co-morbidity, which precludes prostate ablation 
techniques.
Personnel involved
Most of these treatments can be performed by a 
single physician, typically a urologist, in an office or 
clinic setting. The physician should have expertise 
in both the technique and the administration 
of local anaesthetic. A nurse assistant is also 
required together with appropriate reception and 
administration staff. Removal of the catheter can 
be performed at a subsequent office visit or by a 
community nurse. 
Setting
These technologies are suitable for use in the 
office, clinic or ambulatory care facility with a 
typical stay of approximately 4–8 hours. For 
procedures performed under local anaesthetic a 
well-equipped clinic room with basic resuscitation 
facilities, appropriate utility supply and recovery 
area are all that are required; however, for some 
procedures a standard operating theatre set-up 
with anaesthetic support is required. High capital 
costs and concerns regarding effectiveness have led 
to low use of these procedures in the UK, with only 
a few centres using the technology. It is estimated 
that fewer than 1000 procedures in total are carried 
out per year, representing less than 4% of the total. 
Equipment
In general, these technologies require a generator 
and a delivery device, which is typically a single-
use modified urethral catheter. In addition, 
some require cooling circuits, endoscopic 
positioning and transrectal imaging for device 
placement and monitoring of effect. Drugs and 
delivery equipment for local anaesthesia and 
sedation are also required. Patients are generally 
discharged home shortly after completion of the 
procedure with an indwelling catheter. Different 
manufacturers offer competing devices, which 
differ mainly in power output and delivery system. 
For TUMT the main devices are Prolieve™ (Boston 
Scientific, USA), CoreTherm™ (Prostalund, 
Sweden), TherMatrx® (American Medical System, 
USA), and Prostatron® and Targis™ (Urologix, 
USA). TUNA is provided by Prostiva™ (Medtronic, 
USA), WIT by AquaTherm™ (WIT) (ACMI, USA) 
and HIFU by Sonablate® 500 (Focus Surgery, USA). 
The currently available interstitial laser device is 
Indigo Optimax (Indigo LaserOptic™(Johnson & 
Johnson, USA).40,41 The available prostatic stent is 
marketed as Urolume® (American Medical System, 
USA).
Costs
The cost of a TUMT generator is approximately 
£14,000, with an additional cost of disposables of 
approximately £350 per case (Urologix, USA). The 
TUNA machine costs £5750 with an additional cost 
of £700 for the disposable cartridge (Medtronic, 
UK). The purchase cost of the Sonablate 500 HIFU 
system is around £300,000 (UK HIFU). Urolume 
stents cost £1365 (American Medical System, UK). 
The remaining devices are not marketed in the UK.
Transurethral resection of 
the prostate (TURP)
Introduction
TURP has been the standard method of surgical 
management of clinical BPE for 50 years and in 
recent times has accounted for more than 90% of Health Technology Assessment 2008; Vol. 12: No. 35
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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prostatectomies performed for this indication,42 
although in current practice this has been 
reduced to 60–80% by the advent of other ablative 
procedures detailed below.42 The technology 
uses diathermy current for prostate resection 
via a loop electrode using a continuous flow 
endoscope passed down the urethra with non-ionic 
fluid irrigant, usually 1.5% glycine. Coagulative 
haemostasis is achieved during and at the end of 
the procedure with a ball diathermy electrode. For 
most men a skilled urologist can achieve complete 
resection of up to 100 g of tissue within 1 hour. 
Improvements in endoscope design, diathermy 
units and bladder irrigation have reduced both 
operating time and risk of major morbidity. 
Postoperatively the bladder is irrigated for 6–24 
hours; the catheter is removed at 24–48 hours after 
surgery before discharge home.43
Identification of patient subgroups
TURP is a versatile technique that can achieve 
effective relief for men with bothersome moderate 
or severe symptoms. It is also highly effective 
at treating other manifestations of BPE such 
as urinary retention, recurrent infection and 
haematuria. Blood loss and absorption of irrigant 
fluids are the main causes of operative morbidity, 
particularly in men with clotting disorders, those 
taking anticoagulant or antiplatelet medication 
and those with significant cardiovascular morbidity. 
Safety can be improved by use of preoperative 
drug treatment aimed at reducing both the size of 
the prostate and bleeding during the procedure 
and use of preoperative antibiotic prophylaxis. 
Improvements in spinal anaesthesia and better 
videoendoscopic equipment have resulted in 
shorter operation times, and more aggressive 
catheter removal policies have shortened hospital 
stay.44
Personnel involved
TURP requires full operating room facilities with 
a urologist, scrub and circulating nurses and an 
anaesthetist. Standard inpatient pathways with 
experienced ward and recovery room staff and 
porters are also required. 
Setting
Traditionally TURP was considered an inpatient 
procedure requiring admission the day before 
surgery and a 4-day postoperative stay in a 
urology hospital ward. In the UK, the last 1–2 
years have seen the development of managed care 
pathways and a drive towards shortened hospital 
stay, stimulated partly by competing techniques 
and partly by cost containment and avoidance of 
hospital-related morbidity. This has meant that 
stay for straightforward TURP has been shortened 
to 2–3 days with discharge the morning following 
midnight catheter removal.44 
Equipment
A standard diathermy generator is required 
with cutting and coagulation outputs. The 
videoendoscopic equipment is also standardised 
with, typically, a 26Fr sheath, operating element, 
30° telescope, xenon light source and ‘two-chip’ 
camera with appropriate monitor.
Costs
Multiple manufacturers compete for this market, 
which tends to keep actual purchase costs 
low although list prices are high. Most of the 
equipment would be considered standard operating 
department stock with multifunctionality for use 
in open surgery, endourology and laparoscopic 
surgery. Within the NHS the procedure has unique 
Healthcare Resource Group codes, L27 for men 
aged over 69 years and L28 for men aged under 
70 years, with mean costs (2004–2005) set by 
providers of £2060 (interquartile range £1715–
2429) and £1864 (interquartile range £1547–2198) 
respectively.45
Transurethral incision 
of the prostate
Endoscopic incision of the prostate from bladder 
neck to verumontanum at the 7 o’clock position 
using cutting diathermy via a standard resectoscope 
is a relatively simple technique that is claimed to 
have short-term equivalence in effectiveness to 
TURP for men with smaller prostates (< 30 g).46,47 
The advantages of transurethral incision of the 
prostate (TUIP) are reduced bleeding with no 
need for postoperative irrigation and shortened 
catheterisation time together with a lower risk 
of developing retrograde ejaculation.47 The 
disadvantage is that no prostatic tissue is removed 
leading to a high rate of symptom recurrence and 
need for further surgery.43 
Patient selection, personnel required, setting, 
equipment and costs are similar to those for 
TURP.24,45 TUIP has a specific OPCS-4 code 
(M66.2) and data from the NHS suggest that 
2464 procedures were carried out in England 
during 2005, representing 8.5% of the total (main 
operation four-character codes 2004–2005).22 Background
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Other tissue ablative techniques
Vaporisation of the prostate
Introduction
Vaporisation of tissue requires rapid localised 
heating to temperatures of 100°C or more with 
minimal depth of penetration. The anatomy of 
the prostate and in particular the development of 
hyperplasia within the inner periurethral zones 
of the gland mean that transurethral delivery 
of energy for vaporisation is both feasible and 
desirable. At present two alternative sources of 
energy are available for transurethral vaporisation 
of the prostate (TUVP): laser and electrosurgical.48
Interventions using laser technology
Transurethral laser vaporisation of the prostate
Basic research has enabled the identification of 
lasers with source, wavelength and absorption 
characteristics suitable for rapid heating with 
minimal tissue penetration that could be delivered 
by the transurethral route and cause vaporisation 
on contact with the prostate.49 Initially, Nd:YAG 
was used at a power setting of 40 W.50 This had a 
disadvantage for vaporisation purposes of relatively 
deep tissue penetration (4–18 mm) related to low 
absorption and a wavelength of 1064 nm in the 
invisible spectrum.51 These characteristics were 
improved by passing the Nd:YAG-generated beam 
through a potassium-titanyl-phosphate (KTP) 
crystal, which doubles the frequency and halves the 
wavelength. By doing so, the light becomes visible 
in the green spectrum (532 nm), which encourages 
absorption by haemoglobin52 and results in a depth 
of penetration ranging from 0.8 to 3 mm.49 In 
a highly vascular tissue such as BPE, this results 
in a high energy density and rapid vaporisation, 
which is further improved by the higher power 
source (80 W) that is currently available for this 
technology.51 The holmium laser can also be 
used for transurethral prostate vaporisation by 
delivering energy at a wavelength of 2140 nm.53 
This laser has limited tissue penetration (0.4 mm), 
affords excellent haemostasis and is preferentially 
absorbed by water, enhancing the effectiveness of 
tissue ablation. Initially, moderate power (60 W) was 
used but this has now been increased to 80–100 W 
to improve efficiency.49 Contact laser vaporisation 
is performed using an irrigating cystoscope but 
still requires similar anaesthesia and operating 
conditions to TURP, with the operating time 
increased by a factor of approximately 1.5.54
Interventions using non-
laser technology
Transurethral electrovaporisation of the prostate
This technique utilises a standard monopolar 
electrodiathermy device to deliver sufficient power, 
typically 180–300 W on the ‘cut’ setting, to vaporise 
tissue on contact. The procedure is performed 
using an irrigating sheath and telescope passed 
along the urethra, which allows continuous flow 
of a non-ionic solution such as 1.5% glycine to 
maintain a clear view. The current is delivered 
through a grooved ball or modified loop electrode 
giving a depth of penetration of 1–3 mm.55,56 
The procedure is similar to TURP in terms of 
requirement for spinal or general anaesthesia, 
operating time and aftercare.55,57 More recently, 
further modification has allowed the use of bipolar 
current, which enables the use of physiological 
saline as a safer irrigant with tissue effects 
occurring at lower temperatures (ranging from 
40°C to 70°C) than with monopolar electrosurgery 
(300–400°C).58,59
Identification of patient subgroups 
and criteria for treatment
The requirement for general anaesthesia and 
standard operating room conditions and the 
degree of invasiveness mean that indications for 
vaporisation surgery in terms of symptom severity, 
symptom bother and degree of co-morbidity are 
similar to those for TURP. The simultaneous 
haemostatic coagulating effect of vaporisation 
techniques suggests additional usefulness for men 
on long-term anticoagulant or antiplatelet therapy 
who may have been previously advised against 
TURP.60 The increased operating time compared 
with resection procedures, however, suggests 
that these techniques are most suited to small or 
medium-sized prostates up to approximately 60 ml. 
The lack of tissue samples means that prostate 
cancer should be excluded when necessary by 
preoperative investigation.
Personnel involved
Vaporisation of the prostate requires standard 
operating room preparation and facilities. Patients 
will be admitted to a hospital bed or ambulatory 
care facility and prepared for surgery by nursing 
and ancillary staff with preceding anaesthetic 
assessment. On transfer to the operating room, 
the anaesthetist and assistant will administer the 
appropriate anaesthetic. The urologist, supported Health Technology Assessment 2008; Vol. 12: No. 35
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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by a scrub nurse and two circulating nurses, carries 
out the surgery. Following completion, the patient 
is transferred to a staffed recovery room and then 
back to the ward setting to complete the hospital 
stay, which is typically 2 days. If discharged with 
an indwelling catheter this will require planned 
removal by a hospital or community-based nurse. 
Setting
In the UK the procedure will be carried out 
through an inpatient urology unit, typically with 
day of surgery admission and subsequent single 
overnight stay. Some units have set up US-style 
ambulatory care facilities to restrict the hospital 
stay to less than 24 hours if clinically and socially 
appropriate. It is difficult to give precise figures 
concerning the number of such procedures 
performed under the NHS because of imprecise 
coding but it is likely to be fewer than 5000, 
representing less than 17% of the total. 
Equipment
For electrovaporisation, the only equipment that 
is required in addition to that used for TURP 
is the modified ball or loop electrode, which is 
currently designed for single patient use. For 
laser vaporisation, a source generator is required 
together with laser fibres, which are generally 
single patient use, and protective eyewear.
Costs
In comparison with TURP, electrovaporisation 
requires a more expensive modified electrode 
(Gyrus, UK), typically three times the cost of the 
standard loop and ball electrode (£40) used for 
TURP. The major cost for laser vaporisation is the 
capital purchase of the source generator, which 
ranges from £90,000 for the KTP laser (Laserscope, 
Cwmbran, UK) to £120,000 for the holmium 
laser (Sigmacon, Stanmore, UK), together with 
single-use fibre costs of £750 and £550 per patient 
respectively. The main cost saving (and associated 
gain in benefits) is reduced requirement for blood 
transfusion. With modern care pathways, hospital 
stay is likely to be 1 day less than for TURP.
Resection of the prostate
Introduction
These techniques seek to create a similar tissue 
ablative effect to TURP but with reduced bleeding 
and fluid absorption leading to lower perioperative 
morbidity. Modified irrigating cystoscopes or 
resectoscopes are used and the prostate is removed 
piecemeal as in TURP allowing subsequent 
histological examination. At present this can 
potentially be achieved either by holmium:YAG 
laser resection or by bipolar electroresection using 
normal saline. 
Interventions using laser technology
Holmium:YAG laser prostatectomy 
Holmium laser prostatectomy used to be 
performed by resection of small pieces of prostate 
tissue down to the prostate capsule (HoLRP); 
however, this technique has largely been 
superseded by holmium laser enucleation of the 
prostate lobes (HoLEP). HoLEP uses the laser to 
dissect in the surgical planes and is conceptually 
the endoscopic equivalent of open prostatectomy. 
In this technique the holmium laser is used at 
a high power setting of 60–80 W with an end-
firing fibre61. The procedure is performed using a 
continuous flow resectoscope with a video system 
and saline irrigation to maintain a clear view. The 
laser fibre is passed through a stabilising catheter 
with 5–10 cm of cladding stripped off at the distal 
end. Typically, the laser is set at an energy of 2 J 
and a frequency of 50 Hz, with minor variations 
depending on the preference of the surgeon. The 
procedure starts with bladder neck incisions at 
5 and 7 o’clock to define surgical margins. The 
median and lateral lobes are then undermined and 
resected off the prostatic capsule in a retrograde 
direction until the bladder neck is reached. 
The resected lobes are pushed into the bladder, 
morcellated and removed. The procedure can be 
carried out under spinal or general anaesthesia, 
with slightly longer operating times than for TURP 
but with similar postoperative care.51,62–64 
Interventions using non-
laser technology
Bipolar resection of the prostate
The technique of bipolar electroresection requires 
a diathermy generator (200 W capability, a radio 
frequency range of 320–450 kHz and a voltage 
range of 254–350 V) and a cutting loop that is 
similar to a monopolar loop in shape but which 
has the active and return electrode on the same 
axis separated by a ceramic insulator. A chip in 
the loop automatically adjusts the power setting of 
the generator for the best cutting and coagulating 
parameters.65 The underlying principle of this 
technique is the conversion of conductive solution 
into vapour (plasma) containing energy-charged 
particles that cause molecular dissociation of 
tissues. The electric arc (charged particles) takes 
the path of least resistance, the saline irrigant, 
thus controlling temperatures at the treatment site 
and reducing the risk of thermal damage to the 
surrounding tissue.58,66 The procedure is performed 
using a continuous flow resectoscope with saline Background
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irrigation reducing the risks of fluid absorption 
and blood loss.67
Transurethral vaporesection of the prostate
Transurethral vaporesection of the prostate 
(TUVRP) involves simultaneous resection and 
vaporisation with coagulation of prostatic tissue. 
The main differences between standard TURP 
and TUVRP are in the design of the loop and 
the level of electroenergy used. In TUVRP, a 
thick band-like loop is coupled with a high 
electrosurgery cutting energy. The perceived 
advantages of TUVRP are shorter duration of 
catheterisation and hospital stay, less blood loss, 
better visualisation during resection and reduced 
electrolyte disturbances.68 The main disadvantage 
of TUVRP is longer duration of the procedure 
because of slower passage of the band electrode to 
allow for maximum coagulation and desiccation 
of the prostatic tissue, which remain central to this 
technique.
Identification of patient subgroups 
and criteria for treatment
The selection of patients, preoperative 
workup, informed consent, type of anaesthesia, 
postoperative care and clinical follow-up are 
similar to those of TURP. If appropriate, prostate 
cancer should be excluded by biopsy before 
proceeding with HoLEP.69 Improved haemostasis 
with these techniques encourages their use for 
men with clotting abnormalities or those taking 
anticoagulant or antiplatelet drugs. There is 
some suggestion that this procedure is suitable 
for prostate enlargement of any size.51,64 A long 
learning curve and 20–30% longer operative time 
than for standard TURP mean that increased 
surgeon expertise and operating room availability 
are required.70,71 
Personnel involved
Resection of the prostate requires standard 
operating room preparation and facilities. 
Protective eyewear is worn by surgeons, theatre 
personnel and patients to avoid eye damage from 
the laser. Before carrying out the procedures 
the laser machine is checked by trained theatre 
personnel according to the manufacturer’s 
instructions. Patients will be admitted to a hospital 
bed or ambulatory care facility and prepared 
for theatre by nursing and ancillary staff with 
preceding anaesthetic assessment. On transfer to 
the operating room, the anaesthetist and assistant 
will administer the appropriate anaesthetic. The 
urologist carries out the surgery supported by a 
scrub nurse and two circulating nurses. It is difficult 
to define how many procedures a surgeon must 
perform to become competent but it is generally 
agreed that about 30 cases are required for a 
urologist familiar with transurethral surgery to feel 
reasonably safe performing the HoLEP technique. 
Following completion, the patient is transferred 
to the staffed recovery room and then back to the 
ward setting to complete the hospital stay, which is 
typically 2–3 days. If discharged with an indwelling 
catheter this will require planned removal by a 
hospital or community-based nurse. 
Setting
In the UK, laser resection and transurethral 
resection (in normal saline) procedures will be 
carried out through an inpatient urology unit, 
typically with day of surgery admission and 
subsequent single overnight stay. Some units have 
set up US-style ambulatory care facilities to restrict 
hospital stay to less than 24 hours if clinically and 
socially appropriate. It is unclear how many of 
these procedures are performed in the UK but it is 
likely to be fewer than 2500 per year, representing 
less than 9% of the total.
Equipment
For laser resection of the prostate using 
holmium:YAG lasers, in addition to a high-power 
machine (100 W VersaPulse; Lumenis, USA), a 
550-μm end-firing fibre, 6Fr ureteric catheter, 
morcellator and eyewear are required. The 
resection is performed using a 27Fr continuous 
flow resectoscope with a modified inner sheath for 
the laser fibre channel. The irrigating solution is 
0.9% saline.61,72 For bipolar resection in saline, a 
source generator and bipolar resection system with 
special cutting loops are required (Gyrus, USA).65,67 
Costs
A HoLEP generator costs approximately £120,000, 
the tissue morcellator £20,000, laser fibre £550 
and the morcellator blade £440.51 However, a 
holmium:YAG laser can be efficiently used as a 
multifunctional endourological energy source 
in management of other conditions such as 
urinary stone disease, and the laser fibres and 
morcellator blades are designed for multipatient 
use. The main cost saving (and associated gain 
in benefits) is the reduced requirement for blood 
transfusion, possible shorter hospital stay and lower 
requirement for continuous postoperative irrigants. Health Technology Assessment 2008; Vol. 12: No. 35
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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Chapter 3  
Description of care pathways
We therefore decided to formulate strategies 
consisting of sequences of escalating surgical 
intervention based on concepts underlying the 
ranking of particular treatments. A number of 
meetings were held between the clinical members 
of the research team to consider the likely place 
and use of each treatment modality in plausible 
strategies of management of BPE. These were then 
checked with colleagues within their respective 
urology units. Given funding constraints, formal 
consensus-building approaches such as the Delphi 
technique were not used. We first categorised 
treatments as being minimally invasive, typified by 
ambulatory care, reduced anaesthetic requirement 
and no tissue removal; tissue ablative, signifying 
the use of differing energy sources to remove 
prostate tissue; or standard, indicating TURP or 
TUIP. Again, using clinical consensus we defined 
plausible treatment sequences taking into account 
treatment mechanism and effect on the remaining 
prostate tissue. We similarly placed limits on the 
number of retreatments allowed based on current 
concepts of the use and effect of the differing 
procedures. 
Figure 1 details plausible options of care 
informed by current clinical practice for a 
patient with BPE wanting surgery after a trial 
of drug therapy because the treatment has not 
resulted in symptomatic benefit or as a result 
of disease progression after initial benefit from 
drug treatment. The patient could be offered a 
minimally invasive intervention and if this results 
in symptomatic benefit no further treatment may 
be necessary. Should there be inadequate benefit 
or disease progression after initial benefit, the 
patient may be offered a choice of four other 
treatment options (drug therapy, repeat of 
minimally invasive intervention, a TURP or one 
of the other tissue ablative interventions such as 
KTP laser or TUVP). Should the patient have 
inadequate benefit or further disease progression 
after a second minimally invasive intervention, it 
was felt that the most plausible treatment option 
would be either a TURP or one of the other tissue 
ablative interventions. An alternative care pathway 
for a patient with BPE wanting surgery after a trial 
D
uring the first half of the last century open 
prostatectomy was the only treatment option 
for BPE and because of significant mortality it was 
reserved for men with life-threatening problems 
such as urinary retention. The 1960s saw the 
advent of endoscopic transurethral techniques, 
particularly TURP, which allowed much safer 
surgery and widened treatment indications to 
include men with troublesome symptoms. Further 
improvements in perioperative care made TURP 
one of the most frequently performed operations 
towards the end of the twentieth century, 
particularly in the USA. Recent years have seen the 
increased use of drugs that can improve symptoms 
and possibly slow progression,19,73 which has led to 
a decreased rate of surgical intervention, this being 
reserved for those who fail drug treatment or suffer 
complications. 
The treatment strategy of reassurance followed 
by drugs followed by surgery is now standard 
in clinical practice and has been explored in 
previous reviews of cost-effectiveness.74 A parallel 
development has been the trial of differing energy 
delivery technologies to achieve varying degrees 
of surgical prostate tissue ablation, with the aim 
of high efficacy and low morbidity to challenge 
the standard of TURP. In this field there have 
been many false dawns, with technologies being 
introduced in a haphazard and uncontrolled 
manner and then being abandoned, as the hoped-
for advantages over TURP have not been realised. 
In the last few years, however, the application of 
randomised controlled trial (RCT) methodology to 
surgical treatments has stimulated a more evidence-
based approach, partly driven by tighter regulatory 
requirements. 
One deficiency of the current evidence, however, 
is the assumption that surgical treatment of 
BPE involves a single treatment over a patient’s 
lifetime. This head-to-head comparative approach 
does not take into account the balance between 
short- or long-term effectiveness on one hand and 
morbidity and economic costs on the other, which 
differs between treatments, nor does it cater for 
the continued progression of the disease, which 
frequently results in the need for retreatment. Description of care pathways
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of drug therapy would be to have one of the other 
tissue ablative interventions first, such as KTP laser 
or TUVP. Should there be inadequate benefit or 
disease progression after initial benefit, the patient 
may be offered a choice of another tissue ablative 
intervention or a TURP. Should the patient have 
inadequate benefit or further disease progression, 
one further TURP was allowed in the pathway. 
One exception to this rule occurs when HoLEP, 
one of the other tissue ablative interventions, is 
the choice of treatment, because it is felt to be 
equivalent to open prostatectomy and, as such, no 
further ablative procedures are allowed for in the 
care pathway. If, on the other hand, a patient with 
BPE wanting surgery after a trial of drug therapy 
chooses to have the gold standard, TURP, then the 
only option allowed for in the care pathway should 
there be inadequate benefit or disease progression 
is a repeat TURP. Based on current clinical 
practice, a repeat TURP would usually be carried 
out only after reinvestigation, usually in the form of 
urodynamic assessment. Health Technology Assessment 2008; Vol. 12: No. 35
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
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A 
technology is defined as being ‘best’ if it is 
the one that maximises the benefits (achieves 
the goals) that are intended by the decision-
maker(s) from a given budget. Economic evaluation 
involves the comparison of cost and benefit for 
any technology change and thus provides a means 
of informing decisions about which technology is 
best.75
In this study the comparison between the different 
strategies depicted in the care pathways (see 
Figure 1) is made using a decision-analytic model 
(DAM).75 The DAM is intended to show, first, the 
consequences in terms of costs and effects of each 
technology for the given population. These data 
are then used to inform the decision as to which 
technology or, when there is sufficient doubt, which 
technologies are the best, given current belief 
informed by evidence and judgement. Second, the 
DAM, in accounting for uncertainty, can be used 
to provide information about the likely value of 
conducting future research (evidence gathering) to 
reduce the uncertainty surrounding the decision 
about which technology or technologies are best.75
Sensitivity analysis might be used to show the effect 
on the results of the model of plausible variation in 
model structure or parameter values. Deterministic 
sensitivity analysis seeks to identify what change in 
a parameter value is required to produce a decision 
change. However, to account for parameter 
uncertainty with many parameters, each of which 
could have many values, it can be very difficult 
to interpret such thresholds. A solution is to use 
probabilistic sensitivity analysis.76 Probabilistic 
sensitivity analysis can also be used to estimate the 
value of information (VOI), which can be used to 
inform decisions about further research (details of 
this method are available elsewhere76,77).
How such an economic evaluation of alternative 
surgical treatments for BPE might be conducted 
can be informed by a review of the existing 
literature. The purpose of the review was, first, to 
show the extent and results of current literature 
and, second, via a critique, to learn lessons in 
order to conduct the most appropriate economic 
evaluation to aid decision-making.
The following is a list of the information 
requirements for all DAMs:
the population •	
the technologies to compare •	
the epidemiology: model structure  •	
(relationship between parameters)
the epidemiology: parameterisation of the  •	
model (effectiveness, complications, utilities 
and costs)
sensitivity analysis. •	
This list of requirements will form the framework 
used in this chapter to critique existing models 
and then in Chapter 11 the model used in this 
evaluation.
Because of deficiencies in any of the DAM 
information requirements, the results of existing 
economic evaluations were extremely unlikely to 
be sufficient to inform a decision now. Therefore, 
the only studies that were critiqued were those that 
considered at least some of the surgical treatments 
for men with moderate to severe symptoms of 
BPE and no complications, and which estimated 
outcomes using a DAM. 
Search strategy
The following databases were searched for 
information on economic evaluations and quality 
of life: MEDLINE (1966–March Week 2 2006), 
EMBASE (1980–2006 Week 11), MEDLINE 
In–Process (20 March 2006), ISI Science Citation 
Index (1981–1 March 2006), Health Management 
Information Consortium Database (March 
2006), NHS Economic Evaluation Database 
(March 2006) and HTA database (March 2006). 
In addition, recent conference proceedings of 
the European Association of Urology, American 
Urological Association and British Association of 
Urological Surgeons were searched. Reference lists 
Chapter 4  
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of all included studies were scanned to identify 
additional potentially relevant studies. Full details 
of the search strategies used are documented in 
Appendix 1.
The results of the literature searches, after 
deduplication against the Ovid multifile search, are 
presented in Table 2.
Studies selected for critique
Three studies published in six papers that 
contained data relevant to formulation of the 
DAM were identified. One study by Ackerman and 
colleagues was published in three papers,78–80 and 
another by DiSantostefano and colleagues was 
published in two papers.74,81 The third study by 
Howard and Wortley was published as a technology 
assessment report for the Australian Medical 
Services Advisory Committee (MSAC).82
Population
All three studies considered essentially similar 
populations, although DiSantostefano and 
colleagues and Ackerman and colleagues, in 
considering drug treatment and watchful waiting, 
actually considered a broader population. 
Ackerman and colleagues considered a cohort aged 
65 years, Howard and Wortley did not state age, 
and DiSantostefano and colleagues considered the 
effect of varying age from 45 to 85 years.
Technologies
DiSantostefano and colleagues and Ackerman and 
colleagues compared TUMT and TURP in addition 
to drugs whereas Howard and Wortley compared 
TUMT with TURP. None compared strategies, 
i.e. what is the best sequence of treatments if, on 
failure or relapse (judged in some way), another 
procedure is planned. Instead they all assumed that 
should the initial treatment fail then there would 
be some chance of further treatment, which for all 
three studies was TURP. However, if the choice of 
initial treatment is at all dependent on the outcome 
of any future treatments then there is a need to 
consider the outcome of these future treatments in 
the economic evaluation. Of course, there might 
also be reason to consider repeating a procedure 
such as TUMT instead of using TURP immediately 
on failure or switching to a different procedure 
such as TUVP.
The epidemiology: 
model structure
To find the best technology, costs and consequences 
(including utility) must be estimated for each 
technology. Individual variability for a given 
population and technology implies that the various 
health-related events (e.g. degree of symptom 
improvement, death) that can occur over time 
must be expressed as probabilities. Therefore, the 
model estimates the expected (‘average’) cost and 
utility for the population. However, the complexity 
of patient pathways prevents specification of a 
TABLE 2  Results of the search for studies on cost-effectiveness
Database Hits screened
Selected for full 
assessment
MEDLINE/EMBASE/MEDLINE Extra multifile search (after 
deduplication in Ovid)
1213 65
ISI Science Citation Index 88 3
NHS Economic Evaluation Database 45 0
HTA database 21 12
Health Management Information Consortium Database 31 2
Selected from conference abstracts 6 0
Total 1404 82Health Technology Assessment 2008; Vol. 12: No. 35
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probability distribution for every pathway. One 
solution is a Markov model,83 in which events are 
reduced to a set of discrete health states of fixed 
duration (cycle length). An individual may only 
be in one health state at a time and at the end of 
each cycle they face the probability of making the 
transition to another health state. The individual 
will continue moving between health states until 
the prespecified number of cycles has been reached 
or until the individual moves into an absorbing 
health state (normally death) from where further 
transitions are not possible. This enables the 
calculation for each strategy of the expected value 
of cost and utility. These expected values are the 
sum of the value of the cost and utility for each 
state multiplied by the number of cycles spent in 
that state. 
All three studies used a Markov model. The time 
horizon was 5 years for Ackerman and colleagues 
and 20 years for the other two studies. Cycle length 
was 3 months for Ackerman and colleagues, 6 
months for Howard and Wortley and 1 year for 
DiSantostefano and colleagues, thus giving 20, 
40 and 20 cycles respectively. The number of 
health states considered were 25, four and nine 
respectively. 
The epidemiology: 
parameterisation 
of the model
No study claimed to have conducted a systematic 
review of the literature, although Ackerman and 
colleagues used the term ‘comprehensive review’.
Effectiveness
One advantage of the simple ‘chance’ approach to 
second treatments is that the probability of failure 
can be simply assumed to be the probability of 
reoperation. However, the decision-making criteria 
underlying reported reoperation probabilities 
are usually unknown and different criteria might 
mean different outcomes. DiSantostefano and 
colleagues derived estimates of treatment failure 
(‘no improvement’) from the 1994 Agency for 
Health Care Policy and Research (AHCPR) 
guideline19,84 and of reoperation for TURP from 
the AUA guideline19,85 for the period up to 2000. 
Reoperation rates for TUMT were derived from 
two RCTs.86,87 However, the AHCPR guideline is 
over 10 years old and its authors admit that very 
few studies reported symptom scores and that those 
that did used many different methods.84 Although 
this limitation is allowed for to some extent in the 
wide confidence interval (CI) for this estimate (see 
Accounting for uncertainty in Chapter 10, p.112), 
the relationship between degree of symptom 
improvement and probability of retreatment is 
unclear. For example, do those who are counted 
as successful and who thus receive no further 
treatment continue with, ‘on average’, almost 
complete symptom relief or was the change only 
just sufficient to warrant no further treatment? For 
those who fail but receive no further treatment, it 
was not clear to what extent this was because the 
clinician believed that further treatment would not 
work or because further treatment was refused by 
the patient. It was also not clear why those who 
receive TURP have an annual probability of relapse 
(‘disease progression’) of about 1%, but those who 
receive TUMT cannot relapse.
Howard and Wortley used a single RCT82 for TURP 
and several sources for TUNA to estimate ‘early 
treatment failure’ (within 6 months). Longer-term 
failure rates (equivalent to relapse) were stated 
to come from an RCT and a cohort study for 
TURP with a 10-year follow-up. For TUNA, data 
were derived from the percentage undergoing 
retreatment after 5 years. 
Ackerman and colleagues used the same definition 
of treatment success for all treatments: ‘significant 
improvement, achieving a 50% or greater 
decrease in the AUA symptom score; moderate 
improvement, achieving a 30–49% decrease in the 
AUA symptom score; minimal improvement, a less 
than 30% decrease in the AUA symptom score’. 
They cited various publications, as well as the 
‘multispeciality clinical panel’, as sources for their 
probability of each degree of success, although it is 
not clear how these sources were synthesised. These 
probabilities were stated to be time dependent, 
although not all estimates were shown: the 5-year 
probabilities of ‘success’ for TURP and TUMT were 
0.85 and 0.65 respectively.
Ackerman and colleagues78 and DiSantostefano and 
colleagues74,81 also had health states with different 
degrees of symptoms. However, this refinement 
would be important only if the choice of states that 
have differential effects on outcome is contingent 
on the symptom level. For example, if on day one 
90% have some success such that they receive no 
further treatment for the next 10 years, it makes 
no difference whether half of them spend that time 
in a state of ‘mild’ symptoms and half in a state of 
‘no’ symptoms or whether all of them spend that 
time in a single state, as long as the outcome of Systematic review of previous economic evaluations
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that state is equal to the average of the outcome of 
‘mild’ and ‘no’ symptoms, each weighted by 50%.
Complications
All models consider the possibility of 
complications, the most comprehensive being 
that of Ackerman and colleagues.78 However, 
depending on the source of estimates, it is 
possible that there could be some unnecessary 
and perhaps misleading inclusions. For example, 
DiSantostefano and colleagues argue against the 
inclusion of differential mortality rates because 
either there is no difference between treatments 
or the difference is so small that to try to estimate 
would lead to bias.74,81 This is backed up by long-
term studies;85 the same argument can be made for 
life-threatening complications such as myocardial 
infarction (MI).
Retrograde ejaculation occurs as a result of removal 
of prostate tissue by whatever means and does not 
significantly lower the utility value of successful 
treatment and is not associated with any costs. 
Erectile dysfunction (ED) following prostate surgery 
is a difficult and controversial issue: the meta-
analysis presented later and previous systematic 
reviews have shown no statistically significant 
difference in occurrence between types of surgery. 
For the purposes of the cost-effectiveness analysis 
modelled over a 10-year period, we chose not 
to include ED as a complication as it was more 
likely to be caused by other concurrent, randomly 
distributed disease processes than the interventions 
under consideration. In addition, there is 
increasing evidence of an association between ED 
and urinary symptoms that would also confound 
estimated rates.
Utilities
All three studies used cost-utility analysis (CUA) 
and each had a utility of 1 for some states reflecting 
either ‘significant improvement’ or ‘remission’ and 
of 0 for death. Only Ackerman and colleagues78 
elicited preferences using the standard gamble 
approach75 to estimate utilities for each of their 
other health states; however, their sample was small 
(only n = 6 or n = 7 for each of the ‘risk averse’ 
and ‘non-risk averse’ groups). Such data may be 
unreliable as they are based on so few observations. 
They may also not be comparable with utilities 
calculated for other patient populations – a 
larger sample from the general public would have 
been better. DiSantostefano and colleagues74,81 
used utilities from a variety of sources, including 
Ackerman and colleagues78 for incontinence. 
Howard and Wortley simply used opinion (they 
do not state the source) and values for treatment 
success (as full health, i.e. 1) for failure (0.9) or side 
effects (0.95).82
Costs
All three studies estimated costs in at least the 
categories of ‘procedure’, ‘complications’ and 
‘failure’ (implying the inclusion of reoperation 
costs). However, Howard and Wortley and 
Ackerman and colleagues simply used estimates for 
each category and provided no further breakdown. 
DiSantostefano and colleagues provided a 
slightly fuller breakdown by resource use for 
each procedure such as number of physician 
visits. However, none of the studies differentiated 
between procedure and hospital stay and none 
expressed cost of equipment as a function of its 
lifetime or reusability.
Sensitivity analysis
All three studies performed some deterministic 
sensitivity analyses. Only DiSantostefano 
and colleagues used probabilistic analysis for 
parameter uncertainty.74,81 Their distributions 
for probability of treatment failure, reoperation 
and complications were estimated appropriately 
using beta distributions. They stated that they 
were parameterised using the 95% confidence 
intervals from various sources, for example the 
AUA meta-analysis,85 and presumably used the 
means from these sources. The distributions for 
their cost estimates were assumed to be normal 
and parameterised from US national databases for 
TURP and TUMT: they stated that the standard 
deviation was used, but the appropriate statistic is 
the standard error. Given the likely large sample 
size of these databases, the standard deviation 
would probably considerably overestimate the 
uncertainty, although this is a matter of judgement.
Conclusion
Previous studies have attempted to address 
the challenges of constructing a DAM for BPE 
surgical treatments. All of these studies had some 
limitations, which have been discussed. Taking 
these limitations into account it is suggested that a 
future DAM should: Health Technology Assessment 2008; Vol. 12: No. 35
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include more single treatments and treatment  1. 
strategies
develop methods to estimate the probability  2. 
of failure using clinical criteria relevant to the 
UK, comparing the effect of this with simply 
using reoperation rates
develop methods to estimate utilities that more  3. 
explicitly use the main outcome of effectiveness 
evidence, the IPSS
include relevant complications and mortality  4. 
rates for the UK
provide a breakdown of costs that is sufficient  5. 
to estimate the independent effects of 
procedure cost, hospital inpatient stay and 
purchase of any new equipment
conduct sensitivity analysis deterministically  6. 
when appropriate and with probability 
distributions for all relevant parameters, 
obtained by explicit methods in accordance 
with theory and best practice.
When developing the economic model published in 
Chapter 10, consideration was given to how these 
limitations could best be avoided or minimised.Health Technology Assessment 2008; Vol. 12: No. 35
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Methods for reviewing 
effectiveness
Search strategy
Electronic searches were undertaken to identify 
published and unpublished reports of RCTs 
evaluating the effectiveness of established and new 
interventional treatments for the management of 
symptoms and complications subsequent to BPE. 
Searches were not restricted by publication year or 
language and included conference proceedings. 
The databases searched were MEDLINE 
(1966–September Week 3 2006), EMBASE 
(1980–2006 Week 38), MEDLINE In–Process (27 
September 2006), BIOSIS (1985–22 September 
2006), ISI Science Citation Index (1981–23 
September 2006), ISI Proceedings (1990–18 
March 2006), Cochrane Controlled Trials Register 
(CENTRAL) (The Cochrane Library, Issue 1, 
2006), Cochrane Database of Systematic Reviews 
(The Cochrane Library, Issue 1, 2006), Database of 
Abstracts of Reviews of Effectiveness (March 2006), 
HTA database (March 2006), National Research 
Register (Issue 1, 2006), Clinical Trials (March 
2006) and Current Controlled Trials (March 2006). 
In addition, recent conference proceedings of the 
European Association of Urology, the American 
Urological Association and the British Association 
of Urological Surgeons were searched. Reference 
lists of all included studies were scanned to identify 
additional potentially relevant studies. Full details 
of the search strategies used are documented in 
Appendix 1.
All titles and abstracts identified in these ways 
were assessed to identify potentially eligible 
studies. Two reviewers independently assessed 
them for inclusion, using a study eligibility form 
developed for this purpose (see Appendix 2). 
Any disagreements were resolved by consensus or 
arbitration.
Inclusion and exclusion criteria
Types of studies
Individual RCTs were eligible for inclusion 
irrespective of publication language if they 
assessed interventional treatment options for the 
treatment of BPE. Initially, it was intended to 
include population-based observational studies 
with a minimum follow-up of 3 years but this 
was subsequently deemed not to be necessary 
as long-term follow-up data from RCTs was 
sufficient to provide more robust estimates of 
rare complications and effectiveness. Abstracts 
were considered only when no full-text RCTs were 
available for a particular intervention.
Types of participants
Trials of men with a clinical diagnosis of BPE who 
have undergone surgery were included. Patients 
undergoing conservative management (watchful 
waiting or medical therapy) were excluded. 
Types of interventions
Methods of surgical intervention for BPE included:
minimally invasive techniques •	
transurethral  microwave  thermotherapy    –
(TUMT)
transurethral  needle  ablation  (TUNA)  of    –
the prostate
stents   –
high-intensity focused ultrasound (HIFU)   –
transurethral  ethanol  ablation  of  the    –
prostate (TEAP)
water thermotherapy (WIT)   –
transurethral  laser  coagulation  of  the    –
prostate
transurethral incision of the prostate (TUIP) •	
transurethral resection of the prostate (TURP)  •	
– reference standard
other tissue ablative techniques •	
transurethral  laser  prostatectomy  –    –
resection
Chapter 5  
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transurethral  laser  prostatectomy  –    –
vaporisation
bipolar TURP   –
transurethral  electrovaporisation  of  the    –
prostate (TUVP)
bipolar TUVP   –
transurethral vaporesection of the prostate    –
(TUVRP)
bipolar TUVRP.   –
Types of outcomes
Data were sought to describe both short-term 
and long-term outcomes. The following measures 
of outcomes were sought for different follow-up 
periods (3, 6 and 12 months or longer):
Primary outcome
symptom score. •	
Other outcomes
urodynamic •	
peak urine flow rate   –
mean urine flow rate   –
total voided volume   –
residual volume   –
detrusor pressure   –
complications •	
intraoperative complications   –
co-interventions   –
clot retention   –
cardiovascular events   –
transurethral resection (TUR) syndrome   –
blood transfusion   –
septicaemia   –
urinary retention   –
recatheterisation   –
urinary  tract  infection  (including    –
epididymitis)
irritative urinary symptoms   –
incontinence   –
retrograde ejaculation   –
erectile dysfunction   –
stricture   –
reoperation rate   –
mortality   –
other •	
prostate size   –
quality of life score.   –
Data extraction strategy
The titles and abstracts of all papers identified by 
the search strategy were screened. Full-text copies 
of all potentially relevant studies were obtained 
and two reviewers independently assessed them 
for inclusion. Reviewers were not blinded to the 
study authors, institutions or sources of the reports. 
Any disagreements were resolved by consensus or 
arbitration. 
A data extraction form was developed to record 
details of trial methods, interventions, participants’ 
characteristics and outcomes (see Appendix 3). Two 
reviewers independently extracted data from the 
included studies. Any differences that could not 
be resolved through discussion were referred to an 
arbiter.
Quality assessment strategy
Two reviewers working independently assessed the 
methodological quality of the included full-text 
studies. Again, any disagreements were resolved 
by consensus or arbitration. Primary RCTs were 
assessed using an assessment tool, drawing on the 
schema suggested by the NHS Centre for Reviews 
and Dissemination,88 Verhagen and colleagues,89 
Downs and Black90 and the Generic Appraisal Tool 
for Epidemiology (see Appendix 4).
Data synthesis
For trials with multiple publications, only the most 
up-to-date data for each outcome were included. 
Dichotomous outcome data were combined using 
the Mantel–Haenszel relative risk (RR) method 
and continuous outcomes were combined using 
the inverse variance weighted mean difference 
(WMD) method. The results are all reported 
using a fixed-effects model. Chi-squared tests and 
I-squared statistics were used to explore statistical 
heterogeneity across studies and, when present, 
random-effects methods were applied. Other 
possible reasons for heterogeneity were explored 
using sensitivity analyses. The meta-analyses were 
conducted using the standard Cochrane software 
RevMan 4.2. Because of the lack of uniformity of 
the data presented by many studies, a qualitative 
review looking for consistency between studies was 
also performed.
Symptoms assessed with the IPSS and the AUA 
symptom index were considered equivalent and 
therefore trials reporting symptoms in these ways 
were combined. Studies reporting symptoms as 
Madsen–Iversen symptom indexes were analysed 
separately. The IPSS/AUA scale ranges from 0 
to 35. Scores ranging from 0 to 7 are equivalent 
to mild symptoms, from 8 to 19 are equivalent 
to moderate symptoms, and from 20 to 35 are 
equivalent to severe symptoms. Health Technology Assessment 2008; Vol. 12: No. 35
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A large prostate was defined as having an estimated 
weight of more than 40 g, a moderate-sized 
prostate a weight of between 30 and 40 g and a 
small prostate a weight of less than 30 g (Professor 
James N’Dow, University of Aberdeen, 2006). 
As some complications could not be confidently 
separated into those reported in the immediate 
postoperative period and those experienced over 
the course of the trial, all reports of the same 
complication were pooled together regardless of 
the timing of occurrence. Also, for the purposes 
of this review, ‘strictures’ included bladder neck 
stenosis and urethral stricture as it was difficult to 
distinguish between them given the information 
provided in the trials and because definitions 
of these complications were inconsistent from 
report to report. Only blood transfusion, urinary 
retention, urinary tract infection, strictures, TUR 
syndrome and urinary incontinence are presented 
in the results section as these were felt to be the 
most important for the economic model. Other 
outcomes are presented in the appendices.
In terms of urodynamic outcomes, only the results 
for peak urine flow rate are presented in the body 
of this report because clinical experts consider 
this to be a more precise measure of a urodynamic 
outcome. Other urodynamic outcomes were also 
analysed and are presented in the appendices. 
Quantity and quality of 
research available
Number of studies identified 
The search strategies identified 3794 study reports 
after removing duplicates (Figure 2). Of these, 
621 (466 full text, 155 abstracts) were selected for 
further assessment (Table 3).
Number and types of 
studies included
In total, 158 reports met the inclusion criteria for 
the review and these described 88 RCTs (Figure 
2). Apart from one,91 which was an abstract, the 
primary reports of the studies were full-text papers. 
463 reports not meeting inclusion criteria:
145 – not RCTs
122 – abstracts with comparisons already assessed in full-
          text papers
  79 – provision of background data
  66 – not relevant to review
  16 – no usable data
  12 – systematic reviews
  10 – compared other surgical management techniques
    8 – compared other medical management
    2 – watchful waiting
    2 – unobtainable papers
    1 – compared different dosages of ethanol in a TEAP
          intervention
3794 initial search 
3173 studies excluded 
621 selected for full assessment 
158 reports included 
(88 studies) 
         Abstracts
Primary report       1
Secondary reports 32
Total                       33
    Full text reports 
Primary reports     87 
Secondary reports 38 
Total                      125 
FIGURE 2  Study selection process.Methods of, and studies included in, the systematic reviews of clinical effectiveness
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The included studies and associated references are 
listed in Appendix 5.
Number and types of studies 
excluded, with reasons 
for specific exclusions
In total, 178 reports were obtained but 
subsequently excluded because they failed to meet 
one or more of the inclusion criteria (see Figure 2). 
Of these, 145 were not RCTs. Of the 33 remaining 
reports, ten included comparisons involving 
other surgical management,90,92–100 four included 
comparisons involving medical management for 
BPE,101–104 two compared TURP with watchful 
waiting,6,105 and one compared different dosages 
of ethanol within an RCT of transurethral ethanol 
ablation of the prostate.106 An additional 16 reports 
had no usable data.107–122
Study quality 
A summary of the quality assessment of the 88 full-
text RCTs is presented in Table 4 and the detailed 
quality assessment score for each of the included 
studies is reported in Appendix 6. The method 
of randomisation was unclear in the majority of 
the studies (75%); however, in one (1%),123 an 
inadequate approach to sequence generation 
(alternation) was used. Suboptimal approaches 
to concealment of treatment allocation (serially 
numbered sealed envelopes) were used in 12 
studies (14%).57,124–134 It was unclear whether the 
groups were similar at baseline in seven studies 
(8%) with respect to the most important prognostic 
factors.135–141 The eligibility criteria were clearly 
specified in all but one study.142 In the majority of 
the studies (62%) the groups were treated in the 
same way apart from the intervention received, but 
this was unclear in 13 studies (15%).136,138,139,143–151,167 
In most studies (95%) follow-up was long enough to 
detect important effects on short-term outcomes (at 
least 3 months); however, only 69% of the studies 
followed up their participants for at least 1 year.
In the majority of the studies it was unclear 
whether outcome assessors, care providers and 
patients were blinded. Point estimates and 
measures of variability were presented in 88% of 
the studies, although in three studies it was unclear 
whether means or medians were used as the point 
estimate measure.134,152,153 The dropout rate was 
unlikely to cause bias in 12 studies124,138,150,154–162 
but this information was unclear in 74 (85%) of 
the studies. Only 16 studies (18%) stated that 
an intention to treat analysis was performed; 
however, this seems questionable in 11 of these 
studies57,70,125,130,136,139,145,154,163–165 as they failed to 
include the total number of participants in each 
arm in the subsequent follow-up assessments and 
an additional study stated that patients failing 
to complete the treatment or failing to return 
for follow-up were substituted.124 It was unclear 
whether 67 other studies (77%) included an 
intention to treat analysis. It was also unclear in 
some studies how many patients were assessed at 
each follow-up. In 11 studies (13%) it was stated 
that the interventions were undertaken by someone 
TABLE 3  Search results
Database searched Number selected
MEDLINE/EMBASE/MEDLINE In-Process multifile search (after deduplication in Ovid) 370
ISI Science Citation Index 52
BIOSIS 118
CENTRAL 8
Cochrane Database of Systematic Reviews 0
Database of Abstracts of Reviews of Effectiveness 4
HTA database 7
National Research Register 10
Current Controlled Trials 7
Clinical trials 0
Conference abstracts 45
Total selected 621Health Technology Assessment 2008; Vol. 12: No. 35
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TABLE 4  Summary of the quality assessment of the included randomised controlled trials (n = 88)
Criteria Yes No Unclear
 1.  Was the assignment to the treatment groups really random? 21 (24%) 1 (1%) 65 (75%)
 2.  Was the treatment allocation concealed? 10 (11%) 12 (14%) 65 (75%)
 3.  Were the groups similar at baseline in terms of prognostic factors? 65 (75%) 15 (17%) 7 (8%)
 4.  Were the eligibility criteria specified? 84 (97%) 1 (1%) 2 (2%)
 5.  Was the intervention (and comparison) clearly defined? 81 (93%) 2 (2%) 4 (5%)
 6.  Were the groups treated in the same way apart from the intervention 
received?
54 (62%) 20 (23%) 13 (15%)
 7.  Was follow-up long enough to detect important effects on outcomes of 
interest?
    (a) For short-term outcomes, at least 3 months 83 (95%) 3 (3%) 1 (1%)
    (b) For long-term outcomes, at least 1 year 60 (69%) 25 (29%) 2 (2%)
 8.  Were the outcome assessors blinded to the treatment allocation? 13 (15%) 5 (6%) 69 (79%)
 9.  Were the care providers blinded? 3 (3%) 7 (8%) 77 (88%)
  10. Were the patients blinded? 15 (17%) 8 (9%) 64 (74%)
  11. Were the point estimates and measures of variability presented for the 
primary outcome measures?
77 (88%) 7 (8%) 3 (3%)
  12. Was the withdrawal/dropout rate likely to cause bias? 1 (1%) 12 (14%) 74 (85%)
  13. Did the analyses include an intention to treat analysis? 16 (18%) 4 (5%) 67 (77%)
  14. Was the operation undertaken by someone experienced in performing 
the procedure?
11 (13%) 6 (7%) 70 (80%)
experienced in performing the procedure; however, 
another 70 studies (80%) failed to provide this 
information for both types of intervention being 
delivered to the participants. 
Characteristics of included studies
Appendix 7 provides details of the characteristics 
of the included studies. There were 94 relevant 
comparisons in the 88 eligible RCTs (8494 
randomised participants); one trial had four 
arms and four trials had three arms (Table 5). 
In the following chapters an overview of the 
characteristics of the included studies for each 
identified comparison is presented. 
Assessment of effectiveness
The assessment of effectiveness is reported 
in the following chapters, beginning with the 
minimally invasive techniques. No studies 
involved a comparison with HIFU and water 
thermotherapy. Three direct comparisons reported 
in three RCTs204–206 between a minimally invasive 
intervention and other ablative interventions were 
identified. These are presented in Appendix 10.Methods of, and studies included in, the systematic reviews of clinical effectiveness
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TABLE 5  Number of trials and participants for each intervention assessed
Comparison Number of trials Participants References
TUMT vs TURP 6 549 Ahmed et al., 1997;124 Wagrell et al., 2002;165 d’Ancona 
et al., 1998;166 Dahlstrand et al., 1993;167 Dahlstrand et 
al., 1995;168 de la Rosette et al., 2003169
TUMT vs sham 11 1159 Bdesha et al., 1994;125 Blute et al., 1996;126 Ogden 
et al., 1993;133 Abbou et al., 1995;143 Larson et al., 
1998;159 Nawrocki et al., 1997;160 Albala et al., 2002;170 
Brehmer et al., 1999;171 de Wildt et al., 1996;172 
Trachtenberg and Roehrborn, 1998;173 Zerbib et al., 
1994174 
TUNA vs TURP 4 450 Hill et al., 2004;144 Kim et al., 2006;151 Cimentepe et 
al., 2003;175 Hindley et al., 2001176
Stents vs TURP 1 60 Chapple et al., 199591
TEAP vs TURP 1 204 Kim et al., 2006151
Laser coagulation vs TURP 13 1231 Costello et al., 1995;123 Kursh et al., 2003;130 Liedberg 
et al., 2003;131 Donovan et al., 2000;136 Gujral et al., 
2000;139 McAllister et al., 2000;145 Rodrigo Aliaga 
et al., 1998;149 Kim et al., 2006;151 Chacko et al., 
2001;154 Cowles et al., 1995;163 Kabalin et al., 1995;177 
Mårtenson et al., 1999;178 Suvakovic and Hindmarsh, 
1996179
TUIP vs TURP 11 871 Christensen et al., 1990;135 Rodrigo Aliaga et al., 
1998;149 Riehmann et al., 1995;152 Hellström et al., 
1986;157 Dørflinger et al., 1992;180 Jahnson et al., 
1998;181 Li and Ng, 1987;182 Nielson, 1988;183 Saporta 
et al., 1996;184 Soonawalla and Pardanani, 1992;185 
Tkocz and Prajsner, 2002186 
Laser resection vs TURP 5 530 Kuntz et al., 2004;64 Wilson et al., 2006;134 Gupta et 
al., 2006;187 Montorsi et al., 2004;188 Westenberg et al., 
2004189
Laser vaporisation vs TURP 11 955 Carter et al., 1999;127 Bouchier-Hayes et al., 2006;141 
Shingleton et al., 2002;146 Zorn et al., 1999;148 
Tuhkanen et al., 2003;153 Keoghane et al., 2000;164 
Suvakovic and Hindmarsh, 1996;179 Mottet et al., 
1999;190 Tuhkanen et al., 2001;191 Sengor et al., 1996;192 
van Melick et al., 2003193
Bipolar TURP vs TURP 6 336 de Sio et al., 2006;65 Singh et al., 2005;147 Kim et 
al., 2006;150 Seckiner et al., 2006;161 Nuho˘g lu et al., 
2006;194 Tefekli et al., 2005195
TUVP vs TURP 17 1449 Kaplan et al., 1998;55 Fowler et al., 2005;57 Erda˘g i et 
al., 1999;128 Hammadeh et al., 2003;129 Gallucci et al., 
1998;138 Patel et al., 1997;140 Ekengren et al., 2000;142 
Gotoh et al., 1999;156 Kupeli et al., 1998;158 Nathan 
and Wickham, 1996;162 van Melick et al., 2003;193 
Çetinkaya et al., 1996;196 Kupeli et al., 1998;197 Netto 
et al., 1999;198 Nuho˘g lu et al., 2005;199 Shokeir et al., 
1997;200 Wang et al., 2002201
Bipolar TUVP vs TURP 2 211 Hon et al., 2006;70 Dunsmuir et al., 2003137
TUVRP vs TURP 5 429 Talic et al., 2000;68 Liu et al., 2006;132 Gupta et al., 
2006;187 Helke et al., 2001;202 Kupeli et al., 2001203
Bipolar TUVRP vs TURP 1 60 Fung et al., 2005155
TEAP , transurethral ethanol ablation of the prostate; TUIP , transurethral incision of the prostate; TUMT, transurethral 
microwave thermotherapy; TUNA, transurethral needle ablation; TUR, transurethral resection; TURP , transurethral 
resection of the prostate; TUVP , transurethral electrovaporisation of the prostate; TUVRP , transurethral vaporesection of 
the prostate.Health Technology Assessment 2008; Vol. 12: No. 35
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Transurethral microwave 
thermotherapy (TUMT) 
versus TURP
Characteristics of included studies
The characteristics of the included studies are 
summarised in Table 6. Six RCTs, reported in 
19 papers,86,124,165–169,207–218 were eligible for this 
comparison, in which a total of 549 participants 
were randomised. The number of participants 
randomised to TUMT or TURP ranged from 2168 
to 99.165 The total number of participants allocated 
to TUMT was 314 and the total allocated to TURP 
was 235.
Two studies each took place in the 
Netherlands166,169 and Sweden167,168 and one in the 
UK,124 and one was a multicentre study involving 
Sweden, Denmark and the US.165 Only three 
studies gave details of the recruitment dates;165,166,169 
recruitment dates ranged from January 1994 to 
November 1999. 
Four out of the six RCTs reported baseline IPSS/
AUA scores. The total number of participants who 
had moderate symptoms of BPE and underwent 
TUMT was 61 (26%), compared with 51 (31%) with 
moderate symptoms allocated to TURP. There were 
177 (74%) patients with severe symptoms in the 
TUMT group and 112 (69%) with severe symptoms 
in the TURP group. 
Of the studies reporting estimated prostate size, 
69 (22%) and 245 (78%) patients allocated to 
TUMT had moderate-sized and large prostates 
respectively. Of the patients allocated to TURP, 40 
(17%) had moderate-sized and 195 (83%) had large 
prostates. 
Chapter 6  
Clinical effectiveness of  
minimally invasive techniques
TABLE 6  Summary of the baseline characteristics, TUMT vs TURP
Study Comparators
Number of 
participants
Age 
(years)
Symptom 
scorea
Qmax 
(ml/s)
Residual 
volume 
(ml)
Prostate 
size  
(ml)
Ahmed et al., 
1997124
TUMT 30 69 18.5 10.1 94 37
TURP 30 69 18.4 9.5 109 46
Dahlstrand et al., 
1993167
TUMT 39 68 11.2b 8.0 105 33
TURP 40 70 13.3b 7.9 116 37
Dahlstrand et al., 
1995168
TUMT 37 67 12.1b 8.6 194 43c
TURP 32 70 13.6b 8.6 1104 45c
d’Ancona et al., 
1998166
TUMT 31 69 18.3 9.3 49 43
TURP 21 69 16.7 9.3 91 45
de la Rosette et al., 
2003169
TUMT 78 67 20.0 9.2 65 51
TURP 66 66 20.0 8.0 91 52
Wagrell et al., 
2002165
TUMT 99 67 21.0 7.6 106 49
TURP 46 69 20.4 7.8 94 53
TUMT, transurethral microwave thermotherapy; TURP , transurethral resection of the prostate.
Data given as mean values (unless stated otherwise)
a  Symptom scores given as IPSS/AUA (unless stated otherwise).
b  Prostate length (mm).
c  Madsen score.Clinical effectiveness of minimally invasive techniques
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Assessment of effectiveness
Tables giving a detailed description for all 
outcomes can be found in Appendix 8. The results 
of the meta-analyses are given in Appendix 9. Note 
that in terms of long-term evaluation, only the 
longest follow-up is presented.
Symptom scores
At 3 months
Of the six eligible studies, three165,166,213 (n = 290) 
provided information on IPSS/AUA scores 
(Appendix 8.1, Table 42). At 3 months IPSS was 
higher for TUMT than for TURP (Figure 3, 
comparison 01:01:01). Overall, the WMD was 4.08 
(95% CI 2.78–5.39, p < 0.001). There was evidence 
of statistical heterogeneity, but the direction of 
effect was consistent even though the size of effect 
estimates varied. Using a random-effects model did 
not change this pattern. The cause of heterogeneity 
is unclear but in the study by d’Ancona and 
colleagues166 patients appear to have milder disease 
than in the other two studies. 
In total, four studies166,168,210,213 (n = 306) provided 
information on the improvement of Madsen–
Iversen scores after surgery (Appendix 8.1, Table 
42). Meta-analysis of the four trials showed 
heterogeneity, with results tending to favour TURP, 
but the difference was not statistically significant 
(Figure 3, comparison 01:02:01: WMD 0.63, 95% 
CI –0.08 to 1.33, p = 0.08). The direction and size 
of effect varied across studies, with Dahlstrand and 
colleagues168 reporting lower scores for TUMT. 
This study appears to be contributing much of the 
statistical heterogeneity that is present and this 
could be because patients allocated to the TURP 
group had higher residual volumes. Removal of 
this study from the analysis resulted in a substantial 
decrease in heterogeneity.
At 12 months
Meta-analysis of data from three trials165,166,169 
reporting IPSS/AUA scores at 12 months after 
surgery showed a statistically significant worse 
score for TUMT compared with TURP (Figure 3, 
comparison 01:01:03: WMD 2.41, 95% CI 1.40–
3.42, p < 0.001). Again, there was marked statistical 
heterogeneity between the three studies. When a 
random-effects model was applied the direction 
of effect remained the same but the difference 
between the groups was no longer statistically 
significant (WMD 2.26, 95% CI –0.38 to 4.91). 
At 12 months, all four trials reporting Madsen–
Iversen symptom scores166–168,213 reported higher 
(worse) scores following TUMT (Figure 3, 
comparison 01:02:03). Overall, the WMD was 1.97 
(95% CI 1.27–2.66, p < 0.001).
Longer-term follow-up
Two studies reported data beyond 12 months.166,169 
These data also favoured TURP, but again with 
variation between trials in the estimated size of 
difference (Figure 3, comparison 01:01:05: WMD 
8.90, 95% CI 6.65–11.15, p < 0.001). A similar 
trend was observed for the earlier follow-ups. 
Complications
Data describing complications are tabulated in 
Appendix 8.1, Table 43. Information on 13 types of 
complications was identified across the six eligible 
studies for this comparison. Results regarding 
blood transfusion, urinary retention, urinary tract 
infection, strictures, TUR syndrome and urinary 
incontinence are presented in this section (Figure 
4). Results for other complications are presented 
in Appendix 9.1, comparison 01:03. The results of 
these meta-analyses should be treated with caution 
as the length of follow-up of the RCTs varied.
Blood transfusion
Blood transfusion was reported in three 
studies.124,166,168 None of the patients required a 
blood transfusion following TUMT compared 
with four (5%) patients following TURP (Figure 4, 
comparison 01:03:01: RR 0.11, 95% CI 0.01–1.98, 
p = 0.13).
Urinary retention
In both trials with data,165,169 urinary retention 
was reported more commonly in the patients 
undergoing TUMT than in those undergoing 
TURP (Figure 4, comparison 01:03:02: RR 1.64, 
95% CI 0.77–3.50, p = 0.20). 
Urinary tract infection
Meta-analysis of data from five studies124,165–168 
showed no statistically significant differences 
between the two arms; the direction of effect varied 
across studies with two124,165 favouring TUMT 
(Figure 4, comparison 01:03:03: 16/237 versus 
13/174, RR 1.05, 95% CI 0.53–2.08, p = 0.90). 
Stricture
Only one stricture (urethral) was reported amongst 
172 participants allocated to TUMT versus 11 
(including five bladder neck stenoses) amongst 
168 participants allocated to TURP (Figure 4, 
comparison 01:03:04: RR 0.20, 95% CI 0.05–0.75, 
p = 0.02). The direction and size of effect were 
consistent across the four studies reporting this 
outcome. The event rates in this meta-analysis Health Technology Assessment 2008; Vol. 12: No. 35
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Review: BPE
Comparison:  01 TUMTv s TURP
Outcome:0 1 IPSS/AUA
Study or
subcategory n
TUMT
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
013months
d’Ancona, 1998
166 31 15.10 (8.20) 21 5.10 (3.10) 16.92 10.00 (6.82–13.18)
Francisca, 2000
213 57 10.50 (7.90) 55 5.30 (5.20) 28.01 5.20 (2.73–7.67)
Wagrell, 2002
165 85 8.40 (5.50)4 16 .70( 4.30) 55.07 1.70 (−0.06 to 3.46)
Subtotal (95% CI) 173 117 100.00 4.08 (2.78–5.39)
Test for heterogeneity: χ
2 = 21.15, df = 2( p < 0.0001), I
2 = 90.5%
Test for overall effect: z = 6.13 (p < 0.00001)
026months
Ahmed, 1997
124 30 5.30 (3.49) 30 5.20 (3.63) 39.89 0.10 (−1.70 to 1.90)
d’Ancona, 1998
166 28 6.70 (5.50)2 04 .00( 2.10) 25.92 2.70 (0.46–4.94)
Wagrell, 2002
165 95 7.40 (6.20) 43 5.90 (5.00) 34.19 1.50 (−0.45 to 3.45)
Subtotal (95% CI) 153 93 100.00 1.25 (0.11–2.39)
Test for heterogeneity: χ
2 = 3.24, df = 2( p = 0.20), I
2 = 38.4%
Test for overall effect: z = 2.16 (p = 0.03)
031year
d’Ancona, 1998
166 27 5.00 (2.70) 17 3.40 (2.20) 48.19 1.60 (0.14–3.06)
Wagrell, 2002
165 93 7.20 (6.20) 43 7.10 (6.60) 18.74 0.10 (−2.24 to 2.44)
de la Rosette, 2003
169 58 8.10 (6.00) 48 3.20 (3.00) 33.07 4.90 (3.14–6.66)
Subtotal (95% CI) 178 108 100.00 2.41 (1.40–3.42)
Test for heterogeneity: χ
2 = 12.60, df = 2( p = 0.002), I
2 = 84.1%
Test for overall effect: z = 4.66 (p < 0.00001)
042years
d’Ancona, 1998
166 17 7.90 (6.30) 12 6.30 (4.80) 29.62 1.60 (−2.44 to 5.64)
de la Rosette, 2003
169 46 9.30 (7.30) 38 3.70 (4.90) 70.38 5.60 (2.98–8.22)
Subtotal (95% CI) 63 50 100.00 4.42 (2.22–6.62)
Test for heterogeneity: χ
2 = 2.65, df = 1( p = 0.10), I
2 = 62.2%
Test for overall effect: z = 3.93 (p < 0.0001)
053years
de la Rosette, 2003
169 35 11.50 (6.40) 33 2.60 (2.20) 100.00 8.90 (6.65–11.15)
Subtotal (95% CI) 35 33 100.00 8.90 (6.65–11.15)
Test for heterogeneity: nota pplicable
Test for overall effect: z = 7.76 (p < 0.00001)
Review: BPE
Comparison:  01 TUMTv s TURP
Outcome:0 2M adsen-Iversen
Study or
subcategory n
TUMT
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
013months
d’Ancona, 1998
166 31 5.20 (4.10) 21 3.60 (3.20) 12.62 1.60 (−0.39 to 3.59)
Dahlstrand, 1993 Dahlstrand, 1993
167 37 2.30 (2.70) 39 1.60 (2.50) 36.37 0.70 (−0.47 to 1.87)
 D ahlstrand, 1995
168 39 1.60 (2.50) 37 2.30 (2.70) 36.37 −0.70 (−1.87 to 0.47)
Francisca, 2000
213 54 6.40 (5.70) 48 3.50 (3.70) 14.65 2.90 (1.05–4.75)
Subtotal (95% CI) 161 145 100.00 0.63 (−0.08 to 1.33)
Test for heterogeneity: χ
2 = 11.69,d f = 3( p = 0.009), I
2 = 74.3%
Test for overall effect: z = 1.74 (p = 0.08)
026months
d’Ancona, 1998
166 28 4.40 (4.40)2 02 .50( 2.30) 15.21 1.90 (−0.02 to 3.82)
Dahlstrand, 1993 Dahlstrand, 1993
167 28 3.10 (3.00) 23 0.90 (1.60) 33.59 2.20 (0.91–3.49)
 D ahlstrand, 1995
168 37 2.60 (2.60) 32 1.10 (1.80) 51.20 1.50 (0.46–2.54)
Subtotal (95% CI) 93 75 100.00 1.80 (1.05–2.54)
Test for heterogeneity: χ
2 = 0.70,d f = 2( p = 0.71), I
2 = 0%
Test for overall effect: z = 4.71 (p < 0.00001)
031year
d’Ancona, 1998
166 27 4.20 (4.60) 17 2.70 (4.00)7 .20 1.50 (−1.07 to 4.07)
Dahlstrand, 1993 Dahlstrand, 1993
167 25 2.70 (2.90) 22 0.90 (2.20) 22.33 1.80 (0.34–3.26)
 D ahlstrand, 1995
168 33 2.20 (2.40) 31 0.60 (1.40) 52.26 1.60 (0.64–2.56)
Francisca, 2000
213 38 5.50 (4.60) 35 2.10 (2.10) 18.20 3.40 (1.78–5.02)
Subtotal (95% CI) 123 105 100.00 1.97 (1.27–2.66)
Test for heterogeneity: χ
2 = 3.75, df = 3( p = 0.29), I
2 = 20.0%
Test for overall effect: z = 5.57 (p < 0.00001)
042years
d’Ancona, 1998
166 17 5.80 (3.80) 12 3.60 (3.10) 19.93 2.20 (−0.32 to 4.72)
 D ahlstrand, 1995
168 31 2.30 (3.00) 30 1.20 (1.90) 80.07 1.10 (−0.16 to 2.36)
Subtotal (95% CI) 48 42 100.00 1.32 (0.20–2.44)
Test for heterogeneity: χ
2 = 0.59, df = 1( p = 0.44), I
2 = 0%
Test for overall effect: z = 2.30 (p = 0.02)
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Review: BPE
Comparison: 01 TUMT vs TURP
Outcome: 03 Complications
Study or 
subcategory
TUMT
n/N
TURP
n/N
RR (ﬁxed) 
95% CI
Weight
%
RR (ﬁxed) 
95% CI
01 Blood transfusion
Ahmed, 1997
124 0/30 4/30 100.00 0.11 (0.01–1.98)
d’Ancona, 1998
166 0/31 0/21 Not estimable
Dahlstrand, 1995
168 0/37 0/32 Not estimable
Subtotal (95% CI) 98 83 100.00 0.11 (0.01–1.98)
Total events: 0 (TUMT), 4 (TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.50 (p = 0.13)
02 Urinary retention
Wagrell, 2002
165 20/100 7/51 94.88 1.46 (0.66–3.22)
de la Rosette, 2003
169 2/66 0/66 5.12 5.00 (0.24–102.19)
Subtotal (95% CI) 166 117 100.00 1.64 (0.77–3.50)
Total events: 22 (TUMT), 7 (TURP)
Test for heterogeneity: χ
2 = 0.61, df = 1 (p = 0.44), I
2 = 0%
Test for overall effect: z = 1.28 (p = 0.20)
03 Urinary tract infection
Ahmed, 1997
124 1/30 3/30 20.82 0.33 (0.04–3.03)
d’Ancona, 1998
166 5/31 1/21 8.27 3.39 (0.43–26.96)
Dahlstrand, 1993
167 5/39 4/40 27.40 1.28 (0.37–4.42)
Dahlstrand, 1995
168 5/37 4/32 29.77 1.08 (0.32–3.69)
Wagrell, 2002
165 0/100 1/51 13.74 0.17 (0.01–4.14)
Subtotal (95% CI) 237 174 100.00 1.05 (0.53–2.08)
Total events: 16 (TUMT), 13 (TURP)
Test for heterogeneity: χ
2 = 3.61, df = 4 (p = 0.46), I
2 = 0%
Test for overall effect: z = 0.13 (p = 0.90)
04 Strictures
Ahmed, 1997
124 0/30 1/30 11.87 0.33 (0.01–7.87)
  Dahlstrand, 1993 Dahlstrand, 1993
167 0/39 3/40 27.36 0.15 (0.01–2.75)
Dahlstrand, 1995
168 0/37 2/32 21.18 0.17 (0.01–3.49)
de la Rosette, 2003
169 1/66 5/66 39.58 0.20 (0.02–1.67)
Subtotal (95% CI) 172 168 100.00 0.20 (0.05–0.75)
Total events: 1 (TUMT), 11 (TURP)
Test for heterogeneity: χ
2 = 0.15, df = 3 (p = 0.98), I
2 = 0%
Test for overall effect: z = 2.38 (p = 0.02)
05 TUR syndrome
Wagrell, 2002
165 0/51 1/100 100.00 0.65 (0.03–15.62)
Subtotal (95% CI) 51 100 100.00 0.65 (0.03–15.62)
Total events: 0 (TUMT), 1 (TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.27 (p = 0.79)
06 Incontinence
  Dahlstrand, 1993 Dahlstrand, 1993
167 7/39 5/40 31.43 1.44 (0.50–4.14)
Wagrell, 2002
165 3/100 7/51 59.02 0.22 (0.06–0.81)
de la Rosette, 2003
169 0/66 1/66 9.55 0.33 (0.01–8.04)
Subtotal (95% CI) 205 157 100.00 0.61 (0.30–1.26)
Total events: 10 (TUMT), 13 (TURP)
Test for heterogeneity: χ
2 = 5.00, df = 2 (p = 0.08), I
2 = 60.0%
Test for overall effect: z = 1.33 (p = 0.18)
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should be treated with caution as the length of 
follow-up of the RCTs varied.
TUR syndrome
Out of the six included studies, only one reported 
data on this outcome.165 One event was observed in 
the TURP arm amongst 100 patients as opposed 
to none in the TUMT arm. This difference does 
not reach statistical significance, but the confidence 
intervals were wide and therefore important 
clinical differences may exist (Figure 4, comparison 
01:03:05: RR 5.83, 95% CI 0.24–140.55, p = 0.28). 
Urinary incontinence
A total of 10 (4.9%) people were reported to have 
incontinence episodes amongst 205 allocated 
TUMT interventions compared with 13 (8.3%) 
people amongst 157 allocated TURP interventions 
(Figure 4, comparison 01:03:06: RR 0.61, 95% CI 
0.30–1.26, p = 0.18). The direction and size of 
effect varied across studies and there was evidence 
of statistical heterogeneity across the three studies 
reporting this outcome.165,167,169 This may be 
because some of the studies failed to report the 
type of incontinence and the length of follow-up 
varied. 
Quality of life
Two studies165,169 used the IPSS QoL (0–6) 
questionnaire to measure quality of life of people 
undergoing TUMT or TURP (Appendix 8.1, Table 
44 and Figure 5), where 0 is being delighted and 
6 represents feeling terrible concerning urinary 
symptoms.
At 3 months
Both studies165,169 reported better quality of life 
scores at 3 months following TURP. The mean 
difference based on data from one study165 was 
0.40 for TUMT versus TURP, but this result did 
not reach statistical significance (Figure 5: MD 0.40, 
95% CI –0.17 to 0.97, p = 0.17).
Review:  BPE
Comparison:  01 TUMT vs TURP
Outcome:  09 Quality of life (IPSS QoL)
Study
or subcategory n
TUMT
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
013months
Wagrell, 2002
165 84 1.50 (1.40) 41 1.10 (1.60) 100.00 0.40 (−0.17 to 0.97)
Subtotal (95% CI) 84 41 100.00 0.40 (−0.17 to 0.97)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.37 (p = 0.17)
02 12 months
Wagrell, 2002
165 93 1.50 (1.70) 43 1.40 (1.30) 35.86 0.10 (−0.42 to 0.62)
de la Rosette, 2003
169 58 1.90 (1.30) 48 0.60 (0.70) 64.14 1.30 (0.91–1.69)
Subtotal (95% CI) 151 91 100.00 0.87 (0.56–1.18)
Test for heterogeneity: χ
2 = 13.12, df = 1( p = 0.0003), I
2 = 92.4%
Test for overall effect: z = 5.47 (p < 0.00001)
032years
de la Rosette, 2003
169 46 1.90 (1.00) 38 0.90 (1.10) 100.00 1.00 (0.55–1.45)
Subtotal (95% CI) 46 38 100.00 1.00 (0.55–1.45)
Test for heterogeneity: not applicable
Test for overall effect: z = 4.32 (p < 0.0001)
043years
de la Rosette, 2003
169 35 2.30 (1.20) 33 0.60 (0.80) 100.00 1.70 (1.22–2.18)
Subtotal (95% CI) 35 33 100.00 1.70 (1.22–2.18)
Test for heterogeneity: not applicable
Test for overall effect: z = 6.91 (p < 0.00001)
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At 12 months
Evidence from the two studies165,169 showed 
poorer quality of life scores following TUMT than 
following TURP (Figure 5: WMD 0.87, 95% CI 
0.56–1.18, p < 0.001). The size of the estimated 
difference varied but the reasons for this were 
unclear. 
Longer-term follow-up
The mean difference based on data from one 
study169 was 1.70 for TUMT versus TURP in terms 
of quality of life (Figure 5: 95% CI 1.22–2.18, 
p < 0.001). However, this same trial gave higher 
estimates of long-term IPSS/AUA differences than 
other trials, so the size of the difference in quality 
of life should be interpreted cautiously. 
Urodynamic outcomes
Data on peak urine flow rate, voided volume, 
residual volume, detrusor pressure and prostate 
size were reported to a varying extent across the 
six studies.124,165–169 Only peak urine flow rate is 
presented in this section. Results for the other 
urodynamic outcomes are presented in Appendix 
8.1, Table 45 and Appendix 9.1, comparisons 
01:04–01:08.
At all time points considered, the peak urine flow 
rate was statistically significantly lower in the 
TUMT arm than in the TURP arm (Appendix 
9.1, comparison 01:04); at both 3 and 12 months 
there was evidence of heterogeneity between 
studies included in the meta-analyses but there was 
consistency in the direction of effect. At 3 months, 
using the random-effects method, the WMD was 
5.32 ml/s (95% CI –6.95 to –3.70, p < 0.001). The 
main source of heterogeneity appeared to be from 
the study by Wagrell and colleagues;165 however, 
the reasons for this remain unclear. When data 
from this study were excluded from the analysis, 
the trend towards TURP was maintained but the 
WMD increased (WMD 7.04, 95% CI 4.93–9.15, 
p < 0.001). At 12 months, fitting a random-effects 
model only increased the imprecision around the 
estimate of relative effectiveness. 
Descriptors of care
Data describing descriptors of care are tabulated in 
Appendix 8.1, Table 46. Information on length of 
hospital stay and reoperation rates was identified 
to a varying extent across the six eligible studies for 
this comparison.
Duration of operation
No studies reported duration of operation.
Length of hospital stay
Length of hospital stay was reported in two 
studies.166,169 Note that those allocated to TUMT 
were treated as outpatients and therefore hospital 
stay was longer in the TURP arm (Appendix 8.1, 
Table 46; Appendix 9.1, comparison 01:11: WMD 
5.30 days, 95% CI 4.48–6.12, p < 0.001).
Reoperation
Five studies124,166–169 provided details on reoperation 
rates. A total of 22 (10.2%) reoperations were 
reported amongst 215 participants allocated to 
TUMT compared with 9 (4.8%) amongst 189 
participants allocated to TURP. Meta-analysis 
of the five trials just failed to reach statistical 
significance at the conventional 5% level (Appendix 
9.1, comparison 01:12: RR 2.01, 95% CI 0.96–4.18, 
p = 0.06). This result should be treated with caution 
as the length of follow-up of the RCTs varied.
Summary and conclusions 
of the evidence for and 
against the intervention
This review considered data from 549 participants 
across six RCTs of generally moderate to poor 
quality (or poor reporting). Compared with TURP 
the data suggest that, after TUMT, improvement in 
IPSS/AUA symptom scores and quality of life is less, 
peak urine flow rate is lower, but length of hospital 
stay is shorter. Data describing blood transfusion, 
urinary retention, urinary tract infection, stricture, 
TUR syndrome, urinary incontinence and 
reoperation rates are too few to provide sufficiently 
precise estimates of differences but are consistent 
with fewer complications following TUMT, such as 
strictures and incontinence. 
In this review the results for symptom scores, peak 
urine flow rate and urinary incontinence displayed 
statistically significant heterogeneity. Consistency 
in the direction and size of effect varied in the last 
outcome. Much of the heterogeneity might be due 
to differences in the characteristics of participants, 
particularly differences in prostate size. Moreover, 
it may in part have been due to differences in 
power delivery or other technical outputs of 
surgery across studies and to differences in the way 
that urinary incontinence is defined. Other likely 
sources of heterogeneity include differences in the 
length of follow-up. 
Clinical effect size
A summary of the clinical effect sizes for all 
outcomes derived from the meta-analyses for Health Technology Assessment 2008; Vol. 12: No. 35
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TABLE 7  Summary of the clinical effect sizes from meta-analyses, TUMT vs TURP
Outcome
Number of trials 
MA (total) Effect size 95% CI p-value
IPSS/AUA score
3 months 3 (3) 4.08a 2.78–5.39 < 0.001
12 months 3 (3) 2.41a 1.40–3.42 < 0.001
Longer term 1 (1) 8.90a 6.65–11.15 < 0.001
Madsen–Iversen score
3 months 4 (4) 0.63a –0.08 to 1.33 0.08
12 months 4 (4) 1.97a 1.27–2.66 < 0.001
Longer term 2 (2) 1.32a 0.20–2.44 0.02
Blood transfusion 3 (3) 0.11b 0.01–1.98 0.13
Urinary retention 2 (2) 1.64b 0.77–3.50 0.20
Urinary tract infection 5 (5) 1.05b 0.53–2.08 0.90
Stricture 4 (4) 0.20b 0.05–0.75 0.02
TUR syndrome 1 (1) 0.65b 0.03–15.62 0.28
Incontinence 3 (3) 0.61b 0.30–1.26 0.18
Quality of life
3 months 1 (2) 0.40a –0.17 to 0.97 0.17
12 months 2 (2) 0.87a 0.56–1.18 < 0.001
Longer term 1 (1) 1.70a 1.22–2.18 < 0.001
Qmax
3 months 4 (4) –5.35a –7.09 to –3.62 < 0.001
12 months 4 (4) –5.32a –6.95 to –3.70 < 0.001
Longer term 1 (1) –11.10a –15.50 to –6.70 < 0.001
Duration of operation 0 (0) NR NR NR
Length of hospital stay 1 (2) –5.30a –6.12 to –4.48 < 0.001
Reoperation 5 (5) 2.01b 0.96–4.18 0.06
IPSS/AUA, International Prostate Symptom Score/American Urological Association; MA, meta-analysed; NR, not reported; 
TUMT, transurethral microwave thermotherapy; TUR, transurethral resection; TURP , transurethral resection of the 
prostate.
a  Weighted mean difference.
b  Relative risk.
which data were available is given in Table 7. These 
should be interpreted in view of the comments 
mentioned earlier in this section.
Transurethral microwave 
thermotherapy (TUMT) 
versus sham
Characteristics of 
included studies
The baseline characteristics of the included 
studies are summarised in Table 8. A total 
of 1209 participants were randomised 
across 11 eligible RCTs reported in 21 
papers.125,126,133,143,159,160,170–174,219–228 
Three studies took place in the US,126,159,170 three 
in the UK,125,133,160 two in France143,174 and one 
each in Sweden171 and the Netherlands,172 and 
one was a multicentre trial that took place in 
the US and Canada.173 Four studies provided 
details of recruitment dates;133,159,160,172 the earliest 
recruitment date was June 1994 and latest 
recruitment date was June 1996.
Although all 11 studies gave some details of the 
ages of participants, three gave only the mean or 
median age of the participant group as a whole, Clinical effectiveness of minimally invasive techniques
36
TABLE 8  Summary of the baseline characteristics, TUMT vs sham
Study Comparators
Number of 
participants
Age 
(years)
Symptom 
scorea
Qmax 
(ml/s)
Residual 
volume 
(ml)
Prostate 
size  
(ml)
Abbou et al., 
1995143
TUMT 66 65 10.9b 10.4 66 45
Sham 31 66 12.8b 9.9 61 44
Albala et al., 2002170 TUMT 125 65 22.5 8.9 58 50
Sham 65 65 22.7 8.4 53 47
Bdesha et al., 
1994125
TUMT 22 64 19.2 12.3 104 NR
Sham 20 63 18.8 10.8 80 NR
Blute et al., 1996126 TUMT 78 67 19.9 7.3 140 37.4
Sham 37 67 20.8 7.4 145 36.1
Brehmer et al., 
1999171
TUMT 30 14 NR A/B – 58/40c 8.7 NR ≤ 50
TUMT 60 16 NR A/B – 49/36c 7.0 NR ≤ 50
Sham 14 NR A/B – 46/36c 7.9 NR ≤ 50
de Wildt et al., 
1996172
TUMT 46 64 12.9b 9.6 85 49
Sham 47 66 13.7b 9.2 94 49
Larson et al., 
1998159
TUMT 125 66 20.8 7.8 99 38
Sham 44 66 21.3 7.8 104 45
Nawrocki et al., 
1997160
TUMT 38 NR 19 8.8 252 86
Sham 40 NR 17.5 9.4 269 96
Ogden et al., 
1993133
TUMT 22 68 14.5b 8.5 147 38
Sham 21 67 14.2b 8.6 118 35
Trachtenberg and 
Roehrborn, 1998173
TUMT 147 66 23.6 7.7 80 48
Sham 73 66 23.9 8.1 67 50
Zerbib et al., 
1994174
TUMT 38 NR NR 7.6 110 NR
Sham 30 NR NR 10.6 84 NR
NR, not reported; TUMT, transurethral microwave thermotherapy.
Data given as mean values (unless stated otherwise).
Symptom scores given as IPSS/AUA (unless stated otherwise).
a  Median.
b  Madsen score.
c  ICS score (32 questions: ‘A’ question about the actual symptom, ‘B’ question about the bother related to the symptom; 
also includes several questions about sexual function; maximum A and B scores 124 and 92 respectively; high score indicates 
worse symptoms).
regardless of which intervention to which they were 
randomised.160,171,174 
Of the studies reporting IPSS/AUA scores at 
entry, 475 (74%) participants allocated to TUMT 
had severe symptoms of BPE and 60 (9%) 
had moderate symptoms. Of the participants 
randomised to sham, 219 (58%) had severe 
symptoms and 60 (16%) had moderate symptoms. 
Two studies failed to report the prostate size of the 
enrolled participants125,174 and in one study authors 
reported that, to be included, patients had to have 
prostate sizes of less than 50 ml. The total numbers 
of participants who had moderate-sized and large 
prostates in the TUMT group were 225 (34%) and 
438 (66%) respectively. The equivalent numbers 
allocated to a sham procedure were 58 (17%) and 
314 (84%) respectively. Health Technology Assessment 2008; Vol. 12: No. 35
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Assessment of effectiveness
Tables giving a detailed description for all 
outcomes can be found in Appendix 8.2. The 
results of the meta-analyses are given in Appendix 
9.2. Because of the nature of the comparator 
intervention (sham), the most useful information 
comes from short-term outcomes. The value of 
long-term assessment of outcomes is limited by 
a high dropout rate as most of the patients were 
judged to require a true TUMT procedure by 
12 months; it is likely that only the least severe 
patients at baseline remained untreated at this time 
point, thus comparisons limited to untreated men 
are subject to selection bias.
Symptom scores
At 3 months
Of the 11 eligible studies, eight provided 
information on symptom scores at 3 months 
following surgery.125,126,133,159,160,170,172,173 Six of those 
reported IPSS/AUA scores.125,126,159,160,170,173 In all 
studies, IPSS/AUA scores were superior in the 
TUMT group and this was statistically significant in 
all six studies (p < 0.05). Only three studies125,126,159 
presented data in a form that was sufficiently 
similar to allow quantitative synthesis (Figure 6, 
comparison 02:01:01). The WMD was –5.69 (95% 
CI –7.38 to –3.99, p < 0.00001) for TUMT versus 
sham surgery. This result is consistent with the data 
from those trials that provided data that were not 
amenable for meta-analysis.
Meta-analysis of three studies reporting Madsen–
Iversen scores126,133,172 showed that TUMT resulted 
in a greater decrease in score than sham treatment 
(Figure 6, comparison 02:02:01: WMD –5.66, 95% 
CI –6.85 to –4.46, p < 0.000001). There was some 
evidence of heterogeneity and, when a random-
effects model was fitted, the principal change was 
in the width of the confidence interval. The main 
source of heterogeneity appeared to be the study 
by Ogden and colleagues;133 however, the reasons 
for this are unclear. When data from Ogden and 
colleagues were removed from the analysis, the 
trend towards TUMT was maintained but the WMD 
decreased (WMD –5.10, 95% CI –6.40 to –3.79, 
p < 0.00001). 
At 12 months
No studies reported IPSS/AUA symptom scores for 
patients at 12 months after the surgery. 
One study reported Madsen–Iversen symptom 
scores at 12 months following surgery.172 The WMD 
was –4.00 (Figure 6, comparison 02:02:03: 95% CI 
–5.81 to –2.19, p < 0.0001). 
Longer-term follow-up 
No longer-term follow-up data on symptom scores 
have been reported by any of the eligible studies.
Complications
Data describing complications by study are 
detailed in Appendix 8.2, Table 48. Out of the 
eligible studies, complications were reported 
in ten.125,126,133,143,159,160,170–173 Ten categories of 
complications were identified. Results regarding 
blood transfusion, urinary retention, urinary tract 
infection, strictures and urinary incontinence are 
presented in this section (Figure 7). Results for 
other complications are presented in Appendix 
9.2, comparison 02:03. The results of these meta-
analyses should be treated with caution as the 
length of follow-up of the RCTs varied.
Blood transfusion
Only one study159 provided details on blood 
transfusion rates. There were no reports of blood 
transfusions amongst 125 and 44 patients allocated 
to TUMT or sham respectively.
Urinary retention
All seven trials with data showed higher rates of 
urinary retention after TUMT. This applied to a 
total of 77 (12%) patients amongst 644 allocated 
to TUMT compared with two (0.5%) amongst 360 
patients allocated to a sham procedure (Figure 7, 
comparison 02:03:02: RR 10.57, 95% CI 4.11–
27.20, p < 0.0001). This result should be treated 
with caution as the length of follow-up of the RCTs 
varied.
Urinary tract infection
Meta-analysis of data from four trials133,143,159,173 that 
reported urinary tract infections showed a higher 
number of infections following TUMT; however, 
this was not statistically significant (Figure 7, 
comparison 02:03:03: RR 1.49, 95% CI 0.84–2.67, 
p = 0.17). 
Stricture
Urethral strictures were reported in two trials.159,170 
Three cases were reported in one trial following 
TUMT, with no cases following sham treatment 
(Figure 7, comparison 02:03:04: 3/246 versus 0/106, 
RR 2.50, 95% CI 0.13–47.46, p = 0.54).
Incontinence
Data on incontinence from one trial159 showed five 
cases (4%) out of a total of 125 patients following 
TUMT versus no cases after sham treatment. 
This result was not statistically significant 
and confidence intervals were wide (Figure 7, Clinical effectiveness of minimally invasive techniques
38
Review:  BPE
Comparison:  02 TUMT vs sham
Outcome:  01 IPSS/AUA
Study
or subcategory n
TUMT
Mean (SD) n
Sham
Mean (SD)
WMD (ﬁxed) 
95% CI
Weight
%
WMD (ﬁxed) 
95% CI
013months
Bdesha, 1994
125 22 7.10 (5.00) 18 16.20 (7.35) 18.00 −9.10 (−13.09 to −5.11)
Blute, 1996
126 64 11.30 (6.30) 31 16.30 (7.60) 30.00 −5.00 (−8.09 to −1.91)
Larson, 1998
159 123 9.60 (5.94) 40 14.50 (6.77) 52.00 −4.90 (−7.25 to −2.55)
Subtotal (95% CI) 209 89 100.00 −5.69 (−7.38 to −3.99)
Test for heterogeneity: χ
2 = 3.44,d f = 2( p = 0.18), I
2 = 41.8%
Test for overall effect: z = 6.59 (p < 0.00001)
026months
Larson, 1998
159 120 10.50 (7.26) 35 14.30 (6.34) 100.00 −3.80 (−6.27 to −1.33)
Subtotal (95% CI) 120 35 100.00 −3.80 (−6.27 to −1.33)
Test for heterogeneity: not applicable
Test for overall effect: z = 3.02 (p = 0.003)
Review:  BPE
Comparison:  02 TUMT vs sham
Outcome:  02 Madsen-Iversen
Study
or subcategory n
TUMT
Mean (SD) n
Sham
Mean (SD)
WMD (ﬁxed) 
95% CI
Weight
%
WMD (ﬁxed) 
95% CI
013months
Blute, 1996
126 75 6.30 (5.00) 35 10.80 (4.40) 41.86 −4.50 (−6.35 to −2.65)
Ogden, 1993
133 21 4.30 (4.44) 19 12.80 (5.00) 16.46 −8.50 (−11.44 to −5.56)
de Wildt, 1996
172 45 4.70 (3.93) 43 10.40 (4.85) 41.68 −5.70 (−7.55 to −3.85)
Subtotal (95% CI) 141 97 100.00 −5.66 (−6.85 to −4.46)
Test for heterogeneity: χ
2 = 5.10,d f = 2( p = 0.08), I
2 = 60.8%
Test for overall effect: z = 9.29 (p < 0.00001)
026months
de la Rosette, 1994
223 24 5.30 (4.40) 23 9.10 (4.31) 100.00 −3.80 (−6.29 to −1.31)
Subtotal (95% CI) 24 23 100.00 −3.80 (−6.29 to −1.31)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.99 (p = 0.003)
03 12 months
de Wildt, 1996
172 33 4.20 (3.37) 13 8.20 (2.57) 100.00 −4.00 (−5.81 to −2.19)
Subtotal (95% CI) 33 13 100.00 −4.00 (−5.81 to −2.19)
Test for heterogeneity: not applicable
Test for overall effect: z = 4.33 (p < 0.0001)
−10 −5  0  5  10
 Favours TUMT  Favours sham
−10 −5  0  5  10
 Favours TUMT   Favours sham
FIGURE 6  Symptom scores, TUMT vs sham.Health Technology Assessment 2008; Vol. 12: No. 35
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Review: BPE
Comparison: 02 TUMT vs sham
Outcome: 03 Complications
Study or
subcategory
TUMT
n/N
Sham
n/N
RR (ﬁxed)
95% CI
Weight
%
RR (ﬁxed)
95% CI
01 Blood transfusion
Larson, 1998
159 0/125 0/44 Not estimable
Subtotal (95% CI) 00 Not estimable
Total events: 0 (TUMT), 0 (sham)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
02 Urinary retention
Abbou, 1995
143 0/66 0/37 Not estimable
Albala, 2002
170 20/121 0/62 12.01 21.17 (1.30–344.32)
Blute, 1996
126 20/78 0/37 12.30 19.72 (1.23–317.45)
Larson, 1998
159 10/125 1/44 26.95 3.52 (0.46–26.71)
Nawrocki, 1997
160 4/38 0/40 8.88 9.46 (0.53–170.02)
Ogden, 1993
133 5/22 0/21 9.31 10.52 (0.62–179.27)
Trachtenberg, 1998
173 8/147 0/73 12.14 8.50 (0.50–145.26)
de Wildt, 1996
172 10/47 1/46 18.41 9.79 (1.30–73.41)
Subtotal (95% CI) 644 360 100.00 10.57 (4.11–27.20)
Total events: 77 (TUMT), 2 (sham)
Test for heterogeneity: χ
2 = 1.60, df = 6 (p = 0.95), I
2 = 0%
Test for overall effect: z = 4.89 (p < 0.00001)
03 Urinary tract infection
Abbou, 1995
143 13/66 8/31 62.06 0.76 (0.35–1.65)
Larson, 1998
159 11/125 2/44 16.87 1.94 (0.45–8.39)
Ogden, 1993
133 5/22 1/21 5.83 4.77 (0.61–37.52)
Trachtenberg, 1998
173 11/147 2/73 15.24 2.73 (0.62–12.00)
Subtotal (95% CI) 360 169 100.00 1.49 (0.84–2.67)
Total events: 40 (TUMT), 13 (sham)
Test for heterogeneity: χ
2 = 4.90, df = 3 (p = 0.18), I
2 = 38.7%
Test for overall effect: z = 1.36 (p = 0.17)
04 Stricture
Albala, 2002
170 0/121 0/62 Not estimable
Larson, 1998
159 3/125 0/44 100.00 2.50 (0.13–47.46)
Subtotal (95% CI) 246 106 100.00 2.50 (0.13–47.46)
Total events: 3 (TUMT), 0 (sham)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.61 (p = 0.54)
05 Urinary incontinence
Larson, 1998
159 5/125 0/44 100.00 3.93 (0.22–69.63)
Subtotal (95% CI) 125 44 100.00 3.93 (0.22–69.63)
Total events: 5 (TUMT), 0 (sham)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.93 (p = 0.35)
 0.001 0.01  0.1  1  10  100 1000
 Favours TUMT  Favours sham
FIGURE 7  Complications, TUMT vs sham.Clinical effectiveness of minimally invasive techniques
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comparison 02:03:05: RR 3.93, 95% CI 0.22–69.63, 
p = 0.35). 
Quality of life
Four studies,133,159,170,173 using a variety of 
instruments, reported the quality of life of 
people undergoing TUMT or a sham procedure 
(Appendix 8.2, Table 49). In two studies159,173 the 
quality of life was assessed using the IPSS QoL 
(0–6) questionnaire. This was evaluated by patients’ 
responses to the question of how they would feel if 
their current urinary symptoms were to continue 
indefinitely. In the third study170 quality of life 
index was used and in the final study133 quality of 
life was measured using a questionnaire derived 
from the Veterans’ Administration study of TURP 
versus watchful waiting. This questionnaire had 
five sections: A, perception of urinary difficulties; 
B, sexual performance; C, activities of daily 
living; D, general psychological well-being; and 
E, social activities. At the 3-month evaluation, 
two studies133,173 reported higher quality of life 
following TUMT. This difference was statistically 
significant in both studies (p < 0.05). Larson and 
colleagues159 report that the improvement in 
quality of life score remained at a comparable level 
in the 12-month evaluation in the TUMT group. 
Urodynamic outcomes
Data on peak urine flow rate, voided volume 
and residual volume were reported across 11 
studies.125,126,133,143,159,160,170–174 Only peak urine 
flow rate is presented in this section. Results for 
the other urodynamic outcomes are presented 
in Appendix 8.2, Table 50 and Appendix 9.2, 
comparisons 02:04–02:09.
A total of seven studies125,126,133,159,172–174 reported 
peak urine flow rate at 3 months after surgery. 
In all but one study174 the peak urine flow 
rate was higher in the TUMT group. Six 
studies125,126,133,159,172,174 presented data that were 
sufficiently similar to allow quantitative synthesis 
(Appendix 9.2, comparison 02:04:01: WMD 
2.53 ml/s, 95% CI 1.69–3.37, p < 0.001). With 
regard to longer-term follow-up (12 months), only 
one study172 reported this outcome (WMD 2.90, 
95% CI –0.24 to 6.04, p = 0.07). 
Descriptors of care
Data describing descriptors of care are tabulated 
in Appendix 8.2, Table 51. Information on 
reoperation rates was identified in five studies.
Duration of operation
No studies reported this outcome.
Length of hospital stay
No studies reported this outcome.
Reoperation
The percentage of patients requiring a reoperation 
in the TUMT group was 6% compared with 54% 
of patients in the sham group requiring surgery. 
Meta-analysis of five trials125,133,159,171,172 presents 
a RR of 0.14 in favour of TUMT (95% CI 0.09–
0.23, p < 0.00001).37,46,69,80,81 This result should be 
interpreted with caution as the length of follow-up 
varied.
Summary and conclusions 
of the evidence for and 
against the intervention
This review considered data from 1209 participants 
across 11 RCTs of generally moderate to poor 
quality (with respect to conduct and reporting). 
The data suggest that TUMT both reduces 
symptoms and increases peak urine flow rate at 
3 months after the procedure. Reoperation rates 
for TUMT were lower than for sham. Patients who 
underwent TUMT had a high risk of developing 
urinary retention. Confidence intervals were wide. 
The meta-analyses failed to indicate differences in 
the incidence of blood transfusion, strictures and 
urinary incontinence, although the direction of 
effect was consistent with what would be expected 
after an operative procedure, again with wide 
confidence intervals. 
In this review the data contributing to meta-
analyses were too few to provide precise estimates 
of differences, particularly for the complications, 
and confidence intervals were so wide that clinically 
important differences could not be ruled out. 
Clinical effect size
A summary of the clinical effect sizes for all 
outcomes derived from the meta-analyses for which 
data were available is given in Table 9. Again, these 
should be interpreted in view of the comments 
mentioned above. Health Technology Assessment 2008; Vol. 12: No. 35
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Transurethral needle ablation 
(TUNA) versus TURP
Characteristics of included studies
The characteristics of the included studies are 
summarised in Table 10. Four RCTs, reported in 
nine papers,144,151,175,176,229–233 were eligible for this 
comparison, in which a total of 450 participants 
were randomised. These trials took place in the 
US,144 Turkey,175 Korea151 and the UK.176
All four studies provided details of the participants’ 
baseline IPSS/AUA symptom scores, according to 
which all 450 participants had severe symptoms. 
The studies presented variations in relation 
to prostate size. Of the studies reporting this 
characteristic, 65 (32%) and 136 (66%) participants 
randomised to TUNA had moderate-sized and 
large prostates respectively. Of the patients 
allocated to TURP, 56 (28%) had moderate-sized 
prostates and 143 (72%) had large prostates.
TABLE 9  Summary of the clinical effect sizes from meta-analyses, TUMT vs sham
Outcome
Number of trials 
MA (total) Effect size 95% CI p-value
IPSS/AUA score
3 months 3 (6) –5.69a –7.38 to –3.99 < 0.001
12 months 0 (1) NR NR NR
Longer term 0 (0) NR NR NR
Madsen–Iversen score
3 months 3 (4) –5.66a –6.85 to –4.46 < 0.001
12 months 1 (3) –4.00a –5.81 to –2.19 < 0.001
Longer term 0 (0) NR NR NR
Blood transfusion 1 (1) NE NE NE
Urinary retention 8 (8) 9.12b 3.36–24.80 < 0.001
Urinary tract infection 4 (4) 1.49b 0.84–2.67 0.17
TUR syndrome 0 (0) NR NR NR
Stricture 2 (2) 2.50b 0.13–47.46 0.54
Incontinence 1 (1) 3.93b 0.22–69.63 0.35
Quality of life
3 months 0 (2) NR NR NR
12 months 0 (0) NR NR NR
Longer term
Qmax
3 months 6 (9) 2.53a 1.69–3.37 < 0.001
12 months 1 (4) 2.90a –0.24 to 6.04 0.07
Longer term 0 (0) NR NR NR
Duration of operation 0 (0) NR NR NR
Length of stay 0 (0) NR NR NR
Reoperation 5 (5) 0.14b 0.09–0.23 < 0.001
IPSS/AUA, International Prostate Symptom Score/American Urological Association; MA, meta-analysed; NR, not reported; 
TUMT, transurethral microwave thermotherapy; TUR, transurethral resection.
a  Weighted mean difference.
b  Relative risk.Clinical effectiveness of minimally invasive techniques
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TABLE 10  Summary of the baseline characteristics, TUNA vs TURP
Study Comparators
Number of 
participants
Age 
(years)
Symptom 
scorea
Qmax 
(ml/s)
Residual 
volume 
(ml)
Prostate 
size 
(ml)
Cimentepe et al., 
2003175
TUNA  26 60 22.9 9.8 67 46
TURP 33 63 24.1 9.2 76 49
Hill et al., 2004144 TUNA  65 66 23.9 8.8 92 36
TURP 56 66 24.1 8.8 83 36
Hindley et al., 
2001176
TUNA  25 66b 22b 8.5 55 NR
TURP 25 71b 20b 9.0 74 NR
Kim et al., 2006151 TUNA  110 66 20.8 7.0 257 41
TURP 110 67 24.0 11.9 187 44
NR, not reported; TUNA, transurethral needle ablation; TURP , transurethral resection of the prostate.
Data given as mean values (unless stated otherwise).
a  Symptom scores given as IPSS/AUA.
b  Median.
Assessment of effectiveness
Tables giving a detailed description for all 
outcomes can be found in Appendix 8.3. The 
results of the meta-analyses are given in Appendix 
9.3. Note that in terms of long-term evaluation, 
only the longest follow-up is presented.
Symptom scores
At 3 months
At 3 months after surgery, three out of the four 
eligible trials reported AUA/IPSS symptom 
scores.144,151,175 Only two studies reported data that 
were amenable to meta-analysis.144,175 Symptom 
scores were slightly lower following TURP than 
following TUNA (Figure 8, comparison 03:01:01: 
WMD 1.18, 95% CI –0.03 to 2.40, p = 0.06).
At 12 months
Three reports presented IPSS/AUA results at 
12 months of follow-up.144,151,176 Analysis of data 
from one report showed better symptom scores 
in patients undergoing TURP than in those 
following TUNA (Figure 8 comparison 03:01:03: 
MD 3.90, 95% CI 1.27–6.53, p = 0.004). This 
result is consistent with that observed in the 
studies by Hindley and colleagues176 and Kim and 
colleagues.151
Longer-term follow-up
Only one trial144 reported 5-year IPSS/AUA scores. 
At this point in time, TUNA and TURP appeared 
to be equivalent in terms of improvement in 
symptoms, albeit with confidence intervals that 
included differences seen at earlier time points 
(Figure 8 comparison 03:01:07: MD 0.60, 95% 
CI –3.55 to 4.75, p = 0.78). The narrowing of the 
difference reflected better scores in the TUNA 
group. This should be interpreted cautiously as 
this follow-up included 33% of those who initially 
underwent surgery and so could reflect selection 
bias. 
Data for other follow-up times (2 and 3 years) were 
also reported by Hill and colleagues144 and can be 
seen in Appendix 8.3, Table 52 and the respective 
forest plots in Figure 8. 
Complications
Data describing complications are tabulated in 
Appendix 8.3, Table 53. Information on nine 
categories of complications was identified across 
the four eligible studies for this comparison. The 
data were too few to provide precise estimates of 
differences and all confidence intervals were wide 
such that clinically important differences could not 
be ruled out. Results regarding blood transfusion, 
urinary retention, urinary tract infection, strictures 
and urinary incontinence are presented in this 
section (Figure 9). Results for other complications 
are presented in Appendix 9.3, comparison 03:03. 
The results of these meta-analyses should be 
treated with caution as the length of follow-up of 
the RCTs varied. Also, for urinary incontinence 
it was unclear whether the type of incontinence 
considered was the same across all studies.Health Technology Assessment 2008; Vol. 12: No. 35
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Review:  BPE
Comparison:  03 TUNA vs TURP
Outcome:  01 IPSS/AUA
Study or
subcategory n
TUNA
Mean (SD) n
TURP
Mean (SD)
WMD (random)
95% CI
Weight
%
WMD (random)
95% CI
013months
Cimentepe, 2003
175 26 9.70 (2.80) 33 8.30 (2.90) 55.55 1.40 (−0.06 to 2.86)
Hill, 2004
144 59 10.10 (6.70) 47 9.40 (4.80) 44.45 0.70 (−1.49 to 2.89)
Subtotal (95% CI) 85 80 100.00 1.18 (−0.03 to 2.40)
Test for heterogeneity: χ
2 = 0.27, df = 1( p = 0.60), I
2 = 0%
Test for overall effect: z = 1.91 (p = 0.06)
026months
Hill, 2004
144 59 11.00 (7.68) 47 8.40 (5.48) 100.00 2.60 (0.09–5.11)
Subtotal (95% CI) 59 47 100.00 2.60 (0.09–5.11)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.03 (p = 0.04)
03 12 months
Hill, 2004
144 56 11.70 (7.48) 44 7.80 (5.96) 100.00 3.90 (1.27–6.53)
Subtotal (95% CI) 56 44 100.00 3.90 (1.27–6.53)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.90 (p = 0.004)
04 18 months
Cimentepe, 2003
175 24 8.50 (3.20) 33 8.60 (1.80) 100.00 −0.10 (−1.52 to 1.32)
Subtotal (95% CI) 24 33 100.00 −0.10 (−1.52 to 1.32)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.14 (p = 0.89)
052years
Hill, 2004
144 43 15.00 (8.50) 35 9.50 (6.50) 100.00 5.50 (2.17–8.83)
Subtotal (95% CI) 43 35 100.00 5.50 (2.17–8.83)
Test for heterogeneity: not applicable
Test for overall effect: z = 3.24 (p = 0.001)
063years
Hill, 2004
144 38 15.20 (8.01) 31 10.10 (7.80) 100.00 5.10 (1.35–8.85)
Subtotal (95% CI) 38 31 100.00 5.10 (1.35–8.85)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.67 (p = 0.008)
075years
Hill, 2004
144 18 10.70 (5.90) 22 10.10 (7.50) 100.00 0.60 (−3.55 to 4.75)
Subtotal (95% CI) 18 22 100.00 0.60 (−3.55 to 4.75)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.28 (p = 0.78)
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Review: BPE
Comparison: 03 TUNA vs TURP
Outcome: 03 Complications
Study
or subcategory
TUNA
n/N
TURP
n/N
RR (ﬁxed)
95% CI
Weight
%
RR (ﬁxed)
95% CI
01 Blood transfusion
Cimentepe, 2003
175 0/26 0/33
14.69
Not estimable
Hindley, 2001
176 0/20 3/22
85.31
0.16 (0.01–2.85)
Kim, 2006a
151 0/100 19/101
100.00
0.03 (0.00–0.42)
Subtotal (95% CI) 146 156 0.05 (0.01–0.32)
Total events:0(TUNA), 22 (TURP)
Test for heterogeneity: χ
2 = 0.86,d f = 1( p = 0.35), I
2 = 0%
Test for overall effect: z = 3.08 (p = 0.002)
02 Urinary retention
Cimentepe, 2003
175 1/26 0/33 9.03 3.78 (0.16–89.09)
Hindley, 2001
176 1/20 0/22 9.74 3.29 (0.14–76.33)
Kim, 2006a
151 4/100 4/101 81.23 1.01 (0.26–3.93)
Subtotal (95% CI) 146 156 100.00 1.48 (0.49–4.52)
Total events:6(TUNA),4(TURP)
Test for heterogeneity: χ
2 = 0.89,d f = 2( p = 0.64), I
2 = 0%
Test for overall effect: z = 0.69 (p = 0.49)
03 Urinary tract infection
Cimentepe, 2003
175 1/26 0/33 3.95 3.78 (0.16–89.09)
Hindley, 2001
176 4/20 4/22 33.96 1.10 (0.32–3.83)
Kim, 2006a
151 10/100 7/101 62.09 1.44 (0.57–3.64)
Subtotal (95% CI) 146 156 100.00 1.42 (0.69–2.91)
Total events: 15 (TUNA), 11 (TURP)
Test for heterogeneity: χ
2 = 0.53,d f = 2( p = 0.77), I
2 = 0%
Test for overall effect: z = 0.95 (p = 0.34)
04 Strictures
Cimentepe, 2003
175 0/26 2/33 15.84 0.25 (0.01–5.03)
Hill, 2004
144 1/65 4/56 30.75 0.22 (0.02–1.87)
Kim, 2006a
151 0/100 7/101 53.41 0.07 (0.00–1.16)
Subtotal (95% CI) 191 190 100.00 0.14 (0.03–0.62)
Total events:1(TUNA), 13 (TURP)
Test for heterogeneity: χ
2 = 0.55,d f = 2( p = 0.76), I
2 = 0%
Test for overall effect: z = 2.60 (p = 0.009)
05 Incontinence
Cimentepe, 2003
175 0/26 1/33 7.10 0.42 (0.02–9.90)
Hill, 2004
144 2/65 12/56 68.95 0.14 (0.03–0.61)
Hindley, 2001
176 0/20 0/22 Not estimable
Kim, 2006a
151 0/100 4/101 23.95 0.11 (0.01–2.06)
Subtotal (95% CI) 211 212 100.00 0.16 (0.05–0.51)
Total events:2(TUNA), 17 (TURP)
Test for heterogeneity: χ
2 = 0.44,d f = 2( p = 0.80), I
2 = 0%
Test for overall effect: z = 3.07 (p = 0.002)
 0.001 0.01  0.1  1  10  100 1000
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Blood transfusion
There were no cases of blood transfusion in the 
TUNA arms amongst 146 patients across three 
studies.144,151,175 Blood transfusion was required in 
14% (n = 22) of the patients undergoing TURP 
(Figure 9, comparison 03:03:01: RR 0.05, 95% CI 
0.01–0.32, p = 0.002).
Urinary retention
Urinary retention following surgery was reported 
in three studies.151,175,176 Six cases (4.1%) of urinary 
retention were recorded amongst 146 patients 
in the TUNA arms. Four patients (2.6%) who 
underwent TURP exhibited urinary retention. The 
confidence intervals are wide and, therefore, this 
result should be interpreted with caution (Figure 9, 
comparison 03:03:02: RR 1.48, 95% CI 0.49–4.52, 
p = 0.49).
Urinary tract infection
Urinary tract infection occurred more frequently 
in the TUNA arms (10.2%) than in the TURP arms 
(7.0%), but again with wide confidence intervals 
(Figure 9, comparison 03:03:03 RR 1.42, 95% CI 
0.69–2.91, p = 0.34).
Stricture
Across three trials, the incidence of strictures or 
bladder neck contractures was documented in one 
patient (0.5%) in the TUNA group and 13 (6.8%) 
in the TURP group. This difference was statistically 
significant (Figure 9, comparison 03:04: RR 0.14, 
95% CI 0.03–0.62, p = 0.009).
TUR syndrome
No studies reported this outcome.
Urinary incontinence
All four studies reported urinary incontinence 
following surgery. The types of incontinence 
were not fully described across studies (Appendix 
8.3, Table 53). The overall incidence of urinary 
incontinence was 0.9% (n = 2) in the TUNA group 
versus 8.0% (n = 17) in the TURP group (Figure 9, 
comparison 03:03:05: RR 0.16 95% CI 0.05–0.51, 
p = 0.002).
Quality of life
Four studies,144,151,175,176 using a variety of 
instruments, reported the quality of life of people 
following TUNA or TURP (Appendix 8.3, Table 
54). In three studies151,175,176 the quality of life was 
assessed using the IPSS QoL (0–6) questionnaire. 
In one study144 the type of scale used to measure 
quality of life was unclear. 
At 3 months
Two studies151,175 provided details on quality of 
life at 3 months after surgery. Only one study175 
provided data that were amenable to meta-analysis. 
Quality of life was higher for TURP with a mean 
difference of 0.20 (95% CI –0.10 to 0.50, p = 0.19). 
This result was not statistically significant (Figure 
10, comparison 03:08:01). This result should 
be treated with caution as the total number of 
participants available for this evaluation was 
unclear. This result is, however, consistent with that 
provided by Kim and colleagues.151
At 12 months
Three studies144,151,176 provided details on quality of 
life at 12 months after surgery; however, only one 
was suitable for quantitative synthesis. The quality 
of life was higher for TURP with a WMD of 0.60 
(Figure 10, comparison 03:08:02: 95% CI –1.08 to 
2.28, p = 0.48). This result is consistent with those 
reported by Hindley and colleagues176 and Kim and 
colleagues.151
Longer-term follow-up
Evidence from one study144 indicated that the 
quality of life of patients who underwent both 
TUNA and TURP decreased over time; however, 
it remained statistically significantly better 
compared with quality of life measured at baseline 
(p < 0.0001). Up to 5 years the two procedures 
appear to be comparable in terms of quality of life 
(Figure 10, comparison 03:08:03–03:08:07). The 
loss to follow-up is high and caution should be 
taken when interpreting the results of this meta-
analysis.
Urodynamic outcomes
Data on peak urine flow rate, residual volume, 
detrusor pressure and prostate size were reported 
to a varying extent across four studies.144,151,175,176 
These are tabulated in Appendix 8.3, Table 55. 
Only peak urine flow rate is presented in this 
section. Results for the other urodynamic outcomes 
are presented in Appendix 8.3, Table 55 and 
Appendix 9.3, comparisons 03:04–03:07.
Peak urine flow rate was statistically significantly 
lower in the TUNA arm than in the TURP arm at 
all time points (Appendix 9.3, comparison 03:04). 
At 12 months there was evidence of statistical 
heterogeneity in the results; however, the direction 
of effect is consistent across the two studies 
reporting data amenable to meta-analysis144,176 and 
with the results reported by Kim and colleagues.151 
Applying a random-effects model did not change Clinical effectiveness of minimally invasive techniques
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Review:  BPE
Comparison:  03 TUNA vs TURP
Outcome:  08 Quality of life
Study or 
subcategory n
TUNA
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
013months
Cimentepe, 2003
175 16 2.10 (0.50) 33 1.90 (0.50) 100.00 0.20 (−0.10 to 0.50)
Subtotal (95% CI) 16 33 100.00 0.20 (−0.10 to 0.50)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.31 (p = 0.19)
02 12 months
Hill, 2004
144 55 4.30 (3.70) 45 3.70 (4.69) 100.00 0.60 (−1.08 to 2.28)
Subtotal (95% CI) 55 45 100.00 0.60 (−1.08 to 2.28)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.70 (p = 0.48)
03 18 months
Hill, 2004
144 26 1.80 (1.30) 33 1.70 (0.50) 100.00 0.10 (−0.43 to 0.63)
Subtotal (95% CI) 26 33 100.00 0.10 (−0.43 to 0.63)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.37 (p = 0.71)
042years
Hill, 2004
144 43 4.30 (4.59) 33 3.70 (4.02) 100.00 0.60 (−1.34 to 2.54)
Subtotal (95% CI) 43 33 100.00 0.60 (−1.34 to 2.54)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.61 (p = 0.54)
053years
Hill, 2004
144 40 5.40 (4.42) 32 4.70 (5.60) 100.00 0.70 (−1.68 to 3.08)
Subtotal (95% CI) 40 32 100.00 0.70 (−1.68 to 3.08)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.58 (p = 0.56)
064years
Hill, 2004
144 22 5.20 (4.22) 21 3.70 (4.58) 100.00 1.50 (−1.14 to 4.14)
Subtotal (95% CI) 22 21 100.00 1.50 (−1.14 to 4.14)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.12 (p = 0.26)
075years
Hill, 2004
144 18 4.30 (3.39) 22 3.80 (3.28) 100.00 0.50 (−1.58 to 2.58)
Subtotal (95% CI) 18 22 100.00 0.50 (−1.58 to 2.58)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.47 (p = 0.64)
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FIGURE 10  Quality of life, TUNA vs TURP .
this pattern. The total number of patients 
contributing to the measurement of this estimate is 
unclear and it should be noted that only 20% and 
27% of those who underwent TUNA and TURP, 
respectively, were available for the 5-year follow-up 
assessment. Thus, these results should be treated 
with considerable caution.
Descriptors of care
Data describing descriptors of care are tabulated in 
Appendix 8.3, Table 56. Information on duration of 
operation, length of hospital stay and reoperation 
rates was identified to a varying extent across the 
three eligible studies for this comparison.Health Technology Assessment 2008; Vol. 12: No. 35
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Duration of operation
Two studies151,175 provided information on the 
duration of operation (Appendix 8.3, Table 56). 
Only one study provided data that were suitable for 
quantitative synthesis. The duration of operation 
in the TUNA group was on average 11.60 minutes 
longer than the duration of operation in the TURP 
group (Appendix 9.3, comparison 03:09: 95% CI 
6.41–16.79, p < 0.001). This result was consistent 
with that reported by Kim and colleagues151 who 
reported that TUNA took 14 minutes more than 
TURP. 
Length of hospital stay
Length of hospital stay appeared to be longer 
for patients undergoing TUNA than for those 
undergoing TURP in two studies. Hindley and 
colleagues176 reported that patients undergoing 
TUNA are discharged a few days following the 
procedure whereas patients undergoing TURP 
are discharged in the first postoperative day. 
Cimentepe and colleagues175 treated TURP 
patients as outpatients whereas patients allocated 
to TUNA would stay for at least 48 hours. On 
the other hand, Kim and colleagues151 reported a 
shorter length of hospital stay for those patients 
undergoing TUNA, with a mean difference of 5.2 
days.
Reoperation
Across the four trials, reoperations were 
documented in 6.2% (13/211) of patients allocated 
to TUNA compared with 0.5% (1/212) of patients 
in the TURP group (RR 6.89, 95% CI 1.58–29.95). 
Although the difference is statistically significant, 
the confidence interval is wide and it should be 
noted that the follow-up of the three eligible 
studies varied from 12 months144,151 to 2 years.176
Summary and conclusions 
of the evidence for and 
against the intervention
This review considered data from four RCTs of 
moderate quality. A total of 450 participants were 
randomised across the four studies and therefore 
the data were too few to provide precise estimates 
for all of the outcomes. A summary of the clinical 
effect sizes for all outcomes derived from the meta-
analyses for which data were available is given in 
Table 11. 
Stents versus transurethral 
resection of the 
prostate (TURP)
Characteristics of included studies
No full-text reports of RCTs were identified in the 
searches. One abstract of an RCT presented as a 
conference proceeding was identified.91 This UK 
study allocated 34 men to undergo prostatic stent 
insertion and 26 to undergo TURP. 
The mean age of participants allocated to stent 
insertion was 73 years (range 63–86) compared 
with 72.6 years (range 63–86) for patients allocated 
to TURP.
On average, participants in the TURP arm had 
more severe symptoms (mean = 21.6) than those in 
the stents arm (mean = 19.0). 
Participants in both arms presented equivalent 
mean peak urine flow rate measurements of 
8.0 ml/s. 
Assessment of effectiveness
Symptom scores
At 3 months
The mean IPSS scores observed at 3 months were 
11.2 and 11.0 in the stents and TURP groups 
respectively.
Complications
The stents group exhibited a slight increase in 
irritative urinary symptoms compared with the 
TURP group. 
Urodynamic outcomes
The only uroflowmetry data reported were peak 
urine flow rate. There was no statistically significant 
difference between the use of a Urolume stent and 
TURP (MD 0.00, 95% CI –5.84 to 5.84, p = 1.00).
Descriptors of care
The only descriptor of care observed was two 
reoperations in the stents group because of 
misplacement of the Urolume stent. The authors 
describe this as being due to technical reasons and 
therefore a TURP procedure was carried out.Clinical effectiveness of minimally invasive techniques
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TABLE 11  Summary of the clinical effect sizes from meta-analyses, TUNA vs TURP
Outcome
Number of trials 
MA (total) Effect size 95% CI p-value
IPSS/AUA score
3 months 2 (3) 1.18a –0.03 to 2.40 0.06
12 months 1 (3) 3.90a 1.27–6.53 0.004
Longer term 1 (1) 0.60a –3.55 to 4.75 0.78
Blood transfusion 3 (3) 0.05b 0.01–0.32 0.002
Urinary retention 3 (3) 1.48b 0.49–4.52 0.49
Urinary tract infection 3 (3) 1.42b 0.69–2.91 0.34
Stricture 3 (3) 0.14b 0.03–0.62 0.009
TUR syndrome 0 (0) NR NR NR
Incontinence 4 (4) 0.16b 0.05–0.51 0.002
Quality of life
3 months 1 (2) 0.20a –0.10 to 0.50 0.19
12 months 1 (3) 0.60a –1.08 to 2.28 0.48
Longer term 1 (1) 0.50a –1.58 to 2.58 0.64
Qmax
3 months 1 (2) –6.40a –8.90 to –3.90 < 0.001
12 months 2 (3) –8.12a –10.85 to –5.40 < 0.001
Longer term 1 (1) –7.20a –12.28 to –2.12 0.005
Duration of operation 1 (2) 11.60a 6.41–16.79 < 0.001
Length of hospital stay 0 (3) NR NR NR
Reoperation 4 (4) 6.89b 1.58–29.95 0.01
IPSS/AUA, International Prostate Symptom Score/American Urological Association; MA, meta-analysed; NR, not reported; 
TUNA, transurethral needle ablation; TUR, transurethral resection; TURP , transurethral resection of the prostate.
a  Weighted mean difference.
b  Relative risk.
Transurethral ethanol 
ablation of the prostate 
(TEAP) versus TURP
Characteristics of included studies
One RCT was identified.151 In this Korean study, 94 
men were allocated to undergo TEAP and 110 to 
undergo TURP. 
The mean age of participants allocated to TEAP 
was 66 years (range 49–88) compared with 67 years 
(range 60–87) for patients allocated to TURP.
All participants had severe symptoms and the mean 
or median peak urine flow rate measurements were 
7.2 and 11.9 ml/s for the TEAP and TURP groups 
respectively. All participants in the TEAP arm had 
moderate-sized prostates whereas those in the 
TURP arm had large prostates.
Assessment of effectiveness
Symptom scores
The mean IPSS scores observed at 3 months were 
9.6 and 10.6 in the TEAP and TURP groups 
respectively. The mean difference was similar at 
12 months with scores of 7.5 for TEAP and 8.8 for 
TURP.
Complications
Results regarding blood transfusion, urinary 
retention, urinary tract infection, strictures, TUR 
syndrome and urinary incontinence are presented 
in this section (Figure 11). These results should be 
treated with caution as the time points at which the 
complications took place were uncertain. Health Technology Assessment 2008; Vol. 12: No. 35
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Blood transfusion
There were no blood transfusions reported across 
94 patients in the TEAP arm compared with 
19 (19%) reported in the TURP arm (Figure 11, 
comparison 26:01:01: RR 0.03, 95% CI 0.00–0.45, 
p = 0.01).
Urinary retention
Two cases (2%) of urinary retention were 
reported amongst the 94 patients allocated to 
TEAP compared with four cases (4%) across 101 
patients allocated to TURP. This difference was 
not statistically significant (Figure 11, comparison 
26:01:02: RR 0.54, 95% CI 0.10–2.87, p = 0.47).
Urinary tract infection
No statistically significant difference was observed 
between the two arms in terms of urinary tract 
infections (Figure 11, comparison 26:01:03: RR 
0.77, 95% CI 0.25–2.34, p = 0.64).
Stricture
There were no cases of strictures or bladder neck 
stenosis in the TEAP arm as opposed to seven 
cases (7%) in the TURP arm. This result did not 
reach statistical significance (Figure 11, comparison 
26:01:04: RR 0.07, 95% CI 0.00–1.24, p = 0.07). 
Review:  BPE
Comparison:  26 TEAP vs TURP
Outcome:  01 Complications
Study or 
subcategory
TEAP
n/N
TURP
n/N
RR (ﬁxed)
95% CI
Weight
%
RR (ﬁxed)
95% CI
01 Blood transfusion
Kim, 2006a
151 0/94 19/101 100.00 0.03 (0.00–0.45)
Subtotal (95% CI) 94 101 100.00 0.03 (0.00–0.45)
Total events: 0 (TEAP), 19 (TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.52 (p = 0.01)
02 Urinary retention
Kim, 2006a
151 2/94 4/101 100.00 0.54 (0.10–2.87)
Subtotal (95% CI) 94 101 100.00 0.54 (0.10–2.87)
Total events: 2 (TEAP),4(TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.73 (p = 0.47)
03 Urinary tract infection
Kim, 2006a
151 5/94 7/101 100.00 0.77 (0.25–2.34)
Subtotal (95% CI) 94 101 100.00 0.77 (0.25–2.34)
Total events: 5 (TEAP),7(TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.47 (p = 0.64)
04 Stricture
Kim, 2006a
151 0/94 7/101 100.00 0.07 (0.00–1.24)
Subtotal (95% CI) 94 101 100.00 0.07 (0.00–1.24)
Total events: 0 (TEAP),7(TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.81 (p = 0.07)
05 Urinary incontinence
Kim, 2006a
151 0/94 4/101 100.00 0.12 (0.01–2.19)
Subtotal (95% CI) 94 101 100.00 0.12 (0.01–2.19)
Total events: 0 (TEAP),4(TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.43 (p = 0.15)
 0.001 0.01  0.1  1  10  100 1000
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FIGURE 11  Complications, TEAP vs TURPClinical effectiveness of minimally invasive techniques
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Urinary incontinence
Urinary incontinence was observed in four 
patients following TURP amongst a total of 101 
randomised patients. Again, this result did not 
reach statistical significance (Figure 11, comparison 
26:01:05: RR 0.12, 95% CI 0.01–2.19, p = 0.15). 
Quality of life
Quality of life was measured in terms of IPSS QoL 
scores and was found to be improved in both arms 
at both the 3- and 12-month assessments. Quality 
of life measurements at 3 and 12 months following 
surgery were 3.4 and 2.3, respectively, for those 
in the TEAP arm compared with 2.8 and 2.6, 
respectively, for those in the TURP arm.
Urodynamic outcomes
Mean differences in peak urine flow rates at 3 and 
12 months were approximately 7.9 ml/s in favour of 
TURP. 
Descriptors of care
Duration of operation and length of hospital stay 
were shorter in the TEAP arm than in the TURP 
arm. No reoperations were recorded in either arm.
Laser coagulation 
versus TURP
Laser coagulation of the prostate is a method 
that encompasses several techniques including 
interstitial laser coagulation, visual laser ablation 
and transurethral laser prostatectomy. It was not 
possible to confidently describe the actual method 
used from the information available from the 
trials. For analysis purposes these techniques have 
therefore been considered together. 
Characteristics of included studies
The characteristics of the included studies are 
summarised in Table 12. Thirteen RCTs, reported 
in 17 papers,123,130,131,136,139,145,149,151,154,163,177–179,234–237 
were eligible for this comparison, in which a total 
of 1231 participants were randomised. The total 
number allocated to laser coagulation was 612 and 
the total number allocated to TURP was 619.
Five studies took place in the UK,136,139,145,154,179 
three in the US,130,163,177 and one each in 
Sweden,131 Australia,123 Spain,149 Korea151 and the 
Netherlands.178 Six studies provided details on 
recruitment dates.130,131,145,151,163,178 The earliest 
recruitment date was August 1991163 and the latest 
recruitment date was December 2002.151
Overall, the total numbers of participants with 
moderate and severe symptoms allocated to receive 
laser coagulation were 353 (61%) and 225 (39%) 
respectively. There were 343 (58%) moderately 
and 239 (41%) severely symptomatic participants 
allocated to TURP.
In general, studies reported prostate size. Two 
studies154,179 failed to report prostate size of the 
enrolled participants and in one study149 authors 
reported that, to be included, patients had to 
have prostate sizes between 20 and 60 g. The 
total numbers of participants who had small, 
moderate-sized and large prostates in the laser 
coagulation group were 23 (5%), 34 (8%) and 387 
(87%) respectively. Of those allocated to a TURP 
procedure, 22 (5%) had a small prostate, 176 (39%) 
had a moderate-sized prostate and 214 (48%) had a 
large prostate.
Assessment of effectiveness
Tables giving a detailed description for all 
outcomes can be found in Appendix 8.4. The 
results of the meta-analyses are given in Appendix 
9.4. Note that in terms of long-term evaluation, 
only the longest follow-up is presented.
Symptom scores
At 3 months
Of the 13 eligible RCTs, six provided information 
on the mean or median IPSS/AUA scores 3 months 
after surgery.131,149,151,177–179 Two studies149,177 showed 
better scores in the laser group than in the TURP 
group, and four131,151,178,179 favoured TURP. This 
variation may be explained by the fact that trials 
included participants with various levels of prostate 
size. For example, in the trial by Kabalin and 
colleagues,177 participants had an average prostate 
size of 17 g (ml) in the TURP group, whereas in 
the study reported by Mårtenson and colleagues,178 
participants randomised to TURP had on average 
a prostate size of 50 ml (g). Because of this 
heterogeneity we opted not to derive a pooled 
estimate (Figure 12, comparison 04:01:01).
At 12 months
IPSS/AUA scores were reported in a total of seven 
studies.131,145,151,163,177–179 The direction and size of 
effect varied across the studies. The improvements 
in IPSS reported by Cowles and colleagues163 
and Liedberg and colleagues131 were, however, 
consistently lower in the laser coagulation 
intervention group (Figure 12, comparison 
04:01:03).Health Technology Assessment 2008; Vol. 12: No. 35
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TABLE 12  Summary of the baseline characteristics, laser coagulation vs TURP
Study Comparators
Number of 
participants
Age 
(years)
Symptom 
scorea
Qmax 
(ml/s)
Residual 
volume 
(ml)
Prostate 
size  
(ml)
Chacko et al., 
2001;154 CLasP study
Laser coagulation 74 74 17.6 NR NR NR
TURP 74 73 19.4 NR NR NR
Costello et al., 
1995123
Laser coagulation 34 68 NR 8.76 NR 30
TURP 37 68 NR 9.48 NR 34
Cowles et al., 
1995163
Laser coagulation 56 65 18.7 8.9 163 42
TURP 59 67 20.8 9.5 207 39
Donovan et al., 
2000;136 CLasP study
Laser coagulation 117 67 19.1 10.4 124 41
TURP 117 66 19.2 10.3 104 38
Gujral et al., 2000;139 
CLasP study
Laser coagulation 38 70 20.9 11.2 438 41c
TURP 44 70 19.5 8.5 545 50c
Kabalin et al., 
1995177
Laser coagulation 13 65 20.9 8.5 236 24b
TURP 12 69 18.8 9.0 291 17b
Kim et al., 2006151 Laser coagulation 89 69 21.1 8.6 219 43
TURP 110 67 24.0 11.9 187 44
Kursh et al., 2003130 Laser coagulation 37 68 24.0c 9.2c 81c 41c
TURP 35 69 23.0c 9.1c 87c 40c
Liedberg et al., 
2003131
Laser coagulation 20 NR 19c 8c 96c 49c
TURP 11 NR 17c 8c 117c 47c
Mårtenson and de la 
Rosette, 1999178
Laser coagulation 30 > 45 21.7 7.3 116 46
TURP 14 > 45 21.6 9.3 88 50
McAllister et al., 
2000145
Laser coagulation 76 68 18.1 9.6 113 NR
TURP 75 68 18.2 10.0 120.7 NR
Rodrigo Aliaga et al., 
1998149
Laser coagulation 18 NR 25.5 7.0 77 20–60b
TURP 21 NR 24.2 8.3 89 20–60b
Suvakovic and 
Hindmarsh, 1996179
Laser coagulation 10 67 15.7 10.5 47 24b
TURP 10 66 18.8 11.1 162 22b
NR, not reported.; TURP , transurethral resection of the prostate.
Data given as mean values (unless stated otherwise).
a  Symptom scores given as IPSS/AUA.
b  Grams.
c  Median.
Longer-term follow-up
Symptom scores data at 2 years were reported in 
three studies.130,177,178 Again, there was considerable 
variation between the trials (Figure 12, comparison 
04:01:05). 
Complications
Complications listed by study are detailed in 
Appendix 8.4, Table 58. Seventeen types of 
complications were reported to varying extents 
across the 13 studies. Results regarding blood 
transfusion, urinary retention, urinary tract 
infection, strictures, TUR syndrome and urinary 
incontinence are presented in this section (Figure 
13). Results for other complications are presented 
in Appendix 9.4, comparison 04:02. The results of 
these meta-analyses should be treated with caution 
as the length of follow-up of the RCTs varied. For 
urinary incontinence it was unclear whether the 
type of incontinence considered was the same 
across all studies.Clinical effectiveness of minimally invasive techniques
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FIGURE 12  Symptom scores, laser coagulation vs TURP .
Review:  BPE
Comparison:  04 Laser coagulation vs TURP
Outcome:  01 IPSS/AUA
Study or 
of subcategory n
Laser
coagulation
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
013months
Aliaga, 1998
149 18 4.80 (4.80) 21 8.60 (4.20) 48.12 −3.80 (−6.65 to −0.95)
Kabalin, 1995
177 13 7.20 (6.13) 12 9.90 (9.00) 10.58 −2.70 (−8.79 to 3.39)
Martenson, 1999
178 30 11.80 (6.90) 14 4.70 (4.00) 37.37 7.10 (3.86–10.34)
Suvakovic, 1996
179 10 16.80 (15.00) 10 12.80 (5.90) 3.93 4.00 (−5.99 to 13.99)
Subtotal (95% CI) 71 57 100.00 0.70 (−1.28 to 2.68)
Test for heterogeneity: χ
2 = 26.17, df = 3( p < 0.00001), I
2 = 88.5%
Test for overall effect: z = 0.69 (p = 0.49)
026months
Aliaga, 1998
149 18 7.40 (4.20) 21 3.70 (3.80) 19.77 3.70 (1.17–6.23)
Kabalin, 1995
177 11 4.60 (2.32) 10 5.70 (3.80) 17.06 −1.10 (−3.83 to 1.63)
Martenson, 1999
178 30 10.30 (5.40) 14 3.80 (2.40) 23.84 6.50 (4.19–8.81)
McAllister, 2000
145 76 7.90 (6.67) 75 5.90 (5.74) 32.18 2.00 (0.02–3.98)
Suvakovic, 1996
179 9 8.00 (5.70) 9 8.50 (3.00) 7.15 −0.50 (−4.71 to 3.71)
Subtotal (95% CI) 144 129 100.00 2.70 (1.58–3.83)
Test for heterogeneity: χ
2 = 21.21, df = 4( p = 0.0003), I
2 = 81.1%
Test for overall effect: z = 4.70 (p < 0.00001)
03 12 months
Kabalin, 1995
177 10 4.30 (4.11) 10 6.30 (3.48) 18.96 −2.00 (−5.34 to 1.34)
Martenson, 1999
178 21 12.40 (7.70) 10 3.50 (2.90) 15.00 8.90 (5.15–12.65)
McAllister, 2000
145 75 7.70 (6.18) 75 5.10 (5.74) 57.96 2.60 (0.69–4.51)
Suvakovic, 1996
179 9 10.00 (4.90) 9 7.20 (6.10) 8.08 2.80 (−2.31 to 7.91)
Subtotal (95% CI) 115 104 100.00 2.69 (1.24–4.14)
Test for heterogeneity: χ
2 = 18.12, df = 3( p = 0.0004), I
2 = 83.4%
Test for overall effect: z = 3.63 (p = 0.0003)
04 18 months
Kabalin, 1995
177 9 6.00 (3.90) 10 6.40 (4.11) 100.00 −0.40 (−4.00 to 3.20)
Subtotal (95% CI) 91 0 100.00 −0.40 (−4.00 to 3.20)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.22 (p = 0.83)
052years
Kabalin, 1995
177 9 4.70 (5.10) 9 6.80 (5.10) 27.42 −2.10 (−6.81 to 2.61)
Martenson, 1999
178 30 12.00 (4.90) 14 5.00 (4.40) 72.58 7.00 (4.10–9.90)
Subtotal (95% CI) 39 23 100.00 4.51 (2.04–6.97)
Test for heterogeneity: χ
2 = 10.40, df = 1( p = 0.001), I
2 = 90.4%
Test for overall effect: z = 3.58 (p = 0.0003)
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Review:  BPE
Comparison:  04 Laser coagulation vs TURP
Outcome:  02 Complications
Study or 
subcategory
Laser
coagulation
n/N
TURP
n/N
RR (ﬁxed)
95% CI
Weight
%
RR (ﬁxed)
95% CI
01 Blood transfusion
Aliaga, 1998
149 0/18 1/21 2.88 0.39 (0.02–8.93)
Chacko, 2001
154 0/74 4/74 9.31 0.11 (0.01–2.03)
Costello, 1995
123 0/34 3/37 6.94 0.16 (0.01–2.90)
Cowles, 1995
163 0/56 2/59 5.04 0.21 (0.01–4.29)
Donovan, 2000
136 1/117 1/117 2.07 1.00 (0.06–15.80)
Gujral, 2000
139 0/38 3/44 6.72 0.16 (0.01–3.09)
Kabalin, 1995
177 0/13 1/12 3.22 0.31 (0.01–6.94)
Kim, 2006a
151 0/89 19/101 37.81 0.03 (0.00–0.47)
Kursh, 2003
130 0/35 0/35 Not estimable
Martenson, 1999
178 0/30 0/14 Not estimable
  McAllister, 2000 McAllister, 2000
145 0/76 12/75 26.02 0.04 (0.00–0.66)
Subtotal (95% CI) 580 589 100.00 0.11 (0.04–0.26)
Total events: 1 (Laser coagulation), 46 (TURP)
Test for heterogeneity: χ
2 = 5.30, df = 8( p = 0.72), I
2 = 0%
Test for overall effect: z = 4.81 (p < 0.00001)
02 Urinary retention
Cowles, 1995
163 17/56 5/59 53.41 3.58 (1.42–9.06)
Kim, 2006a
151 2/89 4/101 41.100 .57( 0.11–3.02)
Suvakovic, 1996
179 1/10 0/10 5.48 3.00 (0.14–65.90)
Subtotal (95% CI) 155 170 100.00 2.31 (1.11–4.80)
Total events: 20 (Laser coagulation), 9 (TURP)
Test for heterogeneity: χ
2 = 3.59, df = 2( p = 0.17), I
2 = 44.3%
Test for overall effect: z = 2.25 (p = 0.02)
03 Urinary tract infection
Costello, 1995
123 1/34 4/37 12.35 0.27 (0.03–2.32)
Donovan, 2000
136 3/117 2/117 6.45 1.50 (0.26–8.81)
Gujral, 2000
139 1/38 2/44 5.97 0.58 (0.05–6.14)
Kim, 2006a
151 7/89 7/101 21.141 .13( 0.41–3.11)
  Kursh, 2003 Kursh, 2003
130 7/35 4/35 12.89 1.75 (0.56–5.45)
  Liedberg, 2003 Liedberg, 2003
131 16/20 1/11 4.16 8.80 (1.34–57.76)
  Martenson, 1999 Martenson, 1999
178 10/30 4/14 17.58 1.17 (0.44–3.08)
  McAllister, 2000 McAllister, 2000
145 20/76 6/75 19.47 3.29 (1.40–7.73)
Subtotal (95% CI) 439 434 100.00 1.84 (1.22–2.79)
Total events: 65 (Laser coagulation), 30 (TURP)
Test for heterogeneity: χ
2 = 10.21,d f = 7( p = 0.18), I
2 = 31.4%
Test for overall effect: z = 2.88 (p = 0.004)
04 Stricture
Costello, 1995
123 2/34 2/37 9.69 1.09 (0.16–7.30)
Cowles, 1995
163 0/56 9/59 46.85 0.06 (0.00–0.93)
Kabalin, 1995
177 0/13 1/12 7.87 0.31 (0.01–6.94)
Kim, 2006a
151 0/89 7/101 35.590 .08( 0.00–1.30)
Liedberg, 2003
131 0/20 0/11 Not estimable
Subtotal (95% CI) 212 220 100.00 0.18 (0.06–0.56)
Total events: 2 (Laser coagulation), 19 (TURP)
Test for heterogeneity: χ
2 = 4.54,d f = 3( p = 0.21), I
2 = 33.9%
Test for overall effect: z = 2.97 (p = 0.003)
05 TUR syndrome
  Chacko, 2001 Chacko, 2001
154 0/74 2/74 38.51 0.20 (0.01–4.10)
Cowles, 1995
163 0/56 2/59 37.52 0.21 (0.01–4.29)
Kabalin, 1995
177 0/13 1/12 23.96 0.31 (0.01–6.94)
Subtotal (95% CI) 143 145 100.00 0.23 (0.04–1.34)
Total events:0(Laser coagulation), 5 (TURP)
Test for heterogeneity: χ
2 = 0.05, df = 2( p = 0.98), I
2 = 0%
Test for overall effect: z = 1.64 (p = 0.10)
06 Urinary incontinence
Chacko, 2001
154 0/74 3/74 27.66 0.14 (0.01–2.72)
Cowles, 1995
163 0/56 2/59 19.25 0.21 (0.01–4.29)
Kim, 2006a
151 0/89 4/101 33.34 0.13 (0.01–2.31)
Kursh, 2003
130 0/35 2/35 19.76 0.20 (0.01–4.02)
Martenson, 1999
178 0/30 0/14 Not estimable
Subtotal (95% CI) 284 283 100.00 0.16 (0.04–0.71)
Total events:0(Laser coagulation), 11 (TURP)
Test for heterogeneity: χ
2 = 0.08, df = 3( p = 0.99), I
2 = 0%
Test for overall effect: z = 2.41 (p = 0.02)
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Blood transfusion
One (0.2%) laser patient as opposed to 46 (7.8%) 
TURP patients required a blood transfusion (Figure 
13, comparison 04:02:01: RR 0.11, 95% CI 0.04–
0.26, p < 0.001).123,130,136,139,145,149,151,154,163,177,178
Urinary retention
The pooling of data from three studies151,163,179 
showed that 13% (n = 20) of the patients following 
laser coagulation had urinary retention compared 
with 5% (n = 9) of those following TURP (Figure 13, 
comparison 04:02:02: RR 2.31, 95% CI 1.11–4.80, 
p = 0.02). 
Urinary tract infection
Meta-analysis of eight trials123,130,131,136,139,145,151,178 
suggested that the incidence of urinary tract 
infection was higher following laser coagulation 
than after TURP (Figure 13, comparison 04:02:03: 
65/439 versus 30/434, RR 1.84, 95% CI 1.22–2.79, 
p = 0.004). Note that three trials had particularly 
high rates of infection and that two and three 
of the infections in the laser and TURP groups, 
respectively, were actually epididymitis. These 
results should also be treated with caution as the 
length of follow-up of the RCTs varied.
Stricture
In five RCTs with data,123,131,151,163,177 a total of 
two (0.9%) strictures were reported amongst 212 
participants allocated to laser procedures versus 19 
(8.6%) strictures amongst 220 participants allocated 
to TURP procedures (Figure 13, comparison 
04:02:04: RR 0.18, 95% CI 0.06–0.56, p = 0.003).
TUR syndrome
Based on data from three trials154,163,177 the 
incidence of TUR syndrome after laser coagulation 
and TURP was 0% (0/143) and 3.4% (5/145) 
respectively; however, this difference was not 
statistically significant (Figure 13, comparison 
04:02:05: RR 0.23, 95% CI 0.04–1.34, p = 0.10).
Incontinence
A total of five studies130,151,154,163,178 reported urinary 
incontinence. The rates of incontinence were 
consistently lower following laser coagulation than 
following TURP (Figure 13, comparison 04:02:06: 
0/284 versus 11/283; RR 0.16, 95% CI 0.04–0.71, 
p = 0.02).
Quality of life
Six studies,130,136,139,151,154,178 using a variety of 
instruments, reported the quality of life of people 
following laser coagulation or TURP (Appendix 
8.4, Table 59). In four studies136,139,151,154 the quality 
of life was assessed using the IPSS QoL (0–6) 
questionnaire. In one study130 the AUA quality of 
life questionnaire was used and another study178 
used the quality of life index.
In three studies providing data,130,151,178 the 
quality of life scores were poorer following 
laser coagulation than following TURP at 3, 12 
and 24 months (Figure 14, comparison 04:10). 
Meta-analysis of the change of quality of life 
from baseline reported in three trials136,139,154 
was consistent with this although the difference 
between the groups was not statistically significant 
(Figure 14, comparison 04:11).
Urodynamic outcomes
Data on peak urine flow rate, total voided 
volume, residual volume, detrusor pressure 
and prostate size were reported across ten 
studies.130,131,139,145,149,151,163,177–179 These are tabulated 
in Appendix 8.4, Table 60. Only peak urine flow 
rate is presented in this section. Results for the 
other urodynamic outcomes are presented in 
Appendix 9.4, comparisons 04:04–04:08.
At 3 months
All eight studies that provided information on 
peak urine flow rates at 3 months after operation 
reported lower mean or median flow rates in the 
laser coagulation group (Appendix 8.4, Table 60). 
Meta-analysis of five RCTs145,149,177–179 reporting data 
suitable for quantitative synthesis gave a WMD 
of –5.36 ml/s (95% CI –7.28 to –3.45, p < 0.001) 
favouring TURP. This result should be treated with 
caution as two studies failed to report how many 
patients contributed to the analysis.
At 12 months
A total of six studies131,145,163,177–179 provided 
details on peak urine flow rate at 12 months after 
operation. All but one study177 reported higher 
median or mean peak urine flow rates in the TURP 
group. In the four studies145,177–179 that presented 
means and standard deviations, the WMD was 
–4.57 ml/s (Appendix 9.4, comparison 04:04:03: 
95% CI –6.55 to –2.59, p < 0.001). There was 
evidence of statistical heterogeneity amongst the 
studies included in the meta-analysis. Using a 
random-effects model did not change this result. 
Cowles and colleagues163 reported change from 
baseline rather than absolute rates. Their results 
were consistent with those of the meta-analysis. 
Longer-term follow-up
Two studies177,178 reported peak urine flow rates at 
2 years after laser coagulation and TURP. Meta-Health Technology Assessment 2008; Vol. 12: No. 35
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Review:  BPE
Comparison:  04 Laser coagulation vs TURP
Outcome:  10 Quality of Life
Study or 
subcategory n
Laser coagulation
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
013months
Martenson, 1999
178 30 2.30 (1.40) 14 0.90 (1.30) 100.00 1.40 (0.55–2.25)
Subtotal (95% CI) 30 14 100.00 1.40 (0.55–2.25)
Test for heterogeneity: not applicable
Test for overall effect: z = 3.25 (p = 0.001)
026months
Martenson, 1999
178 30 2.20 (1.40) 14 0.50 (0.70) 100.00 1.70 (1.08–2.32)
Subtotal (95% CI) 30 14 100.00 1.70 (1.08–2.32)
Test for heterogeneity: not applicable
Test for overall effect: z = 5.37 (p < 0.00001)
03 12 months
Martenson, 1999
178 30 2.20 (1.50) 14 0.60 (0.80) 100.00 1.60 (0.92–2.28)
Subtotal (95% CI) 30 14 100.00 1.60 (0.92–2.28)
Test for heterogeneity: not applicable
Test for overall effect: z = 4.61 (p < 0.00001)
042years
Martenson, 1999
178 30 2.20 (1.50) 14 0.70 (0.90) 100.00 1.50 (0.79–2.21)
Subtotal (95% CI) 30 14 100.00 1.50 (0.79–2.21)
Test for heterogeneity: not applicable
Test for overall effect: z = 4.12 (p < 0.0001)
Review:  BPE
Comparison:  04 Laser coagulation vs TURP
Outcome:  11 Change in quality of life
Study or 
subcategory N
Laser coagulation
Mean (SD) N
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
01 7.5 months
Chacko, 2001
154 49 −3.10 (1.96) 45 −3.42 (1.59) 26.83 0.32 (−0.40 to 1.04)
Donovan, 2000
136 93 −1.90 (1.72) 85 −2.20 (1.65) 56.56 0.30 (−0.20 to 0.80)
  Gujral, 2000 Gujral, 2000
139 30 −2.80 (1.80) 33 −3.20 (1.90) 16.61 0.40 (−0.51 to 1.31)
Subtotal (95% CI) 172 163 100.00 0.32 (−0.05 to 0.69)
Test for heterogeneity: χ
2 = 0.04, df = 2( p = 0.98), I
2 = 0%
Test for overall effect: z = 1.69 (p = 0.09)
−10 −5  0  5  10
Favours laser
coagulation
 Favours TURP
Favours laser
coagulation
 Favours TURP
−10 −5  0  5  10
FIGURE 14  Quality of life, laser coagulation vs TURPClinical effectiveness of minimally invasive techniques
56
analysis of data from these studies did not show 
any statistically significant difference in peak urine 
flow rate between the two arms (Appendix 9.4, 
comparison 04:04:06: WMD –0.76, 95% CI –5.30 
to 3.77, p = 0.74). Note that the number of patients 
available for this follow-up assessment is unclear.
Descriptors of care
Data describing descriptors of care are tabulated in 
Appendix 8.4, Table 61. Information on duration of 
operation, length of hospital stay and reoperations 
was identified to a varying extent across the 13 
eligible studies.
Duration of operation
Duration of operation was reported in five 
trials.123,151,163,177,179 Combining data from two 
trials163,179 indicated that the duration of operation 
in the laser coagulation arm was statistically 
significantly shorter than that for the TURP arm 
(Appendix 9.4, comparison 04:12: WMD –12.24 
minutes, 95% CI –16.78 to –7.69, p < 0.001). 
This result is consistent with findings from trials 
whose data were not amenable to meta-analysis. 
There was evidence of statistical heterogeneity. 
Using a random-effects model resulted in the 
difference no longer being significant (WMD 
–11.54, 95% CI –31.74 to 8.65, p = 0.29). The 
sources of heterogeneity were unclear. However, 
patients included in the trial by Suvakovic and 
Hindmarsh179 had considerably smaller prostates 
than those included in the trial by Cowles and 
colleagues.163 In addition, there was a high degree 
of uncertainty surrounding the results from the 
former trial because of the small sample size. 
TABLE 13  Summary of the clinical effect sizes from meta-analyses, laser coagulation vs TURP
Outcome
Number of trials 
MA (total) Effect size 95% CI p-value
IPSS/AUA score
3 months 4 (6) 0.70a –1.28 to 2.68 0.49
12 months 4 (7) 2.69a 1.24–4.14 < 0.001
Longer term 2 (3) 4.51a 2.04–6.97 < 0.001
Blood transfusion 10 (10) 0.11b 0.04–0.26 < 0.001
Urinary retention 3 (3) 2.31b 1.11–4.80 0.02
Urinary tract infection 8 (8) 1.84b 1.22–2.79 0.004
Stricture 5 (5) 0.18b 0.06–0.56 0.003
TUR syndrome 3 (3) 0.23b 0.04–1.34 0.10
Incontinence 5 (5) 0.16b 0.04–0.71 0.02
Quality of life
3 months 1 (2) 1.40a 0.55–2.25 0.001
12 months 1 (3) 1.60a 0.92–2.28 < 0.001
Longer term 1 (3) 1.50a 0.79–2.21 < 0.001
Qmax
3 months 5 (8) –5.36a –7.28 to –3.45 < 0.001
12 months 4 (7) –4.57a –6.55 to –2.59 < 0.001
Longer term 2 (3) –0.76a –5.30 to 3.77 0.74
Duration of operation 2 (5) –12.24a –16.78 to –7.69 < 0.001
Length of hospital stay 2 (10) –1.33a –1.68 to –0.98 < 0.001
Reoperation 9 (9) 3.21b 1.63–6.32 0.0008
IPSS/AUA, International Prostate Symptom Score/American Urological Association; MA, meta-analysed; TUR, transurethral 
resection; TURP , transurethral resection of the prostate.
a  Weighted mean difference.
b  Relative risk.Health Technology Assessment 2008; Vol. 12: No. 35
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Length of hospital stay
Nine out of ten studies providing information 
on length of hospital stay reported lower mean 
or median stay in the laser coagulation group. 
Two RCTs reported data suitable for quantitative 
synthesis.145,163 Across them, the average length 
of stay was significantly shorter in the laser 
coagulation group than in the TURP group 
(Appendix 9.4, comparison 04:13: WMD –1.33; 
95% CI –1.68 to –0.98, p < 0.001). 
Reoperation
A total of nine RCTs123,130,139,145,151,154,163,177,178 
provided information on reoperation rates. The 
results of the meta-analysis showed a statistically 
significant higher rate following laser coagulation 
(Appendix 9.4, comparison 04:02:16: RR 3.21, 
95% CI 1.65–6.24, p < 0.001). As the length of 
follow-up ranged from 6 months123 to 5 years,145 the 
results of this meta-analysis should be treated with 
caution.
Summary and conclusions 
of the evidence for and 
against the intervention
Data from over 1000 participants randomised 
across 13 RCTs of generally moderate to poor 
quality (or reporting) were included. The data 
indicate that symptom scores at 12 months or more 
and quality of life and peak urine flow rate at 3 and 
12 months are worse after laser coagulation than 
after TURP. The occurrence of blood transfusion, 
strictures and urinary incontinence was lower in 
the laser coagulation group but urinary retention 
and urinary tract infection appeared to be higher. 
TUR syndrome does not appear to differ between 
the two approaches. In terms of descriptors of care, 
the data suggest that duration of operation and 
length of hospital stay are likely to be shorter after 
laser coagulation than after TURP but that the 
reoperation rate is higher after laser coagulation 
than after TURP.
The results for symptom scores, peak urine 
flow rate and duration of operation displayed 
significant heterogeneity. There was consistency in 
the direction and size of effect across the studies for 
all except symptom scores. This heterogeneity may 
be due to variations in the characteristics of the 
randomised participants, particularly differences 
in baseline prostate size and symptom score. It 
may also be due to differences in the specific aims 
and objectives of the trials, which led to important 
differences in inclusion criteria. 
Clinical effect size
A summary of the clinical effect sizes for all 
outcomes derived from the meta-analyses for which 
data were available is given in Table 13. Health Technology Assessment 2008; Vol. 12: No. 35
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Transurethral incision of the 
prostate (TUIP) versus TURP
Characteristics of included studies
The baseline characteristics of the included 
studies are summarised in Table 14. A 
total of 871 participants were randomised 
across 11 eligible RCTs and reported in 14 
papers.135,149,152,157,180–186,238–240 The total number of 
people allocated to TUIP was 430 and the total 
allocated to TURP was 441.
Two studies took place in the US,135,152 two in 
Denmark,180,183 and one each in Spain,149 Finland,157 
Sweden,181 Hong Kong,182 India,185 Israel184 
and Poland.186 Three studies provided details 
on recruitment dates,135,152,181 with the earliest 
recruitment being January 1985152 and the latest 
August 1990.
In terms of symptom scores, two studies reported 
IPSS/AUA scores149,186 and four reported Madsen–
Iversen scores.135,152,180,181 Of the studies reporting 
IPSS/AUA scores, 50 participants allocated to TUIP 
had moderate symptoms of BPE and 20 had severe 
symptoms compared with 21 with severe and 50 
with moderate symptoms among those allocated to 
TURP.
Assessment of effectiveness
Tables giving a detailed description for all 
outcomes can be found in Appendix 8.5. The 
results of the meta-analyses are given in Appendix 
9.5. Note that in terms of long-term evaluation, 
only the longest follow-up is presented.
Symptom scores
At 3 months
Of the 11 eligible RCTs, five reported IPSS/AUA or 
Madsen scores at 3 months, although for only one 
of these the data were reported in a way that was 
potentially amenable to analysis and there was no 
evidence of a statistically significant difference. Two 
tended to favour TUIP, one TURP and two showed 
no difference. 
At 12 months
Data describing IPSS/AUA scores at 12 months 
were available for six trials but, again, only one 
provided means and standard deviations. Again, 
no clear pattern emerged: three tended to favour 
TURP, one TUIP and two showed no difference.
Longer-term follow-up
Losses to follow-up were high in nearly all studies 
reporting long-term follow-up. Only one study181 
reported Madsen scores at 5 years following 
operation. No significant differences were observed 
between the TUIP and TURP groups (Appendix 
8.5, Table 62). Data for other follow-up times (2 
and 3 years) were also reported by Christensen and 
colleagues,135 Jahnson and colleagues,181 Riehmann 
and colleagues152 and Saporta and colleagues.184 
These can be seen in Appendix 8.5 and the 
respective forest plots in Appendix 9.5, comparison 
05:02. 
Complications
Data describing 18 types of complications are 
tabulated in Appendix 8.5, Table 63. Although 
some data were estimated from the reports of ten 
trials, data describing individual complications 
were available from more than half of the 11 
trials for only five of the 18 complications. The 
reliability and usefulness of data for the other 13 
were therefore very limited. Results regarding 
blood transfusion, urinary retention, urinary tract 
infection, strictures, TUR syndrome and urinary 
incontinence are presented in this section (Figure 
15). Results for other complications are presented 
in Appendix 9.5, comparison 05:03. The results of 
these meta-analyses should be treated with caution 
as the length of follow-up of the RCTs varied. For 
urinary incontinence it was unclear if the type of 
incontinence considered was the same across all 
studies.
Blood transfusion
Seven studies149,157,180–183,185 provided information 
on blood transfusions. There were fewer blood 
transfusions following TUIP in all except one trial, 
which reported no transfusions in either group 
Chapter 7  
Clinical effectiveness of  
transurethral incision of the prostateClinical effectiveness of transurethral incision of the prostate
60
TABLE 14  Summary of the baseline characteristics, TUIP vs TURP
Study Comparators
Number of 
participants
Age 
(years)
Symptom 
scorea
Qmax 
(ml/s)
Residual 
volume 
(ml)
Prostate 
size  
(ml)
Rodrigo Aliaga et 
al., 1998149
TUIP 20 NR 24.2 8.7 89 20–60b
TURP 21 NR 24.4 8.3 146 20–60b
Christensen et al., 
1990135
TUIP 38 63c 16d 7.8 NR ≤ 20
TURP 38 62c 16d 9.7 NR ≤ 20
Dørflinger et al., 
1992180
TUIP 29 69 15d 10 NR ≤ 20
TURP 31 71 15d 8 NR ≤ 20
Hellström et al., 
1986157
TUIP 11 63 NR 8.6 62 ≤ 30
TURP 13 59 NR 7.5 43 ≤ 30
Jahnson et al., 
1998181
TUIP 42 71 15.8d 8.5 109 20–40
TURP 43 70 15.4d 9.0 139 20–40
Li and Ng, 1987182 TUIP 29 65 NR NR NR ≤ 30
TURP 30 70 NR NR NR ≤ 30
Nielsen, 1988183 TUIP 25 73c NR 5c NR NR
TUIP 24 69c NR 5c NR NR
Riehmann et al., 
1995152
TUIP 56 64 15.0d 11 NR NR
TURP 61 65 15.5d 9 NR NR
Saporta et al., 
1996184
TUIP 20 66.8 NR NR NR ≥ 40
TURP 20 71.4 NR NR NR ≥ 40
Soonawalla and 
Pardanani, 1992185
TUIP 110 65.0 NR NR NR NR
TURP 110 62.2 NR NR NR NR
Tkocz and Prajsner, 
2002186
TUIP 50 63 17.1 7.6 75 27.0
TURP 50 63 17.1 6.9 68 28.2
NR, not reported; TUIP , transurethral incision of the prostate; TURP , transurethral resection of the prostate.
Data given as mean values (unless otherwise stated).
a  Symptom scores given as IPSS/AUA (unless stated otherwise).
b  Grams
c  Median. 
d  Madsen score.
(Figure 15, comparison 05:03:01: 3/266 (11%) 
versus 77/272 (28%), RR 0.06, 95% CI 0.03–0.16, 
p < 0.001), reflecting particularly high rates of 
transfusion following TURP in four trials. 
Urinary retention
Meta-analysis of data from four trials181–183,185 
reporting urinary retention showed no statistically 
significant difference between the TUIP and TURP 
groups and wide confidence intervals (Figure 15, 
comparison 05:03:02: 10/206 versus 5/207, RR 
1.84, 95% CI 0.70–4.86, p = 0.22). The direction of 
effect varied across studies with one trial favouring 
TUIP,181 two favouring TURP183,185 and one showing 
no difference.182 
Urinary tract infection
Only one study reported the incidence of urinary 
tract infections (including epididymo-orchitis) 
following surgery.185 A total of five (4.5%) infections 
were reported amongst 110 participants allocated 
to TUIP compared with two (1.8%) infections Health Technology Assessment 2008; Vol. 12: No. 35
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Comparison:  05 TUIP vs TURP
Outcome:  03 Complications
Study or 
subcategory
TUIP
n/N
TURP
n/N
RR (ﬁxed)
95% CI
Weight
%
RR (ﬁxed)
95% CI
01 Blood transfusion
Aliaga, 1998
149 0/20 1/21 1.87 0.35 (0.02–8.10)
Dorﬂinger, 1992
180 0/29 4/31 5.57 0.12 (0.01–2.11)
Hellstrom, 1986
157 0/11 0/13 Not estimable
Jahnson, 1998
181 0/43 1/42 1.94 0.33 (0.01–7.78)
Li, 1987
182 2/29 13/30 16.34 0.16 (0.04–0.64)
Nielsen, 1998
183 1/24 20/25 25.05 0.05 (0.01–0.36)
Soonawalla, 1992
185 0/110 38/110 49.23 0.01 (0.00–0.21)
Subtotal (95% CI) 266 272 100.00 0.06 (0.03–0.16)
Total events: 3 (TUIP), 77 (TURP)
Test for heterogeneity: χ
2 = 5.18, df = 5( p = 0.39), I
2 = 3.5%
Test for overall effect: z = 6.09 (p < 0.00001)
02 Urinary retention
Jahnson, 1998
181 0/43 1/42 25.26 0.33 (0.01–7.78)
Li, 1987
182 0/29 0/30 Not estimable
Nielsen, 1998
183 3/24 0/25 8.16 7.28 (0.40–133.89)
Soonawalla, 1992
185 7/110 4/110 66.58 1.75 (0.53–5.81)
Subtotal (95% CI) 206 207 100.00 1.84 (0.70–4.86)
Total events: 10 (TUIP), 5 (TURP)
Test for heterogeneity: χ
2 = 2.01, df = 2( p = 0.37), I
2 = 0.4%
Test for overall effect: z = 1.23 (p = 0.22)
03 Urinary tract infection
Soonawalla, 1992
185 5/110 2/110 100.00 2.50 (0.50–12.61)
Subtotal (95% CI) 110 110 100.00 2.50 (0.50–12.61)
Total events: 5 (TUIP),2(TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.11 (p = 0.27)
04 Stricture
Dorﬂinger, 1992
180 1/29 0/31 2.53 3.20 (0.14–75.55)
Hellstrom, 1986
157 1/11 0/13 2.42 3.50 (0.16–78.19)
Li, 1987
182 0/29 2/30 12.87 0.21 (0.01–4.13)
Nielsen, 1998
183 16/24 4/25 20.50 4.17 (1.62–10.68)
Riehman, 1994
239 0/60 8/56 45.98 0.05 (0.00–0.93)
Soonawalla, 1992
185 5/110 3/110 15.70 1.67 (0.41–6.80)
Subtotal (95% CI) 263 265 100.00 1.33 (0.77–2.31)
Total events: 23 (TUIP), 17 (TURP)
Test for heterogeneity: χ
2 = 12.75, df = 5( p = 0.03), I
2 = 60.8%
Test for overall effect: z = 1.03 (p = 0.30)
05 TUR syndrome
Li, 1987
182 0/29 0/30 Not estimable
Soonawalla, 1992
185 0/110 7/110 100.00 0.07 (0.00–1.15)
Subtotal (95% CI) 139 140 100.00 0.07 (0.00–1.15)
Total events: 0 (TUIP),7(TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.86 (p = 0.06)
06 Incontinence
Li, 1987
182 1/29 2/30 26.44 0.52 (0.05–5.40)
Nielsen, 1998
183 0/24 1/25 19.77 0.35 (0.01–8.12)
Soonawalla, 1992
185 2/110 4/110 53.79 0.50 (0.09–2.67)
Subtotal (95% CI) 163 165 100.00 0.47 (0.14–1.65)
Total events: 3 (TUIP),7(TURP)
Test for heterogeneity: χ
2 = 0.05, df = 2( p = 0.98), I
2 = 0%
Test for overall effect: z = 1.17 (p = 0.24)
 0.001 0.01  0.1  1  10  100 1000
Favours TURP Favours TUIP
FIGURE 15  Complications, TUIP vs TURP .Clinical effectiveness of transurethral incision of the prostate
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amongst 110 allocated to TURP (Figure 15, 
comparison 05:03:03: RR 2.50, 95% CI 0.50–12.61, 
p = 0.27).
Stricture
Six studies provided data on 
strictures.152,157,180,182,183,185 There was marked 
heterogeneity across the studies, with no clear 
pattern of results (Figure 15, comparison 05:03:04: 
23/263 versus 17/265, RR 1.33, 95% CI 0.77–
2.31, p = 0.30). The source of heterogeneity was 
uncertain, although the lack of separation between 
urethral stricture and bladder neck contracture 
may have been a factor as definitions of these 
conditions varied across the trials. In addition, the 
length of follow-up varied across studies.
TUR syndrome
TUR syndrome was reported in two studies.182,185 
No cases of a TUR syndrome were recorded in 
patients randomised to the TUIP arm. On the 
other hand, 6.4% of the patients (all in one trial) 
allocated to TURP had TUR syndrome (Figure 15, 
comparison 05:03:05: 0/139 versus 7/140, RR 0.07, 
95% CI 0.00–1.15, p = 0.06).
Urinary incontinence
Meta-analysis of three trials that reported urinary 
incontinence showed no statistically significant 
difference between the TUIP and the TURP groups 
even though there were fewer events in the TUIP 
group (Figure 15, comparison 05:03:06: 3/163 
versus 7/165, RR 0.47, 95% CI 0.14–1.65, p = 0.24). 
This result should be interpreted with caution 
as the length of follow-up varied, the types of 
incontinence were not fully described across studies 
and the confidence interval is wide. 
Quality of life
Only one study186 reported quality of life of patients 
following surgery using the IPSS QoL (0–6) 
questionnaire. At 2 years, quality of life appeared 
to be marginally higher for those patients who 
underwent TURP (Appendix 9.5, comparison 
05:08:01: WMD 0.20, 95% CI 0.01–0.39, p = 0.04).
Urodynamic outcomes
Data on peak urine flow rate, mean urine flow rate, 
total voided volume, residual volume and detrusor 
pressure were reported to a varying extent across 
eleven studies.135,149,152,157,180–186 These are tabulated 
in Appendix 8.5, Table 65. Only peak urine flow 
rate is presented in this section. Results for the 
other urodynamic outcomes are presented in 
Appendix 9.5, comparisons 05:05–05:07.
At 3 months
Nine studies135,149,152,157,180–183,185 provided peak urine 
flow rate measurements at 3 months for patients 
treated with TUIP and TURP (Appendix 8.5, Table 
65). Seven studies135,152,157,180,181,183,185 showed that 
patients in the TURP group achieved a higher 
mean or median peak urine flow rate than patients 
in the TUIP group, and two studies149,182 showed 
a higher value in the TUIP group. Only three 
RCTs149,157,182 presented data that were sufficiently 
similar to allow quantitative synthesis (Appendix 
9.5, comparison 05:05:01). Meta-analysis showed 
no statistically significant difference between the 
groups (WMD –0.07 ml/s, 95% CI –3.53 to 3.39, 
p = 0.97).
At 12 months
All six studies135,180,181,183–185 that provided 
information on the mean or median peak urine 
flow rate for patients 12 months after surgery 
reported lower mean or median peak urine flow 
rates following TUIP (Appendix 8.5, Table 65). 
Only one study184 reported data that were suitable 
for analysis (Appendix 9.5, comparison 05:05:03: 
MD –2.71 ml/s, 95% CI –5.77 to 0.35, p = 0.08).
Longer-term follow-up
Two studies152,181 provided 5-year results. A total of 
26 and 32 patients were available for analysis in 
the TUIP and TURP groups respectively. In both 
studies the mean peak flow rate was lower for TUIP 
than it was for TURP. 
Descriptors of care
Data describing descriptors of care are tabulated in 
Appendix 8.5, Table 66. Information on duration of 
operation, length of hospital stay and reoperation 
rates was identified to a varying extent across the 
11 eligible studies for this comparison.
Duration of operation
Seven studies152,157,180–183,185 provided information on 
the duration of operation (Appendix 8.5, Table 66). 
In all studies the duration of operation was shorter 
in the TUIP group. Only two studies157,182 presented 
data in a sufficiently similar form to allow 
quantitative synthesis (Appendix 9.5, comparison 
05:09]; a TUIP procedure was 18.9 minutes shorter 
than TURP (95% CI –24.13 to –13.67, p < 0.001). 
This result was consistent with the other five studies 
reporting medians.
Length of hospital stay
Eight studies135,149,152,157,180,182,183,185 provided 
information on length of hospital stay (Appendix Health Technology Assessment 2008; Vol. 12: No. 35
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8.5, Table 66). Despite marked differences 
between studies in overall length of stay, in 
six135,149,152,157,182,185 they reported it to be shorter 
for TUIP and in two 180,183 there was no difference. 
Two RCTs157,182 reported data that were suitable for 
synthesis. Across them, the average length of stay 
was significantly shorter in the TUIP group than 
in the TURP group (Appendix 9.5, comparison 
05:10: WMD –2.26 days, 95% CI –3.81 to –0.71, 
p = 0.004). The within-trial differences in medians 
tended to be smaller than this.
Reoperation
Reoperations were reported in seven 
trials.135,149,152,180,181,183,184 Reoperation was more 
common in the TUIP groups (17.5%) than in the 
TURP groups (9%) (Appendix 9.5, comparison 
05:04:18: RR 1.87, 95% CI 1.16–3.03, p = 0.01). It 
should be noted that differences between studies in 
timing and completeness of follow-up might have 
introduced bias.
Summary and conclusions 
of the evidence for and 
against the intervention
This review considered data from 871 randomised 
participants across 11 RCTs of moderate to poor 
quality (and reporting). There is no evidence that 
the two interventions are different in terms of 
symptomatic outcome as no clear pattern emerged. 
The data indicate that, after TUIP, improvements 
in peak urine flow rate and quality of life are 
lower than after TURP, whereas the rate of blood 
transfusion and occurrence of TUR syndrome 
are higher after TURP than after TUIP. Urinary 
retention, urinary tract infection, strictures and 
incontinence do not appear to differ between the 
two approaches, although clinically important 
differences could not be ruled out. TUIP appears 
to be associated with shorter duration of operation 
and length of hospital stay but the reoperation 
rate is higher. It is important to note that the 
latest recruitment date was August 1990 and so 
the TURP outcomes then and now would not be 
comparable given the improvements in TURP 
technology over the past 16 years, reflected best by 
the higher transfusion rates reported in the seven 
trials included in this review of TUIP versus TURP. 
Clinical effect size
A summary of the clinical effect sizes for all 
outcomes derived from the meta-analyses for which 
data were available is given in Table 15. These 
should be interpreted in view of the comments 
mentioned earlier in this chapter. Clinical effectiveness of transurethral incision of the prostate
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TABLE 15  Summary of the clinical effect sizes from meta-analyses, TUIP vs TURP
Outcome
Number of trials 
MA (total) Effect size 95% CI p-value
IPSS/AUA score
3 months 1 (1) –0.50a –3.35 to 2.35 0.73
12 months 1 (1) –1.00a –1.73 to –0.27 0.007
Longer term NR NR NR NR
Madsen–Iversen score
3 months 0 (3) NR NR NR
12 months 1 (5) 0.34a –1.55 to 2.23 0.72
Longer term 1 (3) 1.21a –0.87 to 3.29 0.26
Blood transfusion 7 (7) 0.06b 0.03–0.16 < 0.001
Urinary retention 4 (4) 1.84b 0.70–4.86 0.22
Urinary tract infection 1 (1) 2.50b 0.50–12.61 0.27
Stricture 6 (6) 1.33b 0.77–2.31 0.30
TUR syndrome 2 (2) 0.07b 0.00–1.15 0.06
Incontinence 4 (4) 0.47b 0.14–1.65 0.24
Quality of life
3 months NR NR NR NR
12 months NR NR NR NR
Longer term 1 0.20a 0.01–0.39 0.04
Qmax
3 months 3 (9) –0.07a –3.53 to 3.39 0.97
12 months 1 (6) –2.71a –5.77 to 0.35 0.08
Longer term 1 (2) –1.71a –4.74 to 1.32 0.27
Duration of operation 2 (7) –18.90a –24.13 to –13.67 < 0.001
Length of hospital stay 2 (8) –2.26a –3.81 to –0.71 0.004
Reoperation 7 (7) 1.87b 1.16–3.03 0.01
IPSS/AUA, International Prostate Symptom Score/American Urological Association; MA, meta-analysed; NR, not reported; 
TUIP , transurethral incision of the prostate; TUR, transurethral resection; TURP , transurethral resection of the prostate.
a  Weighted mean difference. 
b  Relative risk.Health Technology Assessment 2008; Vol. 12: No. 35
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Interventions using 
laser technology
Holmium laser resection 
versus TURP
Characteristics of included studies
The characteristics of the included studies are 
summarised in Table 16. Five RCTs, reported in 
15 papers,63,64,69,134,187–189,241–248 were eligible for this 
comparison, in which a total of 580 participants 
were randomised. 
Two trials took place in New Zealand134,189 and 
one trial each in India,187 Italy188 and Egypt.64 
Recruitment dates were reported in all five studies 
and ranged from April 1996 to December 2003.
All five studies provided details of the participants’ 
IPSS/AUA symptom scores and prostate size, 
showing that all 580 participants had severe 
symptoms and large prostates at trial entry. 
Assessment of effectiveness
Tables giving a detailed description for all 
outcomes can be found in Appendix 8.6 and also 
in Figure 16. The results of the meta-analyses 
are given in Appendix 9.6. Note that in terms of 
long-term evaluation, only the longest follow-up is 
presented.
Symptom scores
At 3 months
Out of the five eligible studies for this comparison, 
only two reported IPSS/AUA symptom scores 
at 3 months after surgery.189,248 No statistically 
significant differences were observed between the 
two groups (Figure 16, comparison 06:01:01: WMD 
–0.47, 95% CI –1.92 to 0.98, p = 0.53).
At 12 months
Five trials reported IPSS/AUA scores measured 
within 12 months. Pooling of the data displayed 
statistically significantly lower scores for laser 
resection (Figure 16, comparison 06:01:03) 
TABLE 16  Summary of the baseline characteristics, laser resection vs TURP
Study Comparators
Number of 
participants
Age 
(years)
Symptom 
scorea
Qmax 
(ml/s)
Residual 
volume 
(ml)
Prostate 
size  
(ml)
Gupta et al., 2006187 Laser resection 50 66 23.4 5.1 112 58
TURP 50 66 23.3 4.5 84 60
Kuntz et al., 200464 Laser resection 100 68 22.1 4.9 238 53
TURP 100 69 21.4 5.9 216 50
Montorsi et al., 
2004188
Laser resection 52 65 21.6 8.2 4 70
TURP 48 64 21.9 7.8 4 56
Westenberg et al., 
2004189
Laser resection 61 67 21.9 8.9 88 44
TURP 59 67 23.0 9.1 85 45
Wilson et al., 
2006134
Laser resection 30 71 26.0 8.4 113 78
TURP 30 70 23.7 8.3 126 70
TURP , transurethral resection of the prostate.
Data given as mean values.
a  Symptom scores given as IPSS/AUA (International Prostate Symptom Score/American Urological Association) 
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Comparison:  06 Laser-resection vs TURP
Outcome:  01 IPSS/AUA
Study
or subcategory n
Laser resection
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
013months
Tan, 2003
248 29 3.40 (4.84) 28 4.80 (4.23) 37.95 −1.40 (−3.76 to 0.96)
Westenberg, 2004
189 59 5.70 (5.20) 61 5.60 (5.10) 62.05 0.10 (−1.74 to 1.94)
Subtotal (95% CI) 88 89 100.00 −0.47 (−1.92 to 0.98)
Test for heterogeneity: χ
2 = 0.97,d f = 1( p = 0.33), I² = 0%
Test for overall effect: z = 0.63 (p = 0.53)
026months
Gupta, 2006
187 50 5.20 (0.31) 50 6.10 (0.42) 94.23 −0.90 (−1.04 to −0.76)
Kuntz, 2004
64 94 2.20 (1.60) 89 3.70 (3.70) 2.84 −1.50 (−2.33 to −0.67)
Montorsi, 2004
188 48 2.90 (2.60) 52 3.90 (2.90) 1.70 −1.00 (−2.08 to 0.08)
Tan, 2003
248 26 6.00 (5.09) 29 4.80 (3.77) 0.35 1.20 (−1.19 to 3.59)
Westenberg, 2004
189 61 3.80 (3.80) 59 5.00 (4.50) 0.89 −1.20 (−2.69 to 0.29)
Subtotal (95% CI) 279 279 100.00 −0.91 (−1.05 to −0.77)
Test for heterogeneity: χ² = 5.10, df = 4( p = 0.28), I² = 21.6%
Test for overall effect: z = 12.76( p < 0.00001)
03 12 months
Gupta, 2006
187 50 5.20 (0.17) 50 5.60 (0.32) 97.70 −0.40 (−0.50 to −0.30)
Kuntz, 2004
64 89 1.70 (1.80) 86 3.90 (3.90) 1.20 −2.20 (−3.11 to −1.29)
Montorsi, 2004
188 48 3.90 (3.60) 52 4.10 (2.30) 0.69 −0.20 (−1.39 to 0.99)
Tan, 2003
248 25 4.30 (3.50) 27 5.00 (4.68) 0.20 −0.70 (−2.94 to 1.54)
Westenberg, 2004
189 43 4.20 (6.00) 41 4.30 (4.10) 0.21 −0.10 (−2.29 to 2.09)
Subtotal (95% CI) 255 256 100.00 −0.42 (−0.52 to −0.32)
Test for heterogeneity: χ² = 15.28, df = 4( p = 0.004), I² = 73.8%
Test for overall effect: z = 8.30 (p < 0.00001)
042years
Westenberg, 2004
189 45 3.40 (4.90) 41 3.70 (4.90) 100.00 −0.30 (−2.37 to 1.77)
Subtotal (95% CI) 45 41 100.00 −0.30 (−2.37 to 1.77)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.28 (p = 0.78)
054years
Westenberg, 2004
189 43 5.20 (5.90) 30 6.60 (5.00) 100.00 −1.40 (−3.91 to 1.11)
Subtotal (95% CI) 43 30 100.00 −1.40 (−3.91 to 1.11)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.09 (p = 0.27)
−10 −5  0  5  10
Favours
laser resection
 Favours TURP
FIGURE 16  Symptom scores, laser resection vs TURP .
with a WMD of –0.42 (95% CI –0.52 to 
–0.32, p < 0.00001). As there appeared to be 
heterogeneity present in this comparison, a 
random-effects model was applied. The WMD still 
favoured laser resection; however, the difference 
was no longer statistically significant (WMD –0.80, 
95% CI –1.70 to 0.10, p = 0.08). 
Longer-term follow-up
Figure 16, comparison 06:01:05 shows data from 
the single trial that compared IPSS scores of 
patients who underwent laser resection and TURP 
at follow-up after 2 and 4 years. There were lower 
scores for laser resection technology as opposed 
to TURP at both follow-ups, although this was not 
statistically significant. However, losses to follow-
up were high at both time periods (Figure 16, 
comparison 06:01:05: MD –1.40, 95% CI –3.91 to 
1.11, p = 0.27).
Complications
Data describing complications by study are given 
in Appendix 8.6, Table 68. In total, 12 categories 
of complications were identified across the five Health Technology Assessment 2008; Vol. 12: No. 35
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studies. These data are difficult to interpret. For 
seven of the complications, data were only available 
for one or two trials. Even for those complications 
more consistently reported, confidence intervals 
are wide and tend to include clinically important 
differences. Furthermore, the length of follow-
up varied across the trials. Results regarding 
blood transfusion, urinary retention, urinary tract 
infection, strictures, TUR syndrome and urinary 
incontinence are presented in this section (Figure 
17). Results for other complications are presented 
in Appendix 9.6, comparison 06:02.
Blood transfusion
In a meta-analysis of five studies64,187–189,248 patients 
allocated to laser resection were less likely to have 
a blood transfusion than those allocated to TURP 
(Figure 17, comparison 06:02:01: 1/293 versus 
9/287, RR 0.27, 95% CI 0.07–0.95, p = 0.04).
Urinary retention
All five studies provided details on the incidence 
of urinary retention after surgery. There were 
15 (5.1%) reports of urinary retention amongst 
293 participants allocated laser resections versus 
21 (7.3%) amongst 287 participants allocated to 
TURP. The direction of effect varied across studies 
and the difference was not statistically significant 
(Figure 17, comparison 06:02:02: RR 0.71, 95% CI 
0.38–1.32, p = 0.28).
Urinary tract infection
There were five reports of urinary tract infection in 
each arm across two studies.189,248 The direction of 
effect varied and the difference was not statistically 
significant (Figure 17, comparison 06:02:03: 5/91 
versus 5/89, RR 0.98, 95% CI 0.31–3.09, p = 0.97).
Stricture
Strictures were reported in all five studies. There 
were no statistically significant differences between 
the two arms in terms of the incidence of strictures 
after surgery (Figure 17, comparison 06:02:04: 
15/287 versus 17/273, RR 0.84, 95% CI 0.43–1.65, 
p = 0.61).
TUR syndrome
Out of the five eligible studies, only one reported 
TUR syndrome. There were no cases of a TUR 
syndrome amongst 52 patients randomised to laser 
resection. In the TURP arm, one event (2%) was 
recorded amongst 48 randomised patients (Figure 
17, comparison 06:02:05: RR 0.31, 95% CI 0.01–
7.39, p = 0.47).
Urinary incontinence
Meta-analysis of four trials64,187–189 showed no 
difference in the risk of developing urinary 
incontinence following laser resection compared 
with the risk for those allocated to TURP (Figure 
17, comparison 06:02:06: 55/252 versus 54/253, 
RR 0.97, 95% CI 0.72–1.31, p = 0.83). This result 
should be interpreted with caution as the length of 
follow-up varied and the type of incontinence was 
not fully described across studies.
Quality of life
Three studies134,188,189 reported quality of life of 
patients following surgery. The quality of life was 
assessed using the IPSS QoL (0–6) questionnaire 
(Figure 18).
At 3 months
Meta-analysis of data from two studies134,189 showed 
no statistically significant difference between 
holmium laser resection and TURP (Figure 18, 
comparison 06:08:01: WMD –0.19, 95% CI –0.68 
to 0.30, p = 0.45).
At 12 months
At 12 months, evidence from three studies134,188,189 
showed marked heterogeneity present in the 
meta-analysis and the direction of effect was not 
consistent. In two studies the total number of 
participants available for quality of life evaluation 
was unclear and therefore this result should be 
treated with further caution. 
Longer-term follow-up
Based on only one trial,189 quality of life appeared 
to be similar in the laser group when compared 
with TURP at 2 and 4 years after surgery (Figure 
18, comparison 06:08:06). A further caution is that 
the total number of participants available for this 
follow-up assessment was unclear.
Urodynamic outcomes
Data on peak urine flow rate, mean urine flow rate, 
residual volume, detrusor pressure and prostate 
size were reported to a varying extent across the 
five studies.64,134,187–189 Only peak urine flow rate 
is presented in this section. Results for the other 
urodynamic outcomes are presented in Appendix 
8.6, Table 69 and Appendix 9.6. comparisons 
06:03–06:07.
At 3 months
Out of the total of five studies, two134,189 reported 
peak urine flow rate at the 3-month follow-up. Clinical effectiveness of other ablative techniques
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Comparison:  06 Laser resection vs TURP
Outcome:  02 Complications
Study or 
subcategory
Laser resection
n/N
TURP
n/N
RR (ﬁxed)
95% CI
Weight
%
RR (ﬁxed)
95% CI
01 Blood transfusion
Gupta, 2006
187 0/50 1/50 13.50 0.33 (0.01–7.99)
Kuntz, 2004
64 0/100 2/100 22.49 0.20 (0.01–4.11)
Montorsi, 2004
188 1/52 1/48 9.36 0.92 (0.06–14.35)
Tan, 2003
248 0/30 1/30 13.50 0.33 (0.01–7.87)
Westenberg, 2004
189 0/61 4/59 41.15 0.11 (0.01–1.95)
Subtotal (95% CI) 293 287 100.00 0.27 (0.07–0.95)
Total events: 1 (Laser resection),9(TURP)
Test for heterogeneity: χ² = 1.24, df = 4( p = 0.87), I² = 0%
Test for overall effect: z = 2.05 (p = 0.04)
02 Urinary retention
Gupta, 2006
187 2/50 3/50 13.84 0.67 (0.12–3.82)
Kuntz, 2004
64 0/100 5/100 25.38 0.09 (0.01–1.62)
Montorsi, 2004
188 3/52 1/48 4.80 2.77 (0.30–25.73)
Tan, 2003
248 5/30 4/30 18.46 1.25 (0.37–4.21)
Westenberg, 2004
189 5/61 8/59 37.53 0.60 (0.21–1.74)
Subtotal (95% CI) 293 287 100.00 0.71 (0.38–1.32)
Total events: 15 (Laser resection), 21 (TURP)
Test for heterogeneity: χ² = 4.33, df = 4( p = 0.36), I² = 7.5%
Test for overall effect: z = 1.09 (p = 0.28)
03 Urinary tract infection
Tan, 2003
248 0/30 2/30 45.05 0.20 (0.01–4.00)
Westenberg, 2004
189 5/61 3/59 54.95 1.61 (0.40–6.45)
Subtotal (95% CI) 91 89 100.00 0.98 (0.31–3.09)
Total events: 5 (Laser resection),5(TURP)
Test for heterogeneity: χ² = 1.58, df = 1( p = 0.21), I² = 36.7%
Test for overall effect: z = 0.04 (p = 0.97)
04 Stricture
Gupta, 2006
187 1/50 2/50 11.50 0.50 (0.05–5.34)
Kuntz, 2004
64 6/95 2/88 11.94 2.78 (0.58–13.41)
Montorsi, 2004
188 1/52 4/48 23.92 0.23 (0.03–1.99)
Tan, 2003
248 1/29 3/28 17.55 0.32 (0.04–2.91)
Westenberg, 2004
189 6/61 6/59 35.08 0.97 (0.33–2.83)
Subtotal (95% CI) 287 273 100.00 0.84 (0.43–1.65)
Total events: 15 (Laser resection), 17 (TURP)
Test for heterogeneity: χ² = 4.58, df = 4( p = 0.33), I² = 12.6%
Test for overall effect: z = 0.51 (p = 0.61)
05 TUR syndrome
Montorsi, 2004
188 0/52 1/48 100.00 0.31 (0.01–7.39)
Subtotal (95% CI) 52 48 100.00 0.31 (0.01–7.39)
Total events: 0 (Laser resection),1(TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.73 (p = 0.47)
06 Incontinence
Gupta, 2006
187 1/50 1/50 1.81 1.00 (0.06–15.55)
Kuntz, 2004
64 27/89 33/86 60.68 0.79 (0.52–1.20)
Montorsi, 2004
188 26/52 18/48 33.84 1.33 (0.85–2.10)
Westenberg, 2004
189 1/61 2/59 3.68 0.48 (0.05–5.19)
Subtotal (95% CI) 252 243 100.00 0.97 (0.72–1.31)
Total events: 55 (Laser resection), 54 (TURP)
Test for heterogeneity: χ² = 3.15, df = 3( p = 0.37), I² = 4.9%
Test for overall effect: z = 0.22 (p = 0.83)
 0.001 0.01  0.1  1  10  100  1000
Favours laser resection Favours TURP
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Comparison:  06 Laser resection vs TURP
Outcome:  09 Quality of life
Study or 
subcategory n
Laser resection
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
013months
Westenberg, 2004
189 61 1.40 (1.50) 59 1.60 (1.40) 88.06 −0.20 (−0.72 to 0.32)
Wilson, 2006
134 28 1.80 (2.10) 29 1.90 (3.23) 11.94 −0.10 (−1.51 to 1.31)
Subtotal (95% CI) 89 88 100.00 −0.19 (−0.68 to 0.30)
Test for heterogeneity: χ² = 0.02, df = 1( p = 0.90), I² = 0%
Test for overall effect: z = 0.76 (p = 0.45)
026months
Montorsi, 2004
188 52 1.00 (0.80) 48 0.60 (0.20) 75.92 0.40 (0.18−0.62)
Westenberg, 2004
189 61 1.10 (1.30) 59 1.50 (1.40) 16.38 −0.40 (−0.88 to 0.08)
Wilson, 2006
134 26 1.60 (1.53) 29 1.50 (1.07) 7.70 0.10 (−0.61 to 0.81)
Subtotal (95% CI) 139 136 100.00 0.25 (0.05−0.44)
Test for heterogeneity: χ² = 8.82, df = 2( p = 0.01), I² = 77.3%
Test for overall effect: z = 2.46 (p = 0.01)
03 12 months
Montorsi, 2004
188 52 1.40 (0.90) 48 0.80 (1.28) 53.95 0.60 (0.16−1.04)
Westenberg, 2004
189 61 0.88 (1.40) 59 1.60 (1.50) 38.17 −0.72 (−1.24 to −0.20)
Wilson, 2006
134 25 1.50 (2.50) 27 1.40 (1.56) 7.88 0.10 (−1.04 to 1.24)
Subtotal (95% CI) 138 134 100.00 0.06 (−0.26 to 0.38)
Test for heterogeneity: χ² = 14.53, df = 2( p = 0.0007), I² = 86.2%
Test for overall effect: z = 0.35 (p = 0.73)
04 18 months
Westenberg, 2004
189 61 0.72 (1.10) 59 1.30 (1.10) 100.00 −0.58 (−0.97 to −0.19)
Subtotal (95% CI) 61 59 100.00 −0.58 (−0.97 to −0.19)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.89 (p = 0.004)
052years
Westenberg, 2004
189 45 0.98 (1.30) 41 1.00 (1.30) 50.44 −0.02 (−0.57 to 0.53)
Wilson, 2006
134 22 1.25 (0.94) 26 1.25 (1.02) 49.56 0.00 (−0.55 to 0.55)
Subtotal (95% CI) 67 67 100.00 −0.01 (−0.40 to 0.38)
Test for heterogeneity: χ² = 0.00, df = 1( p = 0.96), I² = 0%
Test for overall effect: z = 0.05 (p = 0.96)
064years
Westenberg, 2004
189 43 1.10 (1.10) 30 1.40 (1.40) 100.00 −0.30 (−0.90 to 0.30)
Subtotal (95% CI) 43 30 100.00 −0.30 (−0.90 to 0.30)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.98 (p = 0.33)
−10 −5  0  5  10
Favours
laser resection
 Favours TURP
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Laser resection was associated with a higher 
peak urine flow rate (Appendix 9.6, comparison 
06:03:01: WMD 3.49 ml/s, 95% CI 0.63–6.35, 
p = 0.02).
At 12 months
Again, meta-analysis of five studies64,134,187–189 
reporting peak urine flow rate showed higher peak 
urine flow rates for laser resection at 12 months 
after surgery (WMD 1.43, 95% CI 0.92–1.93, 
p < 0.001). 
Longer-term follow-up
Only one study189 reported peak urine flow rates 
at 4 years after the initial operation and this was 
based on about 60% of the original participants. 
No statistically significant difference was observed 
in this outcome between the two groups but the 
confidence interval was wide (Appendix 9.6, 
comparison 06:03:06: WMD 3.80, 95% CI –1.36 to 
8.96, p = 0.15).
Descriptors of care
Data describing selected aspects of care are 
tabulated in Appendix 8.6, Table 70. Information 
on duration of operation, length of hospital stay 
and reoperation rates was identified across five 
eligible studies for this comparison.
Duration of operation
The duration of a laser resection intervention was 
found to be on average 17 minutes longer than a 
TURP intervention (Appendix 9.6, comparison 
06:10: 95% CI 13.45–20.47, p < 0.001). The 
direction and size of effect were consistent across 
studies.
Length of hospital stay
Across the five studies the average length of stay 
was significantly shorter in the laser resection 
group than in the TURP group (Appendix 9.6, 
comparison 06:11: WMD –1.05 days, 95% CI –1.20 
to –0.89, p < 0.001). The direction and size of effect 
were also consistent across studies.
Reoperation 
Reoperations were reported in four trials.64,188,189,248 
No statistically significant differences were 
observed (Appendix 9.6, comparison 06:02:12: 
10/231 versus 15/232, RR 0.68, 95% CI 0.32–1.44, 
p = 0.31).
Summary and conclusions of the evidence 
for and against the intervention
Five RCTs of moderate quality involving 580 
participants were available to compare laser 
resection with TURP. In terms of symptom scores, 
laser resection appeared to be better than TURP; 
however, this difference was only statistically 
significant at 12 months when a complete data 
set involving all 580 participants was available. 
The data also indicate that peak urine flow rate 
was better after laser resection than after TURP 
at 3 and 12 months after the interventions. 
Although these results are statistically significant, 
the difference is small and therefore may not be 
clinically relevant. The rate of blood transfusion for 
laser resection was lower. The occurrence of urinary 
retention, urinary tract infection, stricture, TUR 
syndrome, urinary incontinence and reoperation 
was similar but with wide confidence intervals. 
Quality of life does not appear to differ between 
the two groups and there is good evidence that 
laser resection is associated with longer duration of 
operation but shorter length of hospital stay. 
Clinical effect size
A summary of the clinical effect sizes for all 
outcomes derived from the meta-analyses for which 
data were available is given in Table 17. These 
should be interpreted in view of the comments 
mentioned earlier in this chapter.
Laser vaporisation versus TURP
Characteristics of included studies
The baseline characteristics of the included 
studies are summarised in Table 18. A 
total of 854 participants were randomised 
across 11 eligible RCTs reported in 27 
papers.121,127,141,146,148,153,164,179,190–193,249–263 The total 
number of people allocated to laser vaporisation 
was 425 and the total allocated to TURP was 429.
Three studies took place in the UK,127,164,179 two 
each in the US146,148 and Finland,153,191 and one 
each in Australia,141 France,190 Turkey192 and the 
Netherlands.193 All but two studies146,179 provided 
details on recruitment dates, with the earliest being 
January 1993164 and the latest in January 2004.141
In terms of symptom scores, all but three 
studies141,153,191 reported IPSS/AUA scores. Of the 
studies reporting baseline IPSS/AUA scores, 285 
(84%) participants allocated to laser vaporisation 
had severe symptoms of BPE and 55 (16%) had 
moderate symptoms compared with 201 (59%) with 
severe and 155 (46%) with moderate symptoms 
allocated to TURP. 
Of the studies reporting prostate size, 226 (57%) 
participants allocated to laser vaporisation had Health Technology Assessment 2008; Vol. 12: No. 35
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TABLE 17  Summary of the clinical effect sizes from meta-analyses, laser resection vs TURP
Outcome
Number of trials 
MA (total) Effect size 95% CI p-value
IPSS/AUA score
3 months 2 (2) –0.47a –1.92 to 0.98 0.53
12 months 5 (5) –0.42a –0.5 to –0.32 < 0.001
Longer term 1 (1) –1.40a –3.9 to 1.11 0.27
Blood transfusion 5 (5) 0.27b 0.07–0.95 0.04
Urinary retention 5 (5) 0.71b 0.38–1.31 0.28
Urinary tract infection 2 (2) 0.98b 0.31–3.09 0.97
Stricture 5 (5) 0.84b 0.43–1.65 0.61
TUR syndrome 1 (1) 0.31b 0.01–7.39 0.47
Incontinence 4 (4) 0.97b 0.72–1.31 0.83
Quality of life
3 months 2 (2) –0.19a –0.6 to 0.30 0.45
12 months 3 (3) 0.06a –0.2 to 0.38 0.73
Longer term 1 (1) –0.30a –0.9 to 0.30 0.33
Qmax
3 months 2 (2) 3.49a 0.63–6.35 0.02
12 months 5 (5) 1.43a 0.92–1.93 < 0.001
Longer term 1 (1) 3.80a –1.3 to 8.96 0.15
Duration of operation 5 (5) 16.96a 13.45–20.47 < 0.001
Length of hospital stay 4 (4) –1.05a –1.2 to –0.89 < 0.001
Reoperation 4 (4) 0.68b 0.32–1.44 0.31
IPSS/AUA, International Prostate Symptom Score/American Urological Association MA, meta-analysed; TUR, transurethral 
resection; TURP , transurethral resection of the prostate.
a  Weighted mean difference. 
b  Relative risk.
large prostates, 112 (28%) had moderate-sized 
prostates and 10 (2%) had small prostates. In the 
TURP arm, 200 (51%) had large prostates, 113 
(29%) had moderate-sized prostates and 86 (22%) 
had small prostates. 
Assessment of effectiveness
As discussed in Chapter 2 there are several 
laser devices that can be used to vaporise the 
prostate. The most commonly used are Nd:YAG, 
holmium:YAG and KTP lasers. These can be used 
either alone or in combination (hybrid laser). For 
analysis purposes, trials reporting a vaporisation 
technique were combined, regardless of the 
method/devices used.
Symptom scores
At 3 months
Of the 11 eligible studies, only five provided 
details on IPSS/AUA scores at 3 months following 
surgery.146,164,179,190,192 Meta-analysis of three of 
these trials164,179,192 is marked by considerable 
heterogeneity in which the direction of effect 
and effect sizes vary across studies with one study 
favouring TURP.164 The source of heterogeneity is 
unclear; however, it may be due to different levels 
of energy delivery across studies. Moreover, there is 
variation in the prostate size of patients measured 
before surgery. On average, patients included in 
the Oxford laser trial164 exhibited large prostates 
whereas those included in the trial by Suvakovic 
and Hindmarsh had small prostates.179 Sengor and Clinical effectiveness of other ablative techniques
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TABLE 18  Summary of the baseline characteristics, laser vaporisation vs TURP
Study Comparators
Number of 
participants
Age 
(years)
Symptom 
scorea
Qmax 
(ml/s)
Residual 
volume 
(ml)
Prostate 
size  
(ml)
Bouchier-Hayes et 
al., 2006141
Laser vaporisation 38 65 NR NR NR 42
TURP 38 66 NR NR NR 33
Carter et al., 
1999127
Laser vaporisation 95 68 20.3 9.0 109 42
TURP 96 67 19.8 9.5 135 42
Keoghane et al., 
2000164
Laser vaporisation 72 69 19.9 11.8 NR 55
TURP 79 70 19.4 11.4 NR 52
Mottet et al., 
1999190
Laser vaporisation 17 64 21.7 8.8 NR 37
TURP 13 67 23.7 7.7 NR 34
Sengor et al., 
1996192
Laser vaporisation 30 61 21.8 8.7 110 NR
TURP 30 66 22.1 8.4 155 NR
Shingleton et al., 
2002146
Laser vaporisation 50 68 22 NR NR 32
TURP 50 67 21 NR NR 30
Suvakovic and 
Hindmarsh,1996179
Laser vaporisation 10 63 18.0 12.2 140 24
TURP 10 66 18.8 11.1 162 22
Tuhkanen et al., 
2001191
Laser vaporisation 21 67b 23b,c 7.2 138 55
TURP 25 67b 19b,c 8.5 125 55
Tuhkanen et al., 
2003153
Laser vaporisation 26 68b 18b,c 8.3b 87b 30b
TURP 26 67b 18b,c 8.6b 83b 28b
van Melick et al., 
2003193
Laser vaporisation 45 67 18.9 12.0 300 37
TURP 50 66 16.8 11.0 350 37
Zorn et al., 1999148 Laser vaporisation 21 71 24.0 8.7 NR 30
TURP 12 69 24.7 9.0 NR 34
NR, not reported; TURP , transurethral resection of the prostate.
Data given as mean values (unless stated otherwise).
a  Symptom scores given as IPSS/AUA (International Prostate Symptom Score/American Urological Association) unless 
stated otherwise.
b  Median.
c  Danish Prostatic Symptom Score (Dan PSS1).
colleagues192 did not provide details on baseline 
prostate size. 
At 12 months
At 12 months, all but one study193 out of eight 
favoured TURP. Pooling the data of three studies 
amenable to meta-analysis showed statistically 
significant better IPSS/AUA scores in support of 
TURP. However, confidence intervals were wide, 
there was evidence of heterogeneity and the trials 
included a small number of participants (Figure 19, 
comparison 07:01:03: WMD 1.30, 95% CI 0.12–
2.47, p = 0.03). 
Longer-term follow-up
At 5 years, combining data from three trials gave 
higher (poorer) scores for laser vaporisation than 
for TURP (Figure 19, comparison 07:01:06: WMD 
2.42, 95% CI 0.08–4.75, p = 0.04). 
Complications
Data describing complications by study are given 
in Appendix 8.7, Table 72. Information from 
one or more of the 11 trials was available for 17 
complications. Results regarding blood transfusion, 
urinary retention, urinary tract infection, strictures, 
TUR syndrome and urinary incontinence are Health Technology Assessment 2008; Vol. 12: No. 35
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presented in this section (Figure 20). Results for 
other complications are presented in Appendix 
9.7, comparison 07:02. The results of these meta-
analyses should be treated with caution as the 
length of follow-up of the RCTs varied.
Blood transfusion
In the ten studies127,141,146,148,153,164,190–193 that reported 
blood transfusion there was only one transfusion 
amongst 374 laser patients versus 24 amongst 415 
TURP patients (Figure 20, comparison 07:02:01: 
RR 0.14, 95% CI 0.05–0.42, p = 0.0004).
Urinary retention
In six studies 127,146,164,190,191,193 a total of 32 (10.5%) 
cases of urinary retention amongst 304 patients 
allocated to laser vaporisation versus 11 (3.6%) 
cases amongst 306 TURP patients were reported 
(Figure 20, comparison 07:02:02: RR 2.89, 95% CI 
1.55–5.42, p = 0.0009). 
Urinary tract infection
Meta-analysis of data from four studies127,153,164,193 
indicated fewer episodes of urinary tract infection 
following TURP with an RR of 1.63 (95% CI 
0.99–2.69, p = 0.05). However, this result depends 
entirely on data from the study by Carter and 
colleagues,127 as epididymitis and prostatitis are 
reported as well as simple urinary tract infections 
that occurred in the early postoperative period. 
When only epididymitis and prostatitis are 
considered, the difference in rates observed in the 
laser vaporisation and TURP groups is no longer 
statistically significant (RR 1.17, 95% CI 0.60–2.26, 
p = 0.32). 
Strictures
The incidence of strictures for those who 
underwent laser vaporisation and TURP was 
available from nine studies.127,141,146,153,164,190–193 The 
proportion of people who developed strictures 
appeared to be lower following laser vaporisation 
than following TURP. The pooled RR of strictures 
among laser patients compared with TURP 
patients was 0.54 (Figure 20, comparison 07:02:04: 
13/350 versus 27/353, 95% CI 0.32–0.90, p = 0.02). 
It should be noted that eight of the 13 strictures 
and 11 of the 27 strictures observed in the laser 
vaporisation and TURP groups, respectively, were 
actually bladder neck contractures.
TUR syndrome
There were no cases of TUR syndrome amongst 
161 patients allocated to laser vaporisation 
compared with one amongst 122 patients allocated 
to TURP (Figure 20, comparison 07:02:05: RR 
0.33, 95% CI 0.01–7.93, p = 0.50).
Incontinence
Taken together, data from five trials suggest 
a higher rate of incontinence following laser 
vaporisation (Figure 20, comparison 07:02:06: 
16/272 versus 7/285, RR 2.24, 95% CI 1.03–4.88, 
p = 0.04). However, this result depended on a single 
trial193 in which rates were high in both groups 
but particularly following laser vaporisation. This 
result should also be treated with caution because 
the length of follow-up varied and the definition of 
incontinence was not fully described in the studies. 
Quality of life
Three studies193,249,250 using a variety of methods 
reported quality of life of patients following surgery 
(Appendix 8.7, Table 73). In one study193 the quality 
of life was assessed using the disease-specific IPSS 
QoL (0–6) questionnaire. In another study249 the 
generic quality of life measure Medical Outcomes 
Study 36-item Short Form Health Study (SF-36) 
was used. In the third study250 quality of life was 
measured using two distinct instruments: SF-36 and 
EuroQol Five Dimensions (EQ-5D) (scored using 
the UK tariffs).
At 3 months there appeared to be little change in 
quality of life as a consequence of either surgical 
intervention, irrespective of which quality of life 
tool was used.250 No differences in quality of life 
were detected in two studies193,250 at 12 months.
Urodynamic outcomes
Data on peak urine flow rate, mean urine flow rate, 
residual volume, detrusor pressure and prostate 
size were reported to a varying extent across eight 
studies.127,146,148,153,164,190–192 Only peak urine flow rate 
is presented in this section. Results for the other 
urodynamic outcomes are presented in Appendix 
8.7, Table 74 and Appendix 9.7, comparisons 
07:04–07:08.
At 3 months 
Six studies146,153,164,190–192 provided details on peak 
urine flow rate for patients at 3 months after 
surgery. Only four,146,153,164,192 however, presented 
data that were sufficiently similar to allow 
quantitative synthesis. The WMD was 1.76 ml/s, 
lower (worse) for laser vaporisation (Appendix 
9.7, comparison 07:04:01: 95% CI 0.57–2.94, 
p = 0.004). This result was consistent with that 
reported by Tuhkanen and colleagues191 but not 
with the small study reported by Mottet and 
colleagues.190 Clinical effectiveness of other ablative techniques
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Review:  BPE
Comparison:  07 Laser vaporisation vs TURP
Outcome:  01 IPSS/AUA
Study or 
subcategory n
Laser
vaporisation
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
013months
Keoghane, 2000
164 55 9.60 (7.50) 62 6.50 (5.10) 34.07 3.10 (0.75−5.45)
Sengor, 1996
192 30 8.50 (4.20) 30 9.80 (3.10) 54.10 −1.30 (−3.17 to 0.57)
Suvakovic, 1996
197 10 9.70 (2.60) 10 12.80 (5.90) 11.82 −3.10 (−7.10 to 0.90)
Subtotal (95% CI) 95 102 100.00 −0.01 (−1.39 to 1.36)
Test for heterogeneity: χ² = 10.84, df = 2( p = 0.004), I² = 81.5%
Test for overall effect: z = 0.02 (p = 0.98)
026months
van Melick, 2003a
193 33 5.90 (5.50) 37 3.20 (2.70) 37.90 2.70 (0.63 − 4.77)
Sengor, 1996
192 30 7.80 (2.60) 30 9.30 (4.20) 51.90 −1.50 (−3.27 to 0.27)
Suvakovic, 1996
197 9 8.70 (5.40) 10 8.50 (3.00) 10.20 0.20 (−3.79 to 4.19)
Subtotal (95% CI) 72 77 100.00 0.27 (−1.01 to 1.54)
Test for heterogeneity: χ² = 9.16, df = 2( p = 0.01), I² = 78.2%
Test for overall effect: z = 0.41 (p = 0.68)
03 12 months
Keoghane, 2000
164 52 8.87 (6.51) 60 5.77 (5.40) 27.67 3.10 (0.86−5.34)
van Melick, 2003a
193 37 3.60 (3.40) 41 4.10 (4.80) 41.16 −0.50 (−2.33 to 1.33)
Shingleton, 2002
146 40 6.00 (6.00) 33 3.80 (4.10) 25.54 2.20 (−0.13 to 4.53)
Suvakovic, 1996
197 9 8.70 (4.90) 10 7.20 (6.10) 5.63 1.50 (−3.45 to 6.45)
Subtotal (95% CI) 138 144 100.00 1.30 (0.12−2.47)
Test for heterogeneity: χ² = 6.78, df = 3( p = 0.08), I² = 55.7%
Test for overall effect: z = 2.16 (p = 0.03)
042years
Keoghane, 2000
164 45 7.80 (6.60) 52 5.70 (6.00) 58.51 2.10 (−0.43 to 4.63)
Shingleton, 2002
146 23 5.90 (5.70) 19 4.60 (4.20) 41.49 1.30 (−1.70 to 4.30)
Subtotal (95% CI) 68 71 100.00 1.77 (−0.16 to 3.70)
Test for heterogeneity: χ² = 0.16, df = 1( p = 0.69), I² = 0%
Test for overall effect: z = 1.79 (p = 0.07)
054years
van Melick, 2003a
193 10 9.30 (5.20) 15 5.80 (7.50) 100.00 3.50 (−1.48 to 8.48)
Subtotal (95% CI) 10 15 100.00 3.50 (−1.48 to 8.48)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.38 (p = 0.17)
065years
Keoghane, 2000
164 25 9.70 (7.50) 32 7.00 (5.70) 43.35 2.70 (−0.84 to 6.24)
Shingleton, 2002
146 29 9.90 (6.70) 33 7.70 (5.60) 56.65 2.20 (−0.90 to 5.30)
Subtotal (95% CI) 54 65 100.00 2.42 (0.08−4.75)
Test for heterogeneity: χ² = 0.04, df = 1( p = 0.84), I² = 0%
Test for overall effect: z = 2.03 (p = 0.04)
077years
van Melick, 2003a
193 17 8.30 (6.40) 15 7.30 (7.10) 100.00 1.00 (−3.71 to 5.71)
Subtotal (95% CI) 17 15 100.00 1.00 (−3.71 to 5.71)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.42 (p = 0.68)
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Review:  BPE
Comparison:  07 Laser vaporisation vs TURP
Outcome:  02 Complications
Study or 
subcategory
Laser vaporisation
n/N
TURP
n/N
RR (ﬁxed)
95% CI
Weight
%
RR (ﬁxed)
95% CI
01 Blood transfusion
Bouchier-Hayes, 2006
283 0/38 1/38 5.79 0.33 (0.01–7.93)
Carter, 1999
127 0/95 5/96 21.12 0.09 (0.01–1.64)
Keoghane, 2000
164 0/72 13/76 50.73 0.04 (0.00–0.65)
van Melick, 2003a
193 0/45 1/50 5.49 0.37 (0.02–8.85)
Mottet, 1999
190 0/23 0/13 Not estimable
Sengor, 1996
192 0/30 2/30 9.65 0.20 (0.01–4.00)
Shingleton, 2002
146 0/50 0/50 Not estimable
Tuhkanen, 2001
191 1/21 2/24 7.21 0.57 (0.06–5.86)
Tuhkanen, 2003
153 0/26 0/26 Not estimable
Zorn, 1999
148 0/12 0/12 Not estimable
Subtotal (95% CI) 412 415 100.00 0.14 (0.05–0.42)
Total events: 1 (Laser vaporisation), 24 (TURP)
Test for heterogeneity: χ² = 2.99, df = 5( p = 0.70), I² = 0%
Test for overall effect: z = 3.51 (p = 0.0004)
02 Urinary retention
Carter, 1999
127 5/93 2/92 17.15 2.47 (0.49–12.43)
Keoghane, 2000
164 17/72 8/76 66.37 2.24 (1.03–4.87)
van Melick, 2003a
193 5/45 0/50 4.04 12.20 (0.69–214.56)
Mottet, 1999
190 0/23 0/13 Not estimable
Shingleton, 2002
146 3/50 1/50 8.53 3.00 (0.32–27.87)
Tuhkanen, 2001
191 2/21 0/25 3.91 5.91 (0.30–116.66)
Subtotal (95% CI) 304 306 100.00 2.89 (1.55–5.42)
Total events: 32 (Laser vaporisation), 11 (TURP)
Test for heterogeneity: χ² = 1.64, df = 4( p = 0.80), I² = 0%
Test for overall effect: z = 3.32 (p = 0.0009)
03 Urinary tract infection
Carter, 1999
127 11/93 6/92 39.72 1.81 (0.70–4.70)
Keoghane, 2000
164 2/72 3/76 19.22 0.70 (0.12–4.09)
van Melick, 2003a
193 4/45 5/50 31.19 0.89 (0.25–3.11)
Tuhkanen, 2003
153 0/26 1/26 9.88 0.33 (0.01–7.82)
Subtotal (95% CI) 236 244 100.00 1.17 (0.60–2.26)
Total events: 17 (Laser vaporisation), 15 (TURP)
Test for heterogeneity: χ² = 1.93, df = 3( p = 0.59), I² = 0%
Test for overall effect: z = 0.46 (p = 0.65)
04 Strictures
Bouchier-Hayes, 2006
283 5/38 8/38 21.49 0.63 (0.22–1.74)
Carter, 1999
127 7/84 15/85 40.06 0.47 (0.20–1.10)
Keoghane, 2000
164 0/72 5/76 14.38 0.10 (0.01–1.70)
van Melick, 2003a
193 2/45 2/50 5.09 1.11 (0.16–7.56)
Mottet, 1999
190 0/23 2/13 8.48 0.12 (0.01–2.26)
Sengor, 1996
192 0/30 0/30 Not estimable
Shingleton, 2002
146 4/50 1/50 2.69 4.00 (0.46–34.54)
Tuhkanen, 2001
191 0/21 1/24 3.77 0.38 (0.02–8.83)
Tuhkanen, 2003
153 0/25 1/25 4.03 0.33 (0.01–7.81)
Subtotal (95% CI) 388 391 100.00 0.54 (0.32–0.90)
Total events: 18 (Laser vaporisation), 35 (TURP)
Test for heterogeneity: χ² = 6.59, df = 7( p = 0.47), I² = 0%
Test for overall effect: z = 2.35 (p = 0.02)
05 TUR syndrome
Bouchier-Hayes, 2006
283 0/38 1/38 100.00 0.33 (0.01–7.93)
Carter, 1999
127 0/93 0/92 Not estimable
Sengor, 1996
192 0/30 0/30 Not estimable
Subtotal (95% CI) 161 160 100.00 0.33 (0.01–7.93)
Total events: 0 (Laser vaporisation), 1 (TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.68 (p = 0.50)
06 Incontinence
Carter, 1999
127 1/84 0/85 6.10 3.04 (0.13–73.47)
Keoghane, 2000
164 0/72 1/76 17.91 0.35 (0.01–8.49)
van Melick, 2003a
193 14/45 4/50 46.49 3.89 (1.38–10.95)
Shingleton, 2002
146 1/50 1/50 12.27 1.00 (0.06–15.55)
Tuhkanen, 2001
191 0/21 1/24 17.23 0.38 (0.02–8.83)
Subtotal (95% CI) 272 285 100.00 2.24 (1.03–4.88)
Total events: 16 (Laser vaporisation), 7 (TURP)
Test for heterogeneity: χ² = 3.98, df = 4( p = 0.41), I² = 0%
Test for overall effect: z = 2.04 (p = 0.04)
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At 12 months
Five studies127,146,148,164,190 provided details on 
peak urine flow rate at 12 months after surgery. 
Only two,146,164 however, presented data that were 
sufficiently similar to allow quantitative synthesis. 
The WMD was 2.02 ml/s, lower (worse) for laser 
vaporisation (Appendix 9.7, comparison 07:04:03: 
95% CI 0.71–4.75, p = 0.15). With regard to the 
studies in which data were not amenable to meta-
analysis, two127,148 favoured TURP and one190 
favoured laser vaporisation. 
Longer-term follow-up
Meta-analysis of data from two146,164 studies 
reporting 5-year data showed no statistically 
significant difference between the two groups 
(Appendix 9.7, comparison 07:04:06: WMD 0.28, 
95% CI 1.76–2.32, p = 0.79). Loss to follow-up was 
high in both trials.
Descriptors of care
Data describing descriptors of care are tabulated in 
Appendix 8.7, Table 75. Information on duration of 
operation, length of hospital stay and reoperation 
rates was identified across the eligible studies for 
this comparison.
Duration of operation
A total of nine studies127,148,153,164,179,190–193 provided 
information on duration of operation. In three 
studies164,179,192 the mean duration of operation 
was shorter in the laser group and in one193 there 
were no differences between the two groups. Meta-
analysis of four studies with suitable data showed 
a non-statistically significant difference between 
laser vaporisation and TURP (Appendix 9.7, 
comparison 07:11: WMD 0.29, 95% CI –2.19 to 
2.78, p = 0.82).
Length of hospital stay
Length of hospital stay was reported in eight 
studies, with six favouring the laser vaporisation 
group and two favouring TURP.153,191 Only one 
study reported means and standard deviations141,193 
and meta-analysis suggested that there was no 
evidence of a difference between the two groups 
(Appendix 9.7, comparison 07:12).
Reoperations
Reoperations were reported in nine 
trials.141,146,148,153,164,190,191,193,249 Reoperation was more 
common in the laser vaporisation group (9.3%) 
than in the TURP groupt (5.4%) (Appendix 9.7, 
comparison 07:03:17: RR 1.60, 95% CI 0.97–2.63, 
p = 0.06). It should be noted that differences 
between studies in timing and completeness of 
follow-up might have introduced bias. 
Summary and conclusions of the evidence 
for and against the intervention
A total of 854 participants were randomised across 
11 eligible studies of generally moderate quality. 
At 12 months or longer, the data indicated that 
symptom scores were worse after laser vaporisation 
than after TURP. There was a tendency for peak 
urine flow rate to favour TURP but this was only 
statistically significant at the 3- and 12-month 
follow-up assessments. The differences observed 
for both symptom scores and peak urine flow 
rate, although statistically significant, may not 
be clinically relevant or appreciable by patients. 
The occurrence of complications such as urinary 
retention, urinary tract infection and incontinence 
was higher for laser vaporisation than for TURP. 
However, blood transfusion and the incidence of 
strictures were lower. The duration of operation 
and length of hospital stay did not appear to differ 
between the two approaches. 
The results for symptom scores displayed 
significant heterogeneity and there was a lack of 
consistency in the direction and size of effect across 
studies. Much of the variation might be due to 
differences in the specific aims and objectives of 
the trials. 
Clinical effect size
A summary of the clinical effect sizes for all 
outcomes derived from the meta-analyses for 
which data were available is given in Table 19. 
These should be interpreted in view of all of the 
comments mentioned earlier in this chapter.
Interventions using non-
laser technology
Transurethral vaporesection 
of the prostate (TUVRP) 
versus TURP
Characteristics of included studies
The characteristics of the included studies are 
summarised in Table 20. Five RCTs68,132,187,202,203 were 
eligible for this comparison, randomising a total of 
271 men to TUVRP and 258 to TURP. 
Single studies took place in India,187 Taiwan,132 
Turkey,203 Saudi Arabia68 and Germany.202 Three 
studies provided details of recruitment dates132,187,203 Health Technology Assessment 2008; Vol. 12: No. 35
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with the earliest in November 1997203 and the latest 
in December 2003.187
In terms of baseline IPSS/AUA scores, the total 
numbers of participants with moderate and severe 
symptoms who were allocated to TUVRP were 93 
(34%) and 178 (66%) respectively. The equivalent 
figures in the TURP group were 142 (55%) and 116 
(45%).
All studies reported prostate size, with all 529 
participants having large prostates.
Assessment of effectiveness
Tables giving a detailed description for all 
outcomes can be found in Appendix 8.8. The 
results of the meta-analyses are given in Appendix 
9.8. Note that in terms of long-term evaluation, 
only the longest follow-up is presented.
Symptom scores
At 3 months
At 3 months after surgery, IPSS/AUA scores were 
reported in three of the five eligible studies.132,202,203 
Two of the three studies reported no statistically 
significant differences between TUVRP and TURP 
(Appendix 8.8, Table 76), whereas in the third study, 
reporting means and standard deviations, the 
mean difference was 0.30 (Figure 21, comparison 
08:01:01: 95% CI 0.63–1.23, p = 0.53).
At 12 months
Evidence from two studies showed no statistically 
significant differences in IPSS/AUA scores at 
12 months after TUVRP and TURP (Figure 21, 
comparison 08:01:03: WMD –0.59, 95% CI –1.40 
to 0.23, p = 0.16).
TABLE 19  Summary of the clinical effect sizes from meta-analyses, laser vaporisation vs TURP
Outcome
Number of trials 
MA (total) Effect size 95% CI p-value
IPSS/AUA score
3 months 3 (8) –0.01a –1.39 to 1.36 0.98
12 months 4 (9) 1.30a 0.12–2.47 0.03
Longer term 2 (3) 2.42a 0.08–4.75 0.04
Blood transfusion 10 (10) 0.14b 0.05–0.42 < 0.001
Urinary retention 6 (6) 2.89b 1.55–5.42 < 0.001
Urinary tract infection 4 (4) 1.63b 0.99–2.69 0.05
Stricture 9 (9) 0.54b 0.32–0.90 0.02
TUR syndrome 3 (3) 0.33b 0.01–7.93 0.50
Incontinence 5 (5) 2.24b 1.03–4.88 0.04
Quality of life
3 months 0 (2) NR NR NR
12 months 1 (3) 0.00a –0.40 to 0.40 1.00
Longer term 1 (1) 0.10a –0.77 to 0.97 0.82
Qmax
3 months 4 (6) –1.76a –2.94 to –0.57 0.004
12 months 2 (5) –2.02a –4.75 to 0.71 0.15
Longer term 2 (3) –0.28a –2.32 to 1.76 0.79
Duration of operation 4 (9) 0.29a –2.19 to 2.78 0.82
Length of hospital stay 2 (9) –1.39a –1.69 to –1.10 < 0.001
Reoperation 9 (9) 1.68b 1.03–2.74 0.04
IPSS/AUA, International Prostate Symptom Score/American Urological Association MA, meta-analysed, NR, not reported; 
TUR, transurethral resection; TURP , transurethral resection of the prostate.
a  Weighted mean difference.
b  Relative risk.Clinical effectiveness of other ablative techniques
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TABLE 20  Summary of the baseline characteristics, TUVRP vs TURP
Study Comparators
Number of 
participants
Age 
(years)
Symptom 
scorea
Qmax 
(ml/s)
Residual 
volume 
(ml)
Prostate 
size  
(ml)
Helke et al., 2001202 TUVRP  93 69 17.3 10.8 76 49
TURP 92 67 18.3 8.5 102 50
Kupeli et al., 2001203 TUVRP  50 61 21.6 9.2 NR 57
TURP 50 59 19.4 7.9 NR 58
Gupta et al., 2006187 TUVRP  50 68 24.9 4.6 103 63
TURP 50 66 23.3 4.5 84 60
Liu et al., 2006132 TUVRP  44 66 25.6 6.9 131 58
TURP 32 65 26.8 6.9 142 60
Talic et al., 200068 TUVRP  34 71 24.9 7.5 NR 57
TURP 34 70 20.1 9.1 NR 52
NR, not reported; TURP , transurethral resection of the prostate; TUVRP , transurethral vaporesection of the prostate.
Data given as mean values.
a  Symptom scores given as IPSS/AUA, International Prostate Symptom Score/American Urological Association.
Longer-term follow-up
IPSS/AUA scores at 2 years after surgery were 
provided in one trial. Again, no statistically 
significant differences were observed between 
TUVRP and TURP (Figure 21, comparison 
08:01:04: WMD 0.60, 95% CI –1.09 to 2.29, 
p = 0.49). 
Complications
The list of complications by study is detailed in 
Appendix 8.8, Table 77. Data describing 12 types of 
complications were variably reported across the five 
studies. The data were too few to provide precise 
estimates of differences and all confidence intervals 
were wide, such that clinically important differences 
could not be ruled out. None of the complications 
proved to be significantly different between TUVRP 
and TURP. Results regarding blood transfusion, 
urinary retention, urinary tract infection, strictures, 
TUR syndrome and urinary incontinence are 
presented in this section (Figure 22). Results for 
other complications are presented in Appendix 9.8, 
comparison 08:02.
Blood transfusion
All five trials provided information on blood 
transfusions.68,132,187,202,203 A total of seven (2.3%) 
patients required a blood transfusion following 
TUVRP as opposed to 12 (4.6%) patients following 
TURP (Figure 22, comparison 08:02:01: RR 0.57, 
95% CI 0.24–1.36, p = 0.20).
Urinary retention
There were six cases of urinary retention 
amongst 144 patients randomised to TUVRP 
versus seven cases of urinary retention amongst 
132 patients randomised to TURP (Figure 22, 
comparison 08:02:02: RR 0.72, 95% CI 0.26–2.05, 
p = 0.54).132,187,203 
Urinary tract infection
No studies reported this outcome.
Stricture
Four studies132,187,202,203 reported the incidence of 
strictures postoperatively. Meta-analysis showed no 
statistically significant differences between TUVRP 
and TURP (Figure 22, comparison 08:02:03: 
9/229 versus 11/218, RR 0.75, 95% CI 0.32–1.77, 
p = 0.51).
TUR syndrome
There were no cases of a TUR syndrome in the 
TUVRP arm amongst 128 patients across three 
studies68,132,203 compared with two (7%) events 
following TURP.
Urinary incontinence
Incontinence was reported in four 
studies.132,187,202,203 There were 15 and 17 reports 
of incontinence amongst 229 and 218 patients 
allocated to TUVRP and TURP respectively (Figure 
22, comparison 08:02:05, RR 0.85, 95% CI 0.45–
1.61, p = 0.62).Health Technology Assessment 2008; Vol. 12: No. 35
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Review:  BPE
Comparison:  08 TUVRP vs TURP
Outcome:  01 IPSS
Study or 
subcategory n
TUVRP
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
013months
Liu, 2006
132 42 8.20 (2.20) 30 7.90 (1.80) 100.00 0.30 (−0.63 to 1.23)
Subtotal (95% CI) 42 30 100.00 0.30 (−0.63 to 1.23)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.63 (p = 0.53)
026months
Gupta, 2006
187 50 5.90 (1.78) 50 6.10 (2.97) 72.20 −0.20 (−1.16 to 0.76)
Talic, 2000
68 34 4.00 (3.40) 34 5.60 (3.10) 27.80 −1.60 (−3.15 to −0.05)
Subtotal (95% CI) 84 84 100.00 −0.59 (−1.40 to 0.23)
Test for heterogeneity: χ² = 2.27,d f = 1( p = 0.13), I² = 56.0%
Test for overall effect: z = 1.42 (p = 0.16)
03 12 months
Gupta, 2006
187 50 5.40 (1.97) 50 5.60 (2.26) 76.66 −0.20 (−1.03 to 0.63)
Helke, 2001
202 79 4.66 (4.30) 73 5.21 (5.10) 23.34 −0.55 (−2.06 to 0.96)
Subtotal (95% CI) 129 123 100.00 −0.28 (−1.01 to 0.45)
Test for heterogeneity: χ² = 0.16,d f = 1( p = 0.69), I² = 0%
Test for overall effect: z = 0.76 (p = 0.45)
04 24 months
Liu, 2006
132 23 9.00 (3.10) 21 8.40 (2.60) 100.00 0.60 (−1.09 to 2.29)
Subtotal (95% CI) 23 21 100.00 0.60 (−1.09 to 2.29)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.70 (p = 0.49)
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FIGURE 21  Symptom scores, TUVRP vs TURP .
Quality of life
Only one study132 reported quality of life of patients 
following TUVRP or TURP (Appendix 8.8, Table 
78). Quality of life was assessed using the IPSS 
QoL (0–6) questionnaire. At 3 months and 2 years 
there appeared to be little difference in quality of 
life between the groups as a consequence of either 
surgical intervention (Appendix 9.8, comparison 
08:05).
Urodynamic outcomes
Data on peak urine flow rate and prostate size were 
reported across five studies.68,132,187,202,203 These are 
tabulated in Appendix 8.8, Table 79. Only peak 
urine flow rate is presented in this section. 
At 3 months
Two studies132,202 provided details on peak urine 
flow rate for patients at 3 months after surgery. In 
one trial132 the mean difference was 0.90 ml/s for 
TUVRP versus TURP (Appendix 9.8, comparison 
08:03:01: 95% CI –0.04 to 1.84, p = 0.06). Helke 
and colleagues202 reported a non-statistically 
significant difference between the two groups.
At 12 months
Two studies,187,202 provided details on peak urine 
flow rate at 12 months after surgery. The WMD 
was 0.10 ml/s for TUVRP versus TURP (Appendix 
9.8, comparison 08:03:03: 95% CI –0.41 to 0.61, 
p = 0.70). 
Longer-term follow-up
One study132 provided results beyond 12 months 
(2 years). At this time point there was a non-
statistically significant difference between TUVRP 
and TURP (Appendix 9.8, comparison 08:03:04: 
WMD 1.60, 95% CI –0.30 to 3.50, p = 0.10).
Descriptors of care
Data describing descriptors of care are tabulated in 
Appendix 8.8, Table 80. Information on duration of 
operation, length of hospital stay and reoperation 
rates was identified to a varying extent across the 
five eligible studies for this comparison.
Duration of operation
Three studies68,132,187 provided information on 
the duration of operation. The results were not Clinical effectiveness of other ablative techniques
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FIGURE 22  Complications, TUVRP vs TURP .
Review:  BPE
Comparison:  08 TUVRP vs TURP
Outcome:  02 Complications
Study or 
subcategory
TUVRP
n/N
TURP
n/N
RR (ﬁxed)
95% CI
Weight
%
RR (ﬁxed)
95% CI
01 Blood transfusion
Gupta, 2006
187 0/50 1/50 11.66 0.33 (0.01–7.99)
Helke, 2001
202 6/93 9/92 70.34 0.66 (0.24–1.78)
Kupeli, 2001
203 0/50 0/50 Not estimable
Liu, 2006
132 1/44 2/32 18.00 0.36 (0.03–3.84)
Talic, 2000
68 0/34 0/34 Not estimable
Subtotal (95% CI) 271 258 100.00 0.57 (0.24–1.36)
Total events:7(TUVRP), 12 (TURP)
Test for heterogeneity: χ
2 = 0.33, df = 2( p = 0.85), I
2 = 0%
Test for overall effect: z = 1.27 (p = 0.20)
02 Urinary retention
Gupta, 2006
187 3/50 3/50 39.31 1.00 (0.21–4.72)
Kupeli, 2001
203 0/50 0/50 Not estimable
Liu, 2006
132 3/44 4/32 60.69 0.55 (0.13–2.27)
Subtotal (95% CI) 144 132 100.00 0.72 (0.26–2.05)
Total events:6(TUVRP), 7 (TURP)
Test for heterogeneity: χ
2 = 0.32, df = 1( p = 0.57), I
2 = 0%
Test for overall effect: z = 0.61 (p = 0.54)
03 Stricture
Gupta, 2006
187 1/50 2/50 17.60 0.50 (0.05–5.34)
Helke, 2001
202 5/93 7/92 61.95 0.71 (0.23–2.15)
Kupeli, 2001
203 0/50 0/50 Not estimable
Liu, 2006
132 3/36 2/26 20.44 1.08 (0.19–6.03)
Subtotal (95% CI) 229 218 100.00 0.75 (0.32–1.77)
Total events:9(TUVRP), 11 (TURP)
Test for heterogeneity: χ
2 = 0.30, df = 2( p = 0.86), I
2 = 0%
Test for overall effect: z = 0.66 (p = 0.51)
04 TUR syndrome
Kupeli, 2001
203 0/50 0/50 Not estimable
Liu, 2006
132 0/44 2/32 100.00 0.15 (0.01–2.95)
Talic, 2000
68 0/34 0/34 Not estimable
Subtotal (95% CI) 128 116 100.00 0.15 (0.01–2.95)
Total events:0(TUVRP), 2 (TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 1.25 (p = 0.21)
05 Incontinence
Gupta, 2006
187 0/50 1/50 8.38 0.33 (0.01–7.99)
Helke, 2001
202 14/93 14/92 78.64 0.99 (0.50–1.96)
Kupeli, 2001
203 0/50 0/50 Not estimable
Liu, 2006
132 1/36 2/26 12.98 0.36 (0.03–3.77)
Subtotal (95% CI) 229 218 100.00 0.85 (0.45–1.61)
Total events: 15 (TUVRP), 17 (TURP)
Test for heterogeneity: χ
2 = 1.03, df = 2( p = 0.60), I
2 = 0%
Test for overall effect: z = 0.49 (p = 0.62)
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statistically significant (Appendix 9.8, comparison 
08:06: WMD –1.91, 95% CI –8.80 to 5.07, 
p = 0.59). 
Length of hospital stay
Only one study132 provided information on length 
of hospital stay (Appendix 8.8, Table 80). The mean 
difference was less than a day (MD 0.41 days), 
favouring TUVRP. This was statistically significant 
(Appendix 9.8, comparison 08:07: 95% CI –0.54 to 
–0.28, p < 0.001).
Reoperation
Two studies132,202 provided information on 
reoperation rates. Reoperation rates appeared to 
be higher in the TUVRP group (11.6%) than in 
the TURP group (5.9%). This difference, however, 
did not reach statistical significance (Appendix 9.8, 
comparison 08:02:13: RR 1.90, 95% CI 0.80–4.52, 
p = 0.15).
Summary and conclusions of the evidence 
for and against the intervention
This review considered data from over 500 
randomised participants across five RCTs of 
generally moderate to low quality (and reporting). 
The data suggest that symptom scores, quality of 
life and peak urine flow rate do not differ between 
TUVRP and TURP. The incidence of blood 
transfusion, urinary retention, strictures, TUR 
syndrome and urinary incontinence was also similar 
in the two groups. The duration of operation and 
reoperation rates were also statistically similar in 
both groups; however, length of hospital stay was 
slightly shorter for TUVRP than it was for TURP. 
Clinical effect size
A summary of the clinical effect sizes for all 
outcomes derived from the meta-analyses for which 
data were available is given in Table 21. These 
should be interpreted in view of the comments 
mentioned earlier in this chapter.
Bipolar transurethral 
resection of the prostate 
(B-TURP) versus TURP
Characteristics of included studies
The characteristics of the included studies are 
summarised in Table 22. Six RCTs65,147,150,161,194,195 
were eligible for this comparison, in which a total 
of 386 participants were randomised, 192 to 
B-TURP and 194 to conventional TURP.
Three trials took place in Turkey161,194,195 and one 
each took place in India,147 Korea150 and Italy.65 
Five studies provided details of recruitment 
dates147,150,161,194,195 with the earliest in 2001194,195 and 
the latest in October 2004.150
All but one study195 provided details of participants’ 
IPSS/AUA scores at baseline, showing that 89 were 
severely symptomatic in each arm and 52 and 
55 moderately symptomatic in the B-TURP and 
conventional TURP arms respectively.
Of the studies reporting prostate size,65,147,161,194 all 
participants had large prostates.
Assessment of effectiveness
Tables giving a detailed description for all 
outcomes can be found in Appendix 8.9. The 
results of the meta-analyses are given in Appendix 
9.9. Note that in terms of long-term evaluation, 
only the longest follow-up is presented here.
Symptom scores
At 3 months
Data were available for only one161 of five eligible 
trials. No differences in IPSS/AUA scores were 
observed between B-TURP and conventional TURP 
3 months after surgery (Figure 23, comparison 
09:01:01). 
At 12 months
Of the three trials65,161,194 providing information 
on IPSS/AUA scores, two161,194 provided data that 
were suitable for meta-analysis. The improvement 
in symptoms in patients undergoing B-TURP was 
similar to that observed in conventional TURP 
patients (Figure 23; comparison 09:01:03: WMD 
0.29, 95% CI –1.12 to 1.71, p = 0.69). This result is 
consistent with that observed in the study by de Sio 
and colleagues.65
Complications
The list of complications by study is detailed in 
Appendix 8.9, Table 82. Data describing nine 
complications were reported for one or more 
studies. The data were too few to provide precise 
estimates of differences and all confidence intervals 
were wide, such that clinically important differences 
could not be ruled out. Meta-analyses of the 
complications showed non-statistically significant 
differences between B-TURP and conventional 
TURP. Results regarding blood transfusion, urinary 
retention, urinary tract infection, strictures, TUR 
syndrome and urinary incontinence are presented Clinical effectiveness of other ablative techniques
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TABLE 21  Summary of the clinical effect sizes from meta-analyses, TUVRP vs TURP
Outcome
Number of trials 
MA (total) Effect size 95% CI p-value
IPSS/AUA score
3 months 1 (3) 0.30a –0.63 to 1.23 0.53
12 months 2 (2) –0.28a –1.01 to 0.45 0.45
Longer term 1 (1) 0.60a –1.09 to 2.29 0.49
Blood transfusion 5 (5) 0.57b 0.24–1.36 0.20
Urinary retention 3 (3) 0.72b 0.26–2.05 0.54
Stricture 4 (4) 0.75b 0.32–1.77 0.51
TUR syndrome 3 (3) 0.15b 0.01–2.95 0.21
Incontinence 4 (4) 0.85b 0.45–1.61 0.62
Quality of life
3 months 1 (1) 0.20a –0.09 to 0.49 0.18
Longer term 1 (1) 0.20a –0.19 to 0.59 0.31
Qmax
3 months 1 (2) –0.90a –1.84 to 0.04 0.06
12 months 2 (2) 0.10a –0.41 to 0.61 0.70
Longer term 1 (1) –1.60a –3.50,0.30 0.10
Duration of operation 2 (2) 1.06a –8.70 to 10.83 0.83
Length of hospital stay 1 (1) –0.41a –0.54 to –0.28 < 0.001
Reoperation 2 (2) 1.90b 0.80–4.52 0.15
IPSS/AUA, International Prostate Symptom Score/American Urological Association; MA, meta-analysed; TR, transurethral 
resection; TURP , transurethral resection of the prostate; TUVRP , transurethral vaporesection of the prostate.
a  Weighted mean difference. 
b  Relative risk.
in this section (Figure 24). Results for other 
complications are presented in Appendix 9.9, 
comparison 09:02. 
Quality of life
Three studies65,147,161 reported quality of life of 
patients following surgery using the IPSS QoL (0–
6) questionnaire, but only one study161 presented 
data in a form that would allow quantitative 
synthesis. No statistically significant differences 
in quality of life were observed between B-TURP 
and conventional TURP at either the 3- or the 
12-month follow-up (Appendix 9.9, comparison 
09:07). This result is consistent with that reported 
by the studies that were not amenable to analysis. 
Urodynamic outcomes
Data on peak urine flow rate, mean urine flow rate, 
residual volume and prostate size were reported to 
a varying extent across four studies150,161,194,195 and 
are tabulated in Appendix 8.9, Table 84. Only peak 
urine flow rate is presented in this section. Results 
for the other urodynamic outcomes are presented 
in Appendix 9.9, comparisons 09:03–09:06.
At 3 months
Two studies161,195 provided details on peak urine 
flow rate for patients at 3 months after surgery. 
Across them, the average peak urine flow rate in 
the bipolar arm was not statistically significantly 
different from that observed in the conventional 
TURP arm (Appendix 9.9, comparison 09:03:01: 
WMD –0.98, 95% CI –2.25 to 0.29, p = 0.13). 
At 12 months
Three studies161,194,195 provided details on peak 
urine flow rate for patients at 12 months after 
surgery. There were no statistically significant 
differences between the two groups (Appendix 9.9, 
comparison 09:03:03: WMD 0.01, 95% CI –1.10 to 
1.08, p = 0.98). Health Technology Assessment 2008; Vol. 12: No. 35
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
83
TABLE 22  Summary of the baseline characteristics, B-TURP vs TURP
Study Comparators
Number of 
participants
Age 
(years)
Symptom 
scorea
Qmax 
(ml/s)
Residual 
volume 
(ml)
Prostate 
size  
(ml)
de Sio et al., 200665 B-TURP  35 59 24.2 7.1 80 52
TURP 35 61 24.3 6.3 75 47
Kim et al., 2006150 B-TURP  25 68 19.0 6.5 NR 53
TURP 25 71 18.6 6.1 NR 52
Nuho˘g lu et al., 
2006194
B-TURP  27 65 17.6 6.9 96 47
TURP 30 65 17.3 7.3 88 49
Seckiner et al., 
2006161
B-TURP  24 61 24.1 8.5 88 49
TURP 24 64 23.2 8.3 138 41
Singh et al., 2005147 B-TURP  30 69 20.5 5.8 124 NR
TURP 30 68 21.6 5.1 136 NR
Tefekli et al., 2005195 B-TURP  51 69 NR NR NR 54
TURP 50 69 NR NR NR 50
B-TURP , bipolar transurethral resection of the prostate; NR, not reported; TURP , transurethral resection of the prostate.
Data given as mean values.
a  Symptom scores given as IPSS/AUA (International Prostate Symptom Score/American Urological Association)
Review:  BPE
Comparison:  09 B-TURP vs TURP
Outcome:  01 IPSS/AUA
Study or 
subcategory n
B-TURP
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
013months
Seckiner, 2006
161 24 9.30 (3.90) 24 10.60 (6.30) 100.00 −1.30 (−4.26 to 1.66)
Subtotal (95% CI) 24 24 100.00 −1.30 (−4.26 to 1.66)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.86 (p = 0.39)
026months
Kim, 2006b
151 25 6.00 (1.00) 25 5.60 (1.40) 90.53 0.40 (−0.27 to 1.07)
Seckiner, 2006
161 23 8.70 (4.10) 21 8.30 (2.90)   9.47 0.40 (−1.68 to 2.48)
Subtotal (95% CI) 48 46 100.00 0.40 (−0.24 to 1.04)
Test for heterogeneity: χ
2 = 0.00,d f = 1( p = 1.00), I
2 = 0%
Test for overall effect: z = 1.22 (p = 0.22)
03 12 months
Nuhoglu, 2006
194 24 5.40 (3.70) 26 5.20 (3.20) 53.99 0.20 (−1.72 to 2.12)
Seckiner, 2006
161 23 8.70 (4.10) 21 8.30 (2.90) 46.01 0.40 (−1.68 to 2.48)
Subtotal (95% CI) 47 47 100.00 0.29 (−1.12 to 1.71)
Test for heterogeneity: χ
2 = 0.02,d f = 1( p = 0.89), I
2 = 0%
Test for overall effect: z = 0.40 (p = 0.69)
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Review:  BPE
Comparison:  09 B-TURP vs TURP
Outcome:  02 Complications
Study or 
subcategory
B-TURP
n/N
TURP
n/N
RR (ﬁxed)
95% CI
Weight
%
RR (ﬁxed)
95% CI
01 Blood transfusion
Nuhoglu, 2006
194 1/27 2/30 55.47 0.56 (0.05–5.79)
Tefekli, 2005
195 1/49 1/47 29.89 0.96 (0.06–14.90)
de Sio, 2006
65 1/35 0/35 14.64 3.00 (0.13–71.22)
Subtotal (95% CI) 111 112 100.00 1.03 (0.24–4.49)
Total events:3(B-TURP), 3 (TURP)
Test for heterogeneity: χ
2 = 0.71, df = 2( p = 0.70), I
2 = 0%
Test for overall effect: z = 0.04 (p = 0.96)
02 Urinary retention
Nuhoglu, 2006
194 1/27 0/30 31.74 3.32 (0.14–78.25)
Tefekli, 2005
195 1/49 1/47 68.26 0.96 (0.06–14.90)
Subtotal (95% CI) 76 77 100.00 1.71 (0.24–12.38)
Total events:2(B-TURP), 1 (TURP)
Test for heterogeneity: χ
2 = 0.34, df = 1( p = 0.56), I
2 = 0%
Test for overall effect: z = 0.53 (p = 0.60)
03 urinary tract infection
Kim, 2006b
151 1/25 1/25 100.00 1.00 (0.07–15.12)
Subtotal (95% CI) 25 25 100.00 1.00 (0.07–15.12)
Total events:1(B-TURP), 1 (TURP)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.00 (p = 1.00)
04 Stricture
Kim, 2006b
151 1/25 2/25 39.83 0.50 (0.05–5.17)
Seckiner, 2006
161 2/24 1/24 19.92 2.00 (0.19–20.61)
Tefekli, 2005
195 3/49 1/47 20.33 2.88 (0.31–26.69)
de Sio, 2006
65 1/35 1/35 19.92 1.00 (0.07–15.36)
Subtotal (95% CI) 133 131 100.00 1.38 (0.45–4.26)
Total events:7(B-TURP), 5 (TURP)
Test for heterogeneity: χ
2 = 1.29, df = 3( p = 0.73), I
2 = 0%
Test for overall effect: z = 0.56 (p = 0.57)
05 TUR syndrome
Kim, 2006b
151 0/25 0/25 Not estimable
de Sio, 2006
65 0/35 0/35 Not estimable
Subtotal (95% CI) 00 Not estimable
Total events:0(B-TURP), 0 (TURP)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
06 Incontinence
Kim, 2006b
151 1/25 1/25 39.52 1.00 (0.07–15.12)
Tefekli, 2005
195 0/49 1/47 60.48 0.32 (0.01–7.66)
Subtotal (95% CI) 74 72 100.00 0.59 (0.08–4.31)
Total events:1(B-TURP), 2 (TURP)
Test for heterogeneity: χ
2 = 0.29, df = 1( p = 0.59), I
2 = 0%
Test for overall effect: z = 0.52 (p = 0.60)
 0.01  0.1  1  10  100
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Descriptors of care
Data describing descriptors of care are tabulated in 
Appendix 8.9, Table 85. Information on duration 
of operation and reoperations was identified to a 
varying extent across the eligible studies for this 
comparison.
Duration of operation
Five studies provided information on duration 
of operation, with the results being inconsistent 
(highly significant heterogeneity). Two161,194 
suggested no difference between the groups 
whereas, in another three,65,150,195 a 3-, 5- and 
17-minute difference in the mean length of 
operation, respectively, was observed, favouring 
B-TURP (Appendix 8.9, Table 85). Four studies 
provided data that were amenable to quantitative 
synthesis. Fitting a random-effects model resulted 
in a WMD of –4.56 minutes in favour of B-TURP. 
This result was not statistically significant (95% CI 
–15.36 to 6.23, p = 0.41).
Length of hospital stay
Evidence from two studies65,150 suggests that the 
average length of stay following B-TURP was 
shorter than the average length of stay following 
TURP. The mean difference was –0.7 days 
(Appendix 8.9, Table 85; Appendix 9.9, comparison 
09:10: 95% CI –01.37 to –0.03, p = 0.04).
Reoperation
Three studies65,194,195 provided information on 
reoperation rates. No differences were observed 
between the two groups (Appendix 9.9, comparison 
09:02:09: 3/111 versus 2/112, RR 1.46, 95% CI 
0.25–8.57, p = 0.67). The time point of reoperation 
was unclear and the length of follow-up across 
studies ranged from 12 to 18 months.
Summary and conclusions of the evidence 
for and against the intervention
A total of 386 participants randomised to undergo 
B-TURP or conventional TURP across six RCTs of 
moderate to low quality were considered for this 
review. The data were too few to provide precise 
estimates for all of the outcomes considered 
and statistically significant differences could not 
be detected, with the exception of duration of 
operation, which bears significant heterogeneity 
and is of doubtful clinical or economic importance. 
A summary of the clinical effect sizes for all 
outcomes derived from the meta-analyses for which 
data were available is given in Table 23. These 
should be interpreted in view of the comments 
mentioned earlier in this chapter.
Bipolar transurethral 
vaporesection of the prostate 
(B-TUVRP) versus TURP
Characteristics of included studies
Only one RCT155 making this comparison was 
identified in the searches (Table 24). This study, 
which was carried out in Hong Kong, allocated 
29 men to undergo B-TUVRP and 31 to undergo 
TURP. Participants in both groups appeared to 
have moderate symptoms. No information was 
available to judge prostate size.
Assessment of effectiveness
This study reported outcomes on symptom scores, 
intraoperative and postoperative complications and 
quality of life. No urodynamic data were reported. 
These results are tabulated in Appendix 8.10, Tables 
86–89.
Symptom scores
At 3 months
IPSS at 3 months were slightly better for B- 
TUVRP than for TURP. Patients in the B-TUVRP 
group showed a 54% improvement in mean scores 
from baseline compared with 39% in the TURP 
arm.
Complications
There was no difference in the incidence of urinary 
tract infections or clot retention after B-TUVRP 
and conventional TURP, with wide confidence 
intervals. There were no cases of TUR syndrome in 
either arm of the trial (Table 25 and Appendix 9.10, 
comparison 10:01). 
Quality of life
Quality of life in patients following B-TUVRP 
was comparable to that in the TURP group at the 
3-month follow-up (Appendix 8.10, Table 88).155
Descriptors of care
There was no statistically significant difference 
between B-TUVRP and TURP in terms of duration 
of operation or length of hospital stay (Appendix 
8.10, Table 89).
Transurethral vaporisation of the 
prostate (TUVP) versus TURP
Characteristics of included studies
The characteristics of the included studies are 
summarised in Table 26. Seventeen RCTs reported 
in 27 papers55,57,128,129,138,140,142,156,158,162,193,196–201,262–271 
randomised a total of 1449 participants. Clinical effectiveness of other ablative techniques
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TABLE 23  Summary of the clinical effect sizes from meta-analyses, B-TURP vs TURP
Outcome
Number of trials 
MA (total) Effect size 95% CI p-value
IPSS/AUA score
3 months 1 (3) –1.30a –4.26 to 1.66 0.39
12 months 2 (3) 0.29a –1.12 to 1.71 0.69
Longer term NR NR NR NR
Blood transfusion 3 (3) 1.03b 0.24–4.49 0.96
Urinary retention 2 (2) 1.71b 0.24–12.38 0.60
Urinary tract infection 1 (1) 1.00b 0.07–15.12 1.00
Stricture 4 (4) 1.38b 0.45–4.26 0.33
TUR syndrome 2 (2) NE NE NE
Incontinence 2 (2) 0.59b 0.08–4.31 0.60
Quality of life
3 months 1 (3) –0.30a –0.92 to 0.32 0.35
12 months 1 (1) –0.20a –0.67 to 0.27 0.41
Longer term NR NR NR NR
Qmax
3 months 2 (4) 0.98a –0.29 to 2.25 0.13
12 months 3 (4) 0.01a –1.08 to 1.10 0.98
Longer term NR NR NR NR
Duration of operation 
(minutes)
4 (5) –4.56a –15.36 to 6.23 0.41
Length of hospital stay 
(days)
1 (2) –0.70a –1.37 to –0.03 0.04
Reoperation 3 (3) 1.46b 0.25 to 8.57 0.67
B-TURP , bipolar transurethral resection of the prostate; IPSS/AUA, International Prostate Symptom Score/American 
Urological Association; MA, meta-analysed; NE, not estimable; NR, not reported TUR, transurethral resection; TURP 
transurethral resection of the prostate.
a  Weighted mean difference.
b  Relative risk.
TABLE 24  Summary of the baseline characteristics, B-TUVRP vs TURP
Study Comparators
Number of 
participants
Age 
(years)
Symptom 
scorea
Qmax 
(ml/s)
Residual 
volume 
(ml) Prostate size (ml)
Fung et al., 
2005155
B-TUVRP 29 72 15.8 NR NR NR
TURP 31 73 19.4 NR NR NR
B-TUVRP , bipolar transurethral vaporesection of the prostate; NR, not reported; TURP transurethral resection of the 
prostate.
Data given as mean values.
a  Symptom scores given as IPSS/AUA (International Prostate Symptom Score/American Urological Association).Health Technology Assessment 2008; Vol. 12: No. 35
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Four studies took place in Turkey,128,158,196,197 three in 
the UK,57,129,162 three in the US,55,140,199 and one each 
in Sweden,142 Italy,138 Japan,156 the Netherlands,193 
Brazil,198 Saudi Arabia200 and China.201 Eight 
studies gave details of the recruitment dates,57,129,158,
193,196,197,199,200 which ranged from 1995 to 2003. 
All but two RCTs55,196 reported participants’ IPSS/
AUA scores. The total number of participants who 
had severe symptoms of BPE and underwent TUVP 
was 487 (75%) compared with 408 (59%) with 
severe symptoms allocated to TURP. There were 
160 (25%) participants with moderate symptoms 
allocated to TUVP and 284 (41%) with moderate 
symptoms allocated to TURP patients. 
In the studies reporting prostate size, 322 (59%) 
and 225 (41%) participants allocated to TUVP had 
large and moderate-sized prostates, respectively, 
compared with 336 (58%) with large and 242 (42%) 
with moderate-sized prostates allocated to TURP. 
Assessment of effectiveness
Tables giving a detailed description for all 
outcomes can be found in Appendix 8.11. The 
results of the meta-analyses are given in Appendix 
9.11. Note that in terms of long-term evaluation, 
only the longest follow-up is presented here.
Symptom scores
At 3 months
Of the 18 eligible studies, 13 provided information 
on IPSS/AUA scores at 3 months after surgery 
(Appendix 8.11, Table 90). Meta-analysis of seven 
studies55,57,138,156,162,199,200 showed no difference 
between TUVP and TURP in terms of symptom 
scores (Figure 25, comparison 11:01:01: WMD 
0.09, 95% CI –0.42 to 0.61, p = 0.72). This result is 
consistent with the data from those trials that were 
not amenable to meta-analysis.
At 12 months
Eight studies provided information on the mean or 
median IPSS/AUA scores at 12 months (Appendix 
8.11, Table 90). A meta-analysis involving five 
studies55,129,138,193,200 reporting data that were 
suitable for synthesis again showed no statistically 
significant difference between the groups (Figure 
24, comparison 11:01:03: WMD 0.34, 95% CI 
–0.19 to 0.86, p = 0.21). This result is consistent 
with the other three studies that were not amenable 
to meta-analysis.
Longer-term follow-up
Data from three studies129,193,199 reporting IPSS 
scores at 5 years also showed little difference in 
symptom scores (Figure 24, comparison 11:01:07: 
WMD –0.32, 95% CI –1.95 to 1.31, p = 0.70). 
Complications
Information about complications is detailed in 
Appendix 8.11, Table 91. Data describing 15 
types of complications were reported to a varying 
extent across 15 studies. Results regarding blood 
transfusion, urinary retention, urinary tract 
infection, strictures, TUR syndrome and urinary 
incontinence are presented in this section (Figure 
26). Results for other complications are presented 
in Appendix 9.11, comparisons 11:02 and 11:03. 
The results of these meta-analyses should be 
treated with caution as the length of follow-up of 
the RCTs varied and the confidence intervals were 
wide.
Blood transfusion
A total of 13 studies55,57,128,129,138,140,156,158,162,193,196,197,199 
reported blood transfusions. Meta-analysis 
suggested a lower rate of blood transfusion 
following TUVP than following TURP (Figure 26, 
comparison 11:02:01: 2/504 versus 29/537, RR 
0.19, 95% CI 0.08–0.44, p = 0.0001).
TABLE 25  Summary of the clinical effect sizes from meta-analyses, B-TUVRP vs TURP
Outcome Number of trials Effect size 95% CI p-value
Urinary tract infection 1 1.43 0.40–5.08 0.58
TUR syndrome 1 NE NE NE
B-TUVRP , bipolar transurethral vaporesection of the prostate; NE, not estimable; TUR, transurethral resection; TURP 
transurethral resection of the prostate.
a  Mean difference.Clinical effectiveness of other ablative techniques
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TABLE 26  Summary of the baseline characteristics, TUVP vs TURP
Study Comparators
Number of 
participants
Age 
(years)
Symptom 
scorea
Qmax 
(ml/s)
Residual 
volume 
(ml)
Prostate 
size  
(ml)
Çetinkaya et al., 
1996196
TUVP 23 68 NR NR NR 48.4
TURP 23 62 NR NR NR 48.8
Ekengren et al., 
2000142
TUVP 26 70 25b NR NR NR
TURP 28 71 22b NR NR NR
Erda˘g i et al., 1999128 TUVP 20 66 21.5 4.6 122.8 37.0
TURP 20 64 20.6 5.1 68.0 32.5
Fowler et al., 200557 TUVP 115 70 20.7 10.1 181.0 54.3
TURP 120 70 20.7 10.5 171.0 51.1
Gallucci et al., 
1998138
TUVP 70 NR 18.8 7.3 84.7 36.6
TURP 80 NR 18.2 8.8 64.6 36.6
Gotoh et al., 1999156 TUVP 23 70 19.6 7.3 56.7 56.7
TURP 28 66 18.9 9.4 41.9 44.7
Hammadeh et al., 
2003129
TUVP 52 67 26.5 8.9 131.0 32.0
TURP 52 70 26.6 8.6 101.0 27.0
Kaplan et al., 199855 TUVP 32 67 NR NR NR NR
TURP 32 73 NR NR NR NR
Kupeli et al., 1998158 TUVP 30 60 21.6 9.2 NR 51.7
TURP 30 62 19.4 7.9 NR 48.9
Kupeli et al., 1998197 TUVP 30 66 13.7 8.3 NR 41.6
TURP 36 62 14.6 8.8 NR 43.6
Nathan and 
Wickham, 1996162
TUVP 20 65 21.9 10.2 132.0 53.5
TURP 20 69 17.0 7.2 120.0 53.4
Netto et al., 1999198 TUVP 40 67 19.6 7.9 73.0 46.9
TURP 38 65 24.3 6.8 88.6 44.7
Nuho˘g lu et al., 
2005199
TUVP 37 64 17.6 6.3 88.0 39.0
TURP 40 65 17.3 5.9 95.0 39.0
Patel et al., 1997140 TUVP 6 66 23.3 7.5 NR 64.6
TURP 6 67 29.6 10.0 NR 54.0
Shokeir et al., 
1997200
TUVP 35 68 26.3 7.8 75.2 44.6
TURP 35 68 25.1 6.9 77.1 48.8
Wang et al., 2002201 TUVP 97 71 20 7.0 1231 NR
TURP 109 72 20 7.0 120 NR
van Melick et al., 
2003193
TUVP 46 64 20.2 11.0 290.0 35.0
TURP 50 66 16.8 11.0 350.0 37.0
NR, not reported; TURP transurethral resection of the prostate; TUVP , transurethral vaporisation of the prostate.
Data given as mean values (unless otherwise stated).
a  Symptom scores given as IPSS/AUA (International Prostate Symptom Score/American Urological Association).
b  Median.Health Technology Assessment 2008; Vol. 12: No. 35
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Urinary retention
Pooling data from 11 
studies55,129,138,142,156,158,162,193,196,197,199 reporting this 
outcome showed a higher risk of urinary retention 
amongst those who underwent TUVP than 
amongst those who underwent TURP (Figure 26, 
comparison 11:02:02: 33/389 versus 15/419, RR 
2.12, 95% CI 1.23–3.68, p = 0.007). 
Urinary tract infection
Eight studies55,128,129,138,156,162,193,197 provided details 
on the incidence of urinary tract infections after 
operation. A total of 21 (7.0%) urinary tract 
infections were reported amongst 298 participants 
allocated to TUVP compared with 33 (10.4%) 
amongst 318 participants allocated to TURP 
(Figure 26, comparison 11:02:03: RR 0.65, 95% CI 
0.40–1.08, p = 0.09).
Stricture
Evidence from 11 studies showed no statistically 
significant difference between TUVP and TURP 
in terms of incidence of strictures or bladder neck 
contractures (Figure 26, comparison 11:02:04: 
12/418 versus 14/446, RR 0.91, 95% CI 0.45–1.85, 
p = 0.80). 
TUR syndrome
A total of three (0.9%) patients suffered a TUR 
syndrome following surgery amongst 314 
randomised to TUVP as opposed to six (1.8%) 
amongst 329 patients randomised to TURP (Figure 
26, comparison 11:02:05: RR 0.59, 95% CI 0.17–
2.12, p = 0.42).
Urinary incontinence
Urinary incontinence was reported in nine studies 
(Figure 26). Urinary incontinence occurred less 
frequently in the TUVP arm than in the TURP 
arm. This difference was not statistically significant 
(Figure 26, comparison 11:02:06: 57/489 versus 
64/533, RR 0.92, 95% CI 0.69–1.21, p = 0.53).
Quality of life
Five studies57,129,142,162,193 reported quality of life of 
patients following surgery. In three studies, quality 
of life was assessed using the IPSS QoL (0–6) 
questionnaire. In the other two studies, authors did 
not provide further information on the measure 
used and later it was assumed that it was the IPSS 
QoL. One of the studies also assessed quality of 
life using the EQ-5D (using the UK tariff) and the 
SF-36 measures and the authors concluded that 
any change in general health-related quality of life 
resulting from their intervention was not detectable 
by either the EQ-5D or the SF-36 tools (the ranges 
and standard deviations were large).
There was no statistically significant difference in 
IPSS QoL at 3 or 12 months or for any longer-term 
follow-ups between TUVP and TURP following 
surgery (Appendix 9.11, comparison 11:10).
Urodynamic outcomes
Data on peak urine flow rate, mean urine flow rate, 
total voided volume, residual volume, detrusor 
pressure and prostate size were reported across 16 
studies.55,57,128,129,138,140,142,156,158,187,193,197–201 Only peak 
urine flow rate is presented in this section. Results 
for the other urodynamic outcomes are presented 
in Appendix 8.11, Table 93 and Appendix 9.11, 
comparisons 11:04–11:09.
At 3 months
A total of 12 studies55,57,128,129,138,140,156,158,187,193,199,200 
provided details of peak urine flow rate at 3 
months after surgery. In five studies128,156,158,187,199 
the average peak urine flow rate was 
higher in the TUVP group. A total of eight 
studies55,57,138,156,158,193,199,200 presented data that were 
sufficiently similar to allow quantitative synthesis 
(Appendix 9.11, comparison 11:04:01). The WMD 
was 0.10 ml/s for TUVP versus TURP (95% CI 
–0.53 to 0.73, p = 0.76). 
At 12 months
Nine studies55,129,138,142,193,197,198,200,201 provided details 
of mean or median peak urine flow rate at 12 
months after surgery. Five of the studies55,142,197,198,201 
reported lower rates in the TUVP group. Data 
from five trials55,129,193,198,200 reporting data that were 
amenable to meta-analysis showed no statistically 
significant difference between TUVP and TURP 
(Appendix 9.11, comparison 11:04:03: WMD 
–0.11, 95% CI –0.97 to 0.74, p = 0.80).
Longer-term follow-up
Three studies129,193,199 reported peak urine flow rate 
measurements 5 years after surgery. Meta-analysis 
of data from these trials showed no statistically 
significant difference between the two groups 
(Appendix 9.11, comparison 11:04:06: WMD 0.60, 
95% CI –1.06 to 2.26, p = 0.31).
Descriptors of care
Data describing descriptors of care are tabulated 
in Appendix 8.11, Table 94. Information on 
duration of operation, length of hospital stay and 
reoperation rates was identified to a varying extent 
across the 17 eligible studies for this comparison.Clinical effectiveness of other ablative techniques
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Review:  BPE
Comparison:  11 TUVP vs TURP
Outcome:  01 IPSS/AUA
Study or 
subcategory n
TUVP
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
013months
Fowler, 2005
57 105 11.80 (7.70) 110 9.80 (7.20) 6.66 2.00 (0.01–3.99)
Galluci, 1998
138 70 5.50 (4.77) 80 5.52 (4.11) 12.87 −0.02 (−1.46 to 1.42)
Gotoh, 1999
156 23 3.70 (2.40) 28 3.80 (2.30) 15.71 −0.10 (−1.40 to 1.20)
Kaplan, 1998
55 32 9.20 (2.70) 32 8.60 (2.50) 16.31 0.60 (−0.67 to 1.87)
Nathan, 1996
162 20 2.86 (2.80) 20 3.10 (2.30) 10.51 −0.24 (−1.83 to 1.35)
Nuhoglu, 2005
199 35 4.70 (3.10) 38 4.80 (4.20) 9.34 −0.10 (−1.78 to 1.58)
Shokeir, 1997
200 35 4.50 (1.90) 35 4.80 (2.20) 28.59 −0.30 (−1.26 to 0.66)
Subtotal (95% CI) 320 343 100.00 0.09 (−0.42 to 0.61)
Test for heterogeneity: χ
2 = 5.09, df = 6( p = 0.53), I
2 = 0%
Test for overall effect: z = 0.35 (p = 0.72)
026months
Fowler, 2005
57 106 8.50 (7.40) 108 6.90 (5.50) 6.66 1.60 (−0.15 to 3.35)
Galluci, 1998
138 70 4.94 (4.68) 80 3.77 (3.30) 11.83 1.17 (−0.14 to 2.48)
Kaplan, 1998
55 32 7.40 (2.90) 32 7.90 (3.10) 9.43 −0.50 (−1.97 to 0.97)
van Melick, 2003a
193 33 3.80 (2.70) 37 3.20 (2.70) 12.70 0.60 (−0.67 to 1.87)
Shokeir, 1997
200 35 4.60 (1.20) 35 4.50 (1.30) 59.38 0.10 (−0.49 to 0.69)
Subtotal (95% CI) 276 292 100.00 0.33 (−0.12 to 0.79)
Test for heterogeneity: χ
2 = 5.59, df = 4( p = 0.23), I
2 = 28.4%
Test for overall effect: z = 1.45 (p = 0.15)
03 12 months
Galluci, 1998
138 70 4.04 (4.26) 80 3.52 (3.04) 19.24 0.52 (−0.68 to 1.72)
Hammadeh, 2003
129 51 4.40 (3.80) 51 5.90 (5.20) 8.87 −1.50 (−3.27 to 0.27)
Kaplan, 1998
55 30 6.60 (2.40) 31 6.10 (1.90) 23.38 0.50 (−0.59 to 1.59)
van Melick, 2003a
193 34 4.80 (4.90) 41 4.10 (4.80) 5.69 0.70 (−1.51 to 2.91)
Shokeir, 1997
200 25 5.20 (1.40) 25 4.70 (1.50) 42.82 0.50 (−0.30 to 1.30)
Subtotal (95% CI) 210 228 100.00 0.34 (−0.19 to 0.86)
Test for heterogeneity: χ
2 = 4.59, df = 4( p = 0.33), I
2 = 12.8%
Test for overall effect: z = 1.26 (p = 0.21)
04 18 months
Gotoh, 1999
156 28 3.83 (4.62) 27 8.68 (2.30) 100.00 −4.85 (−6.77 to −2.93)
Subtotal (95% CI) 28 27 100.00 −4.85 (−6.77 to −2.93)
Test for heterogeneity: not applicable
Test for overall effect: z = 4.95 (P < 0.00001)
052y ears
Fowler, 2005
57 90 8.60 (7.20) 77 7.50 (5.80) 37.74 1.10 (−0.87 to 3.07)
Hammadeh, 2003
129 47 4.30 (3.50) 47 6.30 (4.30) 58.45 −2.00 (−3.59 to −0.41)
van Melick, 2003a
193 12 8.40 (8.70) 15 5.80 (7.50) 3.80 2.60 (−3.62 to 8.82)
Subtotal (95% CI) 149 139 100.00 −0.66 (−1.87 to 0.56)
Test for heterogeneity: χ
2 = 6.86, df = 2( p = 0.03), I
2 = 70.8%
Test for overall effect: z = 1.06 (p = 0.29)
063y ears
Hammadeh, 2003
129 40 4.10 (3.30) 40 7.10 (6.20) 100.00 −3.00 (−5.18 to −0.82)
Subtotal (95% CI) 40 40 100.00 −3.00 (−5.18 to −0.82)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.70 (p = 0.007)
075y ears
Hammadeh, 2003
129 27 5.90 (6.30) 27 8.60 (7.10) 20.71 −2.70 (−6.28 to 0.88)
van Melick, 2003a
193 12 7.00 (5.60) 15 7.30 (7.10) 11.57 −0.30 (−5.09 to 4.49)
Nuhoglu, 2005
199 21 6.50 (3.20) 23 6.10 (3.50) 67.73 0.40 (−1.58 to 2.38)
Subtotal (95% CI) 60 65 100.00 −0.32 (−1.95 to 1.31)
Test for heterogeneity: χ
2 = 2.21, df = 2( p = 0.33), I
2 = 9.3%
Test for overall effect: z = 0.39 (p = 0.70)
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Comparison:  11 TUVPv s TURP
Outcome:  02 Complications
Study or subcategory TUVP n/N TURP n/N RR (ﬁxed) 95% CI Weight % RR (ﬁxed) 95% CI
01 Blood transfusion
Cetinkaya, 1996
196 0/23 2/23 7.71 0.20 (0.01–3.95)
Erdagi, 1999
128 0/20 9/20 29.29 0.05 (0.00–0.85)
Fowler, 2005
57 2/115 9/120 27.16 0.23 (0.05–1.05)
Galluci, 1998
138 0/70 0/80 Not estimable
Gotoh, 1999
156 0/23 0/28 Not estimable
Hammadeh, 2003
269 0/52 1/52 4.63 0.33 (0.01–8.00)
Kaplan, 1998
55 0/32 1/32 4.63 0.33 (0.01–7.89)
Kupeli, 1998a
158 0/30 0/30 Not estimable
Kupeli, 1998b
197 0/30 2/36 7.03 0.24 (0.01–4.79)
van Melick, 2003
193 0/46 1/50 4.44 0.36 (0.02–8.66)
Nathan, 1996
162 0/20 2/20 7.71 0.20 (0.01–3.92)
Nuhoglu, 2005
199 0/37 2/40 7.42 0.22 (0.01–4.35)
Patel, 1997
140 0/6 0/6 Not estimable
Subtotal (95% CI) 504 537 100.00 0.19 (0.08–0.44)
Total events: 2( TUVP),2 9( TURP)
Test for heterogeneity: χ² = 1.32, df = 8( p = 1.00), I² = 0%
Test for overall effect: z = 3.82 (p = 0.0001)
02 Urinary retention
Cetinkaya, 1996
196 4/23 0/23 2.91 9.00 (0.51–158.17)
Ekengren, 2000
142 0/26 1/28 8.42 0.36 (0.02–8.42)
Galluci, 1998
138 12/70 3/80 16.29 4.57 (1.34–15.54)
Gotoh, 1999
156 0/23 0/28 Not estimable
Hammadeh, 2003
269 12/52 4/52 23.28 3.00 (1.03–8.70)
Kaplan, 1998
55 3/32 2/32 11.64 1.50 (0.27–8.38)
Kupeli, 1998a
158 0/30 0/30 Not estimable
Kupeli, 1998b
197 1/30 0/36 2.65 3.58 (0.15–84.81)
van Melick, 2003
193 0/46 0/50 Not estimable
Nathan, 1996
162 0/20 5/20 32.01 0.09 (0.01–1.54)
Nuhoglu, 2005
199 1/37 0/40 2.80 3.24 (0.14–77.06)
Subtotal (95% CI) 389 419 100.00 2.12 (1.23–3.68)
Total events: 33 (TUVP),1 5( TURP)
Test for heterogeneity: χ² = 9.20, df = 7( p = 0.24), I² = 23.9%
Test for overall effect: z = 2.69 (p = 0.007)
03 Urinary tract infection
Erdagi, 1999
128 1/25 5/20 16.93 0.16 (0.02–1.26)
Galluci, 1998
138 1/70 4/80 11.38 0.29 (0.03–2.50)
Gotoh, 1999
156 0/23 0/28 Not estimable
Hammadeh, 2003
269 3/52 2/52 6.10 1.50 (0.26–8.61)
Kaplan, 1998
55 5/32 4/32 12.19 1.25 (0.37–4.23)
Kupeli, 1998b
197 4/30 3/36 8.31 1.60 (0.39–6.60)
van Melick, 2003
193 2/46 5/50 14.61 0.43 (0.09–2.13)
Nathan, 1996
162 5/20 10/20 30.48 0.50 (0.21–1.20)
Subtotal (95% CI) 298 318 100.00 0.65 (0.40–1.08)
Total events: 21 (TUVP),3 3( TURP)
Test for heterogeneity: χ² = 6.45, df = 6( p = 0.38), I² = 6.9%
Test for overall effect: z = 1.68 (p = 0.09)
04 Strictures
Cetinkaya, 1996
196 1/23 0/23 3.27 3.00 (0.13–70.02)
Ekengren, 2000
142 2/26 0/28 3.16 5.37 (0.27–106.88)
Erdagi, 1999
128 0/20 1/20 9.82 0.33 (0.01–7.72)
Gotoh, 1999
156 0/23 0/28 Not estimable
Hammadeh, 2003
269 2/52 8/52 52.38 0.25 (0.06–1.12)
Kaplan, 1998
55 1/32 1/32 6.55 1.00 (0.07–15.30)
Kupeli, 1998a
158 0/30 0/30 Not estimable
Kupeli, 1998b
197 0/30 0/36 Not estimable
van Melick, 2003
193 1/46 2/50 12.55 0.54 (0.05–5.80)
Netto, 1999
198 0/40 0/38 Not estimable
Wang, 2002
201 5/96 2/109 12.27 2.84 (0.56–14.30)
Subtotal (95% CI) 418 446 100.00 0.91 (0.45–1.85)
Total events: 12 (TUVP),1 4( TURP)
Test for heterogeneity: χ² = 7.23, df = 6( p = 0.30), I² = 17.0%
Test for overall effect: z = 0.25 (p = 0.80)
05 TUR syndrome
Erdagi, 1999
128 0/20 0/20 Not estimable
Gotoh, 1999
156 0/23 0/28 Not estimable
Hammadeh, 2003
269 0/52 0/52 Not estimable
Kaplan, 1998
55 0/32 1/32 24.16 0.33 (0.01–7.89)
Kupeli, 1998a
158 0/30 0/30 Not estimable
Nathan, 1996
162 0/20 0/20 Not estimable
Netto, 1999
198 0/40 0/38 Not estimable
Wang, 2002
201 3/97 5/109 75.84 0.67 (0.17–2.75)
Subtotal (95% CI) 314 329 100.00 0.59 (0.17–2.12)
Total events: 3( TUVP),6(TURP)
Test for heterogeneity: χ² = 0.16, df = 1( p = 0.69), I² = 0%
Test for overall effect: z = 0.81 (p = 0.42)
06 Incontinence
Galluci, 1998
138 4/70 7/80 10.33 0.65 (0.20–2.14)
Gotoh, 1999
156 0/23 0/28 Not estimable
Hammadeh, 2003
269 0/52 0/52 Not estimable
Kaplan, 1998
55 17/32 19/32 30.04 0.89 (0.58–1.38)
Kupeli, 1998a
158 6/30 13/30 20.55 0.46 (0.20–1.05)
Kupeli, 1998b
197 17/32 19/32 30.04 0.89 (0.58–1.38)
McAllister, 2003
270 1/107 1/1201 .491 .12( 0.07–17.71)
van Melick, 2003
193 7/46 4/50 6.06 1.90 (0.60–6.08)
Wang, 2002
201 5/97 1/1091 .495 .62( 0.67–47.26)
Subtotal (95% CI) 489 533 100.00 0.92 (0.69–1.21)
Total events: 57 (TUVP),6 4( TURP)
Test for heterogeneity: χ² = 7.32, df = 6( p = 0.29), I² = 18.0%
Test for overall effect: z = 0.62 (p = 0.53)
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Duration of operation
A total of 14 studies55,57,129,140,142,156,158,162,193,196,198–201 
reported duration of operation (Appendix 8.11, 
Table 94). In half of the studies55,57,129,158,162,199,200 this 
was longer in the TUVP group whereas in the other 
half140,142,156,193,196,198,201 it was shorter in the TUVP 
group. Eight studies presented data in a form 
sufficiently similar to allow quantitative synthesis 
(Appendix 9.11, comparison 11:11). The WMD was 
–1.62 minutes, favouring TUVP, although this was 
not statistically significant (95% CI –12.23 to 8.99, 
p = 0.76). 
Length of hospital stay
Ten studies55,57,129,138,140,162,193,197,198,200 provided 
information on length of hospital stay (Appendix 
8.11, Table 94). In all but two studies57,193 length of 
hospital stay was reported to be shorter for TUVP. 
In two studies there were no differences. Eight 
RCTs55,57,129,138,193,197,198,200 reported data that were 
suitable for synthesis. Across them, the average 
length of stay was 1.00 day less following TUVP 
(Appendix 9.11, comparison 11:12: WMD –1.00, 
95% CI –1.25 to –0.75, p < 0.001).
Reoperation
Only seven studies129,142,162,193,197,199,270 out of a 
possible 17 reported reoperation rates. The risk 
of having a reoperation following TUVP was no 
different from that following TURP. However, the 
confidence intervals were wide enough for clinically 
important differences to exist between the two 
groups (Appendix 9.11, comparison 11:03:15: 
14/326 versus 14/346, RR 1.04, 95% CI 0.53–2.07, 
p = 0.90). 
Summary and conclusions of the evidence 
for and against the intervention
This review considered data from 1449 randomised 
participants across 17 RCTs of moderate to low 
quality. The data suggest that the rates of blood 
transfusion and urinary tract infection are lower 
and the rate of urinary retention is higher after 
TUVP than after TURP. The length of hospital 
stay for TUVP was shorter in the trials. There were 
no statistically significant differences in IPSS/AUA 
symptom scores, quality of life and peak urine 
flow rate at 3 or 12 months or at any longer-term 
follow-up between TUVP and TURP. The incidence 
of complications such as strictures, TUR syndrome 
and urinary incontinence was similar. Duration 
of operation and reoperation rates also did not 
appear to differ between the two groups. 
There was evidence of high statistical heterogeneity 
in the results for peak urine flow rate, quality of 
life, duration of operation and length of hospital 
stay. There was no consistency in the direction of 
effect and clinically important differences could 
not be ruled out. Much of the variation might be 
due to differences in participants’ characteristics 
or the ways in which the technologies were used. 
In addition, differences in the specific aims 
and objectives of the studies might have led to 
important differences in their inclusion criteria. In 
the case of duration of operation, the variation may 
be explained by differences in operator experience 
and baseline prostate size, which can be considered 
as a proxy for duration of operation.
Clinical effect size
A summary of the clinical effect sizes for all 
outcomes derived from the meta-analyses for which 
data were available is given in Table 27. 
Bipolar transurethral 
vaporisation of the prostate 
(B-TUVP) versus TURP
Characteristics of included studies
Only two RCTs making this comparison were 
identified by the searches (Table 28).70,137,272 One 
study took place in Australia137,272 and the other 
in the UK.70 A total of 111 men were allocated 
to undergo B-TUVP and 100 to undergo TURP. 
Participants in the bipolar group appeared to 
have severe symptoms whereas 21 (21%) of those 
in the TURP group had moderate symptoms and 
79 (79%) had severe symptoms preoperatively. 
Participants in the bipolar group had moderate-
sized prostates whereas those in the TURP group 
had large prostates.
Assessment of effectiveness
Symptom scores
Data reported in the study by Dunsmuir and 
colleagues137,272 showed better improvement in 
mean AUA scores at 3 months for bipolar TUVP 
than for TURP (Appendix 8.12, Table 95). In 
contrast, Hon and colleagues70 did not find any 
statistically significant difference between the two 
groups at 9 months following surgery (Appendix 
9.12, comparison 12:01:01: MD 0.80, 95% CI –1.23 
to 2.83, p = 0.44).
Complications
Four types of complication were identified, with 
no statistically significant differences between the 
groups (Appendix 9.12, comparison 12:02).Health Technology Assessment 2008; Vol. 12: No. 35
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Quality of life
Both studies reported quality of life of patients 
following surgery. The IPSS QoL scale was used 
in one study70 and the AUA QoL in the other.137,272 
AUA QoL was taken from section C of the AUA7 
system. It comprises five questions to give a 
maximum score of 19. No statistically significant 
differences were observed between the two groups 
at 3, 9 and 12 months following surgery (Appendix 
8.12, Table 97; Appendix 9.12, comparison 
12:04:01). 
Urodynamic outcomes
Data on peak urine flow rate, mean flow rate and 
residual volume were reported across the two 
studies. Results for these outcomes are presented 
in Appendix 8.12, Table 98 and Appendix 
9.12, comparisons 12:05–12:07. No statistically 
significant differences were identified between the 
two groups. 
Descriptors of care
Data describing descriptors of care are tabulated 
in Appendix 8.12, Table 99. Information on 
duration of operation, length of hospital stay and 
reoperation rates were identified across the two 
eligible studies for this comparison.
Duration of operation
Duration of operation was found to be longer in 
the B-TUVP arm than in the TURP arm in the two 
studies reporting this outcome (Appendix 8.12, 
Table 99; Appendix 9.12, comparison 12:08).
TABLE 27  Summary of the clinical effect size from meta-analyses, TUVP vs TURP
Outcome
Number of trials 
MA (total) Effect size 95% CI p-value
IPSS/AUA score
3 months 7 (13) 0.09a –0.42 to 0.61 0.72
12 months 5 (8) 0.34a –0.19 to 0.86 0.21
Longer term 3 (3) –0.32a –1.95 to 1.31 0.70
Blood transfusion 13 (13) 0.19b 0.08–0.44 < 0.001
Urinary retention 11 (11) 2.12b 1.23–3.68 0.007
Urinary tract infection 8 (8) 0.65b 0.40–1.08 0.09
Stricture 11 (11) 0.91b 0.45–1.85 0.80
TUR syndrome 8 (8) 0.59b 0.17–2.12 0.42
Incontinence 9 (9) 0.92b 0.69–1.21 0.53
Quality of life
3 months 1 (2) 0.30a –0.18 to 0.78 0.22
12 months 2 (3) 0.47a –0.23 to 0.32 0.73
Longer term 1 (1) –0.60a –1.30 to 0.10 0.09
Qmax
3 months 8 (12) 0.10a –0.53 to 0.73 0.78
12 months 5 (10) –0.11a –0.97 to 0.74 0.80
Longer term 3 (3) 0.60a –1.06 to 2.26 0.48
Duration of operation 8 (14) –1.62a –12.23 to 8.99 0.76
Length of hospital stay 8 (11) –1.00a –1.25 to –0.75 < 0.001
Reoperation 7 (7) 1.04b 0.53–2.07 0.90
IPSS/AUA, International Prostate Symptom Score/American Urological Association; MA, meta-analysed; TUR, transurethral 
resection of the prostate; TUVP , transurethral vaporisation of the prostate.
a  Weighted mean difference.
b  Relative risk.Clinical effectiveness of other ablative techniques
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TABLE 28  Summary of the baseline characteristics, B-TUVP vs TURP
Study Comparators
Number of 
participants
Age 
(years)
Symptom 
scorea
Qmax 
(ml/s)
Residual 
volume 
(ml)
Prostate 
size  
(ml)
Dunsmuir et al., 
2003137,272
B-TUVP 30 63 24 9.6 112 39
TURP 21 60 17 10.4 96 42
Hon et al., 200670 B-TUVP 81 66 21 12 147 38
TURP 79 68 21 12 182 40
B-TUVP , bipolar transurethral vaporisation of the prostate; TURP , transurethral resection of the prostate.
Data given as mean values.
a  Symptom scores given as IPSS/AUA (International Prostate Symptom Score/American Urological Association).
Length of hospital stay
Both studies reported this outcome (Appendix 
8.12, Table 99). In one study137,272 length of hospital 
stay in the B-TUVP arm was no different from that 
observed in the TURP arm (p = 0.78). The other 
study reported a higher mean length of hospital 
stay in the B-TUVP arm than in the TURP arm 
(Appendix 9.12, comparison 12:09: MD –0.40, 95% 
CI –0.71 to –0.01, p = 0.01).
Reoperation
Evidence based on one study showed that there was 
no statistically significant difference in reoperation 
rates between the two arms (Appendix 9.12, 
comparison 12:02:05: 1/81 versus 2/79, RR 0.49, 
95% CI 0.05–5.27, p = 0.55). Health Technology Assessment 2008; Vol. 12: No. 35
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B
ecause of the lack of RCTs comparing 
minimally invasive interventions with ablative 
methods other than TURP, a narrative review 
investigating trends across the interventions 
was performed to identify the most promising 
minimally invasive and ablative methods. For 
all comparisons considered, symptom scores 
are reported on the same forest plot (Figures 27 
and 28). Plots for other outcomes can be seen in 
Appendix 9.14. These forest plots can be used to 
illustrate the differences between interventions. 
There does not appear to be a clear winner in 
terms of which intervention is the most promising 
to treat BPE. Some interventions perform better 
when assessed in terms of one outcome than 
others. Interpretation is difficult because of the 
paucity of data and the multitude of comparators. 
However, in summary, there seems to be little 
evidence that any treatment is more effective than 
TURP in terms of resolution of symptoms of BPE. 
What evidence there is relates to improvement in 
peak urine flow rate (laser resection better) with 
doubtful translation to clinically significant benefit. 
Several procedures appear to perform better 
than TURP, at least in terms of one measure of 
complications. The performance of the different 
interventions relative to TURP is detailed in Table 
29. 
Given that the results indicate that there are 
trade-offs between the outcomes provided by 
different treatments, patient preference becomes 
more important. However, these choices might be 
informed by the synthesis of the different clinical 
outcomes into a single measure, as performed in 
Chapter 10. 
Chapter 9  
Most promising intervention(s) for 
benign prostatic enlargementMost promising intervention(s) for benign prostatic enlargement
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Comparison:  13 IPSS/AUA
Outcome:  01 3m onths
Study or 
subcategory n
Intervention
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
01 TUMT vs TURP
d’Ancona, 1998
166 31 15.10 (8.20) 21 5.10 (3.10) 16.92 10.00 (6.82–13.18)
Francisca, 2000
213 57 10.50 (7.90) 55 5.30 (5.20) 28.01 5.20 (2.73–7.67)
Wagrell, 2002
165 85 8.40 (5.50) 41 6.70 (4.30) 55.07 1.70 (−0.06 to 3.46)
Subtotal (95% CI) 173 117 100.00 4.08 (2.78–5.39)
Test for heterogeneity: χ
2 = 21.15, df = 2( p < 0.0001), I
2 = 90.5%
Test for overall effect: z = 6.13 (p < 0.00001)
02 TUNA vs TURP
Cimentepe, 2003
175 26 9.70 (2.80) 33 8.30 (2.90) 69.22 1.40 (−0.06 to 2.86)
Hill, 2004
144 59 10.10 (6.70) 47 9.40 (4.80) 30.78 0.70 (−1.49 to 2.89)
Subtotal (95% CI) 85 80 100.00 1.18 (−0.03 to 2.40)
Test for heterogeneity: χ
2 = 0.27, df = 1( p = 0.60), I
2 = 0%
Test for overall effect: z = 1.91 (p = 0.06)
03 Laser coagulation vs TURP
Aliaga, 1998
149 18 4.80 (4.80) 21 8.60 (4.20) 48.12 −3.80 (−6.65 to −0.95)
Kabalin, 1995
177 13 7.20 (6.13) 12 9.90 (9.00) 10.58 −2.70 (−8.79 to 3.39)
Martenson, 1999
178 30 11.80 (6.90) 14 4.70 (4.00) 37.37 7.10 (3.86–10.34)
Suvakovic, 1996
179 10 16.80 (15.00) 10 12.80 (5.90) 3.93 4.00 (−5.99 to 13.99)
Subtotal (95% CI) 71 57 100.00 0.70 (−1.28 to 2.68)
Test for heterogeneity: χ
2 = 26.17, df = 3( p < 0.00001), I
2 = 88.5%
Test for overall effect: z = 0.69 (p = 0.49)
04 TUIP vs TURP
Aliaga, 1998
149 20 4.30 (4.50) 21 4.80 (4.80) 100.00 −0.50 (−3.35 to 2.35)
Subtotal (95% CI) 20 21 100.00 −0.50 (−3.35 to 2.35)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.34 (p = 0.73)
05 Laser resectionv s TURP
Tan, 2003
248 29 3.40 (4.84) 28 4.80 (4.23) 37.95 −1.40 (−3.76 to 0.96)
Westenberg, 2004
189 59 5.70 (5.20) 61 5.60 (5.10) 62.05 0.10 (−1.74 to 1.94)
Subtotal (95% CI) 88 89 100.00 −0.47 (−1.92 to 0.98)
Test for heterogeneity: χ
2 = 0.97, df = 1( p = 0.33), I
2 = 0%
Test for overall effect: z = 0.63 (p = 0.53)
06 Laser vaporisation vs TURP
Keoghane, 2000
164 55 9.60 (7.50) 62 6.50 (5.10) 34.07 3.10 (0.75–5.45)
Sengor, 1996
192 30 8.50 (4.20) 30 9.80 (3.10) 54.10 −1.30 (−3.17 to 0.57)
Suvakovic, 1996
179 10 9.70 (2.60) 10 12.80 (5.90) 11.82 −3.10 (−7.10 to 0.90)
Subtotal (95% CI) 95 102 100.00 −0.01 (−1.39 to 1.36)
Test for heterogeneity: χ
2 = 10.84, df = 2( p = 0.004), I
2 = 81.5%
Test for overall effect: z = 0.02 (p = 0.98)
07 TUVRP vs TURP
Liu, 2006
132 42 8.20 (2.20) 30 7.90 (1.80) 100.00 0.30 (−0.63 to 1.23)
Subtotal (95% CI) 42 30 100.00 0.30 (−0.63 to 1.23)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.63 (p = 0.53)
08 B-TURP vs TURP
Seckiner, 2006
161 24 9.30 (3.90) 24 10.60 (6.30) 100.00 −1.30 (−4.26 to 1.66)
Subtotal (95% CI) 24 24 100.00 −1.30 (−4.26 to 1.66)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.86 (p = 0.39)
09 TUVP vs TURP
Fowler, 2005
57 105 11.80 (7.70) 110 9.80 (7.20) 6.66 2.00 (0.01–3.99)
Galluci, 1998
138 70 5.50 (4.77) 80 5.52 (4.11) 12.87 −0.02 (−1.46 to 1.42)
Gotoh, 1999
156 23 3.70 (2.40) 28 3.80 (2.30) 15.71 −0.10 (−1.40 to 1.20)
Kaplan, 1998
55 32 9.20 (2.70) 32 8.60 (2.50) 16.31 0.60 (−0.67 to 1.87)
Nathan, 1996
162 20 2.86 (2.80) 20 3.10 (2.30) 10.51 −0.24 (−1.83 to 1.35)
Nuhoglu, 2005
199 35 4.70 (3.10) 38 4.80 (4.20) 9.34 −0.10 (−1.78 to 1.58)
Shokeir, 1997
200 35 4.50 (1.90) 35 4.80 (2.20) 28.59 −0.30 (−1.26 to 0.66)
Subtotal (95% CI) 320 343 100.00 0.09 (−0.42 to 0.61)
Test for heterogeneity: χ
2 = 5.09, df = 6( p = 0.53), I
2 = 0%
Test for overall effect: z = 0.35 (p = 0.72)
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FIGURE 27  IPSS/AUA scores by comparison at 3 months.Health Technology Assessment 2008; Vol. 12: No. 35
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Review:  BPE
Comparison:  13 IPSS/AUA
Outcome:  02 12 months
Study or subcategory n
Intervention
Mean (SD) n
TURP
Mean (SD)
WMD (ﬁxed)
95% CI
Weight
%
WMD (ﬁxed)
95% CI
01 TUMT vs TURP
d’Ancona, 1998
166 27 5.00 (2.70) 17 3.40 (2.20) 48.19 1.60 (0.14–3.06)
Wagrell, 2002
165 93 7.20 (6.20) 43 7.10 (6.60) 18.74 0.10 (−2.24 to 2.44)
de la Rosette, 2003
169 58 8.10 (6.00) 48 3.20 (3.00) 33.07 4.90 (3.14–6.66)
Subtotal (95% CI) 178 108 100.00 2.41 (1.40–3.42)
Test for heterogeneity: χ
2 = 12.60, df = 2( p = 0.002), I
2 = 84.1%
Test for overall effect: z = 4.66 (p < 0.00001)
02 TUNA vs TURP
Hill, 2004
146 56 11.70 (7.48) 44 7.80 (5.96) 100.00 3.90 (1.27–6.53)
Subtotal (95% CI) 56 44 100.00 3.90 (1.27–6.53)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.90 (p = 0.004)
03 Laser coagulation vs TURP
Kabalin, 1995
177 10 4.30 (4.11) 10 6.30 (3.48) 18.96 −2.00 (−5.34 to 1.34)
Martenson, 1999
178 21 12.40 (7.70) 10 3.50 (2.90) 15.00 8.90 (5.15–12.65)
McAllister, 2000
145 75 7.70 (6.18) 75 5.10 (5.74) 57.96 2.60 (0.69–4.51)
Suvakovic, 1996
179 9 10.00 (4.90) 9 7.20 (6.10) 8.08 2.80 (−2.31 to 7.91)
Subtotal (95% CI) 115 104 100.00 2.69 (1.24–4.14)
Test for heterogeneity: χ
2 = 18.12, df = 3( p = 0.0004), I
2 = 83.4%
Test for overall effect: z = 3.63 (p = 0.0003)
04 TUIP vs TURP
Trocz, 2002
186 50 4.10 (1.80) 50 5.10 (1.90) 100.00 −1.00 (−1.73 to −0.27)
Subtotal (95% CI) 50 50 100.00 −1.00 (−1.73 to −0.27)
Test for heterogeneity: not applicable
Test for overall effect: z = 2.70 (p = 0.007)
05 Laser resectionv s TURP
Gupta, 2006
187 50 5.20 (0.17) 50 5.60 (0.32) 97.70 −0.40 (−0.50 to −0.30)
Kuntz, 2004
64 89 1.70 (1.80) 86 3.90 (3.90) 1.20 −2.20 (−3.11 to −1.29)
Montorsi, 2004
188 48 3.90 (3.60) 52 4.10 (2.30) 0.69 −0.20 (−1.39 to 0.99)
Tan, 2003
248 25 4.30 (3.50) 27 5.00 (4.68) 0.20 −0.70 (−2.94 to 1.54)
Westenberg, 2004
189 43 4.20 (6.00) 41 4.30 0.21 −0.10 (−2.29 to 2.09)
Subtotal (95% CI) 255 256 100.00 −0.42 (−0.52 to −0.32)
Test for heterogeneity: χ
2 = 15.28, df = 4( p = 0.004), I
2 = 73.8%
Test for overall effect: z = 8.30 (p < 0.00001)
06 Laser vaporisation vs TURP
Keoghane, 2000
164 52 8.87 (6.51) 60 5.77 (5.40) 27.67 3.10 (0.86–5.34)
van Melick, 2003a
263 37 3.60 (3.40) 41 4.10 (4.80) 41.16 −0.50 (−2.33 to 1.33)
Shingleton, 2002
142 40 6.00 (6.00) 33 3.80 (4.10) 25.54 2.20 (−0.13 to 4.53)
Suvakovic, 1996
179 9 8.70 (4.90) 10 7.20 (6.10) 5.63 1.50 (−3.45 to 6.45)
Subtotal (95% CI) 138 144 100.00 1.30 (0.12–2.47)
Test for heterogeneity: χ
2 = 6.78, df = 3( p = 0.08), I
2 = 55.7%
Test for overall effect: z = 2.16 (p = 0.03)
07 TUVRP vs TURP
Helke, 2001
202 79 4.66 (4.30) 73 5.21 (5.10) 100.00 −0.55 (−2.06 to 0.96)
Subtotal (95% CI) 79 73 100.00 −0.55 (−2.06 to 0.96)
Test for heterogeneity: not applicable
Test for overall effect: z = 0.72 (p = 0.47)
08 B-TURP vs TURP
Nuhoglu, 2006
199 24 5.40 (3.70) 26 5.20 (3.20) 53.99 0.20 (−1.72 to 2.12)
Seckiner, 2006
161 23 8.70 (4.10) 21 8.30 (2.90) 46.01 0.40 (−1.68 to 2.48)
Subtotal (95% CI) 47 47 100.00 0.29 (−1.12 to 1.71)
Test for heterogeneity: χ
2 = 0.02, df = 1( p = 0.89), I
2 = 0%
Test for overall effect: z = 0.40 (p = 0.69)
09 TUVP vs TURP
Galluci, 1998
138 70 4.04 (4.26) 80 3.52 (3.04) 13.73 0.52 (−0.68 to 1.72)
Gupta, 2006
187 50 5.40 (1.97) 50 5.60 (2.26) 28.63 −0.20 (−1.03 to 0.63)
Hammadeh, 2003
269 51 4.40 (3.80) 51 5.90 (5.20) 6.33 −1.50 (−3.27 to 0.27)
Kaplan, 1998
55 30 6.60 (2.40) 31 6.10 (1.90) 16.69 0.50 (−0.59 to 1.59)
van Melick, 2003
263 34 4.80 (4.90) 41 4.10 (4.80) 4.06 0.70 (−1.51 to 2.91)
Shokeir, 1997
200 25 5.20 (1.40) 25 4.70 (1.50) 30.56 0.50 (−0.30 to 1.30)
Subtotal (95% CI) 260 278 100.00 0.18 (−0.26 to 0.63)
Test for heterogeneity: χ
2 = 5.73, df = 5( p = 0.33), I
2 = 12.8%
Test for overall effect: z = 0.81 (p = 0.42)
(4.10)
−10 −5  0  5  10
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FIGURE 28  IPSS/AUA scores by comparison at 12 months.Most promising intervention(s) for benign prostatic enlargement
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T
he economic perspective was that of the 
English NHS and, in the base case, the time 
horizon was 10 years, which was chosen because it 
was believed a priori that this would be sufficient 
to show the difference between technologies. 
A discount rate of 3.5% for costs and benefits 
was used in the base case, but this was varied in 
sensitivity analysis. The price year was 2006 and 
the currency was UK pounds sterling. 
Multiple versus single 
cohort analysis 
A time horizon of ‘until death’ was planned 
for a sensitivity analysis. However, the need to 
incorporate capital costs (e.g. for HoLEP) led 
to a change in model structure from one that is 
‘individual based’ [i.e. estimating the expected 
cost and quality-adjusted life-years (QALYs) per 
individual] to one that is ‘population based’. The 
standard individual-based model structure is 
identical to averaging across a cohort of identical 
individuals all starting treatment at the same 
time. The approach used in this analysis allowed 
for new individuals to enter over a time period, 
which we assumed was the approximate lifetime of 
the technologies of 10 years. This is equivalent to 
having multiple versus single cohort analysis. This 
means that there is a ‘mixing’ of individuals over 
time such that at 1-year post technology change 
there will be equal numbers of those receiving 
their first treatment (0 years post treatment) and 
those who are 1-year post first treatment. After 10 
years there will thus be equal numbers from year 
0 to year 10 post treatment. This allows for the 
incorporation of capital equipment costs over the 
time horizon as required for strategies in which 
equipment is not used as the first-line treatment 
but rather to manage subsequent failure of 
treatment or relapse. For example, in the strategy 
TUVP/HoLEP, HoLEP is never used as the first-line 
treatment and it is clear that, over time, as more 
new individuals are treated, the amount of HoLEP 
equipment required will increase. 
Such a model involves greater complexity in that, 
as described below, the model must ‘keep track’ of 
time post technology introduction (for the whole 
population) as well as time post first treatment (for 
the individual, including age-dependent mortality). 
However, this approach allows the simulation of 
the purchasing of new equipment as required over 
the time horizon and produces a more accurate 
estimation of costs and effectiveness and thus cost-
effectiveness. 
The rest of this chapter is subdivided in the 
same way as in the review of economic evaluation 
reported in Chapter 4 except that the section on 
sensitivity analysis deals only with the probabilistic 
analysis. As already explained, deterministic 
sensitivity analysis is reserved for testing the 
effect of parameter variability or model structure 
uncertainty and is therefore dealt with under the 
subheadings below.
Population
The population is men with a specified mean start 
age with a diagnosis of BPE (no other size criteria), 
presence of LUTS (with a measure of IPSS > 7), no 
complications and TURP indicated. This implies 
that medical treatment is either contraindicated or 
has failed. In the base-case analysis the mean start 
age was 70. This value was chosen because it lies 
approximately in the middle of the current range 
of age at treatment. In the sensitivity analysis the 
mean start age has been varied between 50 and 90 
because this represents approximate ranges for the 
defined population.
The technologies to compare
The strategies chosen were those that the clinical 
experts believed to be clinically appropriate and 
were designed to adequately capture events that 
were likely to incur costs and health changes 
over the 10-year time horizon of the model. 
The strategies were formulated over the course 
of several meetings of clinicians involved in the 
study supplemented by discussion with the health 
economist and with additional input from other 
urologist colleagues to resolve differences in 
opinion. A time horizon of 10 years was chosen 
because it was believed a priori that this would 
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be sufficient to show the differences between 
technologies. 
The problem with using strategies is that the 
comparison of each possible sequence of treatments 
is costly in terms of building and estimating the 
model and, until the model is completed, it cannot 
be used to eliminate any sequences. However, 
the guiding principle at each step of the research 
process is the perceived value of information 
analysis, based on the current evidence. Before 
undertaking any calculation of value of information 
based on the model itself, judgement is required 
as to whether a particular sequence is feasible for 
the given setting and is sufficiently important to 
warrant the additional research cost of adding 
that sequence. Therefore, treatment sequences 
were reduced according to a set of clinical rules 
regarding treatments in the minimally invasive (M), 
TURP (T) and other tissue ablative (A) categories, 
and:
Always proceed from less to more invasive. 1. 
Never repeat one of the other tissue ablative  2. 
procedures.
Repeat a minimally invasive procedure no  3. 
more than once.
Repeat TURP only once and only after  4. 
performing a pressure test.
Never change to another treatment from the  5. 
same category.
The basis for (1) is the belief that if a more invasive 
treatment is ineffective then the less invasive one 
will also be ineffective. The second assumption is 
tantamount to saying that any change due to tissue 
ablative treatments renders the prostate ‘immune’ 
to further benefit from this class of treatments. 
The third assumption is based on the belief that 
additional structural change to the prostate is 
extremely unlikely to occur given two previous 
attempts. The fourth is based on standard practice 
within the UK. The fifth is based on the belief 
that if one procedure in a category has failed then 
another from the same category is unlikely to be 
more successful than repeating the same procedure 
and that no more than one treatment from the 
same category is likely to be available in any given 
institution.
The strategies compared in the DAM were:
One treatment only: M, A, T. 1. 
Two treatments: MM, MA, MT, AT, TT. 2. 
Three treatments: MMA, MMT, MAT, MTT. 3. 
Four treatments: MMAT, MMTT, MATT. 4. 
Five treatments: MMATT. 5. 
Out of all possible treatments in each of the 
categories, a representative was chosen based on 
the one most likely to be used in the UK: TUMT 
and laser coagulation in the minimally invasive 
category; and TUVP in the tissue ablative category. 
Two further treatments were added: laser resection, 
as exemplified by HoLEP; and laser vaporisation, 
as exemplified by KTP. HoLEP was treated as a 
TURP substitute but without the possibility that it 
could be repeated as it was believed that it removes 
so much tissue that there can be no subsequent 
treatment. KTP was treated as a substitute for 
TUVP.
The epidemiology: 
model structure
A Markov model was used in which health states 
and order of transitions were determined a priori 
according to a logical sequence of events (e.g. 
treatment cannot follow death) and expert clinical 
judgement (e.g. permanent urinary incontinence 
contraindicates further treatment). The cycle 
length was set at 3 months. This was based on the 
advice by the clinical expert group that there was 
unlikely to be any difference between treatments 
over a shorter time period. Given the length of 
follow-up of 10 years this meant that costs and 
effects were estimated over 40 cycles. As described 
above, as well as estimating the consequences 
(cost and QALYs) accruing to each individual over 
time, these consequences were summed over a 
population over 10 years. This was operationalised 
by creating another ‘state’ from which new 
individuals could enter the model in each cycle. For 
simplicity this state is not included in the diagram 
below. The number of new individuals was assumed 
to be 25,000 per year, which is approximately the 
number of first TURP procedures per year in the 
UK. This was estimated from the NHS reference 
costs, 2005–6,45 assuming that approximately 5% of 
all TURPs in a year are reoperations.
Figure 29 shows a generic component of the 
Markov model, which represents the care pathway 
shown in Figure 1, in which each box corresponds 
to a health state. Given survival (i.e. no death) 
there are two main dimensions of outcome 
(incontinence or not and remission or not), which, 
being independent, imply four possible health state 
transitions following treatment. The state of death, 
which is not shown, is an absorbing state in that it 
cannot be left and it can also be entered from any Health Technology Assessment 2008; Vol. 12: No. 35
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FIGURE 29  Schematic of Markov model component.
of the other states. In keeping with the argument 
presented in Chapter 4, the only long-term 
complication that needed to be included in the 
DAM was incontinence. The states of ‘no remission’ 
(whether with incontinence or not) are entered 
with the probability of failure for that particular 
treatment. This defines failure as a lack of change 
of original symptoms. If there is incontinence then 
no further treatment for BPE can occur and the 
only transitions possible are to death and from the 
‘remission, incontinence’ state to the ‘no remission, 
incontinence’ state. If there is no incontinence and 
no remission and there are further treatments in 
the sequence then transition to the next treatment 
will occur. If the end of the treatment sequence is 
reached then the only transition that is possible is 
to the state of death. If there is no incontinence 
and remission then transition to ‘no remission, 
no incontinence’ can occur with the probability 
of relapse. This defines relapse as return to the 
original symptoms following an initially successful 
treatment. 
All other complications are short term in that they 
are assumed to have resolved within the first 3 
months post operation and are therefore included 
in the treatment state. The events considered 
are acute urinary retention (AUR), bladder neck 
contracture or urethral stricture (labelled BNC), 
blood transfusion, TUR syndrome and UTI.
All parameter values used to estimate the transition 
probabilities and probabilities of adverse short-
term complications are given as expected values. 
Separate tables are presented for cost and utility 
estimation in the relevant sections. Parameter 
distributions that are used in the Monte Carlo 
simulation can be seen in Table 30. 
The epidemiology: 
parameterisation 
of the model
Effectiveness
Probability of failure (1)
In this subsection the method used to estimate 
the probability of failure (defined above as the 
transition from a treatment state to the ‘no 
remission, no incontinence’ or ‘no remission, 
incontinence’ states) of any treatment used on 
the first occasion is described. Its modification 
for repeating the same procedure in a strategy is 
described later in this chapter.
The challenge was to find a definition of failure 
that would be consistent for all treatments and 
a reliable method to estimate its probability. 
Therefore, given that the aim of treatment is to 
improve symptoms (LUTS), treatment failure was 
defined as ‘insufficient improvement’ in symptom 
score. ‘Insufficiency’ might be variably defined 
but, according to the clinical experts (R Pickard, 
University of Newcastle, J N’Dow, S McClinton, 
University of Aberdeen, 2006, personal 
communication), in clinical practice a percentage 
change of less than 10% in IPSS is most often used. Economic analysis
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Formally:
Let f(p) be the probability distribution of p in the 
population where p represents the relative change 
in symptom score pre and post surgery such that:
p = (Ipost−Ipre)/Ipre  (1)
where Ipost is the IPSS score post surgery and Ipre is 
the IPSS score pre surgery.
Therefore, the probability of failure is given by:
P(fail) = P(p < x)  (2)
where x is the minimum percentage change in 
symptom score between pre and post surgery that 
would be considered sufficient (= 0.1).
Substituting (1) into (2) gives the probability of 
failure as:
P(fail) =P ((Ipost−Ipre)/Ipre) < x)  (3)
where the probability of failure, P(fail), is equal 
to the probability that the percentage change in 
symptom score between pre and post surgery, 
((Ipost−Ipre)/Ipre), is less than x.
The main problem in estimating P(p < x) from 
any effectiveness evidence is that these data are 
not reported and the IPSS scores are reported 
only as means of the whole sample at various 
points in time. Ideally, individual level data (ILD) 
for each treatment would be used but such data 
are unavailable. ILD were available, however, for 
two time points, pre treatment (baseline) and 
4-month follow-up, for a sample of men from 
a study population (in particular, pretreatment 
IPSS > 7) who had received TURP (R Pickard, 
2006, personal communication). Details of the 
characteristics of the patient population can be 
found in Appendix 11. The most reliable data 
comparing the effectiveness of TURP with other 
procedures should come from the estimates of the 
WMD derived from the meta-analysis (see Chapters 
6–8). Therefore, the challenge was to estimate 
P(fail) for the other procedures using the ILD 
for TURP and the WMD for the comparison with 
TURP for each other procedure. This constituted 
‘model 1’ for estimating the probability of failure. 
A second model was also developed. In model 2 
the relative risks of retreatment obtained from the 
meta-analysis were used to estimate the relative risk 
of failure of each treatment compared with TURP. 
The results obtained from these two models were 
compared in a sensitivity analysis.
Model 1 (base case)
To estimate Pt(fail) for each treatment t, it is 
known that the mean IPSS score post treatment (as 
reported in a study) is equal to the average score 
of the mean of those who are successful and those 
who fail. This can be represented as:
meant(Ipost) = Pt(fail) · mean(Ipost)fail 
+(1−Pt(fail)) · mean(Ipost)success  (4)
This formula can be rearranged to give the 
probability of failure for each treatment, Pt(fail): 
Pt(fail) = (meant(Ipost)−meant(Ipost)success)/(meant(Ipost)
fail−meant(Ipost)success)  (5)
If it is assumed that the trial sample is similar to 
the ILD sample then the mean IPSS score post 
treatment for treatment t (meant(Ipost)) can be 
calculated as:
meant(Ipost) = meanTURP(Ipost)−WMDtpost  (6)
where meanTURP(Ipost) is the mean IPSS post 
treatment for TURP, and WMDtpost is the weighted 
mean difference in IPSS post treatment for the 
comparison of treatment t with TURP.
Substituting equation (6) into equation (5) gives the 
following:
Pt(fail) = (meanTURP(Ipost)−WMDtpost−meant(Ipost)
success)/(meant (Ipost)fail−meant(Ipost)success)  (7)
In this equation meanTURP(Ipost) can be estimated 
from the ILD and WMD can be estimated from the 
meta-analysis. However, it is not known what the 
mean IPSS is for those who, by some definition, 
fail or have success. To solve this problem it was 
first assumed that a percentage change in IPSS of 
less than 10% (x = 0.1), given sample uncertainty, 
is equivalent to no change in symptoms, i.e. a 
proportion of individuals who are treated will be 
considered to have failed insofar as ‘on average’ 
they do not show any improvement in symptoms 
and this is independent of the initial IPSS. 
The first assumption is, therefore, that the mean 
post-treatment IPSS of those who fail (mean(Ipost)
fail) is the same as the mean IPSS pre treatment 
(mean(Ipre)) and is constant across all treatments, 
i.e.:Economic analysis
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mean(Ipost)fail = mean(Ipre)  (8)
Substituting equation (8) into equation (7) gives:
Pt(fail) = (meanTURP(Ipost)−WMDtpost−meant(Ipost)
success)/(mean(Ipre)−meant(Ipost)success)  (9)
If it is further assumed that the mean IPSS post 
treatment for those for whom treatment was 
a success (mean(Ipost)success)) is constant across 
treatments then: 
Pt(fail) = (meanTURP(Ipost)−WMDtpost−mean(Ipost) 
success)/(mean(Ipre)−mean(Ipost)success)  (10) 
Both of these assumptions imply that the difference 
in mean IPSS between treatments (i.e. the WMD) is 
due only to a difference in the probability of failure 
and not to a difference in mean IPSS of those who 
are successful or mean IPSS of those who fail. This 
is convenient for the Markov model because it also 
means that the utility [which is a function of IPSS 
(see Utilities)] for the states of ‘remission’ and ‘no 
remission’ also does not vary between treatments. 
When t is defined as TURP then the probability of 
TURP failing, PTURP(fail), can be defined as:
PTURP(fail) = (meanTURP(Ipost)−mean(Ipost)success)/
(mean(Ipre)−mean(Ipost)success)  (11)
Rearranging and substituting equation (11) into 
equation (10) leads to a definition of the probability 
of treatment t failing, Pt(fail), as:
Pt(fail) = PTURP(fail)−(WMDtpost/
(mean(Ipre)−mean(Ipost)success))  (12)
In the DAM, PTURP(fail), mean(Ipre) and mean(Ipost)
success were estimated from the ILD, and WMDtpost 
was estimated from the meta-analyses reported 
in Chapters 6–8. Because IPSS values in the 
meta-analysis continued to decline for up to 12 
months post operation, it was assumed that this 
represented continued improvement. Therefore, 
the WMD at 12 months was used as the estimate of 
WMDtpost.
Model 2
As for model 1 it was assumed that the treatments 
only differed by probability of failure and that 
those who failed had a mean IPSS post treatment 
that was the same as the pre treatment score and 
that those who were successful had identical post-
treatment IPSS regardless of the treatment that 
they received. Probability of failure of TURP was 
also still estimated from the ILD. However, in 
model 2 the probability of failure of the other 
treatments was estimated from the retreatment 
relative risks estimate obtained as part of the review 
of effectiveness reported in Chapters 6–8. Of 
course, how the decisions to retreat were made in 
the trials is not known and they were perhaps not 
made according to the rule given above with regard 
to percentage change in IPSS.
Probability of failure (2): repeat 
and subsequent procedures 
Given no other available evidence it was decided 
to estimate the probability of failure of subsequent, 
but different, procedures as if there was no previous 
history of treatment and subsequent repeat 
procedures according to a relative risk (RR):
Ptfail2 = Ptfail/RR(Ptfail/Ptfail2)  (13)
where Ptfail2 is the probability of failure of a second 
(repeat) procedure and the relative risk was 
estimated by clinical expert opinion (R Pickard, 
2006, personal communication).
Probability of relapse
Relapse has already been defined in terms of the 
transition from the ‘remission’ state to the ‘no 
remission’ state. Again there is a lack of long-term 
data for all types of treatment and the data that 
are available are only in the form of the rate of 
retreatment. Also, because long-term retreatment 
is the sum of retreatment following relapse and 
retreatment following failure (as defined above), 
each relapse rate was calculated as the remainder 
from the total retreatment rate once the failure rate 
had been deducted, i.e.:
Pd(relapse) = Ptd(retreatment)−Pt(fail)  (14)
where Pd(relapse) is the probability of relapse, 
Ptd(retreatment) is the total probability of 
retreatment (including that following failure) over 
the time period d (obtained from the literature) 
and Pt(fail) is the probability of failure (estimated 
by either model 1 or 2).
All long-term probabilities were converted to 
transition probabilities by assuming a constant rate 
over the time period. Thus:
P3(relapse) = 1−(1−Pd(relapse)1/d)1  (15)
Long-term data on retreatment were obtained 
for TURP for d = 5 years and for TUMT for d = 8 
years. The other treatments were assumed to be Health Technology Assessment 2008; Vol. 12: No. 35
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identical to TURP or TUMT depending on their 
short-term similarity as shown by the WMD in IPSS 
at 12 months. Thus, TUVP and HoLEP are the 
same as TURP and KTP the same as TUMT. 
Complications (long and short term)
These are the probabilities for those complications 
occurring in the treatment state (AUR, 
BNC, transfusion, TUR syndrome and UTI) 
and incontinence. All non-TURP treatment 
complication probabilities were expressed in terms 
of a relative risk with respect to TURP and were 
based on data from the meta-analyses reported 
in Chapters 6–8. The baseline values for TURP 
were estimated by summing events across all 
TURP treatment arms of this meta-analysis. In the 
base case those from the UK were used and then 
compared with all studies.85 Given the variability 
in reporting, the DAM has not attempted to 
differentiate between the different levels of severity 
of these events. 
Utilities
The following equation expresses how the model 
calculates the discounted expected number of 
QALYs:
Expected QALYsstrategy = Σ (0.25 · EUcycle/
(1+discount rate)cycle)  (16)
where EUcycle is the expected utility of each cycle, 
i.e. the sum of the utilities of each state weighted 
by their probabilities, and ‘0.25’ indicates that 
each cycle was a quarter of a year. Of course, the 
population total was estimated by multiplying 
the probability of each state counted post first 
treatment by the number of individuals from each 
cohort for each cycle and summing across all 
cohorts and all cycles. For example, during year 
1 (1–2 years post technology introduction) there 
will be 25,000 new entrants, whose state transition 
probabilities are those of their first year post first 
treatment, plus 25,000 entrants who entered 
during year 0, whose transition probabilities will 
therefore be those of their second year post first 
treatment.
To estimate the utility of each health state it was 
necessary to express utility as a function of both 
LUTS and complications. As stated already, the 
states of ‘no remission’ and ‘remission’ are already 
defined in terms of IPSS, i.e. ‘no remission’ is the 
study population that have an IPSS greater than 
7 and ‘remission’ is the mean IPSS of those who 
do not fail, as estimated from the ILD. Only one 
study273 that maps IPSS to utility values could be 
found from the search for economic evaluations 
(which included studies reporting utility values).
However, although the clinical experts believed 
that by far the most important factor in making 
a treatment choice is LUTS, it was necessary to 
modify the utility values in the presence of any 
complications, for the incontinence states and for 
the within-treatment state complications (AUR, 
BNC, TUR syndrome and UTI). Therefore, what 
is first shown is how utility values are calculated for 
the states of ‘no remission, no incontinence’ and 
‘remission, no incontinence’.
Utility as a function of IPSS
Kok and colleagues273 elicited preferences using an 
accepted method of time trade-off.75 The sample 
was also fairly large (n = 170) and was composed of 
members of the general public (around Rotterdam 
in the Netherlands), which facilitates comparability 
with the use of utilities to calculate QALYs in 
other populations. In their analysis they mapped 
IPSS scores on to utility values such that (Lo, Li)1 is 
preferred to (Lo, Li)2 if and only if U(Lo, Li)1 > U(Lo, 
Li)2, where (Lo, Li) is a set of levels, Lo referring 
to obstructive and Li to irritative, each defined 
according to a range of the sum of the scores on 
either the obstructive or irritative domains of the 
IPSS measure. For example, Lo = 1 if Io <=4. The 
complete set of levels (derived in the Kok and 
colleagues study from factor analysis of the IPSS 
of 1414 patients over the age of 50 years newly 
referred in 13 hospitals in the Netherlands) is 
given in Table 31.
The resulting utility values are given in Table 32.
Therefore, each combination of obstructive and 
irritative scores can be mapped to a mean utility 
score.
Unfortunately, the IPSS values are only reported 
in the literature in the form of mean total scores, 
which are the sum of the irritative and obstructive 
domain scores. Therefore, an assumption is 
required as to the relative contributions of each 
of these domains to the total. In the absence of 
evidence it could be assumed that the observed 
proportion of the total IPSS of each of the domains 
is the same as the proportion of the maximum 
score, i.e. because Itotal = Io+Ii, where Itotal is the 
total IPSS, Io is the sum of the scores on the 
obstructive domains and Ii is the sum of the scores 
on the irritative domains, and because out of 
seven domains there are four obstructive to three 
irritative, each with the same maximum score, then 
Io = 4 · Itotal/7 and Ii = 3 · Itotal/7.Economic analysis
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From this the utility of the state of ‘no remission, 
no incontinence’ can be estimated, as it is known 
that the mean IPSS estimated from the ILD 
is approximately 22. Therefore, if Itotal = 22, 
Io = (4 × 22)/7 and Ii = (3 × 22)/7, i.e. approximately 
Io = 13 and Ii= 9, which, using the table of Kok 
and colleagues, maps to 2 on both the obstructive 
and the irritative domains. Using the algorithm 
provided by Kok and colleagues273 these give a 
utility of 0.90, i.e. the utility of the preoperative 
state, which is also the state of ‘no remission, 
no incontinence’, is ‘on average’ 0.94. Similarly, 
for ‘remission, no incontinence’ the mean IPSS 
is estimated from the ILD to be about 6, which 
maps to a utility of 1, i.e. ‘on average’ successful 
treatment restores individuals to a state equivalent 
to full health. The ILD provided some support that 
Io and Ii can be treated in the way described above 
in that they had a correlation coefficient of 0.4 
and they occurred in approximately the same ratio 
preoperatively. Also, the mean utility estimated 
from the ILD both pre- and postoperatively was 
found to differ by less than 0.005 when estimated 
according to the assumption or when estimated 
using the actual data. Nevertheless, a sensitivity 
analysis tested the effect of using the minimum 
utility consistent with an IPSS of 7 for the state of 
remission. This corresponds to Io = 1 and Ii = 2 (or 
vice versa) and, thus, using the data provided by 
Kok and colleagues a utility of 0.97 was estimated 
instead of 1.
Utility as a function of IPSS 
and non-LUTS factors
Only one study was found, by Ackerman and 
colleagues78 (see Chapter 4), that estimated utility 
as a function of both LUTS and complications. 
The challenge was to ‘map’ these values to the 
Kok and colleagues utilities.273 This was achieved 
by ‘anchoring’ to the state without complications 
by assuming that the state of ‘moderate to severe’ 
BPE described by Ackerman and colleagues 
was equivalent to the mean IPSS pre treatment 
(estimated from the ILD). This assumption can 
be justified because the definition of ‘moderate 
to severe’ is an IPSS > 7, which is also the IPSS 
in the study population. The Ackerman utilities 
for complications were then used in one of two 
forms, compared in a sensitivity analysis, either 
unadjusted or adjusted, by calculating them as:
UKok(complication) = UAckerman(complication) ·  
(UKok(meanIpre)/U(moderate to severe)Ackerman)  (17)
TABLE 31  Map of IPSS to levels on obstructive and irritative dimensions used to produce utility values (see Table 32)
Domain Summary score Level
Obstructive
Seldom/never ≤ 4 Obstructive 1
About half of the time/sometimes ≥ 5 and ≤ 16 Obstructive 2
Almost always ≥ 17 Obstructive 3
Irritative
Seldom/never ≤ 3 Irritative 1
About half of the time/sometimes ≥ 4 and ≤ 9 Irritative 2
Almost always ≥ 10 Irritative 3
TABLE 32  Utility values corresponding to obstructive and irritative levels (see Table 31)
Obstructive score
1 2 3
Irritative score 1 1.00 0.97 (0.11) 0.95 (0.09)
2 0.97 (0.10) 0.94 (0.12) 0.92 (0.11)
3 0.92 (0.15) 0.90 (0.14) 0.87 (0.14)
Data are expressed as mean (SD).Health Technology Assessment 2008; Vol. 12: No. 35
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This, therefore, allows the estimation of the utility 
of a treatment state as the sum of the utility of the 
short-term complications (AUR, BNC, transfusion, 
TUR syndrome and UTI) that occur within this 
state weighted by their probabilities. Because 
incontinence can occur with or without remission 
from LUTS, there are two utilities: one for the state 
‘incontinence, no remission’ and one for the state 
‘incontinence, remission’. It was assumed that the 
utility of ‘incontinence, no remission’ was equal to 
that for ‘incontinence, remission’ reduced by the 
‘disutility’ (1−utility) of the ‘no incontinence, no 
remission’ health state. The effect of assuming that 
the utility of these states was the same was tested in 
a sensitivity analysis.
Costs
In keeping with the economic perspective, only 
costs applicable to the NHS in England and 
Wales have been included. The following formula 
expresses the discounted cost function estimated 
for each individual (thus excluding capital costs) 
for each treatment strategy:
Expected coststrategy = Σ (expected costcycle/
(1 + discount rate)cycle)  (18)
As for QALYs, the total population costs were 
estimated by multiplying the probability of each 
state at each time post first treatment by the 
number of individuals from each cohort and 
summing across all cohorts and cycles. However, 
in addition, capital costs were included, which 
were the purchase of equipment that could be 
used by more than one individual and over several 
years. This category was assumed to apply only 
to HoLEP, TUMT and KTP. Also, as for utility, 
the cost of each state needs to be estimated. The 
states of ‘no incontinence, remission’ and ‘no 
incontinence, no remission’ incur no costs. The 
states including ‘incontinence’ (‘incontinence, no 
remission’ and ‘incontinence, remission’) incur the 
cost of treating incontinence. The treatment states 
incur the procedure cost and the cost of treating 
the short-term complications of AUR, BNC, 
transfusion, TUR syndrome and UTI. The cost of 
the procedures was also distinguished by:
the length of stay of the procedure  •	
(LOSprocedure), which was taken to be separate 
from any extra LOS due to complications and 
which had a cost, costLOSprocedure
the procedure cost (cost •	 OP excluding hospital 
stay but including perioperative ward time, 
investigations and theatre costs)
complication costs (cost •	 comp)
the cost of purchase of equipment for each  •	
individual (costequipment).
Therefore, the cost of the treatment state for 
treatment t is:
Costt = costtOP + costtLOSprocedure 
+ tcostequipment+ Σ costcomp  (19)
Procedure cost
CosttOP was assumed to be the same for all 
procedures. It was estimated by assuming that 
the 2005 NHS reference cost45 [Health Care 
Resource Group (HRG) code L28 (without 
complications)] for the surgical treatment of BPE 
was the total treatment cost (including LOS due 
to initial procedure and complications). CosttOP 
was calculated by netting out the cost of LOS from 
NHS reference costs using the formula below:
CostOP = costreference –(LOSreference · costday)  (20)
where cost per bed day, costday, was estimated for 
a urological surgery ward from the NHS reference 
costs with HRG code L09 (‘treatment of kidney 
or urinary tract infection’) as this typically does 
not involve surgery. This cost was confirmed by 
estimating the difference in cost between HRG 
L27 (with complications) and L28 (without 
complications) and assuming that this difference 
was due mostly to the difference in LOS. LOSreference 
is the mean LOS given with the reference cost data 
for codes L27 and L28.
Although LOS estimates were retrieved from the 
meta-analysis it was the opinion of the experts that 
these largely reflected local practice and therefore 
the LOS of each procedure (LOStprocedure) was 
based on expert opinion of standard UK practice. 
Therefore, LOStprocedure was assumed to be 3 days 
for TURP or TUVP, 2 days for holmium laser 
resection or laser vaporisation, and 0 days (day-case 
procedure) for TUMT. These values were varied in 
a sensitivity analysis. 
In the absence of direct evidence the day unit cost 
of TUMT was estimated using expert opinion and 
evidence from several sources, including the lowest 
NHS reference costs for a day case and a local 
estimate (with cost elements removed to prevent 
the double counting of ‘operation cost’). The cost 
was estimated to be between £200 and £400, with 
an expected value of £250 and most likely to be no 
more than £250 (the probability of being no more 
than £250 was 0.75). Economic analysis
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TURP and TUVP were assumed to incur no 
additional equipment costs. For KTP, TUMT and 
HoLEP, additional costs of blades/fibres/probes 
were included. Costs of laser equipment were 
estimated from manufacturers (R Pickard, 2006, 
personal communication). The fibre/blade/probe 
costs per individual were calculated by assuming 
that for KTP and TUMT they are not reusable 
but for HoLEP they are. The number of reuses is 
expressed as a distribution based on expert opinion 
and manufacturers estimates (R Pickard, 2006, 
personal communication). All of the data used to 
calculate these costs are reported in Table 30.
Capital costs were those of the purchase of the 
machines and were estimated in the base-case 
model assuming efficient use at 250 uses per year 
with a lifetime consistent with that of the model 
of 10 years. Sensitivity analysis was conducted to 
reduce the number of uses per year. Travel costs 
were not included, as too few data were available on 
the siting of equipment.
Short-term complication costs
All costs of short-term complications were 
estimated based on expert opinion (R Pickard, 
personal communication 2006). More specifically, 
the cost of AUR was calculated as the cost of an 
additional day of LOS for ‘trial without catheter’ 
plus, for the proportion of patients who fail this 
trial (probability of TURP after AUR), the cost of 
TURP. The cost of BNC was assumed to be the cost 
of an additional TUIP. The cost of transfusion was 
calculated based on the cost of a unit of blood of 
£635 (R Pickard, 2006, personal communication) 
multiplied by the number of units (two on average). 
The cost of UTI was estimated as the cost of an 
additional LOS (3 days on average). The cost per 
bed day was costday as estimated by the method 
described above.
Cost of incontinence
The cost of incontinence was calculated partly as 
a recurring cost of oxybutynin [from the British 
National Formulary (www.bnf.org/bnf/) on 3 
November 2006; from 2.5 mg twice a day (£8.98 
for 56-tablet pack) to 5 mg twice a day (£3.26 for 
84-tablet pack)] multiplied by the proportion 
who would have urge incontinence, estimated as 
0.95 by expert opinion. For the remaining 5%, 
incontinence was assumed to be cured by artificial 
sphincter, which incurred a one-off cost of £6000 
(R Pickard, 2006, personal communication).
Accounting for uncertainty
Given that a systematic review and meta-analysis 
were included as part of this project, in estimating 
the parameter distributions for the Monte Carlo 
simulation, the starting point for all parameters 
was always an estimate of the expected value from 
the sample and a sampling distribution, which is 
equivalent to the likelihood. The clinical experts 
were asked to examine all of the estimates from 
the meta-analysis that informed the parameters 
in the DAM to see how credible the mean was as 
an estimate of population expected value and 
whether the size of the 95% confidence interval was 
a suitable estimate of the magnitude of uncertainty. 
When there was other sample evidence, such as 
from the ILD to estimate the probability of failure 
of treatment, the sampling distribution was also 
used. When no such data existed, the posterior 
used in the model was essentially a prior, estimated 
by expert opinion (R Pickard, 2006, personal 
communication) and checked by further expert 
opinion (J N’Dow, S McClinton, 2006, personal 
communication). The distribution was then 
estimated using an expected value and range, 
which implied an approximate 95% confidence 
interval, or, where there was greatest uncertainty, 
only a range, which implied a uniform distribution.
Table 30 contains a list of all parameters, their 
expected values, the standard errors and the 
confidence intervals along with a note of the 
distribution used and the source of data. All 
distribution shapes were chosen according to 
standard practice.77 All relative risk estimates 
from the meta-analysis for complications and 
retreatment and for cost from the NHS reference 
cost data on procedure cost and LOS were log 
transformed to parameterise a symmetrical normal 
distribution. Beta distributions were parameterised 
from sample-based means and standard errors and 
used to estimate the uncertainty of parameters 
bounded by 0 and 1 (baseline probabilities 
and utilities). The normal distribution was 
parameterised from sample data using sample-
based means and standard errors. This approach 
was used for IPSS estimation for the WMDs from 
the meta-analysis; the mean IPSS preoperatively 
(‘no remission, no incontinence’ state) and 
following successful treatment (‘remission, no 
incontinence’ state), both from the ILD; and the 
cost of the pressure test following the first TURP, 
from NHS reference costs.
When there were no sample data, the shape of 
the parameter distribution depended on some 
judgement as to the degree of uncertainty. 
Therefore, the normal distribution was 
parameterised by assuming that the expert opinion 
of upper and lower bounds corresponded to 
the 95% confidence interval. This approach was Health Technology Assessment 2008; Vol. 12: No. 35
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used to estimate the uncertainty surrounding the 
LOS for TUR syndrome and UTI and the cost of 
transfusion. The beta distribution was similarly 
parameterised for estimating the uncertainty of the 
probability of requiring TURP because of AUR. A 
uniform distribution was used for the number of 
reuses of the HoLEP and laser fibres/blades and 
the lifetime of each of the machines as well as the 
probability of the pressure test showing obstruction.
The Monte Carlo simulation was run with 10,000 
samples. The number of samples was chosen 
by trialling the Monte Carlo simulation with 
increasing numbers of samples to determine 
at which point the addition of further samples 
resulted in no changes in the strategies that were 
non-dominated and non-extendedly dominated 
as well as little effect on the incremental cost-
effectiveness ratios (ICERs). Because the analysis 
was carried out at the ‘population level’, the 
expected value of perfect information (EVPI) was 
calculated immediately for an incidence of 25,000 
per year over 10 years at a discount rate of 3.5%.
Results
The cost-effectiveness analysis 
Table 33 shows the results of a Monte Carlo 
simulation with 10,000 samples. 
TABLE 33  Results of a Monte Carlo simulation with 10,000 samples
Strategy Cost (£)
Incremental 
cost (£)
Effectiveness 
(QALYS)
Incremental 
effectiveness 
(QALYS) ICER
TUVP £380,774,844 917,082
TUMT £387,042,593 £6,267,749 906,333 –10,749 (Dominated)
HoLEP £400,549,783 £19,774,939 919,656 2574.1 £7682
TUVP/HoLEP £413,712,972 £13,163,189 921,041 1384.8 £9505
TUVP/TURP £416,466,605 £2,753,633 920,931 –109.3 (Dominated)
TUVP/TURP × 2 £418,264,231 £4,551,258 921,091 50.2 £90,576
TURP £435,632,543 £17,368,313 918,222 –2868.7 (Dominated)
TURP × 2 £457,866,096 £39,601,866 920,340 –751.3 (Dominated)
TUMT/TUVP £502,437,525 £84,173,294 919,219 –1871.9 (Dominated)
TUMT × 2 £504,459,471 £86,195,241 915,639 –5451.6 (Dominated)
TUMT/HoLEP £509,607,654 £91,343,423 919,893 –1197.7 (Dominated)
TUMT/TUVP/HoLEP £512,222,250 £93,958,020 920,231 –860.0 (Dominated)
TUMT/TUVP/TURP £512,936,161 £94,671,930 920,203 –887.7 (Dominated)
TUMT/TUVP/TURP × 2 £513,448,707 £95,184,476 920,243 –848.0 (Dominated)
TUMT/TURP £519,051,244 £100,787,013 919,281 –1810.1 (Dominated)
TUMT/TURP × 2 £525,599,769 £107,335,538 920,059 –1031.5 (Dominated)
TUMT × 2/TUVP £543,805,485 £125,541,255 919,592 –1498.7 (Dominated)
TUMT × 2/HoLEP £546,577,726 £128,313,496 919,798 –1292.5 (Dominated)
TUMT × 2/TUVP/HoLEP £547,091,377 £128,827,147 919,896 –1195.2 (Dominated)
TUMT × 2/TUVP/
TURP × 2
£547,469,842 £129,205,611 919,899 –1191.8 (Dominated)
TUMT × 2/TUVP/TURP £549,476,915 £131,212,685 918,172 –2919.0 (Dominated)
TUMT × 2/TURP × 2 £551,652,179 £133,387,949 919,846 –1244.7 (Dominated)
TUMT × 2/TURP £556,354,850 £138,090,619 919,684 –1406.5 (Dominated)
KTP £557,310,731 £139,046,500 907,708 –13,382.6 (Dominated)
HoLEP , holmium laser enucleation of the prostate; ICER, incremental cost-effectiveness ratio; KTP , potassium-titanyl-
phosphate; TUMT, transurethral microwave thermotherapy; TURP , transurethral resection of the prostate; TUVP , 
transurethral electrovaporisation of the prostateEconomic analysis
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What is clear from the results presented in this 
table is that effectiveness increases (in terms of 
QALYs) when moving from performing only one 
treatment to repeating treatments or adding 
treatments on initial failure or later relapse in a 
strategy. 
The strategy that would be considered cost-effective 
depends upon society’s willingness to pay for a 
QALY. For example, if the threshold is £20,000 per 
QALY, then TUVP/TURP × 2 would not be cost-
effective. However, if current practice is TURP × 2, 
i.e. TURP followed by another TURP as required, 
then TUVP/HoLEP and TUVP/TURP × 2 are both 
less costly and more effective. Therefore, a move 
from current practice to TUVP/HoLEP at such a 
threshold would follow from these results.
The cost-effectiveness acceptability curve (CEAC) 
(Figure 30) gives an indication of the amount of 
uncertainty surrounding point estimates of cost-
effectiveness. Most of the strategies have a zero 
probability of being cost-effective. Assuming 
that society’s willingness to pay for a QALY is 
£20,000, it is clear that not only is TUVP/HoLEP 
cost-effective ‘on average’ but also that it has a 
probability of about 0.8 of being cost-effective. If 
society’s willingness to pay for a QALY is £80,000 
then ‘on average’ TUVP/TURP × 2 would be most 
likely to be cost-effective. However the probability 
of being cost-effective is 0.5, similar to that of 
TUVP/HoLEP (Figure 30). Such uncertainty 
might affect the decision as to which strategy 
to implement. However, the CEAC should be 
interpreted with caution in that it does not reveal 
for each sample what the size of the differences in 
cost and effectiveness are.
Comparisons of all treatment 
strategies against a TURP alone 
as a common comparator
The data reported in Table 33 were used to 
compare each individual treatment strategy 
with the strategy of TURP alone (i.e. patients all 
initially receive a TURP but should the procedure 
subsequently be deemed to have failed then the 
patient is managed non-surgically). 
Table 34 shows the comparison of treatment 
strategies involving only a single surgery with 
TURP alone. For the comparison of TUMT or 
TUVP with TURP, TURP is more costly but more 
effective. The incremental costs per QALY for 
these two comparisons suggest that the savings 
obtained from a move from TURP to TUMT are 
probably not worth the loss of QALYs. Conversely, 
the savings that may be obtained from moving 
from TURP to TUVP may be worth the loss of 
benefits (the incremental cost per additional QALY 
provided by TURP compared with TUVP is greater 
than £30,000). HoLEP appears to be on average 
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less costly and more effective than TURP alone (i.e. 
HoLEP is dominant) and KTP is less effective and 
more costly than TURP (TURP is dominant).
A similar comparison was made for those strategies 
involving a second surgery for those people for 
whom a first surgery was deemed to have failed 
(Table 35). TUMT × 2 is more costly and less 
effective than TURP (TURP is dominant). Other 
strategies involving TUMT as a first-line surgery 
are on average unlikely to be considered cost-
effective. 
Strategies involving TUVP as a first-line 
intervention were found to be less costly and more 
effective than TURP, continuing the trend started 
with the comparison of TUVP with TURP.
The final set of comparisons was for those 
strategies that allow more than one subsequent 
surgery if necessary (Table 36). The only strategies 
considered in this comparison were those in 
which the initial surgery was TUMT or TUVP. 
For all those strategies starting with TUMT, 
the incremental cost per QALY is at best on the 
borderline of what society might consider to 
be worthwhile, as would be expected given the 
analyses reported in Tables 34 and 35. The one 
strategy starting with TUVP is more effective and 
less costly than TURP alone.
Sensitivity analyses
Table 37 shows the results of one-way sensitivity 
analysis on a series of predetermined parameters. 
Varying the values for these parameters did not 
affect the set of non-dominated or non-extendedly 
dominated strategies. The exception to this was 
when the probability of treatment failure was 
based on the risks of reoperation and not changes 
in symptom scores. In this situation the use of 
HoLEP as a single treatment was excluded as it 
was extendedly dominated by the other treatment 
strategies considered. The reason for this is that 
the probabilities of failure all improved when 
the probability of treatment failure was based 
on the risks of reoperation and not changes in 
symptom scores. However, the probability of cost-
effectiveness for HoLEP improved the least. 
In all sensitivity analyses the ICERs are reported 
in Table 37. Any changes in ICERs are intuitively 
sensible. Whether these changes are sufficient to 
affect the choice of strategy depends again on 
society’s willingness to pay for a QALY. However, 
in all cases but two a change from the status quo 
of TURP × 2 would be cost-effective. One case is if 
the LOS of TURP (exclusive of complications) were 
to be reduced from 3 to 2 days in line with that 
of TUVP. Here the decision would depend on the 
opportunity cost of moving to the more expensive 
but more effective TUVP/TURP × 2. In the other 
case, pressure testing is applied after TUVP as 
well as after TURP, which, although not standard 
practice, might be plausible and would thus makes 
TURP × 2 the most effective strategy. Although 
the ICER for TURP × 2 would be extremely high, 
given that it is already current practice it might 
be difficult to cancel the most effective although 
perhaps rather costly treatment.
Multiple cohort (population-based) 
versus single cohort (individual-
based) model comparison
Table 38 shows the effect of estimating costs and 
QALYs for the entire population of men presenting 
for surgery at the rate of 25,000 per year for the 
next 10 years versus the effect of estimating costs 
and QALYs per individual from that population 
over 10 years, each starting now, discounted at 
TABLE 34  Comparison of single surgery strategies with the TURP strategy
Comparison 
with TURP
Cost (£) QALYs
Incremental 
cost (£)
Incremental 
QALYs
Incremental 
cost per 
QALY Alternative TURP Alternative TURP
TUMT  £387,042,593 £435,632,543 90,6333 91,8222 –£48,589,950 –11,890 £4087
HoLEP  £400,549,783 £435,632,543 91,9656 91,8222 –£35,082,760 1434 HoLEP 
dominant
KTP  £557,310,731 £435,632,543 90,7708 91,8222 £121,678,188 –10,514 TURP 
dominant
TUVP  £380,774,844 £435,632,543 91,7082 91,8222 –£54,857,699 –1141 £48,100
HoLEP , holmium laser enucleation of the prostate; KTP , potassium-titanyl-phosphate; QALY, quality-adjusted life-year; 
TUMT, transurethral microwave thermotherapy; TURP , transurethral resection of the prostate; TUVP , transurethral 
electrovaporisation of the prostate.Economic analysis
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TABLE 37  Results of sensitivity analysisa 
Strategy Cost (£)
Incremental 
cost (£)
Effectiveness 
(QALYs)
Incremental 
effectiveness 
(QALYs) ICER
Base caseb 
TUVP £380,774,844 91,7082
HoLEP £400,549,783 £19,774,939 91,9656 2574 £7682
TUVP/HoLEP £413,712,972 £13,163,189 92,1041 1385 £9505
TUVP/TURP × 2 £418,264,231 £4,551,258 92,1091 50 £90,576
Start age 90
TUVP £376,991,192 541,771
HoLEP £397,495,122 £20,503,931 543,268 1497 £13,695
TUVP/HoLEP £405,702,102 £8,206,980 543,703 435 £18,872
TUVP/TURP × 2 £409,475,528 £3,773,426 543,715 12 £309,087
Start age 50
TUVP £381,248,895 1,002,040
HoLEP £400,940,948 £19,692,053 100,4857 2818 £6988
TUVP/HoLEP £414,850,642 £13,909,693 100,6451 1594 £8727
TUVP/TURP × 2 £419,518,524 £4,667,882 100,6511 59 £78,771
Utility of ‘incontinence, no remission’ the same as utility of ‘incontinence, remission’
TUVP £380,774,844 917,131
HoLEP £400,549,783 £19,774,939 919,679 2548 £7762
TUVP/HoLEP £413,712,972 £13,163,189 921,092 1413 £9315
TUVP/TURP × 2 £418,264,231 £4,551,258 921,144 52 £88,045
Utility of IPSS < 8 is 0.97
TUVP £380,774,844 893,516
HoLEP £400,549,783 £19,774,939 894,844 1328 £14,889
TUVP/HoLEP £413,712,972 £13,163,189 895,584 740 £17,791
TUVP/TURP × 2 £418,264,231 £4,551,258 895,611 28 £163,682
BPE risk data from all studies
TUVP £380,774,844 917,082
HoLEP £400,549,783 £19,774,939 919,656 2574 £7682
TUVP/HoLEP £413,712,972 £13,163,189 921,041 1385 £9505
LOS TURP = LOS TUVP = 2 days
TUVP £376,715,152 917,082
TURP £380,679,392 £3,964,240 918,222 1140 £3476
TURP × 2 £400,362,758 £19,683,366 920,340 2117 £9296
TUVP/TURP × 2 £409,495,593 £9,132,834 921,091 751 £12,156
Probability of failure (model 2)
TUVP £380,793,296 918,558
TUVP/HoLEP £404,008,222 £23,214,926 921,217 2659 £8731
TUVP/TURP × 2 £406,972,673 £2,964,451 921,269 52 £56,845
continuedHealth Technology Assessment 2008; Vol. 12: No. 35
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Strategy Cost (£)
Incremental 
cost (£)
Effectiveness 
(QALYs)
Incremental 
effectiveness 
(QALYs) ICER
Test for obstruction after TUVPc
TUVP £380,774,844 917,082
HoLEP £400,549,783 £19,774,939 919,656 2574 £7682
TUVP/HoLEP £405,478,440 £4,928,657 920,051 395 £12,475
TUVP/TURP × 2 £409,175,523 £3,697,083 920,128 78 £47,659
TURP × 2 £457,866,096 £48,690,573 920,340 211 £230,608
HoLEP , holmium laser enucleation of the prostate; IPSS, International Prostate Symptom Score; LOS, length of stay; QALY, 
quality-adjusted life-year; TURP , transurethral resection of the prostate; TUVP , transurethral electrovaporisation of the 
prostate.
a  Based on 10,000 Monte Carlo simulation samples and showing non-dominated and non-extendedly dominated strategies 
only).
b  Start age 70; utility of ‘incontinence remission’ = utility of ‘incontinence, no remission’ –  disutility of ‘no remission’; utility 
of IPSS < 8 is 1; BPE risk data from UK studies only; LOS TURP 3 days.
c  The test is applied after TUVP only in strategies in which TUVP can be followed on failure by HoLEP or TURP . The test 
is also applied, as in the base case, before a second TURP except in the strategy TUVP/TURP × 2, in which it is has already 
been applied after TUVP .
TABLE 38  Comparison of multiple versus single cohort models
Cost (£)
Incremental 
cost (£)
Effectiveness 
(QALYs)
Incremental 
effectiveness 
(QALYs) ICER
Individual based (single cohort model)
TUVP £1794 7.119357
HoLEP £1819 £25 7.139511 0.020154 £1242
TUVP/HoLEP £1958 £139 7.152449 0.012938 £10,755
TUVP/TURP × 2 £1990 £31 7.152964 0.000515 £60,896
Population based (multiple cohort model)
TUVP £380,774,844 917,081.6
HoLEP £386,049,783 £5,274,939 919,655.7 2574.14 £2049
TUVP/HoLEP £412,403,965 £26,354,182 921,040.6 1384.83 £19,031
TUVP/TURP × 2 £418,264,231 £5,860,266 921,090.8 50.24794 £116,627
HoLEP , holmium laser enucleation of the prostate; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; 
TURP , transurethral resection of the prostate; TUVP , transurethral electrovaporisation of the prostate.
3.5%. To make the comparison clearer, capital costs 
have been excluded. It has already been argued 
that the former (population-based) approach is the 
appropriate model for dealing with capital costs 
and therefore this sensitivity analysis is intended 
to show that there is also difference between 
the models excluding such costs because of the 
‘mixing’ effect described above (see the beginning 
of Chapter 11).
It can be seen that the model does make a 
difference to the precise ICERs but that TUVP/
HoLEP and TUVP/TURP × 2 are still more 
effective and less costly (not shown) than TURP × 2 
(assumed to be current practice) and therefore the 
choice of strategy is between these strategies.
Expected value of perfect 
information (EVPI)
As described in Chapter 4 it is possible to use 
the DAM to estimate the value of reducing the 
uncertainty within the model and hence reduce 
the probability of making a wrong decision. 
Uncertainty can be reduced by obtaining further 
information and Table 39 provides an indication of 
the value of reducing all uncertainty in the model 
TABLE 37  Results of sensitivity analysisa (continued) Economic analysis
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(i.e. our choice about which treatment or sequence 
of treatments is most cost-effective is based on 
perfect information). Also included in this table is 
the value of removing all uncertainty surrounding 
estimates of specific groups of parameters (the 
expected value of partial perfect information; 
EVPPI). The EVPI and the EVPPIs reported in 
Table 39 are calculated at a threshold value for 
society’s willingness to pay for a QALY of £20,000, 
given uncertainty as to its value.
What Table 39 provides is an indication of the 
cost of the uncertainty, either overall (the EVPI) 
or in specific groups of parameters (EVPPI), and, 
therefore, the maximum value of future research 
that might be conducted to reduce this uncertainty. 
Parameter groupings such as utilities are not 
included because their EVPI was either extremely 
low or zero, i.e. their uncertainty had little or no 
effect on which strategy was cost-effective. It should 
be noted that this analysis does not reflect the 
value of improving model structure, for example 
the method of mapping IPSS on to utilities. It also 
assumes that the distributions around all of the 
parameters identified are accurate representations 
of the real uncertainty surrounding these 
parameter estimates.
Given an annual number of men undergoing 
TURP in the UK of 25,000, a discount rate of 3.5% 
and a £20,000 per QALY threshold, this places 
an upper limit on all future research investment 
of about £5.3 million over 10 years. If it is 
assumed that the sizes of the EVPPIs are directly 
proportional to the value of conducting further 
research then research focusing on improving the 
estimates of TUVP epidemiology (i.e. estimates 
of relative risks of complications and estimates of 
the WMD in IPSS relative to TURP) would have 
by far the highest priority. This could be achieved 
by undertaking more research comparing TUVP 
with TURP, perhaps within an RCT setting, with an 
upper limit on spending of about £4.1 million. The 
EVPI is highly sensitive to the willingness to pay for 
a QALY in that it almost doubles to £10.2 million 
on moving from £20,000 to £10,000 per QALY. 
This can be understood by observing that on the 
CEAC there is no clear ‘front runner’ at £10,000, 
which implies greatest uncertainty.
Consequences (disaggregated)
The cost-effectiveness analysis reported above 
aggregates the time spent in the various states 
of the model by the quality of life associated 
with these states. Although this has been carried 
out using the best evidence available and using 
explicit methods, further insight can be gained by 
considering the time spent in each of the states 
within the model for each treatment and treatment 
strategy considered (Table 40).
Table 40 shows that each strategy is associated with 
the same risk of death and hence the average time 
spent in that state is the same. The majority of time 
for each strategy is spent in the state of remission, 
although the average number of years spent in 
this state varies between 5.28 years for TUMT only 
and 7.92 years for TUVP/TURP × 2. Except for 
the strategy of KTP (0.21 years), the time spent in 
the state of incontinence is approximately a tenth 
of a year or less. Finally, the time spent in the 
state of no remission also varies considerably, with 
patients receiving TUVP/TURP × 2 and TUVP/
HoLEP spending on average 0.05 of a year or less 
in this state and patients receiving a single TUMT 
spending on average over 2.74 years in this state. 
In Table 41 the different strategies are ranked in 
order of the time spent in two particular states: 
remission from LUTS and incontinence (the 
highest ranked strategy for remission is the strategy 
associated with the longest time spent in remission 
and the highest ranked strategy for incontinence 
is the one in which the least time is spent with 
incontinence). These two states are included as 
they are key determinants of the QALY estimates 
presented above. As this table illustrates there 
is no clear winning strategy. However, the CUA 
presented above suggests that the greater time 
TABLE 39   Expected value of perfect information (EVPI) at a threshold value for society's willingness to pay of £20,000
Parameter group EVPI (£)
All parameters (expected value of perfect information) 5,269,869
Expected value of partial perfect information (EVPPI)
TUVP epidemiology 4,187,062
HoLEP epidemiology 1,652,886
HoLEP , holmium laser enucleation of the prostate; TUVP , transurethral vaporisation of the prostate.Health Technology Assessment 2008; Vol. 12: No. 35
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TABLE 40  Time in years spent in each state of the DAM for the base-case model (‘incontinence’ includes ‘incontinence, no remission’ 
and ‘incontinence, remission’)
Operation Remission No remission Incontinence Death Total
TUMT 0.25 5.28 2.74 0.06 1.67 10
TUVP 0.25 7.27 0.72 0.09 1.67 10
KTP 0.25 5.65 2.21 0.21 1.67 10
TURP 0.25 7.44 0.55 0.09 1.67 10
HoLEP 0.25 7.65 0.33 0.09 1.67 10
TUMT × 2 0.35 6.82 1.08 0.08 1.67 10
TUMT/TUVP 0.35 7.56 0.33 0.08 1.67 10
TUMT/TURP 0.35 7.61 0.27 0.09 1.67 10
TUVP/TURP 0.27 7.89 0.07 0.09 1.67 10
TURP × 2 0.26 7.78 0.18 0.10 1.67 10
TUMT × 2/TUVP 0.40 7.62 0.23 0.08 1.67 10
TUMT × 2/TURP 0.40 7.63 0.21 0.09 1.67 10
TUMT/TUVP/TURP 0.36 7.75 0.13 0.09 1.67 10
TUMT/TURP × 2 0.36 7.71 0.16 0.09 1.67 10
TUVP/TURP × 2 0.27 7.92 0.04 0.09 1.67 10
TUMT × 2/TUVP/TURP 0.40 7.68 0.16 0.09 1.67 10
TUMT × 2/TURP × 2 0.40 7.67 0.17 0.09 1.67 10
TUMT/TUVP/TURP × 2 0.36 7.75 0.12 0.09 1.67 10
TUMT × 2/TUVP/TURP × 2 0.40 7.68 0.16 0.09 1.67 10
TUMT/HoLEP 0.35 7.68 0.21 0.09 1.67 10
TUMT × 2/HoLEP 0.40 7.66 0.19 0.09 1.67 10
TUVP/HoLEP 0.27 7.91 0.05 0.09 1.67 10
TUMT/TUVP/HoLEP 0.36 7.75 0.12 0.09 1.67 10
TUMT × 2/TUVP/HoLEP 0.40 7.68 0.16 0.09 1.67 10
HoLEP , holmium laser enucleation of the prostate; KTP , potassium-titanyl-phosphate; TUMT, transurethral microwave 
thermotherapy; TURP , transurethral resection of the prostate; TUVP , transurethral electrovaporisation of the prostate.
spent in remission tends to be more important 
than the shorter time spent in the state of 
incontinence. Therefore, the findings of the CUA 
that TUVP/TURP × 2 is the most effective in terms 
of QALYs are perhaps to some extent validated by 
this analysis.
Summary
In this chapter our DAM has been presented, 
which responded to the issues raised by the critique 
of previous DAMs reported in Chapter 4. The 
results show that the least costly treatment is TUVP 
followed by TUMT and then HoLEP but that 
TUMT is less effective than TUVP and HoLEP is 
more effective than TUVP. However, HoLEP might 
not be considered to be the most cost-effective 
when balancing all relevant complications with 
LUTS improvement as shown by the use of QALYs. 
This is because no treatment is 100% effective 
and the use of the most effective single treatment 
of HoLEP is believed to preclude any further 
treatment that might otherwise ‘mop up’ those 
who fail. Therefore, treating with a less effective, 
but nonetheless still very effective, treatment that 
allows further treatment should there be failure 
might be the best option. This approach has 
the advantage of most men achieving effective 
symptom relief with reduced complications 
and lower cost, although a few men would be 
disadvantaged by needing a further, more invasive 
treatment.
Whether this is indeed the case and what sequence 
of treatments is optimal depends on two major 
factors, the ‘true’ outcomes of the procedures and 
society’s willingness to pay for a QALY. What is Economic analysis
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TABLE 41  Ranking of strategies by time spent in state (best first)
Rank Remission Incontinence
1 TUVP/TURP × 2 TUMT
2 TUVP/HoLEP TUMT × 2
3 TUVP/TURP TUMT/TUVP
4 TURP×2 TUMT × 2/TUVP
5 TUMT/TUVP/TURP × 2 TUMT × 2/HoLEP
6 TUMT/TUVP/HoLEP TUMT × 2/TUVP/HoLEP
7 TUMT/TUVP/TURP TUMT × 2/TUVP/TURP
8 TUMT/TURP × 2 TUMT × 2/TURP
9 TUMT × 2/TUVP/TURP × 2 TUMT × 2/TUVP/TURP × 2
10 TUMT × 2/TUVP/HoLEP TUMT/HoLEP
11 TUMT × 2/TUVP/TURP TUMT × 2/TURP × 2
12 TUMT/HoLEP TUVP
13 TUMT × 2/TURP × 2 TUMT/TUVP/HoLEP
14 TUMT × 2/HoLEP TUMT/TURP
15 HoLEP TUMT/TUVP/TURP
16 TUMT × 2/TURP TUMT/TUVP/TURP × 2
17 TUMT × 2/TUVP TUMT/TURP × 2
18 TUMT/TURP HoLEP
19 TUMT/TUVP TURP
20 TURP TUVP/HoLEP
21 TUVP TUVP/TURP
22 TUMT × 2 TUVP/TURP × 2
23 KTP TURP × 2
24 TUMT KTP
HoLEP , holmium laser enucleation of the prostate; KTP , potassium-titanyl-phosphate; TUMT, transurethral microwave 
thermotherapy; TURP , transurethral resection of the prostate; TUVP , transurethral electrovaporisation of the prostate.
the appropriate level of society’s willingness to 
pay for a QALY is unclear as it depends upon the 
opportunity cost of the resources required to obtain 
an additional QALY, which is unknown. As for 
the first factor, this study has attempted, through 
economic and statistical methods, to represent the 
beliefs of decision-makers, informed by the best 
evidence, regarding the relationship between the 
outcomes and each strategy. As stressed earlier in 
this report, there are considerable limitations in 
the current evidence base for estimating effects and 
so the values used in the DAM may be subject to 
considerable uncertainty. Nevertheless, the base-
case results should provide a basis to inform the 
current decision as to which technology should 
be implemented. Should it be shown that it is 
affordable then the model suggests that the best 
strategy would be TUVP followed, if necessary, 
by up to two TURPs. In practice, however, these 
results should be interpreted with caution and 
the data on which they are based are probably 
not strong enough to warrant a change in NHS 
practice from the TURP × 2 strategy. However they 
do indicate that strategies of HoLEP alone and 
TUVP followed by HoLEP (TUVP/HoLEP) might 
be worthy of further consideration.
The value of perfect information results indicate 
that it might be worth considering further research 
to better inform a decision in the future and also 
to determine the relative priorities of the types 
of evidence that need to be gathered. It should 
be noted that the results presented depend upon 
the imprecision around estimates being fully 
incorporated into the model. Nevertheless, the 
results indicate that it may be worthwhile gathering 
further evidence to compare TUVP and TURP.Health Technology Assessment 2008; Vol. 12: No. 35
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n common with other areas of medicine the 
surgical treatment of BPE has undergone rapid 
technological change in recent years. Routine 
application of such new technology is dependent 
on many factors but is ideally governed by 
demonstration of benefit over existing standard 
treatment, in this case TURP. A systematic review 
of interventions with meta-analysis of available data 
and an economic evaluation was undertaken to 
determine whether any of the currently available 
newer technologies provide greater effectiveness, 
fewer complications and greater cost-effectiveness 
than TURP. 
Summary of results
In respect of symptoms associated with BPE we 
found that TURP provides a consistently high level 
of improvement, which persists in the long term. 
This is associated with significant improvement 
in quality of life and peak urine flow rate. Of the 
newer technologies, minimally invasive options 
such as TUMT and TUNA result in less symptom 
improvement and a smaller increase in peak urine 
flow rate. Ablative procedures such as TUVP and 
laser resection (HoLEP) give similar symptom and 
quality of life improvements to TURP, and HoLEP 
additionally results in a greater improvement 
in flow rate (WMD + 1.43 ml/s at the 12-month 
follow-up). Purely in terms of effectiveness, HoLEP 
would appear to be unique amongst the newer 
technologies in offering an advantage over TURP, 
although, based on the current short-term outcome 
data available, this is confined to the urodynamic 
outcome, which may not be of importance to 
patients. Longer-term outcome data are keenly 
awaited. Reduction in hospital stay for elective 
surgery is currently considered to provide benefit 
to the patient in terms of avoiding complications 
and to the care provider in terms of reducing costs. 
Some of the newer technologies take longer to 
carry out but in the UK and the US context may 
result in a reduction in stay of up to 1 day, although 
this may be associated with a more prolonged 
period of catheterisation at home. It should 
also be noted that hospital stay for TURP is also 
shortening, from 5–6 days in the older trials to 3 
days in the more contemporary ones. The impact 
of increased operating time and reduced hospital 
stay will vary between care providers and different 
health-care systems. 
The search for alternative methods of prostate 
ablation has been fuelled largely by the risk of 
adverse consequences of bleeding during and 
after conventional TURP. This is a particular issue 
because excessive blood loss and the requirement 
for irrigation during the procedure may contribute 
to perioperative risk, particularly for elderly men 
who often have pre-existing cardiovascular disease. 
Our review confirmed that severe blood loss, as 
indicated by the need for blood transfusion, was 
more common amongst men randomised to TURP 
than amongst those undergoing most, if not all, 
other interventions. It should be noted, however, 
that contemporary studies such as those involving 
HoLEP show much lower rates of transfusion after 
TURP than older studies, suggesting beneficial 
changes to the performance of standard surgery 
over time. 
The situation regarding complications that cause 
continued disability and hence that can be assumed 
to have an adverse effect on quality of life with 
associated ongoing health-care costs is much less 
clear. Sexual side effects of surgery, particularly 
loss of ejaculation and erectile dysfunction, are also 
of concern to men undergoing prostate surgery. 
The risk of retrograde ejaculation is significantly 
lower for minimally invasive procedures and TUIP, 
presumably indicating relative preservation of the 
preprostatic sphincter. For ablative procedures, 
perhaps not surprisingly, the risk is similar to 
that of TURP. Reassuringly, the occurrence of 
ejaculatory dysfunction does not seem to cause 
much in the way of quality of life impairment 
following prostate surgery. Rates of erectile 
dysfunction were similar across all procedures 
although lack of baseline data is a likely source of 
bias. The lack of effect of prostate surgery on this 
aspect of sexual function is supported by data from 
trials including a no intervention arm.6 The rate 
of incontinence, the adverse effect most feared 
by men undergoing surgery for BPE, was similar 
across all interventions with the exception of 
TUNA and laser coagulation (for which reported 
rates were lower), although comparative analysis 
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was hampered by variability in definition. This 
finding is perhaps expected because all of the 
tissue ablative procedures follow the concept of 
removing prostate tissue to achieve benefit and 
therefore have the same risk of sphincter damage 
or pre-existing bladder dysfunction. The other 
most pertinent long-term adverse effect is the 
need for further treatment as a result of stricture 
formation, urinary retention or disease relapse. 
Unfortunately, as is frequently the case, these were 
not primary outcome measures in any of the RCTs 
and the necessary long-term follow-up data were 
either missing or incomplete. Difficulty passing 
urine after surgery reflected by the complication 
of acute retention together with the later need for 
reoperation was, however, more frequently seen 
with newer technologies, especially the minimally 
invasive interventions, which probably reflects the 
generally smaller amount of tissue removed or 
ablated by these procedures. This contention is 
supported by results from trials using HoLEP, in 
which the extent of prostate removal is similar to 
that of TURP, which is reflected in equivalent rates 
of retention and reoperation. 
The results of the review of effectiveness were, 
along with other relevant data (e.g. on costs 
and utilities), combined in an economic model 
(the DAM). The purpose of the DAM was to 
determine which single surgical treatment or 
sequence of surgical treatments for BPE would 
be considered most likely to be cost-effective. 
The DAM can be thought of as a further level of 
evidence synthesis as it sought to combine the best 
available evidence to provide estimates of costs, 
effectiveness (measured in terms of QALYs) and 
cost-effectiveness. The results of the DAM suggest 
that the treatment or sequence of treatments that 
would be considered cost-effective is dependent 
upon what value we think society would be willing 
to pay to obtain an additional QALY. The most 
effective single treatment was HoLEP. However, the 
most effective strategy was TUVP/TURP × 2. The 
difference between these appears to be small on 
average, but the crucial issue is whether society is 
willing to pay for this gain in effectiveness.
HoLEP as a single treatment was found to be 
cost-effective for a willingness to pay of up to 
about £4556 per QALY. Up to £47,221 per QALY, 
TUVP followed by HoLEP would be considered 
cost-effective. Only at higher values for society’s 
willingness to pay would one choose the most 
effective strategy, i.e. TUVP/TURP × 2. However, 
the story does not end there because, even if we 
believe that these results reflect our beliefs as 
informed by the best available evidence, there 
remains uncertainty. This was represented in a 
probabilistic way and can be observed partly in the 
CEAC and also in the EVPI and EVPPI. The CEAC 
shows that, at a willingness to pay of about £20,000, 
there is little doubt that TUVP/HoLEP is cost-
effective. However, there are peaks of uncertainty 
at about £5000 and £50,000 and at these values 
for society’s willingness to pay for a QALY, EVPI 
and EVPPI are highest, particularly at a threshold 
of £5000 per QALY. If one believes that the 
current threshold for the NHS is about £20,000, 
which is probably conservative, then it would 
seem reasonable to recommend changing from 
the current practice of a single TURP to TUVP/
HoLEP. However, the economic model should be 
interpreted cautiously because of the assumptions 
and uncertainties that underpin it as well as the 
threshold value for society’s willingness to pay for a 
QALY. 
These results are consistent with the finding of the 
systematic review of effectiveness. It is important 
to note that even relatively modest changes in 
the parameter estimates used in the DAM might 
change these results because there are few data 
available for many of the comparisons and, as a 
result, estimates of effectiveness (and hence cost-
effectiveness) will change as new data become 
available. 
Strengths and weaknesses 
of the review of clinical 
effectiveness
The strength of the study is the systematic 
approach taken to review the evidence (published 
and unpublished data without language 
restrictions). Exhaustive systematic searches 
were made of the major electronic databases. 
All potentially eligible studies were reviewed 
for eligibility and the study quality assessed. 
Outcome parameters were predetermined and 
data were extracted using standard forms. Despite 
these efforts it is possible that some relevant and 
usable data remained hidden as a result of non-
publication. 
Moreover, more than half of the available evidence 
was reported in abstract form rather than in full-
text published studies. The difficulties in accessing 
raw or summarised data from studies reported 
only in abstract form are well recognised and 
the process was beyond the funding limits of our 
review. The exclusion of these studies prevents Health Technology Assessment 2008; Vol. 12: No. 35
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us from estimating the impact of this form of 
publication bias on the results. The reasons why 
so many trials were only reported as abstracts were 
unclear and ideally should be investigated because 
publication bias has been shown to account for 
up to 45% of an observed association, which may 
change the direction of effect.274 
Empirical research in other fields has shown that 
unpublished reports tend to show less positive 
results than published reports, and so exclusion 
of these could introduce publication bias. In 
total, 88 full-text primary RCTs were identified. 
Although this haul of relevant trials is impressive, 
the majority of studies recruited small numbers of 
patients and covered many different comparisons, 
diluting the opportunities for meta-analysis. The 
confidence intervals around estimates of differences 
were often wide and this problem may result in a 
failure to demonstrate statistical significance for a 
clinically important effect or a failure to rule out an 
effect when it does not exist.275,276 
Another major limitation resulted from the fact 
that the majority of comparisons were made 
against TURP, with few head-to-head comparisons 
of the newer technologies. Study inclusion criteria 
also varied considerably between the trials, which 
calls into question the generalisability of the 
findings on meta-analysis to ‘everyday practice’. 
This was exacerbated by variation in operative 
technique and treatment protocols between studies 
investigating the same technology. These variations 
were of particular concern in studies involving 
laser technology, in which there was variation in 
power settings and temperature, together with 
site and duration of laser application. The limited 
descriptions of technologies in some study reports 
made it hard to determine whether they were 
minimally invasive or tissue ablative. This is an 
important possible explanation for the statistical 
heterogeneity that was common in the analysis. 
The long time base of the studies reviewed (20 
years) in the context of rapidly changing and 
evolving technology also presents difficulties 
in interpretation of the findings. To overcome 
this we categorised interventions conceptually 
according to the mechanism of treatment of BPE 
between standard, minimally invasive and tissue 
ablative. Despite this the ablative group does have 
a range of tissue effects from partial vaporisation 
to complete resection. In addition, the standard of 
conventional TURP has not been static over this 
time frame. Developments in camera and televisual 
display and diathermy generators, improvements 
in perioperative care and concentration of the 
procedure in the hands of specialist urologists have 
all served to make the operation more uniform 
in outcome and less morbid in terms of adverse 
effects. All of these factors are likely to influence 
the findings. Although the review attempted to 
identify and explore sources of variability, for many 
outcomes it remained unclear as to whether any 
conclusions should be drawn from the results given 
the high statistical heterogeneity that was present. 
The role of quality assessment in the conduct of 
a systematic review is important. For this review 
a robust combined checklist assessing different 
sources of bias was produced. We avoided using a 
scoring scale approach as this has been reported to 
be inaccurate concerning the direction of bias277,278 
and can include items that are unrelated to the 
internal validity of a study.279 In this review we 
found that the majority of included RCTs were 
poorly reported, which may be associated with 
low levels of methodological quality.279 There 
are a number of mitigating factors such as space 
limitations in the publishing journals but it is a 
generally held view that if necessary information 
is not provided then the quality will always be 
inadequate.280 Without adequate reporting, 
assessing quality becomes impossible,281 and 
the drive to ensure adherence to standardised 
conduct and reporting guidelines for RCTs has 
much to commend it from the point of view of 
the systematic reviewer.88 It is also of concern 
that reporting of allocation concealment was 
unclear in 74% of the included studies and 14% 
used an inadequate approach to concealment 
of randomisation. This increases the risk of 
selection bias by disrupting the assignment 
sequence and may result in loss of the advantages 
of randomisation.282 The main consequence of 
this is thought to be the generation of larger 
estimates of treatment effects.281 An observational 
study that assessed methodological quality of 250 
RCTs from 33 meta-analyses found that odds 
ratios were exaggerated by 30% for trials with 
unclear concealment protocols.281 There were also 
differences between trials with regard to baseline 
characteristics. For example, studies comparing 
the efficacy and safety of laser resection with the 
efficacy and safety of TURP included patients with 
large prostate glands, whereas those assessing laser 
vaporisation included patients with a wide variation 
in prostate size. Variations such as these make the 
results difficult to interpret. 
Blinding of patients, outcome assessors and care 
providers is another important methodological 
issue and reporting of this was unclear in more Discussion
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than 70% of the studies. For the present review, 
obvious differences in the technologies make 
blinding of the patient and operator difficult, 
but the outcome assessor could be blind to the 
allocated treatment and trial reports should include 
a description of the attempts made to prevent 
ascertainment bias. 
Many studies failed to report point estimates and 
measures of variability, which hinders calculation 
of the precision of the overall pooled estimate and 
calculation of weighted mean differences when 
standard deviations are required.283 In this review 
of effectiveness, when an appropriate measure 
of variability was not reported for continuous 
outcomes, consistency across studies reporting 
the outcome was investigated. Methods to derive 
an estimate of standard deviation have been 
described, based on the imputation of plausible 
values, but doubts as to their validity exist as many 
have not been theoretically derived or empirically 
tested.283 It is possible that if means and standard 
deviations were reported more consistently, effect 
sizes would be different. This is another reason why 
adherence to CONSORT guidelines for reporting 
of clinical trials greatly aids the conduct of robust 
meta-analyses.
A more specific methodological limitation that 
frustrated pooled analysis was the use of differing 
measures of symptomatic outcome in the older 
studies. We did attempt to convert the older and 
now little-used Madsen–Iversen symptom score to 
the present standard of AUA/IPSS using a method 
suggested by Barry and colleagues284 but found that 
the results lacked reliability. This problem forced us 
to analyse studies using the Madsen–Iversen index 
separately, so reducing the power of the meta-
analyses. 
In summary, we believe that we have used the best 
available techniques to identify, review and meta-
analyse the data that were available to us. This 
approach has enabled us to make robust broad 
conclusions concerning the relative beneficial 
and adverse effects of new technologies for the 
invasive treatment of symptomatic BPE compared 
with the standard of TURP. Our ability to consider 
infrequent complications and achieve precise 
separation of the different procedures according 
to relative effectiveness was limited by the small 
numbers of patients studied, inadequate reporting 
of trials, the use of differing outcome measures and 
the pace of technological development. 
Strengths and limitations 
of the DAM
The DAM chapter provides an explicit and detailed 
description of the method used. It sought to use 
a set of criteria to identify which treatments and 
strategies were clinically plausible for the UK 
and these were then compared in terms of their 
costs and consequences. The pathways, developed 
following detailed discussions with the clinical 
experts involved in the study, were used to structure 
the economic model and identify which data 
would be required to parameterise the model. The 
methods used to obtain the parameter estimates 
were explicit and systematic and sought to identify 
the best data available. When assumptions were 
made about which data to use or how they would 
be used in the model, these have been described 
and justified, and, when necessary, they were 
tested in sensitivity analyses. This sensitivity 
analysis was conducted deterministically when 
appropriate, along with probabilistic sensitivity 
analysis. The probabilistic sensitivity analysis and 
probability distributions for all relevant parameters 
were obtained using explicit methods that met 
current guidelines for best practice in economic 
modelling.285 
Despite our best efforts to conduct a rigorous 
economic evaluation using the best methods and 
data available, the results of the economic model 
should be interpreted cautiously because of the 
uncertainties and assumptions that underpin it. In 
particular, as described in the previous subsection, 
the evidence on effectiveness is limited because 
of the paucity of the available evidence base. As 
these data formed many of the input parameters of 
the DAM, this leads to uncertainties in the results 
obtained from the DAM. As indicated above, when 
possible, data inputs to the DAM and assumptions 
were tested in sensitivity analyses. In addition, 
when appropriate, parameters were estimated as 
distributions. These distributions were based on the 
available data and on guidelines for best practice 
and attempted to account for the imprecision 
surrounding the point estimates used within the 
DAM. It is still, however, contestable whether 
the parameter estimates and their associated 
distributions are an accurate measure of the true 
values of the parameters. However, although 
the data used were the best available and all 
distributions were examined in terms of summary 
statistics (expected value and confidence intervals) 
by the clinical experts to test their face validity, it is Health Technology Assessment 2008; Vol. 12: No. 35
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possible that the available data are biased. This is 
because, as described earlier, the data contributing 
to the pooled estimates of effectiveness were 
incomplete and heterogeneous. When sampling 
data were not available, distributions were 
constructed in a pragmatic way; however, expert 
opinion was always sought. Extensive one-
way sensitivity analysis was also used to reveal 
parameters when the decision was sensitive to 
variability within the range of a distribution. 
In addition to the limitations caused by the 
evidence base, the economic evaluation suffers 
from a number of other limitations. First, 
conclusions about cost-effectiveness are sensitive to 
the value that we think society might be willing to 
pay for an additional QALY. Although there have 
been some attempts to define what this value might 
be,286 in this report we do not explicitly identify 
the opportunity cost (i.e. the benefits forgone) of 
redeploying resources to provide a more costly but 
more beneficial procedure. 
The model attempted to compare many different 
strategies, indeed many more than any previous 
evaluation in this area. Nevertheless, it was 
not possible to include every permutation of 
treatments. Therefore, a series of judgements had 
to be made about which strategies to present. This 
judgement was informed by discussions with the 
surgeons involved in the project team. Thus, twenty 
strategies were compared within the model and the 
reasoning behind including these strategies was 
explicit, with justification based on expert opinion 
and logic. 
One of the determinants of cost-effectiveness was 
the probability of treatment failure. Within the 
model, assumptions had to be made as to how 
best to define treatment failure. For the base-
case analysis, the definition used for treatment 
failure was based on clinical criteria relevant to 
the UK (the percentage change in IPSS). However, 
this created problems in terms of estimating 
probabilities of failure from the literature in cases 
in which only reoperation rates were available and 
the criteria for reoperation used in the different 
studies were either unknown or variable. A 
method was found to solve this problem whereby 
the best available evidence, i.e. weighted mean 
differences from the meta-analysis, was used, but 
it necessitated the use of observational individual-
level data and the use of certain contestable 
assumptions. Therefore, the results of this analysis 
were compared with the results obtained when the 
failure was defined using reoperation rates. The 
results using these two different approaches were 
reassuringly consistent. 
IPSS scores were also central to the estimation of 
QALYs. More specifically it was believed that utility 
scores that underpin the QALY estimates should be 
related to IPSS as well as to the presence or absence 
of complications. However, no single reliable source 
could be found that would allow us to do this. Thus, 
a set of assumptions to synthesise data from various 
sources were made. Some of these assumptions are 
contestable but they were tested in the sensitivity 
analysis and were found, on the whole, not to affect 
outcome. Perhaps more importantly, the estimation 
of QALYs relied on a mapping exercise from IPSS 
on to utility scores. There was no alternative source 
of such data and there may be concerns over the 
validity and usefulness of the estimates it produced. 
The estimates of EVPI did not capture the effect 
of removing this uncertainty as no probability 
distribution was specified. However, it is likely that 
further research into the mapping of IPSS on to 
health state utilities would be warranted. 
Estimates of cost were not always easy to obtain; 
however, this study provided a breakdown of costs 
that was sufficient to estimate the independent 
effects of procedure cost, hospital inpatient stay 
and purchase of any new equipment. Nevertheless, 
costing by all resource categories was not possible. 
Therefore, a judgement was made as to those 
resource categories that were most likely to produce 
a difference in the decision. These judgements 
were informed by data that were relevant to the 
UK including the NHS reference costs. However, 
the NHS reference costs are not provided for all 
relevant treatments and, indeed, largely refer 
to TURP only. They also include a length of 
stay component that not only is a function of 
the complications of treatment but also reflects 
variations in practice. Therefore, methods were 
used to replace the length of stay component of 
these costs with length of stay costs based on typical 
length of stay (based on clinical opinion) and the 
cost of a day in hospital on a urology ward. It was 
also assumed, on the basis of availability in a typical 
institution, that TURP and TUVP would incur no 
additional equipment costs but that TUMT, HoLEP 
and KTP would. All of these assumptions were 
tested in sensitivity analyses. 
The incorporation of complications into the 
model was also problematic. For example, there 
were no standard reference costs available for the 
management of complications and, therefore, 
expert opinion was used to inform the cost of these Discussion
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events. The likelihood of complications occurring 
(i.e. the event probabilities) was also important 
for the model. These probabilities were estimated 
using the best available source, i.e. relative risks 
and pooled baseline TURP probabilities from the 
meta-analysis. They are limited, nevertheless, by 
the imprecision of the estimates, the possibility of 
population heterogeneity, variability in reporting 
and uncertainty in the time frame over which these 
events might occur. Thus, it was assumed that all 
complications except incontinence were short term 
and that all cases of incontinence were of urge 
incontinence (although it is possible that some 
cases may in fact be stress urinary incontinence), 
which was assumed to be permanent. Again, these 
assumptions were explicit and justification was 
provided. 
In summary, the DAM has sought to use the best 
available data relevant to the UK and combined it 
within an explicit model that was again structured 
to reflect the costs and consequences of treatments 
and treatment strategies potentially relevant to 
the UK. Although the results of the DAM should 
be treated cautiously, we believe that the results 
provide the best evidence on cost-effectiveness of 
surgical treatments for BPE available to the UK.Health Technology Assessment 2008; Vol. 12: No. 35
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Implications for practice
Based on current evidence it is not possible to 
reliably identify the most promising minimally 
invasive intervention, although, as a group, these 
interventions are less effective than TURP but are 
associated with fewer adverse effects. It is similarly 
not possible to reliably identify the most promising 
tissue ablative intervention for the reasons 
described above. TURP continues to be effective 
although is associated with potentially significant 
morbidity. Each of the surgical interventions 
for BPE has advantages and disadvantages. 
Irrespective of the choice of intervention, the 
true cost to patients and society in terms of 
quality of life has not been quantified to date. 
Given that there are broad similarities in clinical 
effectiveness of the minimally invasive and tissue 
ablative interventions, perhaps the most important 
issue is whether patients would prefer to have a 
minimally invasive procedure if they were aware 
that the intervention, albeit with fewer adverse 
effects, would be less effective than a tissue ablative 
intervention and would have a higher chance of 
requiring a second intervention. 
Current UK clinical practice suggests a preference 
for oral medication using an alpha-blocker 
or 5-alpha-reductase inhibitor, alone or in 
combination, rather than the use of minimally 
invasive interventions. If oral medication fails to 
improve symptoms or if side effects develop, a 
tissue ablative intervention is offered. There is 
some evidence to suggest that the benefits offered 
by minimally invasive interventions are equivalent 
to those gained from oral medication287–289 and so 
this could be a popular option for some men. 
The economic model should be interpreted 
cautiously because of the assumptions and 
uncertainties that underpin it. The model suggests 
that TURP alone or repeated is amongst the more 
effective strategies although it is not cost-effective 
in the Markov model. The model reveals that 
other strategies are possibly less costly and slightly 
more effective. Should it be judged affordable then 
the results of the model suggest that a strategy of 
TUVP followed by up to two more TURPs (should 
a previous procedure fail) would be most likely 
to be considered cost-effective. At lower levels of 
willingness to pay, a policy of TUVP followed by 
HoLEP for failure might be worthwhile. 
For the NHS, increased use of TUVP and/or 
holmium laser prostatectomy would lead to an 
increased requirement for training, which may be 
costly. Because of the limited number of surgeons 
currently providing these treatments it will take 
time to establish an adequate level of provision. It 
is unclear how long this will take as no evidence 
was found to indicate the speed at which surgeons 
may progress up the learning curves for these 
procedures. If interventions such as these are to 
be used as second-line procedures, it would be 
important that their use is limited to specialist 
centres only. However, in the absence of strong 
evidence in favour of newer methods, TURP 
remains clinically effective and cost-effective. The 
use of minimally invasive technologies in the NHS 
is not appropriate until a more effective and/or less 
costly technology is available.
Implications for 
future research
Research efforts in the management of clinical BPE 
should now be concentrated on the performance 
of higher-quality, more rigorous studies. As a 
minimum, these should be RCTs using predefined, 
ideally standardised, measures of outcome, and be 
multicentre to ensure sufficiently precise estimates 
of the various outcomes. Such trials should be 
protocol driven and a detailed protocol of how 
the project is to be conducted should be agreed 
before commencement of the study. The protocol 
should state the research objectives, reasons for 
the study, issues related to study recruitment 
(inclusion and exclusion criteria), information to 
be collected at entry to the study, interventions of 
interest and arrangements for follow-up. A crucial 
stage in the development of a study protocol is 
agreement on the definition of outcome measures 
of interest so that outcomes/complications reported 
in different collaborating centres share the same 
meaning. Although all outcome measures should 
be predefined, this is most important for specific 
outcome measures such as urinary incontinence, 
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urinary tract infection and failure of procedure. It 
is also essential that the reasons for reoperation 
be clearly stated, including when this decision 
is largely driven by patient choice. Future trials 
should also include direct measures of health state 
utilities.
In the context of the NHS and the patient, it is 
highly likely that choices based on strategies of 
management are more important than choices 
based on individual interventions. Areas in which 
further research would be important include: 
For men who might currently be managed  1. 
medically, a systematic review including 
modelling to determine how many years of 
medical treatment are necessary to offset the 
cost of treatment with a minimally invasive or 
ablative intervention in the first instance.
The true costs of the different interventions as  2. 
a critical driver of economic evaluations.
Consensus work in partnership with governing  3. 
bodies such as the British Association of 
Urological Surgeons to agree parameters for 
conducting future trials, such as standardising 
definitions and reporting of outcome measures.
For men judged to need ablative therapy, is  4. 
there an alternative to TURP that is more 
effective, safe or cost-effective? A well-
conducted head-to-head trial of treatment 
strategies – TUVP followed by either TURP 
or HoLEP versus HoLEP versus TURP × 2 – 
would be the most desirable to establish the 
gold standard. Such a trial should take prostate 
size into account and should also include direct 
measures of utility. Newer technologies could 
then be compared against this gold standard 
and, given the rapid developments in this area, 
a tracker trial approach may be appropriate.
Trials of different strategies aimed at  5. 
improving outcomes and minimising adverse 
effects after TURP, particularly bleeding (the 
main serious adverse effect).
It should be stated clearly how data are to be 
collected and processed, what the primary and 
secondary outcome measures are and how statistical 
analysis will be conducted. The early involvement 
of trialists, statisticians and health economists is 
important to ensure that proposed trial designs 
and methods are appropriate, including sample 
size calculations. Consideration should be given 
to establishing a steering committee and a data 
monitoring committee to guide the conduct of the 
study. 
In addition to any future RCT, a further area of 
research relevant to estimating cost-effectiveness, 
which might be performed as part of an RCT or 
as a parallel study, would consider in more detail 
how estimates of IPSS map on to estimates of utility 
and how utility, measured by a generic instrument, 
would change as IPSS changes. Such work would 
facilitate any modelling that may be required to 
extrapolate from the results of a future RCT. Health Technology Assessment 2008; Vol. 12: No. 35
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